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Abstract 
 
Life science firms compete in rapidly changing environments that demand substantial 
resources and capabilities. Nevertheless, there are a growing number of small life science 
firms, and these firms are having a profound impact on innovation in the industry. 
However, little is known on how these firms overcome resource constraints to finance and 
develop R&D resources and capabilities. Consequently, the purpose of this thesis is to 
empirically explore how small life science firms develop R&D and financial resources and 
capabilities. A closely related area that this research is also fundamentally concerned with 
is how R&D and financial resources and capabilities affect firms‟ early growth.    
 
The central aim of this research is to unearth insights on the motivations, assets and 
processes that lead to the development of R&D and financial resources and capabilities. To 
accomplish this, the research draws on the resource-based view and dynamic capabilities. 
The resources-based view is interested in the resources from which firms derive 
competitive advantages. Whilst dynamic capabilities focus on how firms in rapidly 
changing environments – especially high technology environments – configure and 
reconfigure their assets and capabilities to develop competitive advantages. Because this 
research is concerned with the development of key resources and capabilities of firms in 
rapidly changing environments, a resource-based view influenced dynamic capabilities 
framework is used to isolate the development of R&D and financial resources and 
capabilities of life science firms. 
 
An in depth case study approach is used to examine the research questions. It draws on 
longitudinal data collected from six life science firms. Data has been collected from twenty 
interviews and over 3000 pages of secondary data. The interview data is abstracted using 
four techniques: 1) identifying repetitions, 2) looking for transitions, 3) identifying 
similarities and differences and 4) cutting and sorting notable quotes. Following Miles and 
Huberman (1994), the data is then analysed using a multiple step abstraction and 
condensing process. A unique triangulation technique is used at the end of the study where 
the key informants are surveyed on the results of the qualitative analysis.    
 
Results from the study indicate that a unique set of past decisions, future opportunities, 
assets, capabilities and routines leads to the development of R&D and financial resources 
and capabilities. It is evident in all of the case firms in this study that scientific 
breakthroughs, partnership opportunities, the founders‟ experience and the firm‟s ability to 
integrate resources and learn from earlier paths are vital to the development of R&D and 
financial resources and capabilities.  
 
The study makes several contributions to the practice and scholarship of management. It 
provides insights on how small life science firms develop the R&D and financial resources 
to compete in a highly dynamic industry. From a scholarly perspective, it extends the 
dynamic capabilities framework and offers empirical support to several categories of 
dynamic capabilities. It also offers support to R&D and financial capabilities as categories 
of complementary assets. This thesis identifies details of the aforementioned aspects, 
discusses the importance of the findings in relation to the literature, and offers future 
research directions. 
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Definitions and acronyms  
 
CAs Complementary assets. Auxiliary assets and capabilities needed in the 
commercialisation of an innovation. 
 
Endowments For the purposes of this study endowments are the cumulative resources, 
assets and capabilities that a firm possesses. 
 
GCAs Generic complementary assets. CAs that are easily developed or bought on 
the free market. 
 
IO Industrial Organisational economics 
 
NTBFs New Technology Based Firms 
 
Particalise This refers to a process of breaking up matter into very fine particles. 
 
Paths Opportunities that are available to firms or past decisions that affect a firm‟s 
strategy.   
 
Positions Resources, assets or capabilities that a firm possesses. 
 
RBV Resource-Based View  
 
ROI Return On Investment 
 
SCAs Specialised Complementary Assets. Auxiliary assets and capabilities 
that are not easily obtained or contracted.   
 
SEC Securities Exchange Commission. US regulatory body that all firms traded 
on a US stock exchange must report to. 
 
SBIR Grant Small Business Innovation Research grant; US government grant given to 
small innovative firms that have a technology that can help fill a government 
need.  
 
TMT Top Management Team. These are executive-level managers that are in 
charge of the firm. 
 
VC Venture Capital. High risk capital invested in promising ventures. 
 
VCs Venture Capitalists. The study refers to this as the firm(s) that invests in 
high-risk ventures. 
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Chapter 1 – Introduction   
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
 To provide an overview of the life science industry in the USA and globally in the 
contextual setting for the research. 
 To discuss the fundamental issues in the resource-based view of the firm and how 
this interacts with the dynamic capabilities framework that this study draws on. 
 To delineate the broad aims and objectives relating to the development of financial 
assets and capabilities in life science ventures. 
 To provide an overview of the structure of the research and a brief description of 
each chapter.  
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1.1 Background of the research 
This thesis examines the resource and capability development of small life science firms. 
Its focus is on R&D and financial resources and capabilities, what they are, how they are 
determined and deployed by small life science firms towards competitive advantage. This 
study is specifically interested in small life science firms that are less than 250 employees 
and in the early stages of development; which the study refers to as life science ventures. A 
growing number of these ventures are springing up around the world, and these small 
ventures are having a profound effect on the industry (Van Beuzekom & Arundel, 2009). 
Evidence suggests that these ventures require a unique set of R&D and financial resources 
and capabilities to grow (Baum & Silverman, 2004; Murray & Wolfson, 2010; Zheng, Liu, 
& George, 2009). 
 
Although there is a growing recognition of the importance of R&D and financial resources 
and capabilities on the growth of young life science ventures, research on the development 
of these resources is still scarce. Studies on these topics tend to focus on larger firms 
(Mittra, 2007; Rothaermel & Hess, 2007). This is largely attributed to the public nature of 
large life science firms and the fact that data is more readily available. Moreover, Murray 
and Wolfson (2010) suggest that the nature of life science start-ups has changed drastically 
in the last five years. This has made studying these firms difficult, and this coupled with 
the fact that these firms often fail, make studying small life science firms difficult. 
However, it is estimated that over forty per cent of biotech innovations stem from firms of 
under 250 employees, and there are over 300 life science start-ups formulated in the United 
States (US) each year (Van Beuzekom & Arundel, 2009). Thus investigating how these 
firms develop R&D and financial resources and capabilities is an important topic that 
needs to be addressed. This thesis aims to help fill this gap by examining the paths, 
positions and processes that lead to the development of life science ventures‟ R&D and 
financial resources and capabilities.   
 
The literature on life science firms reveals that they are highly innovative and that 
innovation is often the motivation for their start-up (Audretsch, 2001). Furthermore, 
innovation drives the strategic path of these firms. Often life science ventures are focused 
on the development of innovation at the onset and do not have revenues to support the 
firm‟s operations (Baum & Silverman, 2004; Powell, Koput, Bowie, & Smith-Doerr, 
2002). In consequence, life science ventures face large resource constraints. Despite this, 
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few studies examine how life science firms overcome these restraints to develop R&D and 
financial resources and capabilities. 
 
Resources and capabilities are germane to the development of life science firms, and for 
this reason, both the resource based view (RBV) and dynamic capabilities models are 
particularly good lenses for looking at life science firms (Coombs & Deeds, 2000; Madhok 
& Osegowitsch, 2000; Rothaermel & Hess, 2007). The RBV concentrates on the valuable, 
rare, imperfectly imitable and non-substitutable resources that lead to long-term 
competitive advantages (Barney, 1991).  
 
Dynamic capabilities is fundamentally concerned with how firms reconfigure their 
resources and capabilities in response to rapidly changing environments (Teece, 1986; 
Teece, Pisano, & Shuen, 1997). Accordingly, firms use dynamic capabilities, such as 
higher level learning abilities, to create competitive advantages (Winter, 2000). Firms 
develop dynamic capabilities from their paths, positions and processes (Teece et al., 1997).  
Past paths represent the events that shaped the firm‟s present state, such as large scale 
investments in technology. Future paths are the strategic options available to the firm 
(Winter, 2003). The past decisions (past paths) and opportunities (future paths) are often 
the main motivators in a firm‟s strategic decisions; i.e. firms strategize according to the 
opportunities available and restraints caused by previous decisions (Eisenhardt, 2000). 
Positions represent the resources and capabilities of the firm (Madhok & Osegowitsch, 
2000). Processes represent a firm‟s systems and routines of utilising  resources and 
capabilities (Teece et al., 1997). Two important by-products that stems from a firm‟s paths, 
positions and processes are key resources and capabilities. Firms with high-level dynamic 
capabilities are capable of developing complementary assets (Rothaermel and Hess, 2007; 
Teece, 2007).  
 
Complementary assets (CAs) are the auxiliary assets that are needed in the growth of 
technology firms (Rothaermel, 2001a; Tripsas, 1997); e.g. R&D, manufacturing, logistics, 
distribution and service assets. For instance, many firms have a core technology that they 
are aiming to pursue, but in order to bring the technology to market; the firms need 
auxiliary R&D assets to refine the technology. In this instance R&D assets could be 
viewed through a CAs lens (Teece, 1986).   
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Research is especially interested in the specialised complementary assets (SCAs) that are 
needed in firm growth. These are the CAs that are not easily developed or contracted for 
and are a major source of competitive advantage. An example of an SCA is service 
capabilities of a medical device firm. In many cases medical devices require specialised 
service capabilities to maintain the product, and if a firm is unable to service the device, 
then the device cannot be commercialised. These capabilities are such that they require 
sophisticated and often tacit knowledge that cannot easily be replicated. Whilst generic 
complementary assets (GCAs) are needed, they are not a source of competitive advantage 
(Teece, 1986; Teece, 2007; Trispas, 1997). For this reason, most studies focus on SCAs.  
 
The present research takes an integrative approach to looking at the R&D and financial 
resources and capabilities needed in life science firm growth by integrating a framework 
based on the resource-based view (RBV) and dynamic capabilities. At the heart of this 
thesis is dynamic capabilities, and according to this theory, firms continually respond to 
changing environmental conditions by reconfiguring assets and capabilities (Teece et al., 
1997; Winter, 2003). This study also integrates the RBV by incorporating the importance 
of resource picking abilities with dynamic capabilities. Accordingly, a firm‟s resource 
picking abilities and dynamic capabilities is what leads the development of competitive 
advantages ( Eckhardt & Shane, 2010; Makadok, 2001; Teece, 1986; Tripsas, 1997); i.e. 
the firm chooses the best resources available to it and then dynamically works with these 
resources to maximise their resources‟ value.  
 
A review of the literature reveals that a number of resources and capabilities are required 
for the commercialisation of a life science innovation: R&D (Deeds, DeCarolis, & 
Coombs, 2000; Lowe & Taylor, 1998), finance (Powell et al., 2002), specialised 
production (Motohashi, 2008; Rothaermel, 2001b), distribution (Arora & Gambardella, 
1990; Rothaermel, 2001b) and service (Tripsas, 1997). Teece (1986) suggests that the 
resources needed for growth depends on the unique strategic circumstances of the firm. 
Most studies assume that key resources and capabilities come entirely from internal 
sources or partners. This is contrary to the R&D literature which clearly indicates that 
innovation is often the result of the combined effort of many entities, such as universities, 
industry consortiums and governments (Miotti & Sachwald, 2003). Another shortcoming 
of studies investigating resources and capabilities is that they ignore the element of time. 
To date, few studies have looked at the development of key resources and capabilities 
throughout the growth of a firm; nor have studies properly examined the effect of R&D 
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and financial resources and capabilities throughout the early growth of life science 
ventures.   
 
Teece (1986) suggests that the resources and capabilities needed for a firm to grow depend 
on the strategic circumstances of the firms – which are largely influenced by industrial 
forces. The present research is fundamentally concerned with the life science industry, 
which has rapidly-changing technological and regulatory environments, making a firm‟s 
ability to reconfigure its resources and capabilities to respond to these changes paramount 
(Rothaermel & Hess, 2007). Furthermore, previous research indicates that life science 
firms have specific resources and capabilities that are essential to the commercialisation of 
innovations – including R&D and financial resources and capabilities (Arora & 
Gambardella, 1990; Rothaermel, 2001b). Moreover, life science firms in the US are 
heavily reliant on equity investors (Gompers & Lerner, 2004; Lerner & Merges, 1998) and 
the ability to attract capital and manage the finances of a firm –  which is critical to growth. 
Because of this, it is important for this thesis to integrate the influence of VC on the 
development of R&D and financial resources and capabilities.   
 
This thesis examines the resource and capability development of life science ventures. Its 
focus is on strategic R&D and financial resources and capabilities, what they are and how 
they are determined and deployed by firms towards competitive advantage. Life science 
firms have been examined extensively in management studies. However, little work 
examines how new life science ventures develop key R&D and financial resources and 
capabilities. The extant research does not offer sound insight specific to life science 
ventures, nor does it address how these firms develop R&D and financial resources and 
capabilities. Moreover, the existing theory does not provide strong constructs on this topic. 
The objective of this study is to help close these gaps. Thus the research objectives and 
questions are as follows:  
 
Objective 1 
To explore and examine how key R&D and financial resources and capabilities are 
developed. 
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Q1) How does an innovation affect the development of firms? 
1a) Does the source of an innovation affect the development of R&D and 
financial resources and capabilities? 
2a) Does the type of innovation affect the development of R&D and 
financial resources and capabilities? 
 
Q2) Do partnerships have a major bearing on the development of R&D and 
financial resources and capabilities? 
2a) How do life science ventures know what inputs they have to offer 
potential partners? 
2b) How do life science ventures identify what partners have to offer? 
 
Q3) How does the pursuit of financing impact the development of life science 
ventures? 
3a) How do different financial strategies impact the financial trajectories of 
firms?  
 
Q4) Are highly trained, skilled and experienced individuals driving the 
development of R&D and financial resources and capabilities? 
 4a) Are star scientists playing an important role in the development of a 
firm‟s R&D? 
 
Q5) What processes are important to the development of life science ventures‟ 
R&D and financial resources and capabilities?   
 
Objective 2 
To explore and examine the effect of R&D and financial resources and capabilities on the 
growth of life science ventures. 
 
Q6) How are R&D and financial resources integral to life science ventures? 
6a) How closely linked are R&D and financial resources and capabilities? 
6b) Do R&D and financial resources co-evolve? 
 
Q7) Can R&D and financial resources and capabilities serve as a CA? 
 
Q8) Can R&D and financial resources and capabilities act as an SCA?  
 
The first objective stems from the fact that little research investigates the development of 
R&D and financial resources and capabilities in life science ventures. Despite the 
importance of R&D and financial resources and capabilities, research has not paid much 
attention to these in the context of life science ventures. The literature underscores the 
importance of R&D (Kenney, 1986) and financial (Baum & Silverman, 2004; Powell et al., 
2002) resources  and capabilities of larger life science firms – but little work examines 
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these from a small life science firm‟s perspective.  There is a real gap in understanding 
how life science ventures develop R&D and financial resources and capabilities.  
 
The second object stems from the fact that little research examines the effect of R&D and 
financial resources and capabilities on the early growth of life science ventures. It is clear 
from the entrepreneurship literature that new firms are often at a disadvantage because of 
resource constraints and liability of newness  (Singh, Tucker, & House, 1986). Life science 
new ventures face particularly large constraints, as the industry requires substantial 
allotments of financial and human capital (Baum & Silverman, 2004). Despite this fact, 
scores of life science ventures have successfully sprung up all around the globe. However, 
scholarly research fails to properly examine how new life science ventures‟ R&D and 
financial resources and capabilities help them overcome large resource restraints to 
successfully grow and prosper. 
 
This research aims to – at least partially – fill the gaps identified above. In order to do so, 
this research uses a RBV influenced dynamic capabilities framework to examine the paths, 
positions and processes that lead to the development of R&D and financial resources and 
capabilities. This framework provides an ideal lens to isolate the underpinnings of the 
development of R&D and financial resources and capabilities in life science ventures. The 
paths aspect allows questions to be developed that focus on the motivation for developing 
R&D and financial resources; i.e. what opportunities and past decisions influenced these? 
The positions aspect allows for questions to focus on the resources that are leveraged to 
create these resources and capabilities. The processes aspect allows for questions to isolate 
the important routines firms use to develop R&D and financial resources and capabilities. 
 
1.2 Research approach 
This research adopts a qualitative approach in looking at the research objectives. The lack 
of defined constructs on the development of life science firms‟ R&D and financial 
resources and capabilities makes a qualitative approach appropriate. Moreover, this was 
also influenced by the fact that the main theory – dynamic capabilities – pertinent to this 
study is not well- developed. The consequence is a need to uncover meaning in the original 
context and to allow for a theory-building rather than theory-testing approach. The best 
way to accomplish this is through qualitative methods (Edmondson & McManus, 2007; 
Eisenhardt & Graebner, 2007).  
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One method that is often used in a qualitative manner is the case study. This is a 
particularly good method for providing deep insights and for building theory (Eisenhardt, 
1989). Therefore, the case study method was chosen as the research vehicle for this study. 
An abductive process that recognised that research does not have to be purely inductive or 
deductive was used to both extend and build new theory. This study takes a longitudinal 
approach to investigating the development of resources and capabilities over time.  
 
Life science firms were chosen for this research because the researcher has practical 
management experience in a firm in the industry, and this study was spurred by the 
researcher‟s quest to unearth insights on how life science ventures can more effectively 
develop key resources and capabilities. Thus, six small life science firms served as the 
sample for the study. Moreover, the industry and the characteristics of life science firms 
are ideal for the examination of R&D and financial resources. This thesis is also part of 
wider, on-going research at the University of Glasgow‟s Centre for Internationalisation and 
Enterprise Research (CIER), which is looking at the growth of life science firms. 
Following Eisenhardt (1991), this research adopts a funnelling process that consists of 
multiple rounds of interviews where each round builds on the previous round; the first 
round of interviews was conducted, and, subsequently, a more-concentrated interview 
schedule was created with the intent of honing down the results from the first round of 
interviews. A third round of interviews was then conducted with the firms. The interview 
schedule for this round of interviews was created based on the analysis of the first two 
rounds of interviews and triangulated the key findings from the study.  
 
Each round of interviews‟ schedules contained both open and closed-ended questions. The 
open-ended questions allowed the respondents to offer undirected insights, whilst the 
closed-ended questions captured specific points (Kvale & Brinkmann, 2008). These 
questions aimed to unearth insights on the important assets and capabilities needed in 
growth. The second round of interviews probed the paths, positions and processes leading 
to the development of R&D and financial resources and capabilities inherent to the early 
growth of life science firms.  
 
Over 3000 pages of secondary data supplemented the twenty plus hours of interview data. 
The data was analysed using Miles and Huberman‟s (1994) three-level abstraction process. 
The analysis uses several of Russell and Bernard‟s (2003) qualitative data analysis 
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techniques for each level of abstraction; i.e. 1) identifying repetitions, 2) looking for 
transitions, 3) identifying similarities and differences and 4) cutting and sorting notable 
quotes. A case log and a qualitative software program were used to track and query the 
data. A within-case, within-group and cross-case analysis then further refines the data. 
Tables, graphs and charts are used as the basis for the analysis and presentation of the 
findings. 
 
1.3 Structure of the thesis 
This research focuses on the R&D and financial resources and capabilities needed in the 
early growth of life science firms. The fact that this is an industry-based study made it 
important to begin the research with an overview of the life science industry. This review 
reveals that this is a highly innovative industry with rapidly changing environments 
(Cooke, 2002; Madhok & Osegowitsch, 2000). A firm‟s resources and capabilities are vital 
to its competitive position in the industry. Because of the importance of resources and 
capabilities to this study, the resource-based view and dynamic capabilities are appropriate 
models to examine this research through; therefore, the second part of the literature review 
overviews the resource-based literatures. This reveals that the resource based paradigm has 
evolved from Penrose‟s seminal ideas on productive inputs into the RBV, and recently it 
has evolved into the modern-day theory of dynamic capabilities, which is concerned with 
how firms reconfigure their resources and capabilities in response to rapidly changing 
environments (Teece et al., 1997). For this reason it is an ideal lens to look at the 
development of resources and capabilities in life science ventures (Madhok & 
Osegowitsch, 2000) and consequently is the main theory that the present study draws on.  
 
The third part of the thesis presents the qualitative methods chosen to examine the research 
questions. It starts with an overview of the philosophical influences that affected the 
research methods chosen, and it then goes on to detail the data collection process. 
Subsequently the chapter details the rigorous abstraction techniques that were formulated 
on the basis of Miles and Huberman (1994), Bernard and Ryan (2003) and Eisenhardt 
(1989). This abstraction involves a systematic process of identifying themes, trends, 
missing information and patterns in the data. A within-case, cross-group and cross-case 
analysis serves to further refine the data and present the findings in a parsimonious 
manner. The chapter then discusses the measures taken to ensure validity and reliability. A 
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number of techniques – including multiple means of triangulation – assure reliability and 
validity, or trustworthiness, as it is often referred to in the qualitative literature. 
 
The results are presented in a within-group, cross-group and cross-case analysis. 
Subsequently the findings in relation to the literature are put forth. The structure and 
relation of each part of this thesis is depicted in Figure 1-1, and it is then sequentially 
detailed chapter-by-chapter below.  
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Figure 1-1: Thesis structure 
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Chapter One introduces the background of the study, the main bodies of literature that the 
study draws on, the research methods, the research framework, objectives and structure of 
the study. The aim of this chapter is to overview and lay out the thesis.  
 
Chapter Two presents a review of the literature related to the characteristics of life science 
firms. It begins with a brief taxonomy of the industry and a discussion of the main 
characteristics of life science firms. A section on growth is included because this research 
is concerned with how R&D and financial resources and capabilities affect growth. This 
section establishes the appropriate ways to measure and view the growth of life science 
ventures.  
 
Chapter Three presents the second part of the literature review on the core theories upon 
which this thesis draws. The chapter starts with a discussion of Penrose‟s growth of the 
firm, and then moves on to overview the development of the RBV, dynamic capabilities 
and CAs. A section on CAs is included because CAs are auxiliary assets and capabilities 
needed in the commercialisation of innovations, and are especially important to life science 
innovations (Rothaermel, 2001a). Moreover, R&D has been viewed through a CAs 
perspective, which also makes it important to this research. 
 
Chapter Four presents the research‟s framework, objectives and questions. It first lays out 
the dynamic capabilities framework that the study draws on. Subsequently it lays out the 
objectives of the study, and then it details the research questions.  
 
Chapter Five discusses the research methods selected for this study. A qualitative approach 
is taken based on the philosophical influences of the study. The chapter justifies the 
rationale for this approach and further discusses the exact case method used. It then 
justifies the rationale for the choice of case firms.  
 
Chapter Six presents the findings from the analysis. Following Senker and Sharp (1997), 
the six case firms are divided into three groups based on industry subsector. For each 
group a within-case analysis is presented followed by an in depth cross-group analysis. 
Then the triangulation questionnaire that was completed by each firm is presented. This 
provides a framework for a cross-case analysis and serves to validate the findings.  The 
analysis uses the following framework to present the findings: 
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1. Introduction of the firms. 
2. A comparison of the paths, positions and processes that led to the development of 
R&D and financial resources and capabilities.  
3. A comparison on the effect of the R&D and financial resources and capabilities on 
early growth. 
4. Conclusion. 
 
Chapter Seven discusses the findings of the study. It first uses the framework developed in 
chapter six to delineate the findings in relation to the objectives of the research and the 
literature. Next the chapter underscores the significance of the findings to practitioners and 
policy makers. The chapter then moves on to discuss the shortcomings of the study. Finally 
comes an overview of the impact of the research and suggestions for future research.  
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Chapter 2 – Life Science Industry Context     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
 
 To give a background of the life science industry. 
 
  To discuss the general characteristics of life science firms. 
 
 To discuss the importance of specialised financing to life science firms.  
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2.1 Introduction 
Life science ventures compete in a high velocity industry where innovation takes 
substantial capital and time to develop. Despite this, the number of small life science 
ventures is growing at an astonishing rate (Giovannetti, 2010). These firms have unique 
characteristics that influence their ability to compete. Therefore, it is important for this 
study to establish the context of the industry. In order to accomplish this, the chapter 
overviews the life science industry and the important factors that influence the industry. 
The second section presents an overview of the life science industry. This section provides 
important statistics and taxonomy of the firms that constitute the industry. The third 
section discusses the literature on firm growth. This section is included because this thesis 
is concerned with how resources and capabilities are developed in the early stages of life 
science firms‟ growth, and technology firms‟ growth patterns are markedly different than 
non-technology firms (Kazanjian & Drazin, 1990). Therefore, it is imperative to identify 
the appropriate lens to view the early growth of life science firms. The fourth section 
overviews the financing sources and capabilities that young life science firms draw on. 
This section is important because life science ventures usually engage in costly research 
and do not have revenues in their first few years (Murray and Wolfson, 2010).  
 
This chapter establishes the context of the firms and the industry and gives an overview of 
the challenges these firms face and gives a broad understanding of what influences life 
science ventures and what resources they use to compete. 
 
2.2 Life science firms 
Life science firms are broadly defined as all firms involved in the commercialisation of 
products related to the scientific application of living organisms (Owen-Smith, Riccaboni, 
Pammolli, & Powell, 2002b; Powell & Owen-Smith, 1998). This includes the fields 
presented in Table 2-1 below. Although there are thirty fields in this table, there is one 
predominant one – biotechnology. Most of the literature and statistics on life science focus 
on biotechnology. In many cases in the US, the term biotechnology is synonymous with 
the term life science; it could be argued that biotechnology encompasses all of the fields of 
life science in some way, and some scholars accept the use of the two terms 
interchangeably (Powell & Owen-Smith, 1998). The United Nations Convention on 
Biological Diversity (2009, p. 216) defines biotechnology as ‘Any technological 
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application that uses biological systems, living organisms, or derivatives thereof, to make 
or modify products or processes for specific use‟. Van Beuzekom and Arundel (2006, p. 
14) define biotechnology as ‘the application of scientific and engineering principles to the 
processing of materials by biological agents to provide goods and services’. It is evident 
that biotechnology and life science are closely related, and the distinction, if any, is not 
important for the purposes of the present research. It is important to note that the firms this 
study is interested in are ones that could be classified as either life science or 
biotechnology. 
 
Table 2-1: Life science fields 
Agrotechnology Biomedical Engineering Food Science 
Animal Science Biomedical Imaging Genetics and Genomics 
Biochemistry Biomedical Systems Medical Imaging 
Techniques 
Biocontrol Biomolecular 
Engineering 
Molecular Biology 
Biodynamics Biomonitoring Nanotechnology 
Bio-engineering Biophysics Neuroscience 
Bioinformatics and 
Biocomputing 
Biotechnology Plant Science 
Biology Cell Biology Proteome and 
Proteomics 
Biomaterials Ecology Smart Biopolymers 
Biotechnology Environmental Science Tissue Engineering 
Source: Van Beuzekom and Arundel (2006, p. 65) 
 
2.2.1 Life science firms’ characteristics 
Life science firms have unique characteristics that allow them to compete in the high 
velocity environments that they face. In order to better understand the forces that influence 
the resources and capabilities needed in early growth, it is important to understand the 
main characteristics of firms in the industry. The four most relevant to this study are: 1) 
their highly innovative nature, 2) their tendency to form alliances, 3) their capitally 
intensive nature and 4) their reliance on scientific human capital. 
 
The defining trait of life science firms is innovativeness. From 1980 to 2008 the industry 
had more patents than any other; from 2004-2008 almost eight percent of the total patents 
filed in the US were life science patents – over 11,000 (Van Beuzekom & Arundel, 2009). 
A survey of life science executives found the number one goal of R&D is to discover 
breakthrough products (Deloitte & Touche, 2009). Decarolis and Deeds (1999) suggest 
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that innovation in the life sciences is measured and stored in the forms of academic 
citations and patents. They also note that greater stocks of patents and citations are 
correlated with superior performance. The high patenting and publishing propensity 
demonstrates the creative destruction, which is so widespread in the industry, with new and 
better innovations constantly replacing the old (Kenney, 1986; Powell, Koput, & Smith-
Doerr, 1996; Roijakkers & Hagedoorn, 2006).  
 
A body of literature is developing on the influence of innovation on internationalisation 
(Burgel et al., 1998; Chetty & Stangl, 2010; Knight & Cavusgil, 2004). However, few 
researchers have looked at the influence of innovation on the internationalisation of 
biotechnology firms. Madhok and Osegowitsch (2000) is one of the few papers that has 
examined this when they analysed the influence of innovation through a dynamic 
capabilities lens. They found that being able to realign capabilities with other firms is 
important to growth in international markets. Although an interesting paper, especially in 
the dynamic capabilities perspective they take, but there is a lack of development in the 
process of changing capabilities. Moreover, it is based on static and out-dated secondary 
data on US and European biotech alliances. Nevertheless, this paper provides much-needed 
insights on the influence of international activity on the industry and on how life science 
firms‟ resources and capabilities allow them to compete in global markets. More research 
needs to follow Madhok and Osegowitsch (2000) in looking at biotechnology through a 
dynamic capabilities lens; the rapidly changing nature of the industry makes dynamic 
capabilities an ideal lens through which to view it (Deeds et al., 2000). 
 
The second defining trait of life science firms is their reliance on alliances 
(Carayannopoulos & Auster, 2010; Powell et al., 1996) Often life science firms are lacking 
the scientific or commercialisation knowledge to develop their product(s), and for this 
reason they turn to other firms to fill in their knowledge gaps. The Calabrese and 
Silverman (2000) study found that establishing strong alliances is especially important to 
start-up life science firms. They suggest small biotech firms align themselves with partners 
that have complementing capabilities. One important source of these alliances is 
universities. Zucker et. al (1998) looked at the importance that top university researchers 
play in new biotechnology companies.  They found that standout university researchers are 
often the driving force behind new biotechnology firm formation. Furthermore, Rahm 
(1994) study of over 1000 academic researchers found that over seventy-five percent 
engage regularly in consulting, and over eighy percent have former students in industry 
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that they are in regular contact with. This is further evidenced by the fact that 
biotechnology firms tend to cluster spatially near top research universities (Owen-Smith, 
Riccaboni, Pammolli, & Powell, 2002; Zeller, 2001). In many cases innovation is birthed 
in university labs; Rothaermel (2007) suggests that innovation birthed at universities 
disseminate to industry in three main ways: (1) to work with the university scientists and 
VCs on forming a new company; (2) find established firms to partner with in an equity 
sharing agreement; and (3) license the rights to the technology to established firms.  Even 
if a firm‟s innovation was not birthed at a university, universities are still often important 
partners. They often provide testing and research services, and university professors 
regularly consult with firms in the industry (Perkmann & Walsh, 2008; Powell & Owen-
Smith, 1998). 
 
Alliances are central to a cooperative strategy. Gans et al. (2002) examine the alliance 
(cooperative strategy) versus competition strategy for commercialising innovations. Based 
on a study of 118 new innovative firms, this study suggests that firms with strong 
intellectual protection (i.e. patents) have a higher propensity to enter into a cooperative 
strategy; whereas firms with weaker intellectual property protection tend to enter into a 
competitive strategy. In some cases firms earn higher rents from innovations from 
controlling the commercialisation process, which is a competitive strategy. They also find 
that certain industries with a high degree of technology appropriability, such as 
biotechnology, tend to have a higher percentage of firms entering a cooperative strategy 
because of the intensity of CAs needed for commercialisation. This is supportive of 
Rothaermel (2001a) finding that incumbents in certain industries (e.g. biotechnology) have 
an advantage because of their established base of CAs. 
 
The literature on alliances is well developed and provides interesting insights on the 
influence of partnerships within the industry. However, research fails to properly examine 
the importance of alliances in formulating key assets, such as R&D and financial resources 
and capabilities. Rothaermel (2001a, 2001b and 2005) are a few of the only papers to 
investigate this. These studies confirm that alliances provide key inputs, and that the 
partnerships between small and large firms are particularly important to the 
commercialisation of innovations. Future work needs to build on these studies and offer 
more depth on the process of forming alliances amongst life science ventures that lead to 
important assets. Specifically, work is needed to examine how alliances impact the 
development of R&D and financial resources and capabilities. 
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The third defining trait of the life science industry is its capitally intensive nature. It can 
take years from the start of innovation until the time it is commercialised (Hall, 2002; 
Murray & Wolfson, 2010). This lag time from innovation to commercialisation requires 
great upfront investment with no revenue, especially challenging for new firms. To finance 
this incubation and growth many firms turn to VC (Gompers & Lerner, 2004; Lerner & 
Merges, 1998). VC is a form of financing that takes an equity stake in risky projects that 
offer the potential for great returns. In 2008 VCs provided over $4.4 billion in funding to 
biotechnology firms; with the average investment in each firm of $10.24 million dollars 
(Van Beuzekom & Arundel, 2009). Sorenson and Staurt (2001) examined the location of 
biotechnology firms and found that there is a correlation between the location of them and 
VCs; i.e. they are spatially located in the same areas. Furthermore, a statistically significant 
number of biotechnology patents comes from a small number of areas (Zucker et al., 
1998). Powell et al. (2002) find that new biotechnology firms tend to locate in areas near 
sources of VC and of scientific innovation – mainly top tier research universities.  
 
The importance of human capital is the fourth defining trait of the industry. Zucker et al. 
(1998) note the importance of star researchers to the growth and development of 
biotechnology firms. This notion is further supported by Boxeman et al.‟s (2001) findings 
that human and social capital are two of the most important building blocks of new 
technology-based companies. The clustering of biotechnology companies near top 
universities also supports this idea (Blumenthal, Causino, Campbell, & Louis, 1996; 
Zucker et al., 1998). Furthermore, an industry survey of biotechnology executives placed 
attracting scientific talent as one of the biggest challenges in the industry (Deloitte & 
Touche, 2009). One way this challenge is addressed is through the recruitment of foreign 
scientists (Stephan & Levin, 2001); the National Science Foundation estimates that 15% of 
US biotechnology workers are foreign-born (Tsapogas J, 2007). Foreign-trained scientists 
are not only significant as an input to innovation, but also as a possible driver to 
internationalisation. Burgel and Murray (1998) present evidence that foreign-educated 
managers have a higher propensity to globalise their firms than domestically-educated 
managers. Often new life science firms are founded by scientists, so it logically follows 
that foreign-educated scientists could be a driver to internationalisation in the industry. 
Given the international flows of scientific staff, it is perhaps no surprise that they then look 
to make international links when a new life science firm is founded. 
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2.2.2 History and state of the industry during this research 
The application of scientific principles to biological agents started hundreds of years ago. 
However, this was not called biotechnology until the 1970s, when recombinant DNA was 
discovered (Yoxen, 1983). Another major milestone of the modern biotechnology industry 
is when the US Supreme Court ruled in Diamond vs. Chakrabarty (1980) that modified 
organisms could be patented (Argyres & Liebeskind, 1998). This sparked massive 
investment in the industry and launched hundreds of new biotechnology ventures. These 
initial firms were primarily either large pharmaceutical companies or small firms started by 
science professors who kept their full-time faculty positions and started firms on the side 
(Zucker et al., 1998).  
 
The present study focuses on US life science firms, so it is important to understand the size 
and scope of the US life science industry. This paragraph summarizes Van Beuzekom and 
Arundel‟s (2009) OECD statistics of the US life science industry. In 2009 the United 
States had the most life science firms of any country in the world with 3,301. Of these 
firms over seventy-five per cent employed fewer than fifty employees. The industry has 
seen substantial growth in the past few years. Spending in the industry was over $25 
billion in 2009, which is up from an estimated $15 billion in 2000. One clear issue is that 
whilst seventy-five percent of firms in the industry are less than fifty employees, over 
seventy per cent of the industries R&D spending is by firms over 250 employees. The total 
revenue for the industry was $554 billion in 2009, which is up from $318 billion in 2004. 
The average life science firm generated $168 million in revenue. From 2004-2008 11,474 
life science patents were filed in the US, which constituted forty-two per cent of the 
world‟s life science patents. These statistics help put the industry in perspective and clearly 
show that it is an important industry.  
 
The global recession that started in the fall of 2008 greatly slowed the growth of the 
industry. Revenues fell by ten per cent in 2008. Funds raised from initial public offerings 
fell sixty percent from the 2007 levels. Venture capital funding dropped from $5.5 billion 
in 2007 to $4.4 billion in 2008 (Giovannetti, 2010). Only ten per cent of the 370 publicly- 
traded US life science firms had positive cash flow in 2008. Furthermore, in 2008 US 
biotech stocks were down by a mean average of forty-nine per cent, and 87% of the 
publicly-traded firms lost value. There were over eighty companies that laid off 5,000 or 
more employees (BIO, 2009). By the end of the present study (winter 2010), the industry 
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was on the way up. By 2010 early informal indicators were that the industry was 
recovering, but the recession has led to some major changes. Academic research has yet to 
analyse the long-term effect of the recession. The overall consensus of the major 
consulting firms in the industry is that the industry will recover, but this recession will 
fundamentally change the industry. Ernst and Young (2010) and Aon Analytics (2009) 
suggest that firms will become leaner and develop proofs of concepts in a more cost-
effective manner. Several consultant reports also indicate that firms will need to make 
better use of their resources, increase organisational efficiencies and develop strategic 
partnerships in order to stay competitive. Interestingly, many of these reports emphasise 
the challenges to small firms, but do not offer depth into what these challenges are. It 
would be interesting to see how small life science ventures develop the R&D and financial 
resources to compete in such a dynamic and capitally intensive industry.  
 
The global recession is significant to this research because it was conducted in the midst of 
it. This may have impacted the data collected for this project. Lack of VC funding could 
particularly impact the results because VC was extremely difficult to obtain during the 
time of this study, which is significant because VC is germane to the growth of firms in 
industry (Baum & Silverman, 2004).  
 
2.2.3 Government policy  
A number of variables influence the development of scientific knowledge (Gibbons, 
Limoges, & Nowotny, 1994). For life science firms these variables are both internal and 
external. One of the main external variables is government. There are several ways that 
governments influence life science ventures. 
 
One of the biggest influences that government has on life science ventures is through 
government approvals. In the US the FDA is the most influential approval process that 
firms must contend with. Any life science innovation that is used on humans must gain 
FDA approval (Giovannetti, 2010; Olson, 1997).  The FDA approval process is long and 
arduous and typically it takes three to twelve years to get a product through this process. 
Furthermore, it usually costs between $250,000 to $5 million to obtain FDA approval 
(Giovannetti, 2010). These are the direct and indirect costs of testing products and getting 
them ready for the FDA process. Vernon et al. (2009) found that the FDA is one of the 
biggest factors in a life science firm‟s strategy. Firms plan around costs and resources for 
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gaining FDA approval for their innovations. Surprisingly few studies examine the FDA‟s 
impact in regards to small firms. It would seem that the great costs involved with the FDA 
would make planning for their approval even more important for small firms. However, 
there is not a lot of depth in the literature offered on this topic. Furthermore, the FDA is 
more influential on some life science firms than others. For example, drug development 
firms have the most arduous FDA standards to contend with. It typically takes over eight 
rounds of FDA tests and over ten years to get a new drug application approved. In 
comparison, many medical devices that focus on topical applications reach FDA approval 
with two tests and in less than four years (O‟Connor, 2010).  
 
Another policy area that influences the formation of firms are  the regulations involved 
with their start-up. Countries with easier rules and procedures for starting new firms have 
more than countries that have more cumbersome procedures for starting a new business 
(Audretsch, 2001; Gnyawali & Fogel, 1994; Wagner & Sternberg, 2004). Along the same 
lines, a country's legal system, which is important to patent protection, is critical to a 
thriving life science industry. Without this protection many firms would not have the 
incentive to innovate (Jaffe, 2000; Jaffe, Trajtenberg, & Romer, 2005; Trajtenberg, 1990). 
Furthermore, regulations that prohibit certain research or testing influence firms to look 
overseas to get around those in their home countries (Greis, Dibner, & Bean, 1995). 
 
Many governments have used policy to try to develop and grow life science-related 
industries; most often through tax breaks, government grants, and access to government 
property (Chen & McDermott, 1998; Cooke, 2002). Recently governments have become 
increasingly competitive with their incentives, so incentives are not as effective as they 
once were (Blomstrom & Kokko, 2003; Nov, 2009).  Another way governments can 
influence life science firms is through assisting them in internationalisation. Many 
countries create agencies dedicated to helping firms sell their goods abroad. America‟s 
main entity is the Export Agency which provides low cost or free assistance to firms 
wishing to enter international markets. The effectiveness of this entity has is not well 
documented, and the few studies examining this topic are conflicting and inconclusive.  
 
Another important government influence on life science firms is educational policy, and in 
particular the government‟s support for research institutions. These institutions help create 
the places where many life science innovations are born (Blumenthal, Gluck, Louis, Stoto, 
& Wise, 1986; Shane, 2004; Zucker, Darby, & Armstrong, 2002). The US has excelled at 
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transferring academic knowledge to industry. This is largely credited to the fact that 
government supported academic institutions do not take full control of the innovations that 
are created there (Giesecke, 2000). Instead the universities and the researchers that created 
them share the ownership rights, which incentivise researchers to create innovations that 
are marketable. Many universities have streamlined collaborating with industry through 
technology offices (Cardozo, Ardichvili, & Strauss, 2011; Friedman & Silberman, 2003). 
These offices market and license university created innovations and make the transfer of 
innovation more efficient.  
 
2.3 Firm growth  
This study is interested in the development of resources and capabilities in the early 
growth of life science firms. Consequently, it is important to review the different growth 
lenses. Growth is the end goal in entrepreneurship, and at some point every firm has to 
grow or it will go out of business (Churchill & Lewis, 2000). Although easy to grasp in 
theory, in practice it is an elusive concept to define clearly and measure. There are 
numerous ways to look at growth, and there is no commonly agreed upon growth 
definition within the literature (Renko, Carsrud, & Brännback, 2009) .  
 
Some of the most common measures of growth are based on financial indicators. Revenue 
growth is one measure that is particularly prevalent (Delmar, Davidsson, & Gartner, 2003; 
Evans, 1987; Reuber & Fischer, 2002).  Some other measures include employee growth 
(Del Monte & Papagni, 2003; Hart & Oulton, 1996), asset growth (Ijiri & Simon, 1964; 
Lang, Ofek, & Stulz, 1996) and profits (Chittenden, Hall, & Hutchinson, 1996; Jordan, 
Lowe, & Taylor, 1998).  Whilst all of these measures provide an indication of growth, 
Davidson et al. (2010) suggest that in a significant number of cases these numbers are 
contradicting. For example, a firm could have substantial revenue growth; whilst at the 
same time have substantial profit decline. Thus objective financial measures often provide 
insight on growth, but they do not always accurately portray the whole growth picture. 
Financial indicators are particularly deceptive for start-up firms, which often do not have 
revenues or many employees. This is especially true of life science firms, which often go 
years before they generate revenues or profits (Morecroft, Lane, & Viita, 1991; Tapon, 
Thong, & Bartell, 2001). 
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For start-up technology firms a better lens to gauge growth is through how firms develop 
from a start-up into an established firm. The literature offers a number of stages models to 
describe this type of growth. Most suggest firms start-up, develop, grow and then mature 
(Davidsson et al.; Kazanjian & Drazin, 1990; Scott & Bruce, 1987). Stages models are 
fundamentally concerned with change, how firms change from one type of operation into 
another. For example, at the inception, firms are usually informal and do not have an 
advanced infrastructure, and then at some point a firm develops a more advanced 
infrastructure and larger scale distribution; this is a point of growth according to stage 
models. Davidson, Achtenhagen and Naldi (2009) suggest that analysing firm growth 
through stages is often preferred because it captures growth over time. They also contend 
that studies on growth that do not capture this aspect of growth are invalid because they are 
prone to selection bias; i.e. studies select samples and measures of growth conducive to 
their studies. 
 
Whilst stages‟ lens of growth has some positive attributes, these models have also been 
widely criticised – the largest criticism being the lack of clear inflection points between 
stages (Dobbs & Hamilton, 2007; Garnsey, Stam, & Heffernan, 2006; Macpherson & Holt, 
2007). These critics contend that there is no clear and objective way to determine when 
one phase ends and another begins. Certainly this criticism should not be dismissed, but 
several of the proposed models have established inflection points that show where a firm 
goes from one phase and to another (Bleaney & Nishiyama, 2002; Kazanjian & Drazin, 
1989). Another common criticism of stages models is that different business environments 
have different influences on growth; therefore, it is difficult for ceteris paribus 
comparisons (Kazanjian, 1988; Kazanjian & Drazin, 1990). For instance, a life science 
start-up is going have a much different growth path than a start-up bank has; mainly 
because there are drastically different environmental factors that influence the respective 
industries. For this reason, Kazanjiaan (1988) suggests that growth stages models should 
be industry specific.  
 
Kazanjiaan and Drazin (1990) then go on to offer a stages model of growth for technology 
firms. Based on this model several other researchers developed similar ones. For example, 
Autio et al. (2007) offers a four stage model that emphasises the importance of resource 
acquisition and use at each stage. The four stages that most of these models encompass are 
(1) conception and development, (2) commercialisation, (3) growth and (4) stability. All of 
the models emphasise transformation; i.e. firms transforming their organisational structure; 
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and these models recognise that each stage brings a new set of variables and challenges 
and that organisations must react to these challenges to maintain growth.  
 
One challenge in industry studies is to find a suitable metric by which success can be 
measured. As above, growth as a concept is often used, but this can be expressed in various 
ways. Different industries and circumstances dictate which measures of growth are proper 
to use (Kazanjian, 1988). This thesis is concerned with the development of resources and 
capabilities in life science ventures. The life science firm overview has established that 
often these firms do not have revenues for many years. This makes traditional financial 
measures of growth invalid. A better way to look at growth for life science firms is through 
the phases of development. There are a number of models offered, each of which has 
different points of emphasis, but all of them indicate that there are trigger points that 
determine when a firm moves into another stage of growth. Furthermore, each of the 
models encompasses a conceptualisation, commercialisation, growth and maturity phases. 
Kazanjian and Drazin (1990) has emerged as one of the more accepted growth stages 
models of technology-based firms. Based on the review of the growth literature, the 
present study takes the stance that this is the most relevant and accurate model for looking 
at the growth of life science ventures for this thesis. This study is specifically interested in 
the development of R&D and financial resources and capabilities of life science firms 
during the conceptualisation and early part of the commercialisation phase of development. 
It is more important for this study to examine how firms develop an infrastructure, rather 
than to focus solely on financial measures. 
 
2.4 The financing of life science ventures 
The discussion above indicates that capital is paramount to the development of life science 
ventures. Often new ventures will plan on sustaining many years without revenues 
(Gruber, 2009). This, coupled with the capitally intensive nature of developing life science 
innovations, makes investment capital paramount. Financing is one of the biggest 
challenges that a life science venture faces in its early growth (Freear & Wetzel, 1990; 
Wright & Robbie, 1998). Financing is particularly challenging during the 
conceptualisation and early commercialisation stage of development for life science 
ventures, as firms often do not have revenues to support their operations and firms are 
investing heavily in R&D at these stages (Murray and Wolfson, 2010). This section 
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overviews the sources of funds and capabilities that life science ventures draw on to 
finance their development.  
 
Sources of funds 
In the early stages of growth, life science ventures demand a substantial sum of capital – 
even more so than other new technology-based firms (Deeds et al., 2000). At the seed 
stage, capital is especially difficult to attract as the firms often have not proven the 
research concept. The capital at this point is allocated to research and initial product 
development. During the conceptualisation phase, firms often finance their incubation 
through insider funding, VC, public sector grants and business angels (Gruber, 2009). 
However, a true taxonomy of where capital comes from has yet to emerge in the literature, 
though it has noted that the initial capital often comes from the founders and angel 
investors (Freear & Wetzel, 1990; Soleimani & Kharabi, 2010). Nevertheless, there is a 
lack of evidence to substantiate what percentage of life science ventures initially capitalise 
through these means.  
 
Business angels are usually informal investors made up of wealthy individuals who are 
willing to invest in high risk ventures for the potential of hyper returns (Chesbrough, 
2000). Often angels have substantial background in the fields they invest, and they offer 
management inputs along with their capital. They typically invest amounts less than $1 
million, and seldom invest in subsequent rounds (Chesbrough, 2000; Wong, 2009).  
 
In some cases the government offers capital to early stage life science firms (Toole & 
Czarnitzki, 2009). One of the main ways the government invests in firms is through the 
Small Business Innovation Research (SBIR) grant program. Through this program the 
government offers grants from the range of $40,000 to $1.3 million to firms of under 500 
employees that have innovations that have the potential to help society (Bauer & Arthanat, 
2010). In 2010 approximately 6,000 SBIR grants were awarded of which approximately 
2,100 were to life science firms (Lemond, 2011). In a study of grant versus VC backed 
firms Lerner (1996) found that SBIR grant firms display superior performance as 
compared to VC backed firms. He conjectured that this is because the SBIR grants are so 
competitive that only the best firms receive the grants, but he did not offer sufficient 
evidence to substantiate this. Other studies have also supported Lerner‟s (1996) findings 
that grant backed firms display superior performance and that SBIR grants are helpful to 
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firms (Cooper, 2003; Wallsten, 2000). However, like Lerner (1996), these studies also do 
not provide breadth on what is driving the superior performance of SBIR backed firms.  
 
One source of financing that is usually not available to new technology-based firms is bank 
loans because these companies usually do not have the credit history and are high risk 
(Donnelly & Betts, 2006). However, entrepreneurs often secure loans on their personal 
property (e.g., their homes) to finance new ventures (Han, Fraser, & Storey, 2009). This, 
however, should be viewed through insider financing rather than commercial loans.  
 
A fourth source of capital for life science ventures is VC, which is especially important to 
because of the risky nature and the potential for abnormal returns of life science ventures 
(Chakma & Sammut, 2011; Cooke, 2002). The importance of VC has captured the 
attention of a number of researchers (Gompers & Lerner, 2001). The literature identifies 
three main sources of VC: independent venture capital (IVC), corporate venture capital 
(CVC), and angel investors. It is clear that angel investors are markedly different than IVC 
or CVC. Angel investors are the most hands off investors. Angel investors tend to invest 
on the ground level versus investing after a venture has already been established for a 
period of time (Wright & Robbie, 1998). In contrast, IVC and CVC tend to be hands on 
and invest only after the company is established. Many IVCs and CVCs invest in early 
stage firms, but rarely will they invest in a firm that has not been formulated or is only a 
few months old because they like to have some established criteria to base their investment 
decisions on (Gompers, 1995). The difference between IVC and CVC is not as great as that 
of angel investors and IVC/CVC. The literature is well defined on this topic and 
overviewed in Table 2-2.   
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Table 2-2: IVC and CVC differences 
Attribute Difference 
Incentive VCs have larger incentives tied to the performance 
of the portfolio firms than CVCs do.  
Financial risk CVCs are more risk adverse. 
Monitoring of portfolio firms IVCs more closely monitor their portfolio firms. 
Discovering alternative business models IVCs are more likely to help their portfolio firms 
discover alternative business models. 
Time horizon CVCs have a longer term outlook on their 
investments. IVCs strive to get their investment 
returns within the established life of the portfolio. 
Investment size CVCs can invest larger sums of money. 
Source: Author based on Chesbourgh (2000; p. 41) 
 
A fifth source of funding for life science ventures is industry partners. Smaller firms 
sometimes sign agreements with a larger firm where the larger firm finances part of the 
smaller firms R&D. In return the larger firm is offered ownership and or access to the 
smaller firm‟s innovation(s) (Higgins, 2007; Higgins & Rodriguez, 2006; Rothaermel, 
2001a). In general, life science ventures are not able to sign such agreements until they 
have developed their proof of concept and can show that their technology has market 
potential, and often small firms shy away from these agreements until they can protect 
their intellectual property (Dickson & Weaver, 2011; Luukkonen, 2005) .  
 
A sixth source of capital for life science ventures is public stock markets. Generally, firms 
usually do not offer an initial public stock offering (IPO) until they are in the growth stage 
of development (Pástor, Taylor, & Veronesi, 2009). Stock markets tend to embrace firms 
that have a proven revenue model (Lévesque, Joglekar, & Davies, 2010). However, 
recently a number of life science firms in the conceptualisation phase of development have 
launched an IPO (Williams, 2007). 
 
Financial capabilities 
Although there is some understanding on the sources of financing for life science ventures, 
there is still a large gap in understanding how new ventures obtain capital from the sources 
discussed above. The NBTF literature has touched on the process of raising capital, but it 
has not gone into great depth on what resources and capabilities firms use to develop 
financial resources. Hsu (2007) examined the investment behaviour of VCs and found that 
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the founder‟s background is a key element that factored in the investment decision process; 
i.e. VCs are more apt to invest in firms whose founders show a successful track record of 
starting firms. This has been substantiated by several other notable studies (Colombo, 
Delmastro, & Grilli, 2004; Colombo & Grilli, 2005; Stuart & Abetti, 1990). It has also 
been noted that the potential of a firm‟s technology is an important criteria in the 
investment decision (Cockburn & MacGarvie, 2009; Freear & Wetzel, 1990). This is 
particularly important to NTBFs, but as of yet a way to gauge the potential of an 
innovation and how financiers value an infant technology has not emerged. 
 
There are also studies that have examined the importance of alliances to attracting 
investment capital. These studies have shown that firms that are well networked have more 
access to capital (Hite & Hesterly, 2001; Shane & Cable, 2002). For example, Shane and 
Cable (2002) suggest that firms with deeper industry ties are able to raise more than firms 
that are not well connected in the industry. However, this study did not shed light on how 
these alliances are formed. There is little work that looks at how the networking 
capabilities lead to financial resources.  
 
Studies have also shown that capabilities in conserving capital are important to new 
ventures. There is an emerging body of literature on „bootstrapping‟; which Winborg and 
Landstrom  (2001, p. 236) refers to as „the use of methods for meeting the need for 
resources without relying on long-term external finance from debt holders and/or new 
owners’. Accordingly, firms operate as lean as possible and cut all non-essential costs to 
preserve capital.  Several studies have indicated that bootstrapping capabilities are 
essential to start-up ventures because resources are almost always in short supply (Auken, 
2005; Jones & Jayawarna, 2010; Winborg & Landstrom, 2001a). However, there is little 
work that has looked at how bootstrapping capabilities affect the development of life 
science ventures. It would seem that cost containment capabilities would be critical in an 
industry where R&D expenses are high and difficult to project for.  
 
Investor relations is another capability that becomes important as firms develop and take 
on larger amounts of investment. Gorman and Sahlman (1989) found that executives‟ in 
VC backed firms spend over 100 hours a year meeting with their VCFs. Similarly, Bushee 
and Miller (2009) findings  indicate that after an IPO firm‟s CEO‟s devote up to twenty per 
cent of their time to functions related to investor relations. Moreover, research indicates 
that capabilities related to dealing with investors are critical because one of the largest 
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sources of future investment capital is previous investors; it is therefore crucial to maintain 
strong relations with investors. Laurent-Ottomane and Weimer (2010) suggest investor 
relations capabilities mainly revolve around communicating with investors on the status of 
the firm and „selling‟ the investors on investing more capital. 
 
2.5 Industry context conclusions 
The discussions in this chapter have highlighted the dynamic nature of life science firms. 
Innovation is paramount in this industry, and rapidly changing environments underscore 
the importance of effectively choosing and developing resources and capabilities. 
Furthermore, new life science innovation takes millions of dollars and specialised 
scientific resources and capabilities. Despite this, there are over 2,500 life science firms in 
the US that are under 250 employees and over 300 new life science ventures are launched 
every year  (Van Beukezekom & Arundel, 2009). Even with the importance of small firms 
to the industry, there is a major gap in the understanding of how small resource-
constrained firms develop the R&D and financial resources and capabilities needed to 
incubate innovation. 
 
This review has highlighted that human capital, university inputs, industry partners and 
government inputs underpin the development life science ventures‟ R&D. However, there 
is still not a deep understanding of how these combine to help a firm develop its R&D 
resources and capabilities. There is also a lack of understanding of how firms obtain inputs 
from these sources. Furthermore, few studies look at how the nature of a life science 
innovation affects its development; i.e. do different life science innovations have different 
effects on the development of a firm?  
 
It is also apparent that life science ventures are costly to incubate and that investment 
capital is paramount to the incubation of life science ventures. The review suggests that 
this investment comes from several sources; insider finance, angel investors, VC, 
government grants, industry partners and IPOs. However, there is a real gap in 
understanding how firms obtain capital from these sources. More specifically, there is little 
understanding of the capabilities needed to attract investment and mange financial 
activities. Moreover, research does not properly identify which combinations of sources of 
capital are used early in the development of life science firms.    
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 It is clear from this review that R&D and financial resources and capabilities are germane 
to the early development of life science ventures. The review also shows there are 
deficiencies in the knowledge base of how life science ventures formulate these resources 
and capabilities. Because of the importance of resources and the dynamic nature of the 
industry, the resource- based view (RBV) and dynamic capabilities offer good lenses 
through which to examine the development of resources and capabilities of life science 
ventures. The next chapter is devoted to tracing the evolution of the resource-based 
literature and establishing a theoretical lens through which to view this research.  
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Chapter 3 – The Resource-Based Paradigm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives: 
 
 To discuss the evolution of the resource-based literature.  
 
 To review the major conceptual and empirical studies on the Resource-Based 
View, dynamic capabilities and CAs. 
 
 To evaluate the shortcomings and identify research gaps in the resource-based 
literature. 
 
 To discuss the potential applications of dynamic capabilities in the examination of 
life science firms. 
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3.1 Introduction 
Chapter two emphasised the importance of resources and capabilities to the development 
of life science firms. Central to the strategic management of life science firms is how to 
acquire, build, use and reconfigure resources. A number of prominent theories have sprung 
up based on this. The RBV and dynamic capabilities is clearly rooted to this theoretical 
approach (Barney, 1991; Teece et. al., 1997), but resources are still paramount to other 
theories as well. For example, Porter‟s five forces model recognises resources are 
important, but it emphasises this in regards to how environments shape the development of 
firms‟ resources (Porter, 1985). Upwards of ten strategic management theories touch on 
resource development and use (Aimé, 1997). Most of these are specific to one sub-
discipline within management. Following Aime (1997), the present study takes the stance 
that a strategic management issue should be isolated within one main theoretical paradigm. 
This is not to contend that one theory is necessarily better than another; rather it is better in 
a single study to isolate a phenomenon under the umbrella of one rather than many 
strategic management theories (Eisenhardt, 1989a). Furthermore, this is not to suggest that 
other theories should not be incorporated in a study, as multiple theoretical perspectives 
are good for comparative purposes and looking at the problem from different angles (Yin, 
2008). Rather, this is to suggest that it is important to have one overarching research 
paradigm guiding a study. Because of the importance of resources and capabilities to life 
science ventures, this thesis uses a resource-based paradigm to examine life science 
ventures. 
 
The RBV has gained significant scholarly attention in the last twenty years. It has become 
one of the most prominent strategic management theories, as thousands of articles draw on 
it. Out of the RBV, dynamic capabilities has developed. This theory looks at how firms 
reconfigure their resources to respond to rapidly changing environments (Teece et al., 
1997). The present study is interested in the growth of life science firms, and because of 
the rapidly changing environments life science firms face, dynamic capabilities makes an 
excellent lens through which to examine life science firms. A firm displaying high-level 
capabilities is able to create complementary assets (CAs), which are the auxiliary assets 
needed in the commercialisation of an innovation (Teece, 2007). Figure 3-1 below traces 
the evolution of the resource-based literature. Starting with Penrose‟s (1959) Growth of the 
Firm, this review systematically works through this evolution. 
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Figure 3-1: Resource-based paradigm evolution 
 
Source: Author 
3.2 Penrose 
Penrose‟s (1959) growth of the firm is one of the earliest theories to address why some 
firms grow at a faster pace than others. Not only is this an important piece because it is one 
of the first significant pieces to look at firm growth from a strategic management 
perspective, but it is also the basis for the RBV and several other modern strategic 
management theories. Because this thesis is directly seeded in the aforementioned theories, 
Penrose‟s early theory is where this discussion begins.  
 
According to Penrose (1959), a firm is an administrative structure with productive 
resources. These productive resources are both physical and human. The physical are the 
tangible assets, such as plants and materials. Human resources are the labour that the firm 
has available. The function of the firm is to engage these resources to create outputs. In 
order to maximise outputs, the firm must recognise productive opportunities, which are the 
opportunities of output that are available to the firm (Penrose, 1959).  
 
Arguably, Penrose‟s largest contribution is her managerial view of the firm (Kor & 
Mahoney, 2004). Prior to her work in The Growth of the Firm, scholars mostly ignored the 
influence of management. She, on the other hand, saw management as one of the most 
important resources of the firm. Resources themselves are not enough to make a firm 
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grow. Management is needed to convert resources to valuable outputs (Teece, 1986; 
Winter, 2003). These valuable outputs she calls „productive services,‟ which she 
differentiates from resources that have no value until they are converted to something 
productive (Kor & Mahoney, 2004). A manager‟s firm-specific knowledge can adjust and 
expand, which allows a firm to grow over time; managers can be hired and trained in the 
long run. However, in the short run management expansion is limited because of the time it 
takes to hire them. This causes a bottleneck to growth, which is known as the „Penrose 
Effect‟ (Uzawa, 1969). Penrose also makes significant contributions to the process of 
innovation within the firm. Specifically she attributes unused resources as the source of 
firm innovation. This excess capacity is one of the key variables to firm growth (Penrose, 
1959).    
 
The variables described above are the building blocks of the RBV. One of the main 
architects of the RBV, Barney (1991, p.103), credits Penrose‟s contributions: 
 
 ‘Her work portrayed how resources may provide long-term rent streams’. 
 
Many of the prominent theories in management trace back to Penrose‟s The Theory of the 
Growth of a Firm. Most notably are the RBV, transactions‟ costs and dynamic capabilities 
models. Penrose‟s ideas on physical and human resources provided the foundation for the 
RBV (Rugman & Verbeke, 2005). The Theory of the Growth of the Firm also lays the 
groundwork for other growth theories, as it describes firm growth happening over a series 
of steps (Rugman & Verbeke, 2005).  
 
3.3 RBV 
Penrose‟s main ideas are disseminated in her 1959 piece, but it was not until years later 
that her ideas were fully realized. Throughout the 1960‟s, 1970‟s and into the early 1980‟s, 
Industrial Organisational (IO) economics became popular in the strategic management 
literature (Conner, 1991). This literature is concerned with the influence of the outside 
forces on the market. By far the most influential work to come out of this school is Porter‟s 
Forces Model. According to the theory, the firm holds some degree of control in its 
strategic direction, but its ability to compete is limited within the confounds of its 
industrial environments (Miller & Dess, 1993). Whilst there is a sound basis for looking at 
environmental forces, critics contend that IO-related theories are overly concerned with 
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outside forces and neglect firm resources and abilities. Although Hendry (1990) finds fault 
in assuming that markets work in equilibrium, many economic and political barriers show 
otherwise. Furthermore, studies have found that even firms that operate within sub-optimal 
environmental conditions are able to achieve above average economic rents (Schoemaker, 
1990). 
 
These shortcomings brought scholars back to Penrose‟s growth ideas. Wernerfelt (1984) 
and Barney (1986) extended her ideas into the RBV of the firm. These pieces, concerned 
with integral resources, examined firm competitiveness from the resource side, instead of 
the product or industrial standpoint. Accordingly, the basis of competitive advantage in lies 
in a firm‟s bundle of resources (Wernerfelt, 1984); thus firms with superior bundles of 
resources enjoy superior performance. Conceptually, this is an easy theory to grasp, but in 
practice it is difficult to understand clearly. For starters, what constitutes a resource?  
Penrose defines a resource in terms of either physical or human capital. Physical capital 
consists of the tangible property of the firm (e.g. land, equipment, etc.), and human capital 
is the knowledge and abilities of a firm are contained within it workers. Werenerfelt (1984, 
p.171) offers a similar definition: „Those attributes of a firm’s physical, human, and 
organisational capital that do enable a firm to conceive of and implement strategies that 
improve its effectiveness’. 
 
Figure 3-2 presents Maier‟s (2004) comprehensive categorisation of resources. He divides 
resources into tangible and intangible assets. He then further breaks each of these 
categories down. Tangible assets are divided into two groups: financial and physical. 
Intangible assets are divided into person independent and person dependent resources. This 
is a comprehensive categorisation that is similar to several others offered in the literature 
(Black & Boal, 1994; R. Hall, 1992; Ray, Barney, & Muhanna, 2004). 
  
47 
 
Figure 3-2: Organisational resources 
 
Source: Maier (2004, p. 221) 
 
In theory, the categories and definitions of resources are straightforward. In practice 
though, they are not as clear cut. For example, when is access to a network considered a 
resource? If a life science firm can simply join a large network, such as the US Bio 
Organisation, is this still a resource? This grey area is a large source of criticism for the 
RBV (Priem and Butler, 2001). Measuring resources has proven even more problematic, 
especially for intangible ones. For example, how can the reputation of a firm be 
convincingly measured?  To overcome these shortcomings, a number of RBV scholars 
have created ways to measure intangibles. Bontis, et al. (1999)  suggest that there a host of 
correlations that can be looked at between intangible assets and objective measures, such 
as return on investment (ROI); these suggestions are further supported by several other 
studies (Barth & Clinch, 1998; Bowman & Ambrosini, 2003; Rodov & Leliaert, 2002). 
However, even these studies acknowledge that there is no perfect way to measure 
resources. It is especially difficult to measure all of a firm‟s resources. In an in-depth 
analysis of studies using the RBV, Newbert (2007, p. 141) found that 76%  of RBV studies 
only examine one resource. Furthermore, he finds that less than 5% of studies looked at 
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more than two resources, perhaps because it is so difficult to isolate resources; most 
modern firms are a web of interconnected resources, and often resources share functions 
(R. Hall, 1993). This is the central argument of Priem and Butler (2001) who contend that 
how resources create value cannot possibly be discerned. For example, how does a life 
science firm discern between the value of the scientific staff and their equipment? Life 
science firms usually have advanced scientific equipment, but it is rendered useless 
without the skilled scientists who use it; so in this instance which is more valuable, the 
equipment or the scientists? As this example illustrates, it is extremely difficult to gauge 
the value of a resource. 
 
Barney (1991) and others contend that the valuable, rare, imperfectly in-imitable and non-
substitutable (VRIN) framework discerns how a resource creates value. Accordingly, a 
resource must meet the VRIN criteria for it to help the competitive position of a firm; i.e. 
the resource is valuable, rare, imperfectly imitable and non-substitutable. A number of 
scholars feel that it is too difficult to discern whether or not a resource meets these criteria, 
and for this reason have rejected, at least parts, of the theory (Priem & Butler, 2001). 
However, many management scholars, at least to an extent, have accepted the VRIN 
framework, which explains why it is such a prevalent theory in management. However, not 
all resources are a source of permanent competitive advantage, as changing environmental 
factors influence the relative value of a resource (Eisenhardt & Martin, 2000; Fiol, 2001); 
i.e. changing environments and organisational factors degrade the value of certain 
resources whilst increasing the value of other resources. However, some scholars contend 
that firms consistently find and better allocate resources; therefore, some types of resources 
are a source of sustained competitive advantage (Barner, 2001; Mikado, 200). 
 
Although the VRIN framework provides a basis for how a resource gives rise to 
competitive advantages, it does not explicitly state how resources are obtained or 
developed (Hoopes, Madsen, & Walker, 2003). Some contend that firms develop resources 
from superior resource picking abilities (Barney, 2001; Lounsbury & Glynn, 2001); whilst 
others contend that firms develop resources from other resources (Makadok, 2001; Teece 
et al., 1997; Winter, 2003). The lack of clarity in how resources are developed and used 
has even led to the contention that the RBV has no management implications (Priem & 
Butler, 2001). Accordingly, the RBV tells managers to obtain VRIN resources, but it offers 
no prescriptions or insights on how to obtain these resources. Furthermore, it gives little 
input on how to use the resources once they are obtained (Miller, 2003). Barney (2005) 
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suggests that these are not problematic because the theory was never intended to be 
prescriptive. However, Starkey and Madan (2001) clearly show that there is a major 
disconnect between scholars and practitioners, and that if  management research does not 
provide relevance to practitioners, then it will become irrelevant. Furthermore, Vila and 
Canales (2008) suggest that managers must have a clear picture of the issues they wish to 
address in the planning process. In its current state, the RBV makes it difficult for 
practitioners to define resource based issues, and for this reason the RBV needs to make 
strides to make a clearer connection to the practice of management.  
 
There is also little work that used the RBV in the examination of small firms (Trott, 
Maddocks and Wheeler, 2009; Sapienza et al., 2006). Trott, Maddock and Wheeler (2009) 
call for more work to apply a RBV to the examination of small to medium size enterprises 
(SMEs). They assert that the RBV makes an ideal lens for SMEs, but work is needed to 
refine the RBV framework for these firms. This connection especially needs to be made 
within the life science industry, and chapter two surfaced some resources vital to the 
growth and development of life science ventures. For example, the chapter underscored the 
importance of R&D, scientific human capital, alliances and specialised financing. 
However, the literature does not clearly specify how these resources give rise to 
competitive advantage. Ambiguity in the understanding of how these resources are 
formulated or obtained also exists, and these are vital issues to the present study, which is 
specifically interested in how life science ventures formulate R&D and financial resources.  
 
3.4 Dynamic capabilities  
The previous discussion indicates that the RBV has become one of the most widely used 
theories in management. It also suggests that it is a useful theory, but there are several 
flaws that limit its application. The most common criticism of it is its static nature (Priem 
& Butler, 2001). This makes applying a RBV lens to a fluid industry, such as the life 
sciences, difficult. Life science resource demands rapidly change, which changes the 
values of a firm‟s resources (Carayannopoulos & Auster, 2010). To get beyond the 
criticisms, researchers started applying a dynamic view of how resources are integrated, 
built, and reconfigured to respond to changing environments to create sources of sustained 
competitive advantage (Teece & Pisano, 1994). This view evolved into what is now called 
dynamic capabilities, which is one of the only frameworks to offer plausible insights on the 
growth of technology based firms, such as life science firms.  
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3.4.1 Evolution of dynamic capabilities                        
Dynamic capabilities stems from the RBV (Helfat & Peteraf, 2003; Mikado, 2001; Teece 
et al., 1997). However, several other fields have also influenced its evolution; including 
organisational learning (Argyris & Schon, 1978; March, 1991), evolutionary economics 
(Schumpeter & Opie, 1934), transactions cost analysis (Coase 1937; Monteverde and 
Teece 1982)  and competencies (Patel & Pavitt, 1997; Prahalad & Hamel, 1994). Dynamic 
capabilities draws heavily on how the firm absorbs and applies knowledge. In doing so it 
makes extensive use of Nelson and Winter‟s (1982) emphasis of routines, and the 
importance of the individual on organisational routines (Cyert & March, 1992). Whilst 
dynamic capabilities evolved from the RBV, it is important to note that the idea of 
resources does not simply go away because of the introduction of dynamic capabilities. 
Resources are central to how dynamic capabilities are formed and what they reconfigure. 
Several scholars (Bowman & Ambrosini, 2003; Eisenhardt & Martin, 2000; Helfat & 
Peteraf, 2003; Makadok, 2001) suggest that the traditional resource picking view is still 
important as well as complementary to dynamic capabilities; i.e. firms can have a 
competitive advantage in picking resources, but they can also use these resources more 
effectively by reconfiguring them in the most optimal manner.  
 
Collis (1994) is one of the first to explicitly identify dynamic capabilities in his 
categorisation of static, dynamic and creative. A static capability is the ability of a firm to 
perform basic functions, including marketing and simple manufacturing; functions that 
almost any firm could easily become proficient at. He refers to dynamic capabilities as 
those that help the firm learn or grow. These are capabilities such as improving operational 
efficiency through trial and error. Creative capabilities he describes as „metaphysical‟ 
(p.146), and are used for higher-level innovation. Whilst the ideas introduced by Collis are 
not markedly different than those in the modern-day theory of dynamic capabilities, he is 
rarely mentioned as a pioneer on the topic. Most notably, he is not cited in the most 
influential papers on dynamic capabilities, Teece, Pisano and Sheen (1997). This piece also 
emphasises the ability of a firm to reconfigure its resources, but it focuses on paths, 
positions and processes. Paths refer to the firm‟s history and future opportunities available 
to the firm. Past paths represent how it evolved, what it has learned and the major events 
that have influenced its decision-making. Future paths represent the strategic alternatives 
available to the firm. Positions refer to the resource stocks of the firm. These resource 
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stocks have a large bearing on dynamic capabilities because resources are what dynamic 
capabilities reconfigure. Processes refer to the internal routines of the firm, especially 
those that have a significant impact on changing the firm.  Another distinction of Teece et 
al.‟s (1997) ideas on dynamic capabilities is the emphasis of rapidly changing 
environments, especially technical environments. The next section further compares 
notable dynamic capabilities‟ definitions offered in the literature.      
 
3.4.2 Definitions and frameworks of dynamic capabilities     
Most research follows Teece et al.‟s (1997, p. 516) definition: ‘the firm’s ability to 
integrate, build, and reconfigure internal and external competences to address rapidly 
changing environments’. In a different vein, Eisenhardt et al. (2000, p. 1106) emphasise 
the importance of resources in their definition of dynamic capabilities: ‘strategic and 
organizational processes like product development , alliancing, and strategic decision 
making that create value for firms within dynamic markets by manipulating resources into 
new value creating strategies’. Solo and Winter (2002, p. 340) offer another definition 
emphasising the importance of the customer and the competition: ‘A dynamic capability is 
a learned and stable pattern of collective activity through which the organization 
systematically generates and modifies its operating routines in pursuit of improved 
effectiveness’.  The problem with these, along with the other definitions scattered 
throughout the literature, is that they are vague. Conceptually, most of the definitions make 
sense, but operationally it is almost impossible to pin down what a dynamic capability is 
from these definitions. Zahra et al. (2006) suggest that three common elements are 
confounded in the literature: 1) substantive capability, 2) environmental characteristics and 
3) higher order capabilities. This problem is largely because of the lack of clear and 
specific definitions (Salvato, 2003). There has been a movement to clarify the definition, 
but this has gone in many uncoordinated directions, highlighted in Table 2-1. From this 
table, it is evident there are several inconsistencies. A central problem is that these 
definitions assume that a capability is only dynamic if it provides a competitive advantage. 
Tautologically this assumption is flawed. For example, the definition offered by Rind ova 
and Taylor (2002, p. 16): ‘A newer source of competitive advantage in conceptualising 
how firms are able to cope with environmental changes’. This definition does not delineate 
where competitive advantages stem from. It also fails to consider that a dynamic capability 
is often only a building block or one part of a competitive advantage.  
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In short, the definitions presented in the literature give a good sense of what dynamic 
capabilities are, but they are still not specific enough. A better direction for defining 
dynamic capabilities is to trace it back to its ontological roots and hierarchically break it 
down. Put differently, the concept is too complicated to define in one sentence, and it 
would be better for the literature to break the definition into interrelated pieces.  
 
Table 3-1: Definitions of dynamic capabilities 
Author                                                                                  Definition
 
Helfat (Kaplan, Murray, & 
Henderson, p. 342) 
The subset of the competences/capabilities that allow the firm to create new 
products and processes and respond to changing market circumstances. 
 
Teece et al. (1997, p. 516) The firm‟s ability to integrate, build and reconfigure internal and external 
competences to address rapidly changing environments. 
Eisenhardt and Martin (2000, p. 
1107) 
The firm‟s processes that use resources – specifically the processes to integrate, 
reconfigure, gain and release resources – to match or even create market change. 
Dynamic capabilities thus are the organizational and strategic routines by which 
firms achieve new resources configurations as market emerge, collide, split, 
evolve and die. 
Griffith and Harvey (2001, p. 598) A global dynamic capability is the creation of difficult-to-imitate combinations 
of resources, including effective coordination of inter-organizational 
relationships, on a global basis that can provide a firm a competitive advantage. 
Lee et al. (2002, p. 729)  A newer source of competitive advantage in conceptualizing how firms are able 
to cope with environmental changes. 
Rind ova and Taylor (2002, p. 16) Dynamic capabilities evolve at two levels: a micro-evolution through „upgrading 
the management capabilities of the firm‟ and a macro-evolution associated with 
„reconfiguring market competencies‟. 
Zahra and George (2002, p. 186)  Dynamic capabilities are essentially change-oriented and help firms redeploy 
and reconfigure their resource base to meet evolving customer demands and 
competitor strategies. 
Solo and Winter (2002, p. 340) A dynamic capability is a learned and stable pattern of collective activity 
through which the organization systematically generates and modifies its 
operating routines in pursuit of improved effectiveness. 
Winter (2003, p. 991) Those that operate to extend, modify or create ordinary (substantive) 
capabilities. 
Zahra et al. (2006, p. 920)  The abilities to reconfigure a firm‟s resources and routines in the manner 
envisioned and deemed appropriate by the firm‟s principal decision-maker(s). 
Helfat (2007, p.1)   
Helfat and Peteraf (2009,  p. 91) 
The capacity of an organization to purposefully create, extend, and modify its 
resource base. 
Source: Author based on Zahra et al. 2006.  
 
Dynamic capabilities frameworks  
The unbounded definitions of dynamic capabilities are complemented by the lack of a 
coherent framework. Many different authors (most notably, Eisenhardt & Martin, 2000; 
Makadok, 2001; Zahra et al., 2006) have proposed theoretical frameworks. However, as of 
yet not one of these has become commonly accepted. These models share several 
commonalities. Almost all of the models view dynamic capabilities as a standalone theory 
that stems from the RBV. One notable exception to this is Mikado (2001), whose model 
does not substitute dynamic capabilities for resources. Instead his model views them as 
complementary; i.e. managers help firms grow by both strategically picking resources and 
using dynamic capabilities to optimise their resources. 
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Winter (2000) develops a hierarchical conceptualisation of dynamic capabilities based on 
Collis‟ categorisation. Winter‟s conceptualisation includes an ordered level categorisation 
of zero-level, first-order and second-order dynamic capability. A zero-level capability is 
the most basic and is the operational capabilities needed to run a firm in the short term. A 
first-order capability is dynamic, the ability of a firm to reconfigure resources and respond 
to market conditions. An example is the ability of a pharmaceutical firm to recognise an 
opportunity for a new drug development opportunity. A second-order is the capability of 
learning. This capability facilitates identifying, creating and modifying dynamic 
capabilities that are most useful in the firm's operations. According to this hierarchical 
model, all three are linked together and build off of one another to create the total 
capabilities of a firm. Another premise of the model is that higher-level capabilities are not 
always beneficial to a firm, and in some cases, the cost of developing them is a poor use of 
resources. Whilst this is an interesting model, there are still many holes in it. Most notably, 
this model does not clearly define each level. Furthermore, it could also be argued that 
learning is a key element to the broader concept of dynamic capabilities. For these reasons 
few studies have used this model. Nevertheless, this hierarchical conceptualisation of 
capabilities has the potential to unearth insights on the values of their different types of 
dynamics. It would be beneficial for future research to synthesise and further the ideas 
presented by Collis (1994) and Winter (2003) into a more specific model(s). 
 
The dynamic capabilities literature tends to emphasise three elements: (1) learning, (2) 
routines and (3) the environment. Each of these is detailed below. 
 
Learning        
The importance of learning is scattered throughout the dynamic capabilities literature. In 
their conceptualisation of dynamic capabilities, Eisenhardt et al. (2000) suggests that 
learning mechanisms underlie the development of dynamic capabilities. They suggest that 
firms with more experience in responding to change are more apt to develop dynamic 
capabilities. However, anecdotal and empirical evidence (Boccardelli & Magnusson, 2006; 
Macpherson, Jones, Zhang, & Street, 2004; Newbert, 2005) suggests the opposite. Take for 
example the rise of Google, Microsoft and Dell. These firms were all inexperienced and 
were in competition with well-established firms, yet all of them significantly outgrew their 
competitors because they learned quicker and responded better to changing business 
environments, even though they had little previous learning experience. Furthermore, 
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Autio et al. (2000) found that new ventures have an advantage in the internationalisation 
process because of their learning advantage of newness; i.e. new firms do not have the bad 
habits of established firms and respond to market conditions more swiftly. Solo and Winter 
(2002, p. 348)  propose a better view on the development of dynamic capabilities through 
three learning-related mechanisms: 1) past experience, 2) knowledge articulation and 3) 
knowledge codification processes; accordingly, these three mechanisms underpin learning 
capabilities.  
 
Winter (2000) goes against the grain of these studies to explore when learning adversely 
effects a firm‟s dynamic capabilities. In this paper she suggests that firms can focus too 
much on learning and not make the most effective use of their resources. This piece is 
unique because it challenges the rhetoric so often seen in the literatures of dynamic 
capabilities, absorptive capacity and organizational learning that say learning always has a 
positive effect. Though learning is one of the most popular themes in dynamic capabilities, 
relatively little empirical support backs it up. Most of the learning studies cited in dynamic 
capabilities are studies from other fields that are synthesised into the analysis of dynamic 
capabilities. One notable empirical study is the Engelhard et al. (2002) analysis of the 
dynamic learning of a major pharmaceutical company. Their analysis indicates that it is 
critical for biopharmaceutical firms early on to enable learning capabilities and to create 
actionable knowledge based on what they have learned. Engelhard et al. (2002) also 
support the idea that knowledge is only important if it is actionable. In a similar study 
Swift and Hwang (2008) suggest that organisational learning requires organisation-wide 
commitment, including top managers, mid-level managers and line workers in order to 
articulate, codify, and disseminate knowledge derived. This piece is also significant in that 
it takes a holistic look at the learning approach, instead of just looking at the importance of 
top management in the learning process. In a similar vein Davies and Brady (2000) found 
in their study of telecommunication manufacturing firms that it is vital to develop 
organisational-wide learning capabilities from previous experiences.   
 
Routines   
The second reoccurring theme in the dynamic capabilities literature is routines. Teece et al. 
(1997) referred to these as processes in their conceptualisation of dynamic capabilities and 
defined this as the way things are done within the firm. This emphasis on routines is a 
central source of criticism. The critics note that this is tautological, vague and 
immeasurable (Blomqvist, Kyläheiko, & Virolainen, 2002; Priem & Butler, 2001). 
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Eisenhardt and Martin (2000) argue that these are criticisms of the RBV and that dynamic 
capabilities is differentiated because such routines are identifiable and empirically 
measurable. They point to product development and strategic decision making as examples 
of identifiable and measurable routines. However, strategic decision making is an abstract 
topic to measure, and there is little empirical support of how routines influence dynamic 
capabilities; so Eisenhardt and Martin‟s (2000) arguments do not completely dispel the 
critic‟s points of contention. 
 
 Zahra et al. (2006a) propose that organisational routines are an antecedent to 
organisational learning and change. This notion is supported by Inanity and Clark‟s (1994) 
study on the integration of dynamic capabilities in automobile and computer industries. 
Although an interesting and insightful study, its findings are far from conclusive because 
of the weak measures they drew from secondary data. Another study by Abuja and 
Lambert (2001) concludes that the routine of continual experimentation is critical to 
reconfiguring capabilities to respond to environmental conditions in the global chemical 
industry. According to this study, experimental routines are the basis of how new 
knowledge on which these firms compete is created. Whilst the aforementioned studies 
offer insights on the importance of routines, they do not empirically support the emphasis 
placed on routines as suggested in marquee works on dynamic capabilities (Eisenhardt & 
Martin, 2000; Teece et al., 1997; Winter, 2003; Zollo & Winter, 2002). This is not to 
suggest that routines are not important; rather more empirical work needs to isolate the 
importance of routines in dynamic capabilities.  
 
Research is especially needed in the context of life science ventures. This research needs to 
examine what routines underpin the development of life science ventures‟ key assets and 
capabilities. The previous chapter in this thesis underscored the importance of R&D and 
specialised financing to the development of life science firms. The importance of these 
resources is well-documented, but there are gaps in understanding the routines that firms 
practice to develop R&D and financial resources and capabilities. This is one area that the 
present research specifically addresses. 
 
Environment                                                                                                                                      
A third emphasis of dynamic capabilities models is the importance of the environment. 
Dynamic capabilities is an especially useful lens to examine firms in rapidly changing 
business environments (Blyler & Coff, 2003; Davies & Brady, 2000; Eisenhardt & Martin, 
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2000; D. Teece & Pisano, 1994; Teece et al., 1997). The importance of responding to a 
rapidly changing environment is a plausible explanation as to how young resource 
constrained firms can enter markets and outperform large and rich competitors (March, 
1991). A prime example of this is the rise of Microsoft: A young firm started by two 
college dropouts who out-performed multibillion dollar firms, Microsoft credits much of 
their success, especially their early success, to their ability to out manoeuvre and respond 
to the tremendous technical changes taking place in the software industry (Stross, 1997). 
Researchers emphasise the importance of dynamic capabilities in technology-based 
industries such as software, biotechnology and semiconductors because the changing 
technology in these industries requires firms to quickly change their operations and 
product offerings in order to stay competitive. Conventional wisdom and anecdotal 
evidence support the effect rapidly changing environments have on firms; however; there 
is little empirical work to fully substantiate it. Most of the studies on the influence of 
environments cited in dynamic capabilities are from studies not specific to dynamic 
capabilities.  
 
The previous chapter highlighted the rapidly changing environments that life science 
ventures face, but research has not thoroughly investigated how these environments 
influence these firms. One aim of the present study is to investigate how these 
environments impact life science ventures.   
 
Figure 3-3 conceptualises the effect that the environment has on the firm. The figure starts 
with an original resource combination that is then shocked by an outside event. Outside 
events are either new market opportunities or external shocks. Examples of external shocks 
are changing economic conditions, technological shifts or political events. The dashed line 
from external shocks to new opportunities in the figure represent the new paths that arise 
as the result of external shocks (Deeds et al., 2000; Zahra & George, 2002); thus external 
shocks either directly or indirectly impact the firm. A shock or combination of shocks 
causes a firm to respond and reconfigure its assets and capabilities. This is represented by 
the original resource recombination being reconfigured to the post-shock resource 
combination. Figure 3-3 below offers a simple example, but in actuality there can be 
hundreds, if not more, reconfigurations that a firm can go through. In this example only 
two of the three sets of resources are reconfigured post shock: AB and CD reconfigured to 
DA and BC, whilst EF stayed the same. This illustration shows that in many cases firms 
will reconfigure many operations, but some units or divisions will stay the same even after 
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a shock. The reconfigured resources then either lead to superior performance, average 
returns or poor performance. This is an important part of the conceptualisation because it 
illustrates Winter‟s (2000) notion that reconfiguration does not always lead to superior 
performance; if resources are not optimally reconfigured to respond to the external events, 
it can also lead to average or poor performance.  
 
Figure 3-3: Conceptualisation of dynamic capabilities 
 
Source: Author 
 
3.4.3 Empirical studies on dynamic capabilities 
Although the quantity and depth of empirical work is lacking, there are several notable 
empirical studies that help to substantiate the theory. Table 3-2 highlights these studies and 
shows that a broad consensus is emerging. One industry that has recently gained popularity 
for use in the empirical testing of dynamic capabilities is the life science industry (Anand, 
Oriani, & Vassolo, 2010; Ingelgard et al., 2002; Rothaermel & Hess, 2007). A  recent 
study by Rothaermel and Hess (2007) looked into the antecedents of dynamic capabilities. 
Unlike previous studies on the topic, their research factored in the interaction of the three 
antecedents (individual, firm and network) of dynamic capabilities; instead of isolating 
them individually as previous studies have done (Christensen, 1997; Henderson & 
Cockburn, 1994; Zucker & Darby, 1997). Rothaermel and Hess (2007) suggest that there is 
important interaction between the individual, firm and networks levels in creating dynamic 
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capabilities. In some cases they work as complements, but in others they can work as 
substitutes. Their study indicates that firms can substitute superior human capital for firm-
level factors such as R&D capacity. Thus this study established that managers must weigh 
individual, firm and network resources when developing an overall firm strategy 
constitutes the most important contribution of this study. Although a noteworthy study, it is 
based on weak secondary data and ill-defined constructs and measurements. Therefore it 
needs further refinement and testing.  
 
Another dynamic capabilities study that uses life science firms as the sample is Zucker and 
Darby‟s (1997) study on the influence of star scientists on the transformation of an 
organisation. Their findings suggest that star scientists greatly influence the growth and 
direction of a firm through their innovative abilities. The scientists‟ innovations set the 
direction of the organisation and force it to reorganise to commercialise the star scientists‟ 
discoveries. Zucker and Darby (1998) followed this study up with an investigation clearly 
showing that knowledge spills over from universities to biotech firms located near 
universities. This tacit knowledge is a large source of dynamic capabilities for the recipient 
firms of the knowledge. Deeds et al. (2000) is another empirical study on dynamic 
capabilities that uses life science firms as the sample; it also highlights the importance of 
human capital and supports the notion that knowledge spilled over from universities 
provides important antecedents to dynamic capabilities. Another important finding from 
this paper is that it is better to keep top scientists in R&D than to have them as top 
executives. The management duties take away from their tacit scientific knowledge, which 
serves as a driving force to creating innovations that change a firm. This study suggests 
that it is important to have a top management team with business experience and scientific 
knowledge. 
 
In a different vein, Madhok and Osegowitsch (2000) use dynamic capabilities at the 
macro-level to look at the diffusion of biotechnology around the world. They studied 
alliance and innovation flows of the US and Europe; their findings show that initially the 
technology flows were one way from the US to Europe, but over time the innovative 
capabilities built up in Europe and the flow of innovation became two way. Although an 
interesting study that gives a good overview of the evolution of the cross continental flow 
of biotech knowledge, it would have been even more interesting had they included some 
firm-level examples.  
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These studies clearly demonstrate that dynamic capabilities is starting to gain the empirical 
support that it needs to become a strong theory. Also apparent from the discussion above is 
that the life science industry offers an ideal setting in which to apply a dynamic capabilities 
framework. The industry fits the key prerequisites as it is rapidly changing and has 
constructs that lend themselves to empirical testing. For instance, the industry is heavily 
dependent on patents, which are a good proxy to measuring innovation (Acs & Audretsch, 
1989). There are also critical technological inflections in the industry, which lead to 
interesting research opportunities on how firms reorganise themselves to respond to these 
opportunities. However, empirical work as a whole on dynamic capabilities needs further 
development. Table 3-2 presents the key empirical studies done on dynamic capabilities 
from 1992-2010. From this table it is evident that Arend and Bromiley (2009) were 
justified in their assertion that dynamic capabilities does not have enough empirical 
support. Specifically there is little longitudinal work, and many of the studies examine 
dynamic capabilities post hoc. There are also few studies that have used mass surveys, and 
scant work on small firms exists.  
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Table 3-2: Empirical studies on dynamic capabilities 
Study  Measurement Research focus Findings 
*1. Van de Ven and 
Polley (1992) 
 
Single biomedical 
innovation over a five 
year period; in-depth case 
study with multiple 
sources and on-going 
observation 
Examined the process of  trial and 
error learning in technological 
innovations by a joint venture created 
to commercialize products. 
– Observed greater escalation of commitment and 
other types of non-rational behaviour than implied 
in the learning literature 
– Suggested the following to increase adaptation 
ability:       
        • separate planning from resource funding                             
• limit „impression management‟ opportunities                    
• foster frank communication across     
departments and    levels. 
2. Eisenhardt and 
Tabrizi (1995) 
36 Computer-related 
firms, (72 projects); case 
studies – multi-
respondents per project 
Examined effects of planning, CAD 
tools, teams, supplier involvement, 
reward, and time schedules on 
product development time. 
– Found planning and CAD tools increase the time 
to develop new products 
– Cross-functional teams, frequent iterations, 
leader power, and 
trial-and-error learning decrease development time. 
3. McGrath 
(McGrath, 1995) 
 
23 Financial services 
firms; over 200 interviews 
Exploratory research to see how firms 
process and learn from poor outcomes 
in internal corporate venturing. 
– Noted three processes needed to learn from 
disappointments:                                                                   
• recognition of failure (measurement, involvement, 
communication of results)                                                     
• interpretation of  results into a business model 
that can be tested                                                                                                                   
• action taken  to change routines. 
4. Helfat (1997) The 26 largest energy 
firms over extended 
period of time; historical 
and secondary data 
Examined if success of responses to 
changes in external conditions 
depends on existing stocks of 
complementary know-how and assets. 
– Firms with larger stocks of complementary 
technological knowledge and physical assets 
experienced greater increase in capabilities. 
– Yet, such increased capabilities could not 
compensate for the large drop in real oil prices. 
5. Brown and 
Eisenhardt (1997) 
 
6 firms in computer 
industry (41 projects); 
case studies 
Examined the ability of firms to 
change their competences 
continuously in response to high 
velocity environments. 
– Reject notion of punctuated equilibrium and 
event-based approaches in favour of time-paced 
responses. Learning and dynamic capability 
creation based on:  
• well-defined managerial responsibilities and 
project priorities                                                                                
• extensive communication                                                           
• frequent low-cost experiments and iterations. 
6. Moorman and 
Miner (1998)  
 
One electronics 
instruments firm; one 
food products firm (107 
action events over nine 
months); survey data on 
selected events 
Examined the effects environmental 
turbulence, improvisation, and 
organization memory on product and 
process efficiency/effectiveness. 
– Turbulence has a weak positive effect on use of 
improvisation. 
– When turbulence is low, improvisation  has 
negative effect on 
effectiveness; when turbulence is high, the effect is 
positive. 
– Organization memory has a negative effect on 
improvisation. 
– However, organization  memory significantly 
improves positive effects of improvisation on all 
process and product outcomes. 
7. Kazanjian and 
Rao (1999) 
 
225 Computer-related 
companies; survey data in 
two waves 
 
Hypothesis tests on 
survey data 
Examined factors influencing 
engineering capability 
institutionalization in firms highly 
dependent on this expertise. 
– Found managerial advocacy key positive factor. 
– Found mixed results with regard to CEO 
background. 
– Found institutionalization  more likely with 
smaller TMTs. 
– Found no effects of formalization or 
centralization.. 
8. Bosch et al.  
(1999) 
Publishing firms; 
illustration of two cases 
Focused on  how organization form 
and combinative capabilities mediate 
effects of prior related knowledge on 
absorptive capacity. 
– Definitive conclusions hard to draw, but 
arguments regarding organization forms are                                                      
• Functional form is + for efficiency, - for 
flexibility, - for speed.                                                                                                   
• Divisional form is - for efficiency, + for 
flexibility, + for speed.                                                                                            
• Matrix form  is - for efficiency + for flexibility, + 
for speed 
9. Majumdar (2000) 
 
39 telecommunication 
firms over 16 yrs; 
secondary data 
Examined effects of structural 
changes in the environment on 
resource accumulation, configuration, 
and utilization capabilities of firms. 
-Concludes that contrary to popular beliefs, larger 
more stable firms can indeed transform their 
capabilities in the face of overwhelming structural 
changes to the industry. 
10. Autio et al. 
(2000) 
59 electronics firms; 
panel survey data over 
four-year period, some 
validation from repeat 
surveys and secondary 
sources 
 
Hypothesis testing based 
on survey responses 
Examined the effects of early inter-
nationalization on the prospects of 
smaller firms‟ growth. Argued that 
such firms may possess learning 
advantages over older firms. 
– Found that internationalization at an early age 
was associated with greater growth both 
domestically and internationally. 
– Found product imitability to be positively rather 
than negatively associated with growth. 
– Found knowledge intensity positively related to 
growth. 
*11. Madhok and 
Osegowitsch (2000)  
Data on  international 
alliances, joint ventures, 
licensing, acquisitions and 
new Greenfield 
subsidiaries of European 
and US biotechnology 
firms  
Examined the cross national flow of 
biotechnology innovations between 
the US and Europe. 
-Found that initially biotechnology innovation was 
a one way flow from the US to Europe.  
-Found that as Europe developed capabilities, 
innovation became a two-way flow 
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Study  Measurement Research focus Findings 
 
Hypothesis testing based 
on secondary data 
*12. Deeds et al. 
(2000) 
94 publicly held 
biotechnology firms 
 
Hypothesis testing based 
on secondary data 
Examined the effects of technological 
and management skills on new 
product development. 
-Found that location  near research based 
universities is key to developing scientific dynamic 
capabilities. 
-Found that top scientists are  more effective in a 
research role than  in a top management role. 
13. Zahra et al. 
(2000) 
 
321 high technolog y 
firms (from 12 different 
sectors); survey data with 
validation from second 
respondents and 
secondary data 
 
Hypothesis testing based 
on survey responses  
Examined the effects of international 
diversity and mode of market entry on 
technological learning and 
performance of high technology 
firms. 
– Found that international diversity had positive 
effects on the breadth, depth and speed of 
technological learning in new internationalizing 
high technology ventures. 
– Found that knowledge integration significantly 
enhanced the positive effects of diversity on the 
breadth, depth and speed of technological learning. 
- Found that modes of entry also significantly 
affected breadth, depth and speed of learning. 
– Found a positive relationship between 
international diversity and performance. 
14. Abuja and 
Lambert (2001) 
97 global chemical; 
secondary data, especially 
patent citations 
 
 
Examined how large corporations 
create breakthrough inventions and 
how exploration of  novel, emerging, 
and pioneering technology helps them 
overcome competency traps. 
– Found inverted-U shaped relationship of 
exploration of novel and emerging technologies 
with creation of breakthrough invention. 
– Found positive relationship of exploration of 
pioneering technologies with creation of 
breakthrough invention. 
– Concluded that continual activity and 
experimentation are needed for firms to renew and 
reconfigure capabilities. 
*15. Engelhard et al. 
(2002) 
Action research: 
interviews with 26 
different individuals 
involved with R&D at 
three different pharmacy 
firms. 
Examined organizational learning 
techniques in the creation of 
actionable knowledge. 
-Suggests that the learning capability of a firm  has 
to be dynamic in order to create complex 
knowledge. 
-Suggests knowledge assessment is an important 
capability. 
16. Katila and 
Abuja (2002) 
124 Robotics firms; 
secondary data, especially 
patent citations 
 
Hypothesis testing based 
on secondary data 
Examined the effects of search 
depth and search breadth on a firm‟s 
ability to create change in product 
introduction. 
– Found a positive relationship between search 
breadth and depth on  new product introduction; 
but beyond a certain level, additional depth begins 
to reduce new product  introduction. 
– Concluded that exploitation  is a broader concept 
and more beneficial than previously believed. 
*17. Rothaermel 
Hess (2007)  
A cross national sample 
of 35 pharmaceutical 
firms‟ alliances and 
innovation output; data 
collected from secondary 
sources of information 
covering 24 years    
 
Hypothesis testing based 
on secondary data 
Examined the antecedents of dynamic 
capabilities looking at the interaction 
of individual, firm  and  network 
antecedents. 
-Found that the 3 levels of antecedents are not 
always complementary. 
-Often human capital (individual level) can 
substitute for the other two levels (firm and 
network) 
18. Harreld and 
O‟Reilly (2007) 
A case study on IBM. 
Data collected from 
secondary data. 
Examined the success of IBM from a 
dynamic capabilities perspective. 
-Found IBM has been able to thrive largely based 
on the ability to reorganize itself in the face of 
rapidly changing technology and competition 
environments . 
19. Kale and Singh 
(2007)  
175 computer, 
telecommunications, 
pharmaceutical, chemical 
and electronics firms that 
have been involved in 
alliances  
 
Hypothesis testing based 
on survey responses 
Examined the process of  learning in 
alliances. 
-Found that learning that involves articulation, 
codification, sharing, and internalization of alliance 
management know-how leads to superior 
performance.  
20. Macher and 
Mowery (2009)  
93 manufacturing 
processes in 36 different 
manufacturing facilities 
from  32 different 
semiconductor firms from 
1995 to 2001.The sample 
consisted of firms from 
the US, the EU, Japan, 
Korea and Taiwan 
 
Hypothesis testing based 
on secondary data 
Examined the role of R&D and 
learning on capabilities . 
 
-Found support for the arguments of Teece et al. 
(1997), Eisenhardt and Martin (2000), Solo and 
Winter (2002) and Winter (2003) that managing 
and reconfiguring capabilities is crucial in high-
technology industries. 
-Found that deliberate learning is important to 
creating capabilities. 
-Found „learning before doing‟ is the most 
effective approach. 
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Study  Measurement Research focus Findings 
*21. Chiaroni et al. 
(2009)  
Two step  (1) an interview 
panel of 20 industry 
experts (2) An analysis of 
the open innovation 
modes used by 20 large 
pharmaceutical 
companies  
Examined the organizational modes 
of open innovation and how these 
effect drug development.  
-Found that  the characteristics of the biotech 
industry are mitigating variables in the 
implementation of open innovation. 
22. Newey and 
Zahra (Newey & 
Zahra, 2009) 
40 interviews with multi 
informants from two firm 
case analysis and 
comparison 
Examined how dynamic capabilities 
react to changes within the individual 
firm. 
-Found  that firms build absorptive capacity in 
value networks whilst they are developing new 
products.  
-Found that learning captured at the product 
planning level is the most beneficial. 
23. McKelvie and 
Davidsson (2009)  
Sample of 108 Swedish 
new (<10years) SMEs 
from various industries 
 
Hypothesis testing based 
on survey responses 
Examined the effect the founder 
human capital, access to employee 
human capital, access to technological 
expertise, access to other specific 
expertise and access to two types of 
tangible resources had on the 
development of dynamic capabilities. 
-Found that resources and changes to resources are 
important to forming dynamic capabilities. 
-Found changes in resources have more influence 
on the development of dynamic capabilities then 
the stock of resources does. 
-Suggested that the firm is a dynamic stock of 
resources rather than a static stock. 
*24. Narayanan et 
al. (2009) 
Multiple interviews with 
several layers of 
management at one 
pharmaceutical firm 
Examined the cognitive orientations 
of key personnel, managerial action 
within the firm and the firm‟s internal 
and external contexts and how these 
effected the development of 
capabilities. 
-Suggests that key personnel have a significant 
impact on the development of capabilities; not 
because their actions were inimitable but because 
of their persistence in developing the capabilities 
led the dynamic capabilities.  
-Found that external contingencies have a major 
impact on the development of dynamic 
capabilities.  
25. Romme, Zollo 
and Berends (2010)  
Experiment simulation of 
how executives develop 
knowledge routines in the 
face of different 
environmental variables 
 
Hypothesis testing based 
on experiment results  
Examined how firms respond to 
various factors to develop knowledge.  
-Suggests that the impact of deliberate learning 
on dynamic capability is non-linear, complex, 
and in some instances counter-intuitive.  
Source: Adaptation and expansion of Zahra et al. (2006)              *Life science studies 
 
 
The table above shows that some studies are starting to surface that use hypothesis testing, 
and certain areas are justified to do so. In certain areas the theory has grown to a point 
where it can be tested. However, there are many areas related to dynamic capabilities, such 
as the development of capabilities in small firms that cannot be properly tested because of 
the lack of defined measures and constructs. The largest problem restraining empirical 
testing in dynamic capabilities is the lack of a consistent framework. Teece et al.‟s (1997) 
paths, positions and processes framework offers a way to address this. Essentially, this 
framework contends that competitive advantage lies in a firm's processes, which are 
determined from a firm's paths and positions. Previous paths are the past decisions and 
future opportunities that shape where a firm can go. Past decisions commit resources and 
often create rigidities because the firm is deeply tied to its earlier commitments. For 
example, Deeds and DeCarolis‟ (2000) study on new life science firms shows that a firm‟s 
future development opportunities is limited by investments made in earlier research. They 
suggest that often firms invest so heavily in a technology that they drain resources that 
could be used for future projects. Future paths represent opportunities available to the firm 
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and how the firm strategizes and organises its resources to pursue these opportunities. 
Positions are the resources the firm uses to leverage in their pursuit of future paths. For 
example, life science firms often leverage their patents in the pursuit of developing a 
technology (Deeds et al., 2000; Madhok & Osegowitsch, 2000; Ziedonis, 2004). 
 
Although Teece et al.‟s (1997) paper lays out a viable framework for examining dynamic 
capabilities; i.e. probe the paths, positions and processes that lead to competitive advantage 
– little work examines all of these in a single study. As discussed above in the section on 
key empirical studies relating to dynamic capabilities, studies have examined competitive 
advantage and firm growth using parts of the framework, but surprisingly little work 
holistically examines the paths, positions and processes in a single study. Furthermore, it is 
hard to take a study that examines the paths leading to competitive advantage and then 
compare it to a study that examines the positions that lead to competitive advantage. 
Dynamic capabilities is fundamentally process-based, and processes are hard to dissect and 
compare in multiple studies (Pettigrew, 1992). Therefore, a sharp need for research to 
examine the paths, positions and processes leading to growth in a single study exists. In-
depth qualitative work is especially needed to unearth insights on: 
 
 What past decisions create path rigidities?  
 What future opportunities motivate reconfiguring resources and capabilities?  
 What positions do firms leverage to create key resources and capabilities? 
 What are the processes the firms use to create key resources and capabilities?  
 
Qualitative work has the potential to show how a firm develops dynamic capabilities and 
what the outputs of dynamic capabilities are. In turn, this will give quantitative scholars 
more measureable and valid constructs to work with. 
 
3.4.4 Dynamic capabilities’ shortcomings and conclusions   
Intermixed in the discussion above are several shortcomings of dynamic capabilities: lack 
of a coherent definition, weak empirical support and difficult to measure constructs. Arend 
and Bromiley (2009) note these shortcomings along with several others; they even go as 
far as to use these shortcomings as a basis to abandon dynamic capabilities. One of their 
main assertions is that the theory does nothing more than restate previous work of 
absorptive capacity, strategic fit, first-mover advantage, organisational learning and change 
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management. Accordingly, dynamic capabilities must add value beyond these theories and 
have a basis for prediction to be considered a credible theory. Their second criticism of 
dynamic capabilities is the inconsistent definitions in the literature. This is a view that is 
shared by many scholars, including those who publish on dynamic capabilities (Collis, 
1994; Williamson, 1999; Winter, 2003). Arend and Bromiley‟s (2009) third grievance is 
that dynamic capabilities lacks rigorous empirical support. They clearly show that the little 
empirical support for dynamic capabilities mainly comes from weak quantitative studies 
that do not include a longitudinal component. They also illuminate the fact that most of the 
empirical support comes from post hoc studies; i.e. research that finds successful firms that 
have dynamic capabilities. A fourth grievance of Arend and Bromiley is the lack of 
coherent and logical proxies for measuring dynamic capabilities; there are too many 
measures of dynamic capabilities, which indicate that there are incoherent constructs. The 
fifth grievance of Arend and Bromiley (2009) is the lack of practical implications for 
dynamic capabilities.  
 
Whilst Arend and Bromiley‟s (2009) criticisms have some merit, they do not take into 
account the entire body of work on dynamic capabilities and fail to consider that the theory 
is a young theory. Helfat and Peteraf (2009) offer a well thought out rebuttal to Arend and 
Bromiley (2009) that clearly acknowledges and addresses their concerns. They show that 
dynamic capabilities is a young theory that is just emerging from its conceptual stage; 
therefore, it will have some foundational issues to iron out. Helfat and Peteraf (2009) also 
refute the suggestion that there is weak empirical support. They point to several strong 
empirical studies (Helfat, 1997; Ingelgard et al., 2002; Zahara, Ireland, & Hitt, 2000), and 
also reiterate that because of its youth, dynamic capabilities should not be expected to have 
an established body of empirical work.  
 
In short, dynamic capabilities has the underpinnings of a strong theory. First, it can show 
causality. For example, several of the studies discussed above show how dynamic 
capabilities can cause a firm to have more creative capacities (Eisenhardt & Tabrizi, 1995; 
Harreld et al., 2007; Majumdar, 2000). Second, it is measurable. For example, it can be 
measured through new product development (Drnevich & Kriauciunas, 2011), patents 
(Katila & Ahuja, 2002) and learning outcomes (Zollo & Winter, 2002). Third, dynamic 
capabilities has shown predictive powers. For example, studies have predicted that firms 
with learning capabilities can better contend with rapidly changing environments (Romme 
et al., 2010; Zollo & Winter, 2002). Furthermore, the importance of learning capabilities in 
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certain settings has been disconfirmed (Kale & Singh, 2007), which shows that dynamic 
capabilities has the theoretical quality of being able to be falsified. Although dynamic 
capabilities has shown the underpinnings of a theory, it is still far from robust.  It is still in 
its nascent stage and lacks defined measures and constructs for small firms, especially for 
small life science ventures.    
 
Conclusions                                                                       
There is no perfect theory in management – whether the RBV, the five forces model, or 
transactions cost analysis. Dynamic capabilities is no exception. It has ill-defined 
constructs and measures and little empirical support to back it up. Although many of the 
criticisms are valid, there is potential for future research to address these. Moreover, it is 
one of the few theories that can properly account for rapidly changing environments. It 
also has a sound theoretical basis because it draws heavily on the RBV (Eisenhardt & 
Martin, 2000; Teece et al., 1997; Winter, 2003). Furthermore, Teece et. al. (1997) paths, 
positions and processes framework offers a way to tie the theory together. At the highest 
level firms are able to use their paths, positions and processes to create CAs (Teece, 1997; 
Trispas, 1997, Rothaermel, 2001). These are auxiliary assets needed in the 
commercialisation of a technology. CAs are often a large source of competitive advantage 
as they create unique competitive positions (Teece, 1986; Tripsas, 1997). The next section 
of this review delineates the literature on CAs. 
 
3.5 Complementary Assets 
This section is dedicated to further discussing one of the highest levels‟ outputs of dynamic 
capabilities – CAs. These are high level auxiliary assets and capabilities needed in the 
commercialisation of innovations (Teece, 2007). CAs are especially relevant to life science 
firms as these are needed to commercialise innovations in the field (Rothaermel, 2001a). 
This topic is also relevant to the present study because R&D has been viewed through a 
CAs lens (Gans et al., 2002; Teece, 1986). This section provides a description of CAs, 
overviews the empirical work on CAs and discusses the shortcoming of the CAs 
framework. 
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3.5.1 Description of CAs 
Teece (1986) formally introduced CAs as the auxiliary assets and capabilities needed to 
commercialise an innovation. Edvinsson and Sullivan (1996, p. 360) offer a slightly 
different definition specific to knowledge-based firms: „the string of assets through which 
the technology must be processed in order to reach the customer’.  Teece (1986) further 
proposes three broad categories of CAs: 1) general CAs (GCAs) 2) specialised (SCAs) and 
3) co-specialised complementary assets (CCAs). GCAs are generic assets needed in 
commercialisation that are easily purchased on the open market, for example, general 
shipping. If a firm can ship its goods through a company like UPS or Federal Express, then 
this is a GCA; the shipping is needed for commercialisation, but it is easily obtained on the 
free market. SCAs are similar to GCAs, but they cannot be obtained on the free market. 
They are assets with a unilateral dependence that are needed for commercialisation. An 
example of an SCA is service capabilities of a medical device firm. In many cases medical 
devices require specialised service capabilities to maintain the product, and if a firm is 
unable to service the device, then the device cannot be commercialised. In many cases 
medical device firms partner with specialised service firms to provide the specialised 
service for their medical device(s), which could be a unilateral dependence because the 
medical device has to have the specialised service capabilities to be commercially viable, 
but the service provider does not need the medical device firm to stay in business; they 
have other clients that could sustain their business. CCAs are assets that are mutually 
dependent on each other. An example of this is Microsoft and IBM in the early 1980‟s. In 
the beginning of Microsoft they needed IBM for the hardware platform to run their 
software, and IBM needed the Microsoft software platform for programs to make their 
hardware usable and desirable. 
  
Figure 3-4 presents Teece‟s (1986) illustration of the CAs needed to commercialise an 
innovation. He identifies four areas that are usually involved with the commercialisation of 
an innovation: 1) competitive manufacturing, 2) distribution, 3) service and 4) 
complementary technologies. The illustration also includes „other‟ boxes to represent CAs 
not encompassed in the four other areas, an example being compliance capabilities for a 
pharmaceutical company. In many cases biopharmaceutical companies have to have 
specialised capabilities in meeting government regulation before their products can be sold 
(Hopkins & Nightingale, 2006). This illustration gives a good conceptualisation of the CAs 
needed in commercialisation.  
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The present research is specifically interested in R&D and financial resources, and as 
discussed earlier, R&D has been viewed through a CAs lens. It would be interesting for 
empirical work to explicitly see where R&D fits in within a CAs framework, as there is 
little research that has looked at this. Furthermore, finance has not been viewed through a 
CAs lens, but it would be interesting to see if it could be. Capital should not be viewed 
through such a lens, but the capabilities in raising capital could be.  Conceptually they 
meet the definition of CA, auxiliary assets or capabilities needed in the commercialisation 
of an innovation (Teece, 1986); i.e. the capabilities to raise capital are auxiliary capabilities 
needed to fund the development of other assets.   
 
Figure 3-4: CAs needed in commercialisation 
 
Source: Teece (1986, p. 289) 
 
The ideas discussed above indicate that CAs is rooted in the RBV. Many researchers 
contend that capabilities are resources that can be used to build competitive advantages 
from (Barney & Hansen, 1994; Helfat & Peteraf, 2003; Mahoney & Pandian, 1992; 
Peteraf, 1993). It follows that SCAs/CCAs are resources that can be used to build 
competitive advantages; they meet the criteria of the RBV; valuable, rare, imperfectly 
imitable and non-substitutable (Barney, 1991). SCAs and CCAs are valuable because 
commercialisation cannot happen without them. By definition, they are rare because they 
are not easily purchased on the free market. They are inimitable because they are not easily 
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reproduced. Lastly, they are non-substitutable, as little else can fill the void needed for the 
SCAs/CCAs. If a CA does not meet all of these requirements, then it is a GCA. Moreover, 
SCAs and CCAs are the product of the highest level of dynamic capabilities (Teece, 2007). 
Firms must be able to either create the CCAs and SCAs needed for the commercialisation 
of innovations or cooperate with other firms to obtain these assets (A. M. Arora & 
Ceccagnoli, 2006; Rothaermel, 2001a). This requires firms, both internally and externally, 
to constantly manage their asset combinations and rearrange them to create the appropriate 
CCAs and SCAs needed to commercialise their innovations. Moreover, abnormally high 
profits are obtained when a firm creates a platform that other firms need as CCAs (Meyer, 
1997; Yang & Jiang, 2006). For example, Microsoft created an operating system that other 
software firms needed to commercialise their software. This platform provided a source of 
competitive advantage that yielded massive profits for Microsoft.  
 
The discussion above shows why CCAs and SCAs are at the pinnacle of the resource 
pyramid presented at the beginning of the chapter in Figure 3-1. They are the most refined 
resources needed in the commercialisation of innovations. Even though CCAs and SCAs 
offer possible insights into how firms obtain hyper-returns, there is little research that 
looks at the topic. The next subsection looks into the reasons for this. 
 
3.5.2 Empirical work on CAs 
Although Teece‟s (1986) seminal work on CAs is well-noted, there is relatively little 
empirical work to support it. Numerous studies touch on CAs, but few directly examine it. 
This section highlights the noted empirical studies to date. 
 
Moorman and Slotegraaf (1999) looked  at the CAs needed for product commercialisation. 
Their study identifies and tests a model of complementary capabilities. The model 
emphasises the interaction between information and capabilities (namely marketing, 
technical, R&D and distribution) of the firm. It suggests that flexibility is imperative to 
responding to new information; i.e. firms‟ capabilities must be flexible and work in 
conjunction in developing the assets needed for product commercialisation. In a similar 
study, Mitchell (1992) looked at the role of CAs in the medical diagnostic imaging 
industry. His research indicates that the SCAs of sales and service buffer, to a point, 
incumbents from new, more innovative competitors.  Similarly, Trispas (1997) analysed 
the typesetter industry between 1886 and 1990 and found that SCAs played a critical role 
69 
 
in buffering incumbents from new competition. The new and often more innovative firms 
lacked specialised sales and service capabilities that kept them from overtaking the 
incumbents that possessed these SCAs. The buffering property of SCAs is also backed up 
by Rosenbloom and Christensen (1994), who suggest firms have a whole value network 
that has to change in order for a new firm with a new innovation to enter the market.  
 
Much of the recent work on CAs focuses on alliances and networks (e.g, Eckhardt & 
Shane, 2010; Motohashi, 2008; Rothaermel, 2001a; Rothaermel, 2001b). Rothaermel 
(2001b) examines the role of inter-firm alliances and CAs in the biopharmaceutical 
industry, suggesting that incumbent firms enhance their industry position by using their 
established CAs to commercialise the innovations of new entrants. The study also indicates 
that often incumbents have well-established positions and SCAs, but often are not as 
innovative as the new entrants. In addition, the study finds new entrants lack the SCAs that 
established firms have, such as specialised manufacturing. Thus it is often better for the 
incumbent and the new entrant to form alliances to fully exploit innovations and SCAs. 
Rothaermel (2001a) came to similar conclusions from another 2001 study of CAs in the 
biotechnology industry. This study differed from his other 2001 study in that it focused on 
the alliances of large biotechnology companies, finding that firms focusing on exploiting 
CAs outperform firms focusing on creating new innovations. The study also indicates that 
the biotechnology industry focuses on establishing mutually beneficial CAs. Interestingly, 
he did not follow Teece (1986) in calling these CCAs because, in his view, it was too 
difficult to discern between SCAs and CCAs and that the difference was irrelevant for the 
study. Similarly, Rothaermel (2001b) felt the real importance is whether an asset was 
generic or specialised. In a similar vein, Rothaermel and Hill (2005) justifies using SCAs 
and CCAs interchangeably because it was not critical to the study. In this study they also 
conjecture that it is very difficult to a draw a distinction between CCAs and SCAs. Several 
other studies follow the same protocol in not distinguishing between SCAs and CCAs 
(Arora & Ceccagnoli, 2006; Christmann, 2000; Tripsas, 1997); instead calling any 
specialised assets, whether and SCA or CCA, an SCA. Although the distinction between 
CCAs and SCAs was not critical to these studies, distinguishing them would have 
improved the studies by magnifying the importance of bilateral alliances.  
 
Many others have taken a similar approach as Rothaermel (2001, 2001a, 2005) and looked 
at the role of alliances in the creation of CAs. Harrison et al. (2001) notes the importance 
of resource complementarities in the formation of alliances. According to this study, 
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synergies are created between two firms that mutually create assets that are needed for 
commercialisation. In a similar vein, Teece (2003) notes the importance of CAs that are 
created through alliances in the commercialisation of knowledge-based innovations. 
Several others look at the importance that alliances play in establishing CAs for start-up 
firms. Most notably, Baum et al. (2000) suggest that start-ups benefit themselves by early 
along in the venture aligning themselves with alliances, integrating themselves in efficient 
alliances and aligning themselves with rivals when the opportunity for learning outweighs 
the risks of working with a competitor. Hopkins and Nightingale (2006) put forward that 
alliances offer a CA in the form of risk reduction. Their study looks at the risk-spreading of 
biotechnology firms and concludes that firms can reduce risk by creating alliances with 
firms that have specialised risk management capabilities.   
 
It is interesting that these studies note the importance of alliances to life science firms in 
creating CAs. However, studies on CAs and alliances do not examine how alliances 
interact to create the CA of R&D. The life science literature discussed in chapter two 
emphasised the importance of alliances to R&D, and the present chapter put forth R&D as 
a possible category of CA (Lowe & Taylor, 1998), yet studies have not thoroughly probed 
whether or not alliances lead to the CA of R&D. This thesis is specifically interested in 
R&D and probes whether partnerships lead to the development of CAs.   
 
The discussion in the two paragraphs above indicates that cooperation is important. Even 
firms pursuing competitive strategies will most likely have to have some degree of 
cooperation with other firms; i.e. suppliers, competitors or customers. Teece (1986) 
highlighted this in his conceptualisation in figure 3-5 below. This illustration shows that 
many areas (shaded) are jointly controlled through alliances (cooperative strategies), whilst 
other areas are completely controlled by the innovating firm (competitive strategy). 
Although this figure gives a good conceptualisation of the fact that often cooperative and 
competitive strategies are pursued at the same time, it fails to consider that individual CAs 
can have elements of cooperation and competition. For example, R&D can mostly be 
undertaken by an individual firm, but the individual firm may have partners for select 
R&D functions.  
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Figure 3-5: CAs under joint control 
 
Teece (1986, p. 291) 
 
The largest problem plaguing the empirical work on CAs is the lack of defined measures. 
The studies on CAs use many different measures. Whilst it is good to have different 
measures to look at the theory from different perspectives, consistent measures are needed 
for comparative purposes (Johnson & Onwuegbuzie, 2004). Furthermore, the lack of 
consistent measures also raises reliability and validity concerns for the framework. Gans 
and Hsu (2002) developed five-point Likert scales to measure the importance and degree 
of specialisation of CAs. Their scales are the most accurate measures offered to date and 
are adapted by several others (Parmigiani & Mitchell, 2009; Pries & Guild, 2007, 2010). 
Other than the measurements offered by Gans and Hsu (2002), there have been few other 
reliable and valid independent variable measures offered to date. The dependent measures 
are not as problematic in CAs because these measures are adapted from studies in related 
areas, such as firm growth, the RBV, and transactions costs.  
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CAs and patents 
Patents are an important resource that influences CAs. Arora and Ceccagnoli (2006) 
looked at the effect that patents have on CAs and found that firms with weaker patent 
protection rely more on stronger CAs to commercialise their products. They also find that 
firms with stronger patents rely more on licensing to commercialise their goods; because 
their value added activities are in the patent and not the SCAs/CCAs. This work has been 
supported by several others (Colombo, Grilli, & Piva, 2006; Deeds et al., 2000; J. S. Gans 
& S. Stern, 2003). Grauff et al. (2003) examines the effect of intellectual property in the 
mergers and acquisitions of agricultural biotechnology firms. The results from their study 
indicate that firms merge with each other to align their complementary intellectual 
property portfolios. In a similar vein, Edvinsson and Sullivan (1996) suggest that patents 
themselves do not fully protect technology. Instead they contend that SCAs/CCAs are 
needed to protect novel innovation. Though patents protect innovations as a whole, some 
important processes or ideas cannot always be patented. Furthermore, processes and ideas 
can be exposed in the licensing process when information is shared; the exposed 
information could be used to create competing innovations (Lanjouw & Schankerman, 
2001). Difficult to obtain, SCAs/CCAs offer protection that patents cannot because they 
protect knowledge and make it so other firms cannot commercialise a similar innovation. 
Edvinsson and Sullivan (1996) emphasise this in their model of innovation, which is based 
off of four major elements: human capital, structural capital, complementary assets and 
intellectual property.  
 
Size is another mitigating factor in the development of CAs needed to commercialise 
patents. Arora and Fosfuri (2003) offer a model of rent vs. revenue for patents. This model 
looks at what factors drive a firm to either license their innovations or to commercialise 
their innovations themselves. One mitigating factor is the size of the firm. Small firms 
often do not have the resources and capabilities to commercialise an innovation; instead 
they often focus on one particular process such as R&D. Because of the lack of assets and 
capabilities to commercialise an innovation, small firms often license their ideas; even 
though the rents they earn are less than if they commercialised the products themselves 
(Pries and Guild, 2010). Conversely, large firms that develop innovations often control the 
upstream and downstream activities. Not only does this allow them to earn higher rents 
from their innovations, but it also shields them from competition. Furthermore, controlling 
the downstream activities also allows firms to reduce transactions costs (Heller & 
Eisenberg, 1998). Each company that is involved in commercialisation adds layers of 
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transactions; especially in the case of patent licenses where contracts consume substantial 
time and resources in developing (Hennart, 1988; Oxley, 1997). 
 
From the discussion above it seems natural that large firms should control the upstream 
and downstream activities in developing an innovation. However, an increasing percentage 
of downstream research comes from small firms (Jones, 1999; Nicholas, Ledwith, & Perks, 
2011; Van Beuzekom & Arundel, 2009). For this reason large firms are working with 
small firms to create CCAs/SCAs to commercialise the innovations conceived by small 
firms. The competition for the most novel ideas is intense and has led to large firms 
investing in smaller R&D firms that have ideas with grand potential (Arora & 
Gambardella, 1990). This investment helps secure the innovation rights for the larger 
company.  
 
It is surprising that small firms are often the source of knowledge and innovation needed 
for the development of CCAs and SCAs, especially in capitally intensive industries such as 
the life science industry. This phenomenon is credited to two things: the spill-over effect 
from universities and the fact that small firms are more flexible and can more quickly 
respond to changing technological environments. There is a clear correlation between the 
spill-over of innovations from universities to industry, especially to small firms. Studies 
indicate that in areas with top-tier research universities, there are  an inordinately high 
number of innovative start-ups (Anselin, Varga, & Acs, 1997; Jaffe, Trajtenberg, & 
Fogarty, 2000; Jaffe et al., 1993). The ideas for innovations are often birthed in universities 
and then either sold to firms located near the university or a spin off firm is created near 
the university. This is especially prevalent in life science innovations where scientists like 
to stay on the university‟s faculty whilst still pursuing the opportunity to commercialise 
innovations (Audretsch & Stephan, 1999; Zucker et al., 2002). The second reason 
attributed to the innovativeness of small firms is flexibility. Small firms have the 
advantage of newness and are not entrenched in bureaucratic routines the way large, 
established firms are (Autio et al., 2000). Acs and Audretsch (1987) suggest that small 
firms have an advantage in innovating in industries, such as life science, that are 
technologically intensive. Furthermore, the literature on absorptive capacity suggests that 
new firms often have an advantage in recognising opportunities (Cockburn & Henderson, 
1998a; Stock, Greis, & Fischer, 2001). In short, small firms are often innovative because of 
their university ties and the fact that they are flexible and dynamic.  
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3.5.3 An unexplored framework 
Perhaps the reason so many researchers avoid the explicit use of the term CAs is that it is 
so elusive to define and measure. Teece (1986) describes CAs as support assets or 
capabilities needed for the commercialisation of an innovation. Whilst in theory this seems 
clear, in practice it is much more difficult to pin down, especially for SCAs and CCAs. 
Take the example of manufacturing capabilities in the pharmaceutical industry: if a firm 
has truly unique manufacturing capabilities, then this would be considered an SCA or 
CCA. However, if a firm could contract the manufacturing of a drug out, would this be an 
SCA or CCA? If the contract manufacturer has truly unique capabilities and formed a 
partnership with a pharmaceutical firm, and both were reliant on each other, then this 
would be a CCA. But if the R&D firm in this example could set this alliance up with a few 
different manufacturing firms that had unique and specialised production capabilities, 
would this be an SCA or CCA? As this example shows, there is clearly a grey area in 
defining CAs, especially in discerning amongst GCAs, SCAs and CCAs. Moreover, 
measuring CAs has proven even more difficult. For example,  Rothaermel (2001a) 
attempted to measure complementary alliances based on secondary data of 
biopharmaceutical alliances and new product development. The results indicate that 
incumbents prefer alliances to leverage CAs over those to create new innovations. 
However, the analysis fails to show how a coded variable based on secondary data can 
differentiate between an alliance for the purposes of obtaining a CA and an alliance for 
creating new innovations. This is not to criticise this research, as it was an excellent study 
that provided much needed insight on CAs; rather this illustrates how difficult it is to 
measure CAs. One way to overcome these difficulties is to capture the essence of CAs in 
survey and interview studies. Qualitative work is especially needed to unearth insights on 
the connections between CAs and firm growth. These insights are needed to create valid 
and reliable measures.  
 
Table 3-3 below outlines the major empirical work done on CAs. This table is much leaner 
than the table presented earlier in the chapter on the empirical work on dynamic 
capabilities. CAs lacks the conceptual and empirical robustness of a major framework. 
However, there are several strong studies that have conceptually laid the ground work for 
the framework (e.g., Eckhardt & Shane, 2010; Edvinsson & Sullivan, 1996; Teece, 1986), 
and several other studies that provide an empirical base for it (e.g, Rothaermel & Hill, 
2005; Tripsas, 1997). More studies in the fields of strategic management, 
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internationalisation, entrepreneurship and marketing need to study the role of CAs in firm 
growth.  
 
Year over year a higher percentage of firms in developed countries are technology-based 
firms (Conway, Janod, & Nicoletti, 2005). Technology firms require ancillary assets to 
commercialise their innovations (D. J. Teece, 1986), yet the management literature has 
failed to properly investigate the topic. Stieglitz and Heine (2007) make a strong argument 
on the merits of using CAs in the study of strategic management. Specifically they 
conjecture that CAs are an important part of the strategic direction of firms and need to be 
factored in. They also suggest that CAs should be centrally coordinated by management, 
and that controlling CAs on an ad hoc basis to the firm does not work because the whole 
firm must be integrated with the CAs, a key point that other studies on the topic have 
missed. Another area that is specifically lacking, especially with regard to new ventures, is 
how firms create CAs. Many of the studies discussed above note the importance of 
alliances in ascertaining key CAs, but not all CAs are accessed through partners. Little 
work investigates how firms internally develop CAs. Moreover, there are few studies that 
examine the interface between creating CAs and finance; i.e. how CAs are capitalised, 
which is especially relevant for new ventures that are resource constrained. Thus the 
question remains: how do young firms overcome financial restraints to create or acquire 
CAs?  
 
 
Table 3-3: Key CAs studies 
 
Author  Area of CA Looked At Type Of Study Results 
Teece (1986) Introduction and 
conceptualization of 
complementary assets 
Conceptual Paper -Introduces GCAs, SCAs, and CCAs  
Edvinsson and 
Sullivan (1996) 
Conceptual model of 
intellectual capital 
Conceptual Paper -Introduces a model of intellectual 
capital based on human capital, 
structural capital, complementary 
business assets, and intellectual 
property 
Tripsas (1997) CAs as a buffer to 
competition 
Hypothesis testing 
based on historical data 
of the typesetter 
industry 
-Firms can buffer themselves from 
new more innovative firms if they 
have well established specialised CAs 
Shane (2001) Developed and tested a 
model of firm formation 
based on four variables: the 
age of the technical field, 
effectiveness of patents, the 
tendency of market 
segmentation, and the 
importance of CAs 
Took 1,397 patents 
from MIT and looked 
at how many of these 
led to firm foundation. 
-Found that firm foundation off of 
university patents is more likely when 
technical fields are young, markets 
are segmented, patents are more 
effective, and marketing CAs are less 
important 
*Rothaermel 
(2001a) 
Alliance formation for the 
purposes of developing CAs 
Testing based on 
secondary data of 
Alliances of large 
-Incumbents that focus on developing 
networks to exploit CA outperform 
firms which focus on networks to 
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Author  Area of CA Looked At Type Of Study Results 
international 
biopharmaceutical 
firms 
develop innovation 
*Rothaermel 
(2001b) 
Alliances formation for the 
purposes of developing CAs 
Testing of secondary 
data of alliances of 
large international 
biopharmaceutical 
firms. Focuses on 
incumbents alliances 
with new firms to 
access new 
technologies. 
It is better for firms to focus on 
developing SCAs and CCAs than on 
further developing technology. 
*Rothaermel (2002) Alliance formation. How 
firms go about forming 
alliances  
Testing secondary data 
of 325 new 
biotechnology firm 
alliances 
New biotech attractiveness is related 
to its new product development. 
Funk (2003)  Looked at how firms can 
exploit information 
advantages to gain 
preferential access to CAs 
Examining five major 
Japanese cell phone 
producers. Collected 
data through 17 
interviews. 
Found that firms that had an 
information advantage over the 
competition were able to gain 
preferential treatment to valuable 
CAs. 
*Graff et al. (2003) Tests an overarching 
hypothesis that the biotech 
agriculture seed industry has 
changed because of 
advanced CAs 
Taking two sets of 
mergers and alliance 
data on agriculture 
biotech firms: one set 
of 60 and one set of 46. 
Found that the agriculture biotech 
industry has reorganized itself 
through mergers and acquisitions to 
exploit CAs. 
West (2003) Looks into the optimal 
combination of open and 
closed source code in 
software platforms 
Uingd four major 
software companies as 
case studies:  Apple, 
IBM, SUN, and 
Microsoft. 
Suggested that hybrid strategies of 
open and closed source will provide 
the highest returns. This strategy will 
enable other firms to use the 
platforms as CCAs. 
*Hopkins and 
Nightingale (2006) 
Risk management as a 
complementary asset 
Examining four 
biotechnology case 
studies. 
Found that risk management is a 
useful SCA/CCA. Firms should align 
themselves with partners that have 
complementing risk management 
capabilities.   
Swink and Nair 
(2007) 
Tested the theory of 
complementarities on 
manufacturing design and 
advanced technologies 
A survey of 224 
technical 
manufacturing firms 
Found that manufacturing design is 
important complementarily to 
advanced manufacturing. 
Stieglitz and Heine 
(2007) 
The role of CAs in strategy Conceptual Suggested that CAs are an important 
factor in strategy. 
Suggested that top managers must 
properly account for CAs and also 
create or secure CAs needed to be 
competitive. 
Suggested that CAs are important 
resources that fit into the RBV 
framework. 
Motohashi (2008) Strategic use of patents by 
Japanese firms 
Secondary data testing 
of Japanese patents 
Indicated that smaller firms with 
undeveloped CAs have a higher 
propensity to license than firms with 
developed CAs.           
Indicated that large firms tend to be 
the licensor to obtain innovations so 
that they can exploit their developed 
CAs.              
Parmigiani and 
Mitchell (2009) 
Source of complementary 
manufacturing assets 
A survey of 193 US 
manufacturing firm.  
Found that firms often concurrently 
source manufacturing assets from 
several sources. 
Noted that knowledge is a key factor 
on the source of manufacturing 
assets. 
Indicated that experience firms are 
more apt to concurrently source than 
inexperienced firms.  
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Author  Area of CA Looked At Type Of Study Results 
Eckhardt and Shane 
(2010) 
Technological innovation 
and entrepreneurial activity 
Secondary data on 201 
industries over a 15 
year period  
Found that technical innovation is an 
important driver to entrepreneurship. 
Discovered that CAs are not a big 
restraint to the dissemination of 
innovation. 
*Ceccagnoli et al. 
(2010) 
The role of CAs in 
technology outsourcing  
Secondary data from 
the pharmaceutical 
industry 
Found that firms with more CCAs 
outsource less of their technology. 
Indicated that increased transactions 
costs can stimulate the demand for 
technology from external sources. 
Source: Author                                                                                    *Life science studies 
 
 
CAs is an offshoot of dynamic capabilities, and as the name suggests, it has potential to 
complement research on dynamic capabilities. CAs offers unique insights into the auxiliary 
assets and capabilities needed in the commercialisation of innovations, especially in high 
tech innovations. It has sound theoretical backing, but unfortunately lost momentum 
shortly after it was introduced. However, as of late it has started to regain momentum and 
is being led by Frank Roethermel who has produced several influential pieces (2001a, 
2001b, 2005) in the last ten years. Several others have also joined him (Arora & 
Ceccagnoli, 2006; Ceccagnoli, Graham, Higgins, & Lee, 2010; Colombo et al., 2006; 
Helfat & Peteraf, 2003; Hopkins & Nightingale, 2006; Stieglitz & Heine, 2007; Swink & 
Nair, 2007), and the topic should see great progress in the next ten years. CAs has great 
research potential in many different fields, especially those interested in high tech firms.  
 
This section discussed several shortcomings of CAs with two notable ones being (1) it is 
difficult to empirically define and measure and (2) it lacks a clear framework. This makes 
it difficult to generate and test hypotheses and is why there is not a more robust body of 
empirical studies that have tested CAs. However, CAs is an off shoot of dynamic 
capabilities, which allows it to be examined from a dynamic capabilities framework; i.e. 
probe the paths, positions and processes that lead the development of CAs. In the context 
of new life science ventures, work is especially needed to examine how R&D CAs are 
financed and developed. The importance of R&D resources to the development of new life 
science firms is well documented, but little work looks at how these resources are financed 
and developed.  
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3.6 Resource based paradigm conclusions  
It is clear from this chapter that Penrose‟s (1959) ideas on the importance of resources and 
management to firm growth are alive and well. Her ideas evolved into the RBV and are 
now transforming into the theory of dynamic capabilities. Findings from the review 
suggest that dynamic capabilities is a unique theory rooted in the RBV that has particular 
potential for use in the study of high technology firms. This chapter also suggests that CAs 
is a complementary framework rooted in dynamic capabilities. CAs offers unique insights 
on the auxiliary assets and capabilities that are needed to commercialise innovations. It is 
an especially useful framework on firm growth because it allows research to look at 
growth from several different angles. In short, dynamic capabilities and CAs offer 
frameworks that could help unravel the growth process of high tech firms. 
 
The literature on dynamic capabilities is fragmented and difficult to bring together, largely 
because of a lack of coherent direction in the literature. There are many incongruent ideas 
and weak frameworks manifested in an undeveloped body of empirical studies; a group of 
work marked by vastly different and unsubstantiated studies. However, in the past ten 
years it has made large conceptual and empirical strides towards becoming a strong theory. 
This review clearly shows that there is potential for dynamic capabilities to become a 
powerful framework for explaining life science firm growth. Furthermore, work needs to 
use a dynamic capabilities framework to look at how key resources and capabilities are 
formed; i.e. what paths, positions and processes lead to the development of key resources 
and capabilities.  
 
3.7 Literature review summary 
The literature on life science firms suggests that they are highly innovative in high velocity 
environments. Resources and capabilities are paramount to the development of firms in the 
industry. Despite this, the prominence of smaller firms is increasing (Giovannetti, 2010). 
These small firms are contributing significantly to innovation in the industry. Surprisingly 
little research has examined how firms develop their R&D resources and capabilities. 
Furthermore, the research is limited on how life science ventures develop financial 
resources. Some work exists that looks at the role of alliances, universities and venture 
capital in supplying R&D and financial inputs. However, most of this examines the topic 
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from the supplier side. Little work has been done on the motivations and assets that lead to 
the development of R&D and financial resources and capabilities in life science ventures. 
 
The discussion on the evolution of the resource-based paradigm suggests that resources are 
paramount to growth. In highly dynamic environments it is critical for firms to reconfigure 
their resources and capabilities in response to industry changes. The dynamic capabilities 
framework examines the paths, positions and processes that lead to the configuration and 
reconfiguration of resources and capabilities that lead to long-term competitive advantages. 
This framework is still in a juvenile state, but it has proved to be a good lens to examine 
life science firms through. It provides a particularly good lens for investigating the paths, 
positions and processes that lead to key resources and capabilities. The next section 
introduces the study‟s framework that is based on this.  
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Chapter 4 – Problem Statement                        
and Research Questions 
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
 To outline the theoretical background of this study. 
 To develop the framework of this study. 
 To establish the research questions of this study. 
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4.1 Introduction 
It is estimated that over forty per cent of life science innovations stem from firms that have 
fewer than 250 employees and that there are over 300 new life science ventures formulated 
in the US each year (Van Beuzekom & Arundel, 2009). The innovations that life science 
ventures develop require unique R&D resources and capabilities. These typically cost 
millions of dollars to develop and often new ventures sustain years without revenues whilst 
their innovations are being developed (Murray and Wolfson, 2010). Despite this, research 
has not thoroughly investigated how firms develop the R&D and financial resources and 
capabilities to develop novel life science innovations.   
 
Although there is a growing recognition of the importance of R&D and financial resources 
and capabilities to the growth of young life science ventures, research on the development 
of these resources and capabilities is still scarce. Studies on these topics tend to focus on 
larger firms (Mittra, 2007; Rothaermel & Hess, 2007). This is largely attributed to the 
public nature of large life science firms and the fact that data is more readily available for 
large firms. Moreover, Murray and Wolfson (2010) suggest that the nature of life science 
ventures has changed drastically in the last five years. This has made studying these firms 
difficult, and this, coupled with the fact that these firms often fail, makes studying small 
life science ventures difficult. Thus investigating how these firms develop R&D and 
financial resources and capabilities remains an important topic. This thesis examines it.  
 
This chapter is devoted to identifying the conceptual framework and research questions of 
the study. It starts with a discussion of the influences on the research topic. From this, the 
theoretical framework for the study is then presented. Subsequently, the research questions 
are then presented in relation to the study‟s framework.   
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4.2 Theoretical basis 
The literature review emphasised that resources and capabilities are germane to the 
development of life science firms, and for this reason both the resource-based view (RBV) 
and dynamic capabilities models are particularly good lenses for looking at life science 
firms (Coombs & Deeds, 2000; Madhok & Osegowitsch, 2000; Rothaermel & Hess, 
2007). The literature review also underscored that there are few defined measures and 
constructs on the topics related to this research. For this reason a framework is called for 
that allows the study to deeply probe how R&D and financial resources and capabilities are 
developed. The paths, positions and processes dynamic capabilities framework proposed 
by Teece et al. (1997) answers this call. This framework allows the study to isolate the 
paths, positions and processes that lead to the development of R&D and financial resources 
and capabilities.   
 
Previous paths are the past decisions and future opportunities that shape where a firm can 
go. Past decisions commit resources and often create rigidities because the firm is deeply 
tied to its earlier commitments. For example, Deeds and DeCarolis‟ (2000) study on new 
life science firms shows that a firm‟s future development opportunities are limited by 
investments made in earlier research. They suggest that often firms invest heavily in a 
technology, and this drains resources that could be used for other projects. Future paths 
represent opportunities available to the firm, influencing the firm‟s strategies. Positions are 
the resources that firms use in their pursuit of future paths. For example, life science firms 
often leverage their patents in the pursuit of developing an innovation (Deeds et al., 2000; 
Madhok & Osegowitsch, 2000; Ziedonis, 2004). Processes represent a firm‟s systems and 
routines. A firm‟s processes are determined by its paths and positions; i.e. firms develop 
processes based on the available opportunities, the restraints caused by past decisions and 
resources available to them. Examples of processes are learning and sensing. Life science 
firms require competencies in sensing out technologies and learning from their earlier 
research (Kaplan, Murray and Henderson, 2003). 
 
The paths, positions and processes framework allows this research to deeply probe how 
R&D and financial resources and capabilities are formulated. Figure 4-1 presents the 
framework this study draws on. The paths aspect allows the study to develop questions 
pertaining to the decisions and opportunities that influenced the development of the firms‟ 
R&D and financial resources and capabilities. For example, what investments in 
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technology influenced the development of a firm‟s financial resources and capabilities? 
The positions aspect allows questions to probe the resources that the firms used in the 
pursuit of developing R&D and financial resources and capabilities, such as whether or not 
a firm‟s scientists were an important resource that helped in the development of R&D. The 
processes aspect of the model allows questions to be developed that probe the routines that 
proved important to the development of the firm‟s R&D and financial resources and 
capabilities. For example, whether or not learning routines were important to the 
development of the firm‟s R&D. In turn, the study is then interested in how R&D and 
financial resources and capabilities help a firm grow. The two loop-backs in the figure 
represent the resources and capabilities feeding back into the paths and positions of the 
firm; i.e. the new resources and capabilities will affect the positions and strategic paths 
available. For example, a firm with initial paths, positions and processes that lead to the 
development of advanced R&D resources and capabilities will be affected by these 
resources and capabilities. The newly created resources and capabilities provide the firm 
additional positions on which to compete and open new research and market paths. In turn, 
the firm leverages its expanded paths and positions to broaden its R&D and finances, and 
ultimately this perpetuates the firm‟s growth.    
  
84 
 
Figure 4-1: Research framework 
 
Source: Author 
 
 
4.3 Research objectives and questions 
The literature review indicates that existent theory does not offer deep insight into the 
R&D and financial resource and capability development of life science ventures. 
Moreover, the existing theory does not provide strong constructs on this topic. Thus the 
overarching objective of this study is to close the gap in the deficiency of knowledge 
related to the R&D and financial resources and capabilities of life science ventures. Based 
on the topic and discussion above, two research objectives are set forth:  
 
Objective 1 
To explore and examine how R&D and financial resources and capabilities are developed.  
 
Objective 2 
To explore and examine the effect of R&D and financial resources and capabilities on the 
growth of life science ventures. 
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Each of these is discussed below along with the research questions for each objective. The 
questions are defined by the findings from the literature. These questions focus the study; 
however, they are purposely asked in order to allow for flexibility in the findings. This is 
important in qualitative research where interviews are used to collect data (Yin, 2008). The 
next chapter further elaborates on this point.     
 
4.4 Objective 1 
The first objective stems from the fact that little research investigates the development of 
R&D and financial resources and capabilities in life science ventures. Despite its 
importance, this topic has not properly been examined. The literature underscores the 
importance of R&D (Kenney, 1986) and financial (Baum & Silverman, 2004; Powell et al., 
2002) resources and capabilities of larger life science firms, but little work examines these 
from a small life science firm‟s perspective. There is a real gap in understanding how life 
science ventures develop R&D and financial resources and capabilities. This objective is 
examined under the guise of the study‟s paths, positions and processes framework. 
 
4.4.1 Paths and positions 
The defining trait of life science firms is innovativeness. From 1980 to 2006 the industry 
had more patents than any other; in 2008 almost eight percent of the total patents filed in 
the US were life science patents, over 11,000 (Van Beuzekom & Arundel, 2009). A survey 
of life science executives found the number one goal of R&D is to discover breakthrough 
products (Deloitte & Touche, 2009). Decarolis and Deeds (1999) suggested that innovation 
in the life science industry is measured and stored in the forms of academic citations and 
patents. They also note that greater stocks of patents and citations are correlated with 
superior performance. The high patenting and publishing propensity demonstrates the 
creative destruction that is so widespread in the industry, with new and better innovations 
constantly replacing old ones (Kenney, 1986; Powell et al., 1996; Roijakkers & 
Hagedoorn, 2006). Other than noting that life science ventures are often created to pursue a 
novel innovation, the literature has not provided great depth on the influence that 
innovation has on the development of life science ventures. Further knowledge is needed 
as to how innovation affects the development of firms. More specifically, little work has 
explored how the type and source of knowledge affect the development of a firm‟s R&D 
and financial resources and capabilities. The first set of questions aims to address this gap: 
86 
 
 
Q1) How does an innovation affect the development of life science ventures? 
 
1a) Does the source of an innovation affect the development of R&D and 
financial resources and capabilities? 
 
2a) Does the type of innovation affect the development of R&D and 
financial resources and capabilities? 
 
In the context of this research framework these questions are viewed through a paths lens. 
The decision to pursue a technology is a past decision that influences the development of 
firms; whilst future technological opportunities influence the future paths that a firm takes.  
 
Another distinctive trait of life science firms is their reliance on alliances 
(Carayannopoulos & Auster, 2010; Powell et al., 1996). Often life science firms are 
lacking the scientific or commercialisation resources and capabilities to develop their 
product(s), and for this reason they turn to other firms to fill these gaps. Calabrese and 
Silverman‟s (2000) study found that establishing strong alliances is especially important to 
start-up life science firms. They suggest that small life science firms align themselves with 
partners that have complementing capabilities. One important source of these alliances is 
universities. Zucker et al (1998) looked at the importance that top university researchers 
play in new life science companies. They found that star university researchers are often 
the driving force behind new life science firm formation, an idea that is further evidenced 
by the fact that life science firms tend to cluster spatially near top research universities 
(Owen-Smith et al., 2002; Zeller, 2001). Although there is little work specific to small life 
science firms, it follows from the discussion above that partnerships provide important 
inputs to life science ventures, which leads to the second set of questions: 
 
Q2) Do partnerships have a major bearing on the development of R&D and 
financial resources and capabilities? 
 
2a) How do life science ventures know what inputs they have to offer 
potential partners? 
 
2b) How do life science ventures identify what partners have to offer? 
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In the context of the framework of this study these can be viewed through both a paths and 
a positions lens. Previous work has shown that partnerships in the life science industry 
open research opportunities that influence strategy (Haeussler, Patzelt, & Zahra, 2010; 
Rothaermel, 2001a); thus it follows that alliances can have an influence on paths. Alliances 
also provide important resource inputs, such as scientific knowledge (Powell et al., 1996; 
Rothaermel, 2001a), and thus they can supply important resources (positions).    
 
The literature review also underscored the capitally intensive nature of the life science 
industry. It takes years from the time an innovation is conceived until the time it is 
commercialised (Hall, 2002; Murray & Wolfson, 2010). This lag time from innovation to 
commercialisation forces life science ventures to sustain long periods without revenues 
whilst they are developing their innovations. During the conceptualisation phase, firms 
often finance their incubation through insider finance, VC, public sector grants and 
business angels (Fraer, 1990; Murray & Wolfson, 2010).  
 
Furthermore, the amount and type of financing that a firm acquires will have a major 
bearing on its development. For example, VC has been shown to have a major impact on 
the development of their portfolio firms (Sapienza, Manigart, & Vermeir, 1996). Raising 
VC requires substantial effort, and the VCs have a major impact on their portfolio firms‟ 
management; furthermore, the capital they supply is a catalyst to firm growth (Gompers & 
Lerner, 2001; Unger, Greiman, & Leybourne, 2010). In comparison, firms that bootstrap 
their operations do not exert great effort in attracting outside investors, but it also limits 
them in the capital that they have to invest in the development of their innovation 
(Winborg & Landstrom, 2001). It logically follows that financing has a major bearing on 
the development of a life science firm, which leads to the third set of research questions. 
 
Q3) How does the pursuit of financing impact the development of life science 
ventures? 
3a) How do different financial strategies impact the financial trajectories of 
the firms?  
 
In the context of this study‟s framework both these questions can be viewed through a 
paths lens. The pursuit of financing is a major event that firms devote substantial resources 
to. It takes time and effort to obtain the investment capital needed to finance a life science 
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venture. Moreover, once investment capital is obtained, it opens up future opportunities, as 
it allows firms to invest in new areas (Chakma & Sammut, 2011; Gompers & Lerner, 
2004).  
 
Another important finding from the literature review is the importance of human capital to 
life science ventures. Zucker et al (1998) note the importance of star researchers to the 
growth and development of life science firms, which is further supported by Boxeman et 
al‟s (2001) findings that human and social capital are two of the most important building 
blocks of new technology-based companies. The clustering of life science companies near 
top universities also supports this idea (Blumenthal et al., 1996; Zucker et al., 1998). 
Furthermore, an industry survey of life science executives placed attracting scientific talent 
as one of the biggest challenges in the industry (Deloitte & Touche, 2009). From a 
financial standpoint, investment in a new technology-based business is often determined 
by the key individuals involved in a venture (Murray and Wolfson, 2010). Similarly, Baum 
and Silverman (2004) found that an important criterion that investors look at in life 
sciences ventures is the background of the top managers.  
 
The discussion above underscores the importance of key individuals to developing a firm‟s 
R&D and financial resources and capabilities. It follows that key individuals are the 
drivers to the development of R&D and financial resources and capabilities, which leads to 
the fourth set of research questions:  
 
Q4) Are highly trained, skilled and experienced individuals driving the 
development of R&D and financial resources and capabilities? 
 
 4a) Are star scientist playing an important role in the development of a 
firms R&D?  
 
In the context of this study‟s framework this question is viewed through a positions lens. 
Key individuals are resources that firms draw on to develop their R&D and financial 
resources and capabilities. From an R&D standpoint, scientists provide vital inputs from 
their scientific abilities that allow firms to develop their R&D (Zucker et al., 2002). From a 
financial standpoint the TMTs‟ backgrounds supply a resource that firms use to attract 
investment capital. Furthermore, the TMTs in new ventures are the ones who use their 
skills and abilities to secure investment capital (Colombo & Grilli, 2009).  
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4.4.2 Processes 
The literature review emphasised the importance of a firm‟s processes to the development 
of their resources and capabilities. Two processes of particular emphasis are sensing and 
learning. The importance of learning is scattered throughout the dynamic capabilities 
literature. In their conceptualisation of dynamic capabilities Eisenhardt et al. (2000) 
suggest that learning mechanisms underlie the development of dynamic capabilities. They 
suggest that firms with more experience in responding to change are more apt to develop 
dynamic capabilities. Autio et al. (2000) found that new ventures have an advantage in the 
internationalisation process because of their learning advantage of newness; i.e. new firms 
do not have the bad habits of established firms and learn from changing market conditions 
more swiftly. Helfat (1997) is one of the few studies that have directly looked at learning 
in life science firms. This study found that learning from experimentation is vital to the 
progress of a firm‟s R&D. Although few studies have directly looked at learning in life 
science firms from a dynamic capabilities perspective, studies in other areas have also 
indicated that learning is important to the development of R&D (Cohen & Levinthal, 1989; 
Powell et al., 1996). Similarly, studies have indicated that learning from earlier financial 
investment decisions is an important process for NTBFs. That is, firms must learn how to 
better use their capital and how to attract additional investment (Unger et al., 2010).   
 
Processes relating to sensing opportunities is another area that has been emphasised in the 
literature (Teece, 2007). In an in-depth study on the IBM Corporation Harreld and 
Tushman (2007) found that sensing opportunities is a process that IBM has mastered, and 
this has been one of the firm„s main sources of competitive advantage. IBM„s sensing 
processes have allowed them to find unique innovations to develop, and these innovations 
have been important to the firm„s competitive position. Similarly, Trispas and Gavetti 
(2000) in an in-depth study of the Polaroid corporation find that sensing new technological 
opportunities was an important process that the firm developed and  has been one of the 
this firm‟s main competitive advantages. In a similar vein, Kaplan, Murray and Henderson 
(2003) took an in-depth statistical look at fifteen pharmaceutical firms‟ TMTs ability to 
recognise scientific opportunities. Their findings suggest that sensing is a process that 
gives firms a competitive advantage by allowing them to develop drugs that have unique 
and desirable characteristics.  
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A third set of processes that have been found to be important to NTBFs is networking 
routines. As discussed above, partners provide important inputs to small resource- 
constrained firms in dynamic environments. In order to develop partnerships, small firms 
must develop a number of formal and informal processes. They must identify partners, 
negotiate partnership agreements and develop working relationships with partner 
organisations. The literature has shown that these processes can lead to alliances that 
provide access to inputs such as R&D (Rothaermel, 2001a) and capital (Bygrave, 1988; 
Sengupta, 2011).  
 
Although there is little work that has examined the processes that lead to the development 
of life science ventures‟ R&D and financial resources and capabilities, from the discussion 
above it follows that several processes, including learning, sensing and networking, are 
important to the development of R&D and financial resources and capabilities, which leads 
to question five: 
 
Q5) What processes are important to the development of life science ventures‟ 
R&D and financial resources and capabilities?   
 
4.5 Objective 2 
The second objective stems from the fact that little research examines the effect of R&D 
and financial resources on the early development of life science ventures. It is clear from 
the entrepreneurship literature that new firms are often at a disadvantage because of 
resource constraints and liability of newness  (Singh et al., 1986). Life science ventures 
face particularly large constraints, as the industry requires substantial financial and human 
capital (Baum & Silverman, 2004). Despite this fact, scores of life science ventures have 
successfully sprung up all around the globe (Giovannetti, 2010), and scholarly research 
fails to properly examine how life science ventures‟ R&D and financial resources and 
capabilities help them overcome large resource constraints to successfully grow and 
prosper.  This objective is examined through the second part of the model presented in 
Figure 1 (above) and it examines what the impact of R&D and financial resources and 
capabilities are. 
 
The literature review suggests that R&D and financial resources and capabilities are at the 
heart of a life science ventures development. Often a unique innovation is the motivation 
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for the start-up of a life science firm (Audretsch, 2001), and innovation sets the strategic 
path of life science firms. For this reason R&D, coming in the form of scientific 
capabilities and resources such as advanced laboratories, is paramount to the growth of 
these firms. .   
 
Often life science ventures are focused on the development of innovation at the onset and 
do not have revenues to support the firm‟s operations (Baum & Silverman, 2004). For this 
reason, investment capital is crucial to the firm‟s growth, and frequently this capital comes 
from VCs (Gompers & Lerner, 2001; Powell et al., 2002). A new firm without a track 
record requires a compelling case to attract the capital that is required to develop a novel 
innovation. In order to attract this investment, firms must have a business that offers the 
potential for great return and the firm must have capabilities in attracting investment 
capital (Gompers & Lerner, 2001). From the arguments above it follows that R&D and 
financial resources and capabilities are central to the development of life science ventures 
and are closely linked. This leads to the sixth set of research questions: 
 
Q6) How are R&D and financial resources integral to life science ventures? 
                   6a) How closely linked are R&D and financial resources and capabilities? 
 6b) Do R&D and financial resources co-evolve? 
 
The literature review emphasised that a number of resources and capabilities are needed in 
the development of new firms. Research has noted the importance of CAs to the 
development of life science innovations (Eckhardt & Scott Shane, 2010; Rothaermel, 
2001a). CAs are the auxiliary assets and capabilities required for the commercialisation of 
an innovation (Trispas, 1997). R&D has been put forth as a CA but has not yet been fully 
substantiated. Teece (1986) suggests that a complementary technology is a category of 
CAs; i.e. technologies that go along with the core technology that a firm is attempting to 
commercialise. Similarly, Gans et al. (2002) suggest that the research assets needed to get 
through government approval is a category of CA. Moorman and Slotegraaf (1999) discuss 
product development capabilities and allude to R&D as a potential category of CA. 
Similarly, Lowe and Taylor (1998) allude to R&D as a CA, but do not explicitly call R&D 
a CA. It follows from these studies that R&D can be a CA. 
 
Although financial resources and capabilities have not been looked at through a CAs lens, 
it follows that they could be viewed as such. Financial capital is needed for the growth of a 
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life science firm, but the capital itself is not a CA. In management research capital is 
generally viewed as a generic proxy or transactional tool. However, financing is much 
more encompassing than just being a transactional tool or a proxy. The capital is a generic 
asset, but it follows that capabilities in raising capital could be viewed through a CAs lens, 
as these are auxiliary capabilities needed to develop an innovation. Although the extant 
research does not explicitly look at finance through a CAs lens, financing lends itself to 
being a CA.   
 
From the discussion in the two paragraphs above it follows that both R&D and finance can 
be viewed through a CAs lens. This leads to the seventh question: 
 
Q7) Can R&D and financial resources and capabilities serve as a CA? 
 
Specialised complementary assets (SCAs) are the auxiliary assets and capabilities that are 
not easily developed or contracted for that are needed in the commercialisation of an 
innovation. These can serve as a source of competitive advantage (Teece, 1986; 
Rothaermel, 2007). An example of an SCA is service capabilities of a medical device firm. 
In many cases medical devices require specialised service capabilities to maintain the 
product, and if a firm is unable to service the device, then the device cannot be 
commercialised. These capabilities are such that they require sophisticated and often tacit 
knowledge that cannot easily be replicated.  Likewise, little work has explored whether 
financial capabilities are SCAs; as discussed above, it follows that capabilities in raising 
and managing capital could be an SCA. These are capabilities that are not easily created 
but can serve as a source of competitive advantage, especially true in the context of new 
life science ventures where there is hyper-competition for investment capital (Chakma & 
Sammut, 2011).  
 
From the discussion in the paragraph above it follows that both R&D and financial 
resources and capabilities in certain circumstances serve as SCAs. This leads to the eighth 
question: 
 
Q8) Can R&D and financial resources and capabilities serve as a SCA?  
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4.6 Summary of framework and research questions 
There is a gap in the understanding of how small resource constrained life science ventures 
create advanced R&D and financial resources and capabilities that allow them to develop 
novel innovations. There are few defined constructs and measures on this topic, which 
calls for a framework that allows it to deeply probe the matter. The paths, positions and 
processes framework answers this call. The paths aspect allows questions to be developed 
that focus on the motivation for developing R&D and financial resources. The positions 
aspect allows for questions to focus on the positions that are leveraged to create these 
resources and capabilities, and the processes aspect allows for questions to isolate the 
important routines firms use.  
 
This section develops a dynamic capabilities research framework. This framework 
underpins the eight main research questions of this study, which are summarised in Table 
4-1 below.  
 
This research is embedded in an era of massive shifts in technology, a new age in 
innovative life science ventures, and is at the forefront of a very important topic, as young 
life science firms are having a profound effect on the life science industry. Moreover, it is 
a critical topic as R&D and finance are central to the development of life science ventures. 
The two sets of questions set forth in this chapter allow the research to examine how R&D 
and financial resources and capabilities are formulated and what affect they have on the 
development of life science ventures. The framework and research questions presented in 
this chapter dictated the research methods of this study. The next chapter details the 
specific methods used to address this research. 
  
94 
 
Table 4-1: Research questions 
Q1) How does an innovation affect the development of firms? 
1a) Does the source of an innovation affect the development of R&D and 
financial resources and capabilities? 
2a) Does the type of innovation affect the development of R&D and 
financial resources and capabilities? 
 
Q2) Do partnerships have a major bearing on the development of R&D and 
financial resources and capabilities? 
2a) How do life science ventures know what inputs they have to offer 
potential partners? 
2b) How do life science ventures identify what partners have to offer? 
Q3) How does the pursuit of financing impact the development of life science 
ventures? 
3a) How do different financial strategies impact the financial trajectories of 
firms?  
 
Q4) Are highly trained, skilled and experienced individuals driving the 
development of R&D and financial resources and capabilities? 
 4a) Are star scientists playing an important role in the development of a 
firm‟s R&D? 
 
Q5) What processes are important to the development of life science ventures, 
R&D and financial resources and capabilities?   
 
Q6) How are R&D and financial resources integral to life science ventures? 
            6a) How closely linked are R&D and financial resources and capabilities? 
       6b) Do R&D and financial resources co-evolve? 
 
Q7) Can R&D and financial resources and capabilities serve as a CA? 
 
Q8) Can R&D and financial resources and capabilities serve as an SCA?  
 
Source: Author 
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Chapter 5 – Research Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
 To overview the philosophical assumptions underlying the study. 
 To identify the appropriate research paradigm for the study. 
 To justify the research methods chosen for the study.
 To discuss the techniques used to ensure the reliability and validity of the study.
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5.1 Introduction 
Chapters two and three introduced the relevant literature to this study and chapter four 
presented the research questions based on this review. This chapter introduces the methods 
used to explore these questions.  
 
This thesis aims to generate insights on how life science ventures develop R&D and 
financial resources and capabilities, and how these resources and capabilities affect the 
early growth of these ventures. Initially the research was intended to explore the research 
questions through quantitative techniques. However, a look into the literature found few 
defined constructs and measures with which to properly conduct an empirical, positivist 
study. The dynamic capabilities framework that this thesis draws on also made a positivist 
study difficult to conduct, as it is a young theory that does not have many well-defined 
constructs and measures (Helfat & Peteraf, 2009). Furthermore, in positivist social science 
research the phenomenon of interest is separated from it social setting (Easterby-Smith, 
Thorpe, & Lowe, 2002). After further information on the research questions were gathered, 
the researcher came to the determination that to unearth insights on the research topic, the 
phenomenon of interest could not be separated from its social setting. Put differently, life 
science firms should be examined in their setting to find insights on the research questions. 
For this reason, the research adopts a phenomenological approach that stresses that 
meaning stems from the interaction with the phenomenon of interest (Bryman and Bell, 
2003).  
 
Regardless of the research method used, reliability and validity is a major issue. For this 
reason the present study kept reliability and validity at the forefront of this research. 
Reliability and validity in qualitative work refers to the trustworthiness of the study 
(Lincoln and Guba, 1985). From the onset this study established dependability from proper 
design, well-crafted questions, appropriately selected cases and reliable data collected from 
multiple sources. Another challenge of qualitative work is to properly apply the findings 
from the study. This study adopts Miles and Huberman‟s (1994) data reduction and 
packaging to produce themes related to the research topics. Data was collected, compared 
across cases and funnelled into themes through multiple data reduction steps. To manage 
the massive amount of data, the researcher used case record and qualitative data analysis 
software to aid in the reduction of the data. The resulting themes were then compared 
across existing theory.  
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There are no perfect research methods in business (Bryman and Bell, 2003). All research is 
contextually based, and the proper methods depend on the research setting. Furthermore, 
methodology is restrained by time and budgets (Easterby-Smith & Lowe, 2002). It is not 
the purpose of this chapter to review all of the literature on research methods. An effort 
such as this would take years to complete and volumes of manuscript. Rather this chapter 
focuses on the methods that were considered and used in this study. The research process 
is generally illustrated in a linear fashion (Bell & Bryman, 2003; Creswell, 2008). 
However, Edmondson and McManus (2007) suggest that whilst research ultimately 
follows a sequential process, it often happens in an iterative manner. Figure 5-1 presents 
the iterative process followed in this study.  
 
To summarise: the research started with a broad interest (1) on the resources and 
capabilities important to life science ventures and then the researcher discussed the interest 
with topic experts (2). Followed by this the researcher reviewed the literature and designed 
the study based on the literature and discussion with topic experts. The study then 
underwent an iterative process of collecting data (5, 7 and 9), then analysing the data (6, 8 
and 10) and then comparing the data to the literature. In the last step (11) the results were 
written up. Figure 5-1 serves as the framework for this chapter.   
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Figure 5-1: The study's research process 
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5.2 Steps 1-3: background 
The literature review in chapters two and three examined the major literatures (i.e. RBV, 
dynamic capabilities, CAs, life science, and VC value added) most relevant to this 
research. Dynamic capabilities is the overarching theory used here because this work is 
fundamentally concerned with how life science ventures respond to changing 
environments to develop key resources. More specifically, this thesis is concerned with the 
paths, positions and processes that lead to the development of R&D and financial assets 
and capabilities (D. J. Teece, 1986, 2007).  
 
The literature review clearly showed that the central focus of this thesis was still early on 
its theoretical development. There is little empirical support for many of the constructs and 
propositions, and there are several grey areas that need clarification. Furthermore, little 
work has attempted to tie together the theory of dynamic capabilities with firm growth. 
The main research questions emerged from the review and discussion with industry and 
scholarly experts.  
 
5.3 Step 4: Study Design 
Steps 1-3 established the background of the research and positioned where the research 
questions are in terms of their theoretical development. Prior to establishing a research 
paradigm it is important to establish the philosophical stance of the research (Edmondson 
& McManus, 2007). In Step 4 this stance was established and the research framework was 
created based on this stance.  
 
5.3.1 Method choice for the present study 
Bell and Bryman (2003) suggest that there are five forces that influence a study towards a 
quantitative or qualitative paradigm. Figure 5-2 illustrates the major influences on business 
research, and how each of these influenced this work towards qualitative or quantitative 
methods. Each influence from figure 5-2 is analysed below, and then the research 
paradigm chosen for this study is presented based on this analysis.  
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Figure 5-2: Research influences 
 
Source: Author 
 
The theories involved in this research favour a qualitative approach. The literature review 
chapters established that dynamic capabilities is beyond its nascent stage of development, 
but it is still far from developed and it is in need of further empirical refinement. Further 
knowledge on the understanding of the underpinnings of how life science ventures develop 
R&D and financial resources and capabilities is what is most needed at this point. These 
are best gleaned from qualitative work (K. M. Eisenhardt, 1989b). The second influence 
from above, values, neither favours a quantitative or qualitative approach. Bell and 
Bryman (2003 p. 27) define values as „either the personal beliefs or the feelings of the 
researcher’. Values have a large impact on the outcome of research – especially 
interpretive research. Bias can result at any stage of research. Just because a researcher 
does not have preconceived biases does not mean that these cannot be formed (Easterby-
Smith et al., 2002; Yin, 2008). Bias is prevalent in all types of research, both quantitative 
and qualitative, and it is the job of the researcher to minimise the effect of bias in the 
research (K. M. Eisenhardt, 1989b). The validity and reliability section later on in this 
chapter further elaborates on how biases were minimised for the present study. Overall, 
bias did not have a major influence on the philosophical stance of this research and 
therefore is placed in the middle. 
 
The third major influence on business research is practical considerations. Ideally 
researchers in business should capture both great depth and generalisibility. However, it is 
usually not practical to capture both of these in a single study (Creswell, 2008). There are 
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time, cost and feasibility constraints that inhibit a researcher from being able to obtain 
everything he would like to. For this reason practical considerations are a major influence 
in designing a research project. The context and philosophical stance of the research, plus 
the previous research on the topic(s) dictate the practical considerations. (Hurmerinta-
Peltomaki & Nummela, 2004). Put differently, practical considerations are what the 
research is trying to accomplish, its main objectives. On the highest level this is concerned 
with whether the research is theory building, theory testing or both. The present study is 
concerned primarily with unearthing new insights on how life science ventures develop 
R&D and financial resources and capabilities. Therefore an interpretive approach is more 
appropriate for this and the reason why practical considerations in figure 5-2 are towards 
the qualitative end of the spectrum.    
 
The fourth influence on business research is epistemological influences. For this study the 
epistemological influences slightly favour a qualitative approach. Pettigrew (1992) 
emphasises that organisational processes are embedded in an organisation. This is 
especially true in the growth process of the firm; it would be extremely difficult to unearth 
insights on the growth process of life science firms if the researcher did not interact with 
the firms themselves. Furthermore, it would be difficult for the researcher to take an 
objective stance on the key R&D and financial resources needed for life science firm 
growth because there are few defined and tested constructs and measures on the topic. 
Therefore the epistemological influences on this study favoured a qualitative approach. 
 
The fifth influence on business research is ontology. This refers to what social entities exist 
and whether their existence is driven by established principles or if the social entities 
themselves drive the establishment of the principles. The latter is known as 
constructionism, which sees the social actors as the ones constantly constructing and 
reconstructing the principles that guide the actors (Bell & Bryman, 2003). In the context of 
a business organisation the actors (managers, employees, customers, and suppliers) drive 
the guiding principles of the firm. These principles constantly change depending on the 
interaction of the actors. The opposite view is objectivism, which sees the principles of the 
organisation as the guiding force of the actors. In the case of the firm, the established 
principles of the organisation guide the actors. For example, established work hours 
determine the actions of employees. The present study takes the stance that the managers 
in the firms are the ones that construct and guide the growth process. Because the 
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constructs related to the social entities (i.e. the managers) in this study are not well-
developed, a more qualitative approach is favoured.  
 
The analysis of the forces influencing the present study indicates that overall a qualitative 
approach is more appropriate for this thesis. However, the analysis from Figure 5-2 above 
shows that mixed approaches could also be appropriate. Table 5-1 summarises the main 
types of research designs. This table shows that there are three main research paradigms: 
qualitative, quantitative and mixed methods.  
 
Table 5-1: Methodological approaches 
Paradigm  Types of Studies 
Quantitative  Survey, hypothesis testing using primary or secondary data, 
experiment, quasi experiment 
Qualitative Case studies, ethnography, action research, grounded 
research  
Mixed methods: with 
equal emphasis 
Combination of quantitative and qualitative with equal 
emphasis 
Mixed: with quantitative 
emphasis 
Combination of quantitative and qualitative with the 
quantitative being more dominant  
Mixed with qualitative 
emphasis 
Combination of qualitative and quantitative with the 
qualitative being more dominant  
Source: Author 
 
It would seem since the present research is towards the middle of qualitative-quantitative 
spectrum, that mixed methods would be ideal. Mixed methods give a good alternative to 
strictly quantitative or qualitative approaches and are often good for research in the middle 
of the qualitative-quantitative spectrum. They are not without flaws though. One of the 
main weaknesses of mixed methods is that it is difficult for a single researcher to execute. 
A second major weakness of mixed methods is that it tends to be expensive (Perry, 1998).  
 
5.3.2 Method Considerations  
After sifting through the many possible methods that could be used for this research, two 
general approaches surfaced as the most appropriate: 1) mixed methods and 2) the case 
method. This is based on the philosophical influences discussed above and that the topics 
in the research had some theoretical underpinnings, but still needed further development. 
Mixed methods and the case method are the most appropriate for topics in this stage of 
development because they both can serve to further develop constructs into a more 
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quantifiable state (Bell & Bryman, 2003; Edmondson & McManus, 2007; Eisenhardt, 
1989b).  
 
In recent years the use of mixed methods in the social science has become accepted 
(Creswell, 2008; Jick, 1979; Johnson & Onwuegbuzie, 2004). Mixed methods is especially 
useful when the phenomenon of interest is neither at the nascent stage of theoretical 
development nor at the advanced stage of theoretical development (Greene & Caracelli, 
1997). In instances such as this, qualitative research adds insights that extend the prior 
empirical base. Kuhn (1961) suggests that qualitative work is a prerequisite to quality 
quantitative work. Before jumping into a research paradigm, McManus and Edmonson 
(2007) emphasise that fit between the methods and the state of theory is the most important 
element of a research design. Theories fall between a developmental spectrum of nascent 
to mature. Nascent theories call for a qualitative approach because the constructs and 
measures needed to quantitatively test the theory are not available; thus a qualitative 
approach is needed to develop these constructs and measures. Mature theories call for a 
quantitative approach to reaffirm or disconfirm theory. Because the theories of interest to 
this study have some defined constructs and measures, a purely qualitative approach is 
repetitive, unless it is intended to look at the topic from a different angle. Theories in the 
intermediate stage of development can use a qualitative, quantitative or mixed approach. 
Qualitative work can further establish constructs and measures, which then can be tested 
using quantitative techniques. It is critical to pair the right methods for the stage of 
development that a theory is in; pairing the wrong methods for the development that a 
theory is in has become endemic to management research (Edmondson & McManus, 
2007). Table 5-2 summarises the problems associated with this.  
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Table 5-2: Methods and theoretical maturity 
Prior work on research 
question 
Data collection and analysis Problems encountered Outcome 
Mature: Extensive literature 
complete with constructs 
and previously tested 
measures  
Qualitative only Reinventing the wheel; 
Study findings risk being 
obvious or well known. 
Research fails to build 
effectively on prior work to 
advance knowledge about 
the topic 
 Hybrid Under status of evidence; 
Paper is lengthened but not 
strengthened by using 
qualitative evidence. 
 
Intermediate: One or more 
streams of literature 
offering some but not all 
constructs and measures 
needed 
Quantitative only Uneven status of empirical 
measures; New constructs 
and measures lack 
reliability and external 
validity 
Results are less convincing, 
producing potential 
contribution to the 
literature. 
 Qualitative only Low opportunity; 
Insufficient provisional 
support for a new theory; 
Lessens papers‟ 
contribution 
 
Nascent: Little or no prior 
work on the constructs and 
process under investigation 
Qualitative only Fishing expeditions; 
Results vulnerable to 
finding significant 
associations among novel 
constructs and measures by 
chance 
Research falls too far 
outside guidance for 
statistical inference to 
convince others of its 
merits 
 Hybrid Quantitative measures with 
uncertain relationship to 
phenomena; Emergent 
constructs may suggest new 
measures for subsequent 
research, but statistical tests 
using same data that 
suggested the constructs are 
problematic 
 
 
Source: Edmonson and McManus (2007, p. 1170) 
 
According to Yin (1981, p. 59) the distinguishing characteristics of a case study are ‘that it 
attempts to examine: (a) a contemporary phenomenon in its real world context, especially 
when (b) the boundaries between phenomenon and context are not clearly evident’. Unlike 
many other approaches, especially strictly quantitative methods, case study research has 
the potential to uncover novel theory (Eisenhardt, 1989); the unique and flexible nature 
allows fresh insights to emerge. Case studies are also particularly useful for the 
development of hypotheses. They provide a sound basis for defining constructs and 
measures (Eisenhardt, 1989). There are no defined rules for case study research. They can 
use qualitative methods, quantitative methods, or a combination thereof. Although there 
are no defined rules or set protocols for case research, it is important for a case study to be 
properly designed based on the study‟s objectives (Eisenhardt, 1989a; Yin, 2008). Put 
differently, the objectives should determine the research protocols.  
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Researchers must first establish what a case study‟s purpose is. Case studies serve multiple 
purposes. They can be exploratory, descriptive, explanatory or a combination thereof. An 
exploratory case study looks at „what‟ is happening around the phenomenon of interest; 
e.g. what motivates life science firms to start up? A descriptive case study is intended to 
categorise events and paint a portrayal of the phenomenon. An explanatory case study 
seeks to establish and explain causal relationships. In many instances, including the present 
study, a combination of these is appropriate.  
 
This study adopted a strictly qualitative research approach for two main reasons: (1) the 
major theories and other major research influences involved with the research favoured a 
qualitative approach and (2) there were time and resource constraints that would not have 
allowed a proper mixed-methods study to be conducted. Case studies make an ideal bridge 
between qualitative and quantitative research (Eisenhardt, 1989a; Larsson, 1993; Miles & 
Huberman, 1994). The rich insights from the cases can be used to develop constructs and 
measures for quantitative studies. Gilmore and Coviello (1999) suggest that in qualitative 
entrepreneurial research a study design should allow for refinement through multiple 
stages and multiple techniques; this allows for new themes to emerge. Case studies answer 
this call and allow for research to unfold over multiple stages, and it also allows for the use 
of multiple techniques in a single study. Furthermore, Coviello and Jones (2004) call for 
research to integrate positivist and interpretivist methodologies, whilst at the same time 
incorporating time as a key dimension. Case studies also answer this call because of their 
ability to incorporate different data and method techniques over specified time periods. For 
the reasons outlined above, the present study used a qualitative case method.   
 
It is important before conducting a study to establish the philosophical stance of the 
research. The case method can use either positivist or phenomenological assumptions. In 
positivist paradigm the extraneous variables are attempted to be minimised so the observed 
variables can be isolated (Bell & Bryman, 2003). In a positivist study, results usually come 
from statistical testing of hypothesis. Generally speaking this type of research does not 
allow for great flexibility (Easterby-Smith et al., 2002). In contrast, phenomenological 
research observes the variables of interest within their wider context. Variation and 
flexibility in the study design are accepted. The basis for moving data to theory stems from 
comparison. In the context of cases, this is comparison is to both other cases in the study 
and to the literature (Eisenhardt, 1989a). The present study establishes a phenomenological 
paradigm that is inductive in nature. This decision was based on the researcher‟s stance 
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that the best means to unearth insights on the research questions stemmed from unearthing 
fresh insights from life science ventures in the context of their operations.    
 
Although the case approach taken in this study is inductive, it is not purely inductive. 
There are few instances when research is truly inductive or deductive (Miles & Huberman, 
1994; Reichertz, 2004). Langley (1999, p. 694) sees „rigid adherence to purely deductive 
or inductive strategies as unnecessarily stultifying‟. The present study started with an 
inquiry based on existing literature; thus from the start it was not truly inductive. If it were 
truly inductive it would have followed a grounded approach where no information was 
gathered on the topic prior to the start of the study. On the other hand, and as discussed 
previously, the study is not purely deductive. A better classification of the approach used 
in this study is abductive, which Reichertz (2004, p. 305) defines as „a cerebral process, 
an intellectual act, a mental leap, that brings together things which one had never 
associated with one another‟.  
 
Abduction is in between induction and deduction, but does not necessarily fall exactly in 
the middle. It can follow ontological assumptions that are more inductive, but it also can 
follow ontological assumptions that are more deductive (Dubois & Gadde, 2002; Kovács 
& Spens, 2005). For the present study the ontological drivers were more inductive; 
therefore the study used an abductive approach more towards the inductive side of the 
spectrum. Abduction also emphasises an iterative process of refining theoretical prospects 
and concepts (Dubois & Gadde, 2002).  
 
This thesis follows Bonoma (1985) in using four iterative steps in the research process: 1) 
drift, 2) design, 3) prediction and 4) disconfirmation. In the first stage the problem is 
defined; that is, its nature and scope. Essentially this stage is concerned with getting 
intimately familiar with the topic. The drift stage then becomes the design stage. At this 
point data collection begins, the major areas of inquiry are further refined, and 
conceptualisations are fleshed out. The design stage then becomes the prediction stage 
where ideas are further refined and compared. The prediction stage then becomes the 
disconfirmation stage where the findings are attempted to be refuted.  
 
Whilst the present study followed the steps outlined above, it also still followed 
Eisendhardt‟s (1989b) suggestion not to follow a rigid research structure when using the 
case method. Instead this thesis uses the four steps in a dynamic manner. This research 
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continually iterated backwards and forwards between the four steps, redefined concepts 
and questions and gathered additional data from multiple sources. Figure 5-3 depicts the 
iterative steps of this research. Each step taken is shown in the diamond and the bi-
directional arrows between and across the diamond represents the backward and forward 
iteration that occurred amongst all of the steps in the process. Each of the steps taken in 
this research is further discussed below.  
 
Figure 5-3: The dynamic process of the research 
 
 
Source: Author 
 
In the drift stage research topics are probed. This research started with informal interviews 
with industry and subject experts, and these were followed by an overview of the literature. 
This helped to further refine the research questions and focus. At this stage the research 
established the broad research questions and objectives. This stage established the context 
of the phenomenon; including the industry terminology, trends and industry concepts. 
   
In the design stage ideas were further fleshed out and the framework for the research was 
constructed and refined. Following Eisenhardt (1989) and Bonoma (1985), this study 
constantly referred back to the theory in a theory/data/theory fashion. This led to using 
dynamic capabilities as the overarching framework. It also led to the further refinement of 
the concepts of this study. Furthermore, the major concepts that surfaced aided in the 
selection of the case firms and the development of the first formal interview schedule. The 
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analysis from the exploratory interviews in this stage led to the further refinement of the 
studies direction. Most notably, analysis of the first round of interviews also underscored 
the importance of R&D and financial resources and capabilities in early growth. In 
summary, in the design stage the research concepts and ideas were refined to narrower but 
still relatively broad categories.   
 
In the prediction stage, ideas from the design stage were again referenced against the 
literature and the previous findings of the study. This led to the further refinement of the 
research concepts and the development of a second interview schedule and then 
subsequently the second round of interviews. This stage led to the development of general 
propositions related to the research questions.  
 
In the disconfirmation stage, the data from the interviews was scrutinised. Researchers 
often fixate on data that supports their notions and ignore data that might disconfirm their 
notions (Spiggle, 1994). This is especially problematic in interview analysis, and because 
this research relied heavily on interview data, it was important to include a step in the 
research process to disconfirm or refute findings. This study relied on three main refutation 
techniques. The first was in the data analysis where the data was attempted to be refuted. 
This was accomplished by going back through the data once major themes had been 
abstracted and looking for data to refute them. This process is further detailed later in this 
chapter in the data analysis discussion. The second refutation technique involved gathering 
data from multiple sources. The third refutation technique involved triangulating the 
findings with the key informants from each firm. This process it detailed later in this 
chapter.  
 
5.4 Steps 5, 7, and 9:  data collection 
Steps 1-4 established the background of the research and laid out a paradigm for the study. 
Steps 5, 7, and 9 were devoted to collecting the data. In case study, research data can be 
qualitative, quantitative, or both (Miles & Huberman, 1994). Data can come from many 
places, but in qualitative case studies common sources of case data include documents, 
observation and interviews with key informants. The present study utilised all three of 
these sources. However, the core of the data came from interviews with the key informants 
from the focus firms of the study. The researcher conducted a total of eighteen formal 
interviews, which totalled over twenty hours and produced over 500 pages of transcripts.   
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In qualitative case research it is helpful to establish the unit of analysis prior to selecting 
the case firms (Yin, 2008). This allows for the selection of firms that provide the richest 
information for the research questions and objectives. In this study the main unit of 
analysis is R&D and financial resources and capabilities. This unit of analysis is complex 
because of the many factors that influence the development of R&D and financial assets 
and capabilities needed in growth. However, properly selecting case firms that isolate the 
unit of analysis can allow for complex ideas to be captured (Eisenhardt, 1989a; Yin, 2008). 
Because the process is so central to the unit of analysis of the present study, it was 
important to isolate firms in a particular stage of growth.  Following this logic, the present 
study identified firms that were at the commercialisation stage of development. Firms at 
this stage of development were chosen because it is a critical stage to survival and growth 
(Kazanjian & Drazin, 1989). Furthermore, Perry (1998) suggested that replication and 
validity is enhanced by purposeful sampling where results can be compared. Having firms 
in the same stage of development allowed for a basis of comparison for the present study.  
 
The literature and informal interviews with industry experts were instrumental in choosing 
the unit of analysis. It is clear from both of these that the R&D and financial resources and 
capabilities needed in growth are best captured from high level executives who are 
intimately familiar with the firm‟s history and development, so this research follows suite. 
Isolating the firms to capture the unit of analysis through this lens also helped to delimit 
the study. It is not possible for one researcher to capture the all of the data relevant to a 
research topic from all possible sources (Bonoma, 1985; George & Bennett, 2005); this 
produces far too much data to process.    
 
Another important factor in the collection of data for this project is its longitudinal design. 
A longitudinal design is important in research involving growth because it allows complex 
processes to be captured and broken down into steps (Johanson & Wiedersheim-Paul, 
1991; Welch & Luostarinen, 1988). By definition, process studies are looking at change 
over time; therefore, studies that capture a static snapshot cannot convincingly explain 
processes. Longitudinal studies help increase the reliability and validity of a study by 
capturing the steps that make up the processes. Thus qualitative studies, such as the present 
one, increase their trustworthiness by imploring a longitudinal design, ensuring that 
important events that may have affected processes are not overlooked (Pettigrew, 1990). A 
longitudinal design is appropriate for the present study because it is interested in the R&D 
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and financial resources needed in firm growth.  Longitudinal studies are more complex, 
especially in qualitative studies where thousands of pages of data can be collected (Yin, 
2008). It is therefore essential to collect and analyse data systematically. Consequently, 
this study collected and analysed data in three systematic steps to ensure reliability and 
credibility. These steps are further detailed later in section 5.5.  
 
Table 5-3 overviews the data collected for this study. The data was collected over a three 
year period and chiefly came from interview data, but other sources were used as well. 
This section further elaborates on the data, the sources of data and how it was collected.  
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Table 5-3: Kinds of data  
 
                                                                                                                         Case firm 
 
Data type BA1 BA2 DD1 DD2 MD1 MD2 
 
Interview  Aug 2008: 55 
minutes 
 Mar 2009: 65 
minutes 
 Feb 2011: 52 
minutes 
 Aug 2008: 63 
minutes 
 Feb 2009: 71 
minutes 
 Dec 2010: 38 
minutes 
 
 Aug 2008: 71 
minutes 
 Mar 2009: 77 
minutes 
 Dec 2010: 37 
minutes 
 Sept 2008: 52 
minutes 
 Feb 2009: 45 
minutes 
 Jan 2011: 65 
minutes 
 Sept 2008: 65 
minutes 
 Feb 2009: 45 
minutes 
 Feb 2011: 52 
minutes 
 Sept 2008: 50 
minutes 
 Jan 2009: 55 
minutes 
 Dec 2010: 62 
minutes 
 
Archive  7 news 
articles: 2,800 
words 
 4 websites: 
9,000 words 
 8 news articles: 
2,600 words  
 5 websites: 
17,000 words    
 1 industry brief: 
1,600 words                                                            
 12 news 
articles: 4,200 
words 
 6 patent 
records: 35,000 
words   
 12 websites: 
18,000 words                                                               
 
 21 news 
articles : 6200 
words  
 14 patent 
records: 
45,000 words    
 6 websites: 
15,000 words                              
 3 news articles: 
900 words    
  3 patent 
records: 11,000 
words 
 2 websites: 
4,000 words                                                                        
 8 news articles: 
2,700 words 
 3 patent 
records: 6,000 
words  
  2 websites: 
2,000 words                                                                                
Direct observation  August 2008: 
90 minutes 
 March 2010: 
40 minutes 
 Feb 2011: 50 
minutes 
    Feb 2010: 60 
minutes 
 Feb 2011: 60 
minutes 
 
Source: Author
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5.4.1 Case selection 
Ensuring research design to acquire an accurate sample used to represent the population is 
especially challenging in qualitative work, where sample sizes are usually small (Yin, 
2008). On the other hand, qualitative studies are not used to create law, and therefore these 
studies can afford to have more latitude in their sampling accuracy. The lack of 
randomness does not mean that case studies should not represent the population though. 
Seawright and Gerring (2008, p. 296) suggest that ‘a case should provide useful variation 
on the dimensions of theoretical interest’. The present study is particularly interested in the 
R&D and financial resources of firms in rapidly changing environments. Therefore life 
science firms were deemed as appropriate cases for this study: life science firms are high 
tech and have a high propensity to use VC (Gompers & Lerner, 2001; Mayer, Schoors, & 
Yafeh, 2005).  
 
Eisenhardt (1989b) suggested using between four and ten cases because this number 
allows for an in-depth analysis within a reasonable amount of time. Following Eisenhardt 
(1989), twelve firms were selected for the research. Case selection was based on the 
following criteria: 
 
1. Is a life-science firm. 
2. Is in the early stages of the commercialisation phase of development.  
3. Has less than 250 employees.   
 
These criteria were chosen based on the research topic. Life science firms make an 
excellent choice because of their dynamic nature, and the life science industry is the 
industry that the research has practical experience in and was most interested in. For these 
reasons firms from this industry served as the sample for this study. The E.U definition of 
small business as 250 or fewer employees was used. Firms were chosen at various points 
within the size spectrum (i.e. 4-225) to examine the effects of the various sizes of firms on 
the research question; e.g. do micro firms of four employees have different experiences 
than firms of 225 employees.  
 
Figure 5-4 depicts the steps taken to identify and select the case firms for this study. In the 
first step the potential population of firms that met the study‟s requirements was identified, 
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which was believed to be approximately 1,500 (Van Beuzeken and Arundel, 2008). 
Because most firms that fit these criteria are private firms, they are not transparent with 
their operational information. This made it difficult to find firms.  
 
In the second step of the selection process potential firms from with the population were 
identified. The areas of San Diego, San Francisco, and south Florida were targeted because 
of the large number of life science companies present in those areas. In order to find the 
names of the firms and the contact name of the founders and/or the senior management, 
several databases were cross referenced. The main databases crossed referenced are: 1) 
Grow Think Research (www.growthinkresearch.com), 2) Bio Space (www.biospace.com), 
3) Jigsaw (www.jigsaw.com) and 4) 411 Lead (www.411lead.com). 
 
The first of these databases, Grow Think Research, is dedicated to collecting research on 
early stage technology ventures. Several noted studies used such a database for filtering 
firms (e.g. Deeds, 2002; Lynsay, 2009; Rothaermel, 2001). The Grow Think Research 
database attempts to track all of the information available on high technology ventures. 
The website has a built-in search engine to locate companies that have received venture 
funding. It also has further options to narrow the search down by industry, size of 
company, size of investment received, age and location. Once the inputs are entered, a 
query is run, and the results are listed alphabetically. The user can then click on each firm 
to find out more information on the company, including its product or service offering. For 
this research the following inputs entered were 
 
 Industry: Life science  
 Company Size: <250 employees 
 Age: <15 
 Investment Received: Early Stage 
 Location: San Francisco, California; San Diego, California; and Miami, Florida  
 
The query yielded 262 companies. Subsequently, all 262 firms‟ profiles in the Grow Think 
database were reviewed. The objective of the review was to further weed out firms that did 
not meet the criteria of the exploratory study. The review disqualified 87 firms, which 
reduced the number of firms to 175. The relevant information for the 175 firms was 
recorded in a tracking database the researcher used as part of the research records.  
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The qualifying companies were then cross-referenced in the Biospace database; which is a 
database of life science firms in the U.S that has been used to glean information on life 
science firms in several noted studies (e.g. Deeds, 2002; Rothaermel, 2001; Smith, 1999). 
Each company was entered into the Biospace database, and the reference found no 
significant discrepancies from the information found in the Grow Think database. 
However, for seventy-nine of the companies it found additional information that was 
useful and which was added to the information in the tracking database.  
 
The resulting firms were then cross-referenced in the Jigsaw database, which contains the 
names of employees at companies. For each company the names, phone numbers and 
email address of the founders and/or the key executives was recorded in the tracking 
database. A similar process was followed in the 811 Lead database, one with similar 
information and function as Jigsaw. This process yielded the names and phone numbers of 
exectutives at 176 firms. These names and numbers were then recorded in the tracking 
database.  
 
In the third step (Figure 5-4, step 3), all of the founders and or key executives that met the 
parameters for the exploratory study were contacted via telephone to see if they would be 
willing to participate in the study. This yielded seventeen executives who consented to 
participate in the study. After the phone calls, emails explaining the research and asking 
for help were sent out to the forty-two firms that were unable to be contacted by phone. 
The emails resulted in seven more firms expressing interest in assisting with the study; 
thus a total of twenty-four firms consented to participate in the study. These firms were 
then contacted a second time and asked a series of filtering questions to see which firms 
would be best for the study. From these questions twelve firms emerged as optimal for the 
study and were subsequently interviewed.  
 
The initial round of interviews was then conducted, and the data for these interviews was 
analysed. At that point the researcher decided to further focus on six firms (focus firms) in 
order to allow for more depth with each.   
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Figure 5-4: Case selection 
 
Source: Author 
 
Firm groups 
All of the firms were coded to keep their identities anonymous; to help protect the 
proprietary information of the firms and to also make the firms more comfortable in 
participating in the study. These codes are based on the firms‟ subsectors (Senker & Sharp, 
1997), and they categorised the firms into three groups: 1) Biological Analysers (BAs), 2) 
Drug Development (DDs) and 3) Medical Device (MDs). Previous studies have used 
industry subsectors to classify firms for comparative purposes; subsectors provide 
variation that is a good basis for comparative purposes (Dewick, Green, & Miozzo, 2004; 
Feldman, 2005; Hendry & Brown, 2006). The firms used in the present study were small 
life science firms in the commercialisation phase of development.  
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Table 5-4 highlights the revenues and financing obtained of each of the firms examined in 
this study.  
 
Table 5-4: Case firm profiles 
Firm  Year Founded Revenues in 2009. Specialised financing obtained as 
of December 2010. 
BA1*** 2004 <$1 million $1.1 million 
BA2*** 2003 <$1 million $4 million 
BA3 2005 $8 million $75 million 
BA4 2005 $42 million $40 million 
DD1*** 2001 <$1 million $28 million 
DD2*** 2001 <$1 million $8 million 
DD3 2000 $15 million $105 million 
DD4 2000 $60 million $70 million 
DD5 2000  $25 million $450 million 
MD1*** 2000 <$1 million $10 million 
MD2*** 2003 <$1 million <$2 million 
MD3 2004 <$1 million <$14 million 
Source: Author 
*** Focus firm 
 
The noticeable differences amongst these firms were the revenues and the amount of 
capital raised. Although these differences are in some cases significant, these firms are still 
relatively similar. Furthermore, some variation amongst cases is desirable for the sake of 
comparison (Eisenhardt, 1989a; George & McKeown, 1985). Thus the bounded variation 
in the cases is ideal.   
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5.4.2 Interviews 
The bulk of the data for this study came from interviews. These interviews transpired over 
a five-year period (2006-2010) and consisted of informal and formal interviews with key 
personnel. There were three rounds of interviews, and each round of schedules was based 
on the literature and the previous round of interviews analysis. The researcher developed 
the interview schedules based on the Jones, Wheeler, Vlachos and De Opacua (2008) 
interview schedule; which was originally designed to explore the growth and 
internationalisation of Scottish life science firms.   
 
The interviews started with open-ended questions to allow the interviewee to offer 
unsolicited insights. Close-ended questions then captured specific points. The interview 
schedule for each round of interviews is detailed later in this section. The interviews took 
place with key personnel from each firm who had been with the firm from or near 
inception; which is ideal in the field of management because intimate knowledge of the 
firms‟ operations is needed to capture deep insights (Eisenhardt, 1989a). Each interview 
was taped, transcribed and field notes were taken. Subsequently, a second round of 
interviews ensued with the firms to narrow down the generalisations found from the first 
round of interviews. These interviews were transcribed, analysed and compared to the data 
from the first round of interviews. Next a third round of interviews was conducted. This 
round was different in that it aimed to validate the first two rounds. This time the 
respondents were asked to validate findings from their firm.   
 
Interviews are one of the best methods for studies intending to unearth fresh insights 
(Kvale & Brinkmann, 2008). Gillham (2000) suggests that one of the biggest benefits of 
interviews is the flexibility to probe new paths that were not originally considered, whilst 
still capturing specific information. Interviews using open-ended and close-ended 
questions encourage two-way conversation between interview and interviewee, allow for 
flexibility to further probe for relevant information and allow the interviewers to offer 
insights that may not have been considered before the interview. These insights are 
captured through interpretive content analysis of the interviews, whilst close-ended 
questions allow for specific points to be captured (Seawright & Gerring, 2008). The close-
ended responses also help with in-site validation of key issues and are useful for cross-case 
comparisons. The research topics in the present study are in the earlier stage of 
development, but there is some theoretical development on the topics. For this reason an 
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open and close-ended interview schedule provided the best means to capture new concepts 
whilst still capturing specific data to compare to existing theories.  
 
The interviewer is an essential part of the research process, especially in open-ended 
interviews (Yeung, 1995). Researchers should first make the interviewee comfortable. For 
the present study this was particularly important as the case firms were all high tech, which 
tend to be sensitive about divulging information about their operations (Unikel, 1997). In 
order to gain the confidence of the interviewee, three main tactics were used: 1) a thorough 
description of the research project and its aims and objectives was given to the interviewee, 
2) a confidentially agreement was given to each of the interviewees before the interview 
was conducted and 3) the questions in the interview avoided asking specifics about trade 
secrets. Another challenge for an interviewer is asking appropriate questions to probe for 
information; if appropriate questions are not asked, then irrelevant or no information would 
emerge from the interview (Benjamin, 1974). To overcome this challenge, the interview 
schedules stemmed from the existing literature, the informal interviews, and information 
gathered on the case firms.  
 
A third challenge for the interviewer is to make sure that the interviewee understands the 
questions being asked (Easterby-Smith et al., 2002). The present study ensured that the 
questions were clear and concise; all possible unfamiliar terms were defined and the 
respondent was encouraged to ask the interviewer clarifying questions. Furthermore, the 
interviewee first told his or her own story of the firm and its growth, allowing for fresh 
insights to emerge and helping to increase the credibility of the interview by reducing the 
possibility of directing the respondent towards certain responses (Gillham, 2000). Multiple 
interviewers also helped ensure the emergence of accurate and meaningful information. 
The primary researcher and his supervisor, Professor Marian Jones, conducted the first 
round of interviews. A fourth challenge for interviewing is eliminating the interviewer‟s 
bias. The researcher attempted to eliminate all preconceived biases; mainly though the 
development of unbiased interview schedules.  
 
Another mechanism used to eliminate bias was to get feedback on the interview schedules 
from subject experts before the interviews were conducted. Furthermore, a number of 
triangulation techniques, which are discussed in the next section, were employed to help 
eliminate researcher bias. The fifth challenge in interviewing and arguably the biggest 
challenge for a researcher conducting interviews is listening (Benjamin, 1974; Yin, 2008). 
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Interviews yield massive amounts of data, and during the open interview process, the 
interviewer must filter the most relevant data to use for probing questions during the 
interview. In order to filter information during an interview, Kvale and Brinkmann (2008) 
suggest taking field notes, listening for key terms and asking clarifying questions 
throughout. The present study followed this advice. Furthermore, at the end of the session 
the interviewer presented the respondent key points taken from the interview to verify 
(Yin, 1983).    
 
5.4.3 Interview Design 
Conducting multiple interviews and designing the subsequent interviews from the prior is 
an ideal method to capture specific theoretical concepts (Hurmerinta-Peltomaki & 
Nummela, 2004). Based on the first round of interviews, a second round of interviews on a 
narrower set of topics was conducted with the six focus firms. This set of interviews 
intended to draw further information on what had emerged from the first set of interviews. 
The third set of interviews confirmed findings from the first two rounds of interviews with 
the focus firms, but also left room for new insights.   
 
Interviewing respondents intimately familiar with the phenomenon of interest helps to 
increase the validity and reliability of the data gathered from an interview (S. Kvale & 
Brinkmann, 2008). Qualitative research in management often involves gathering 
information from high-level executives because they are knowledgeable in all of the firm‟s 
operations (Harrigan, 1983); thus they are able to offer data which is more reliable. To 
increase the reliability and validity, many studies on small firm growth (e.g., J. Bell, Crick, 
& Young, 2004; Boter & Holmquist, 1996; Burgelman, 1983; Knight & Cavusgil, 2004) 
have used interviews with executives as a source of data. The fact that all of the 
interviewees in the present study were with the firm from (or really close to) its inception 
also helped increase the trustworthiness of the data. Table 5-5 further details each 
informant‟s relationship with the firm. 
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Table 5-5: Data collected from 
Firm Informant(s) Notes 
BA1*** CEO; Board member Founder 
BA2*** CEO Founder 
BA3 CEO Founder 
BA4 Operations manager His father started the 
business, and he has worked 
there since inception. 
DD1*** CEO 
Chairman  
Director of research 
CEO is not technically a 
founder but has consulted 
with the firm since the 
beginning and owns a 
significant amount of the 
firm. 
DD2*** CEO 
Chairman 
Founder 
DD3 Chief scientific officer Founder 
DD4 Chief operating officer Came on within three 
months of the firm‟s 
founding. 
DD5 CEO Founder 
MD1*** CEO Founder 
MD2*** CEO 
Founder 
 
CEO is not a founder, but 
has been with the firm since 
year 2. 
MD2 CEO Founder 
 Source: Author 
*** Focus firm 
 
First round of interviews 
At the time of the first round of interviews the research had four objectives: 1) gaining a 
background on the firms, 2) exploring the resources and capabilities needed in growth, 3) 
probing out what general effects the VCs non-financial resources had on the firms and 4) 
giving the interviewees a chance to offer unsolicited insights on the research topic (from 
the general open-ended questions) to draw themes from. The first point of interest in the 
study was the development of key resources. In order to examine it, the first interview 
schedule looked at six areas: 
 
A. The firm‟s current position 
B. The foundation process of the firm 
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C. The critical events of the firm 
D. The impact of international activity 
E. The firm‟s boldness, creativity, and innovativeness 
F. The firms R&D and product portfolio management  
 
The first category of questions intended to provide an overview of the firm‟s competitive 
positions in both domestic and international markets. These questions were designed to 
establish the competitive position of the firm and what the important contributors to getting 
in that position were. The interview schedule consisted of a series of open and close-ended 
questions. This category stemmed from the assets and capabilities literature, which 
suggests that several factors such as unique resources (Oviatt, McDougall, & Loper, 1995), 
R&D spending (Burgel & Murray, 1998), executives with international backgrounds 
(Westhead, Wright, & Ucbasaran, 2001), important CAs (Teece 1986; Rothaermel 2001) 
and growth orientation (Autio, Yli-Renko, & Salonen, 1997) affect firm growth.  
 
In the second category of questions respondents were asked to 1) provide a history of the 
firm, 2) establish why the firm was founded, 3) establish how the firm was funded, 4) see 
if there were any international activities that were important in the foundation of the firm 
and 5) see what the aims and objectives of the founders were when they started the firm. 
This set of questions was aimed at probing what the main drivers of the firm‟s foundation 
were in order to probe the motivation of the firm‟s foundation and what major assets 
influenced the firm‟s early growth.  
 
The third category of questions probed the significant milestones that influenced the 
direction of the firm. This category gave the interviewee an opportunity to discuss any 
major events that affected the growth and development of the firm. There were probing 
questions asked to get the respondent to discuss the effect that equity investors had on the 
process. Studies suggest that VC is an important milestone in the development process of 
firms (Gompers, 1995; Timmons & Bygrave, 1986); the questions were designed to see the 
importance of the VC, especially relative to other major milestones. In a similar vein, the 
questions in category four explored the important activities that impacted the firms‟ 
development.   
 
Categories five and six aimed to unearth insights on the influence of innovation on the 
development of the firms. Innovation is critical to the growth of new technology-based 
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firms (Löfsten & Lindelöf, 2002). The main purpose of these questions was to see what the 
effect of innovation was, as well as to see what the sources of innovation were. Moreover, 
innovation is a driver of internationalisation (Bloodgood, Sapienza, & Almeida, 1996), and 
studies indicate that VC has a significant positive impact on innovation (R. Florida & 
Smith Jr, 1990; R. L. Florida & Kenney, 1988; Kortum & Lerner, 2000; Timmons & 
Bygrave, 1986). Thus these questions also explored the impact of VC on the firm‟s 
innovation and internationalisation.     
 
Second round of interviews 
A second round of interviews was conducted with the case firms. The interview schedule 
was based largely on the analysis of the first set of interviews. The first round of interviews 
established the background on the case firms in this study and also raised three major 
themes: 1) R&D and financial assets and capabilities are at the heart of early growth, 2) 
unique paths, positions and processes lead the development of R&D and financial 
resources and capabilities and 3) VC has various effects on the growth of life science 
firms, but these effects are not always positive.  
 
Results from the first round of interviews suggest that R&D and financial resources and 
capabilities are vital to the firms‟ foundation and growth. The second and closely related 
theme that emerged is that R&D and financial resources and capabilities come from a 
variety of sources: internal resources, industry partners, university partners, the 
government and VCs. Furthermore, there are a unique set of paths, positions and processes 
that lead to the development of R&D and financial resources and capabilities. The third 
theme that emerged from the first round of interviews is that the VC business model is 
inherently flawed. There is little extant literature on this topic. Therefore the questions 
were drawn on the basis of the first round of interviews. Although this topic is not directly 
related to the first topic, it does have an effect on the development of firms.  
 
Like the first round of interviews‟ schedule, the second round schedule used both open and 
close-ended questions. This type of interview schedule allows for new themes to emerge, 
whilst still being able to capture specific points (Labaw, 1981). The questionnaire 
consisted of five sections. It started off with questions pertaining to the R&D and financial 
assets and capabilities important to the firms‟ growth. It then moved into questions about 
where R&D and financial assets and capabilities stem from. Subsequently, the 
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questionnaire asked questions relating to the effect of the VCs business model. Each 
section of the interview schedule is further explained below.  
 
Section A 
This section hones in on the key resources important to the firm‟s early growth, namely, 
which R&D and financial resources are paramount. The open-ended questions in section A 
provided the respondents an opportunity to provide fresh insights on these questions; 
whilst the questions in section A1 captured specific information relating to paths, positions 
and processes leading to the development of key resources and capabilities. Another 
objective of this group of questions was to probe the source of the key resources and 
capabilities. Questions 1.1-1.16 in A1 specifically ask about how alliances led to the 
development of the key resources and capabilities. These questions were developed on the 
basis of alliances literature (Coombs & Deeds, 2000; Lindsey, 2008) and the resources and 
capabilities literature (Teece, 1986; Trispas, 1996). 
 
Section B 
This section follows a similar rationale to section A in that it aimed at going into further 
depth on the events that led to the development of key resources by focusing on the major 
milestones. Miles and Huberman (1994) suggest that insights on major events in time can 
help to establish important facts in theory building. Similarly, Yin (2003) suggests critical 
events are important to establishing the context of a case. Thus the purpose of the open-
ended questions in this section was to probe the time frame and events that led to the 
development of the critical resources and capabilities. Moreover, this section also included 
some questions to probe the effect that resources and capabilities had on the growth of the 
firm. 
  
Section C 
The first two sections aimed to establish the resources and capabilities important to firm 
growth. Section C goes into more depth on the role of VC. The rationale for this section 
comes from the literature on VC networks (Lynsey, 2009; Sorenson and Stuart, 2001; 
Wright and Lockett, 2003) and VC value-added literature (Gompers and Lerner, 1996; 
HSU, Hellman and Puri, 2002). However, this literature is vague and there is only specific 
coverage on the value of VC networks in aligning future financing. For this reason the 
section starts out with open-ended questions to let the respondents offer new insights on 
the influence of VC on the firms‟ growth. These were followed by a set of more specific 
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questions on whether resources and capabilities were created from VC inputs or VC 
networks.  
 
Section D 
The first round of interviews suggested that firms tended to have a few partners that 
provide inputs. This section presents a table to capture data relating to these partners. It is 
intended to see if any patterns from the top partners emerge. This table is based largely on 
resources literature, which suggests that partners are important sources and that firms tend 
to have a few key partners (Arora & Gambardella, 1990; Graff et al., 2003; Rothaermel, 
2001a, 2001b). The table captures specific points relating to how the partners influenced 
the firms‟ growth.  
 
Section E  
One of the themes that emerged from the first round of interviews is the inherent flaws in 
the VC business model. Almost no literature exists on this topic. For this reason the section 
starts off with open-ended questions that are based on the results of the first round of 
interviews. The questions in section E1 ask close-ended questions to capture specific 
points about the problems with the funding models available to life science firms.  
 
Third round of interviews 
This round of interviews was intended to validate the findings of the first two rounds of 
interviews. Pragmatic validation, a powerful means to triangulate findings, is a form in 
which the perspective of the findings is judged by the sample of interest (Kvale, 1987), 
which in this study is the case firms. One of the main validation techniques that this study 
uses is a survey on the major findings. Each of the major influences that the study found 
important to the development of R&D and financial resources and capabilities was 
presented in a survey to each of the case firms in this study, and the respondents rated the 
importance of each influence. This data does not serve for statistical testing, but instead 
each response is compared to the analysis from the qualitative data for each of the firms. 
This serves to validate the findings. In general, most of the findings were validated, but 
there were a few small discrepancies. In those instances more information was gathered to 
clarify the discrepancy, and an explanation for the discrepancy was established.   
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Archives and observation 
The research supplemented the data collected from the interviews with all publicly 
available data for each of the case firms. This included new articles, websites, analyst 
reports, patent records and articles in scholarly journals. All of this data was recorded in a 
case record for each firm. Case  records help to organise a study, keep track of information 
and provide a common framework for tracking data for each case in a study (Stake, 1999). 
Observation was also utilised in the data collection. The researcher spent a total of twelve 
hours (four hours each at three different case firm sites) observing the operations, sitting in 
top management meetings and touring facilities. Copious observation notes were taken and 
recorded in the case records for each of these visits. Collecting data from multiple sources 
is a good way to triangulate a study. Data from other sources offer potential new insights 
and can confirm or disconfirm ideas from other sources of data (Yin, 2008); the 
supplementary data collected in this study served this purpose.  
 
5.5 Steps 6, 8, 10: data analysis 
The analysis of case research depends on the type of case study, the number of cases used 
and the objectives of the study. The present study used six case studies, is concerned with 
unearthing new insights on the development of life science ventures and relied primarily 
on qualitative data. Eisenhardt (1989b) suggests that for qualitative case research there are 
two main approaches to analysis: within-case and cross-case. In within-case analysis the 
goal is to narrow down the massive amounts of data into manageable amounts that can be 
properly analysed in a scientifically valid manner; whereas cross-case analysis is 
concerned with comparison and theme narrowing and replicating (Eisenhardt, 1991). 
However, using both within-case and cross-case analysis is often the preferred choice for 
research involving multiple cases (Miles and Huberman, 1994; Yin, 2008). That this study 
used multiple cases as well as the nature of the study made using both approaches of 
analysis appropriate. Each case was analysed individually and the emergent data was 
recorded for each case. Data was then analysed across groups and cases. The within-case 
allowed the findings from each to be analysed individually, whilst the cross-case provided 
a means of replication. 
 
The core of the data for this study emanated from a series of interviews that consisted of 
three separate rounds of interviews. However, the study also captured numerical data 
consisting of financial and operations data (e.g., number of employees, revenues, etc.) and 
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is presented in tables. Rather than being statistically tested, it is used to help construct case 
histories. The cross-case analysis tables were constructed for each major category with 
each case represented.  
 
5.5.1 Data coding 
Before discussing the reduction and packaging of the data, it is important to discuss the 
techniques used to identify the codes. These codes emanated from the literature (priori 
codes) and the emergent inductive themes found throughout the analysis. Below the 
multiple step process used to code the qualitative data is described.  
 
In the first step, coding of the text, transcripts and the field notes was done using four 
techniques outlined by Ryan and Bernard (2003): 1) identifying repetitions, 2) looking for 
transitions, 3) identifying similarities and differences and 4) cutting and sorting notable 
quotes. For each of these techniques the data was uniquely read (i.e. the transcripts were 
read four separate times during this step), and the elements were coded along the lines of 
the particularities of each technique, and were then recorded on a coding sheet.  Repetition 
is one of the most basic ways to identify themes and was the first technique used. 
Essentially the researcher is looking for ideas that reoccur throughout the text (Silverman, 
2006). Examples that reoccurred throughout the first set of interviews were the importance 
of finances; several key R&D and financial resources and capabilities critical to growth; 
and that the VC business model is flawed. The second data analysis technique searched for 
transitions in the data. Abrupt pauses or shifts in a interviewee‟s thoughts often indicate 
significant events or issues, and these are often a basis for themes (Ryan & Bernard, 2003). 
The third analytical technique used in this study identified similarities and differences. 
Glaser and Strauss (1967) call this constant comparison, which is essentially comparison 
occurring across units of data. There are several approaches to constant comparison. The 
most detailed is line-by-line analysis where every line is compared. The least detailed 
constant comparison technique is comparing blocks of texts. The text block method is 
much less time intensive than the line by line method, and because of the large amount of 
data collected, this study used the text comparison technique. Notes were taken for each 
section of text and compared to each other. Cutting and sorting of notable quotes is the 
fourth text analysis technique used in this study. These were placed into categories based 
on themes. There are many techniques to sort amongst themes, ranging from sorting into 
many different themes to sorting into broad themes. This study used a relatively broad 
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sorting system of twelve categories for the emergent themes. A comparison of the four 
analytical techniques produced the broad categories of themes for the study‟s framework.  
 
The first four coding techniques yielded almost twenty-five themes, but in order to more 
finely glean the data, two more coding techniques suggested by Russell and Bernard 
(2003) were used. The first is theory matching. In this step the interviews were searched 
for themes relating to prior and emerging theory. Sections of text were analysed and 
compared to the existing literature on life science firms, the RBV, dynamic capabilities and 
CAs. The second step taken in the second stage of the refinement process looked for 
missing data. Often respondents will intentionally or unintentionally leave out pertinent 
information in responses that are important to a topic (Taylor & Bogdan, 1984). 
Entrepreneurs are known to overemphasise their role in a venture (King & Roberts, 1992). 
Since most of the interviewees in the present study are the entrepreneurs who started the 
firm, it follows that the interviewees may have left important information out of their 
responses to emphasise their role in the firm‟s development.  
 
5.5.2 Data categorising, reduction and structure 
The coding processes described above serve to identify the themes of the study. Figure 5-5 
depicts the steps in the analytical process used to summarise, reduce and aggregate the 
data. In the first part the researcher gathered data from interviews and secondary data and 
analysed each part using Miles and Huberman‟s (1994) three level analytical abstraction 
process. At the first level major themes were summarised and packaged together in major 
categories.  At the second level data was abstracted and categorised along narrower 
themes. At the third level data was reduced to major themes and an explanatory framework 
was developed. Part II then deductively validated the findings from the first part.  
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Figure 5-5: Data categorisation, reduction and structure 
 
Source: Author 
 
Part I of the data analysis began with the coding techniques described in section 5.4.1 
above. Seventeen of these codes stemmed from literature (a priori codes) and twelve 
inductive codes emerged during the analysis (Appendix A, Table A1). At this stage in the 
analysis it emerged that R&D and financial resources and capabilities drove the early 
development of the firms, as was evidenced in over seventy-five per cent of the codes 
related to R&D and finance, despite the fact that only a few of the questions asked in the 
interview directly probed these areas. Consequently, step two of the analysis repackaged 
the data along the lines of R&D and financial resources and capabilities (Appendix A; 
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Table A2). At level three of the analysis the research then further refined and created a 
structure for the data categorising it into two main groups (R&D and financial) with each 
of the groups having three sub-group: paths, positions and processes (Appendix A: Table 
A3). At the third level in the data analysis Miles and Huberman (1994) suggest that data 
should be tested. In order to do this the study then presented the findings to the respondents 
(Part II of Figure 5-5).   
 
In part II the research created a questionnaire (Appendix D) aimed at validating the 
findings. The questionnaire is based on pragmatic validation, which is a powerful means to 
triangulate findings. This is a form of validation, which the perspective of the findings is 
judged by the sample of interest (Kvale, 1987). The respondents from each firm were 
presented with each of the themes produced from the first part of the study on a scale of 1 
(not important) to 7 (very important). Based on the first two parts of the analysis, the 
questions were pre-coded for each of the firms. These codes were then compared to the 
responses from the key informant from each firm. The researcher then gathered more 
information on any major discrepancies between the pre-coded responses and the 
responses by the respondents.   
 
The careful coding and analysis techniques described above are important, as researchers 
often have no systematic approach to coding data; they often rely on intuition to come up 
with categories whilst they are reading through the transcripts (Ryan & Bernard, 2003). 
This is often a good initial technique, but it limits the information that can be gleaned from 
the transcripts. Even in a grounded study a more structured approach to analysing data is 
needed. The systematic approach taken in the coding of the data in the present study 
helped to uncover ideas, and it also added to the credibility of the study by ensuring that 
the themes and ideas were drawn from all angles of the data.  
 
One particular challenge for researchers analysing qualitative data is managing their data.  
To aid in this, the present study used software and a case database. RDQA is a qualitative 
data analysis program. This relatively new program has powerful functions to store, trace 
and query data. Qualitative data analysis software such as this is quite popular in 
qualitative management studies (Yin, 2008). A custom-created database by the researcher 
also aided in tracking the key case information for all of the firms. On top of the electronic 
filing, the researcher printed, labelled and filed each page of data.  
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5.5.3 Reliability and credibility 
There are several shortcomings of the methods implored for this study. Quantitative purists 
might fault it for the lack of generalisability. However, this is not one of the main 
objectives of the study. Rather the main objective is to capture rich insights on the R&D 
and financial resources and capabilities needed in the growth of life science ventures, and 
as discussed earlier, these are best captured through qualitative techniques such as the case 
methodology used in this study (Bell & Bryman, 2003; Easterby-Smith et al., 2002). 
Qualitative research is also criticised for lack of rigor. However, even quantitative purists 
recognise that a properly designed and executed qualitative study can be just as rigorous as 
the best quantitative study. Closely related to rigor, and the source of the third and biggest 
criticism of qualitative work is the lack of reliability and credibility. In many cases this 
criticism is valid: qualitative researchers often dismiss the importance of reliability and 
credibility.  
 
Reliability is an elusive term to define in qualitative research. In quantitative research it 
refers to the ability of the results to be replicated (Bell & Bryman, 2003). By the nature of 
qualitative work it is difficult, if not impossible in many instances, to produce results that 
are completely replicable. For this reason reliability takes on another meaning in 
qualitative research. Lincoln and Guba (1985, p. 317) contend that reliability is best 
described as „dependability‟ in qualitative research. Dependability comes from the quality 
of the processes and products of the work. To capture dependability, the present study took 
careful consideration to create consistent measures and processes to explore the research 
questions. The first way dependability is captured is through the design. The study used 
consistent processes throughout the research, the three most important being the design of 
the interview schedule, the selection of the case firms and the analysis of the data. The 
interview schedule was carefully crafted on the basis of the literature and discussions with 
industry experts. This produced theoretically sound questions. The selection of the case 
firms is the next major process that was carefully controlled for. As discussed previously in 
this chapter, the study used life science firms, which are used extensively as samples in 
studies on the major theories related to this project. The study also carefully controlled for 
the analysis of the data. As discussed above, the study used several commonly accepted 
and rigorous techniques to draw themes. To further ensure reliability, the study took 
careful consideration to use the same techniques for all of the case firms‟ data. 
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The reliability discussed above is a prerequisite to the validity of the study (Lincoln & 
Guba, 1985); i.e. the findings could not be valid unless the reliable processes discussed 
above were used to find them. Like reliability, validity in qualitative work is elusive to 
define. Denzin (1970) sees validity scales as dependent on the accepted body of knowledge 
in the research community. He says they ‘are only symbolic – they have no meaning other 
than that given by the community of scientists’ (p. 106). The main way that validity is 
established in this study is through using reliable processes and basing the work off of 
existing theories and methods that are accepted in the literature. Ultimately validity and 
reliability in qualitative work is judged by how credible and trustworthy a study is.  
 
Table 5-7 summarises the steps taken in this study to establish trust. These steps were 
taken from the beginning to the end of the study to ensure trustworthy findings were 
produced. Often qualitative researchers only consider reliability and credibility issues in 
certain parts of a study, such as in the data collection or analysis, but unless a concerted 
effort is made throughout a study, the results are not seen as trustworthy (Denzin & 
Lincoln, 2005; Yin, 2008). For this reason the present study made a concerted effort to 
keep reliability and credibility at the forefront of each step of the research process. One of 
the best ways to increase the credibility and trustworthiness of a qualitative piece is to use 
strong triangulation techniques. The next section further delineates the triangulation 
techniques used to establish trustworthiness in this study. 
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Table 5-6: Trustworthiness approaches 
Steps Approaches taken to ensure 
trustworthiness 
Steps 1-3: Research background -A thorough literature review was conducted, 
which helped to identify and properly position 
the study.  
-Scholarly and industry experts were 
consulted to establish an appropriate research 
paradigm.  
Step 4: Study design -Systematic approach was designed from the 
onset. 
-All philosophical influences were properly 
analysed before the study was designed. 
-Design peer was reviewed by multiple 
experts.  
Steps 5,7, and 9: Data collection -Triangulation through an iterative data 
collection process from multiple sources. 
-The bulk of data came from high level 
executives intimately familiar with the firm‟s 
history. 
-Six cases used; a sufficient number for 
comparative purposes, but still a manageable 
size to analyse.  
Steps 6,8, and 10: Data analysis -A systematic approach to analysing the data: 
 Data triangulated by analysing it through 
different approaches 
 Looking at the data through multiple 
theoretical lenses  
 In site validation 
-Results presented in different formats, which 
allows for different angles of comparison.  
 Source: Author 
 
5.5.4 Triangulation 
Triangulation is one of the main tools that qualitative researchers have to establish 
reliability and validity.  O‟Donoghue and Punch (2003, p. 78) see triangulation as a 
„method of cross-checking data from multiple sources to search for regularities in the 
research data’. Denzin and Lincoln (2005) identify four main types of triangulation: 1) 
data, 2) multiple researcher, 3) multiple theory and 4) multiple method. The present study 
utilised all four.   
 
Collecting data from multiple sources is one means to triangulate case research (Yin, 
2008). Data for the present study emanated from several sources. The main data source of 
data came from the interviews with key informants from the firms. The secondary sources 
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of data came from news articles, patent records, industry reports, SEC filings and the 
internet. The internet data was collected from the case firms‟ websites, life science industry 
websites and life science web blogs. The web can provide rich qualitative data for 
academic research (Robinson, 2001; Romano Jr et al., 2003; Sixsmith & Murray, 2001). 
For this study web data served for comparative and confirmatory purposes; i.e. the study 
compared the secondary data to the data from the interviews. Until recently data collected 
from the web has not been used in academic research. However, Herring (2001) provides 
strong evidence that the web is becoming an accepted place for academic studies to draw 
from. Furthermore, the prolific use of the web has made it a large and rich source of data 
appropriate for academic research (Lefever, Dal, & Matthiasdottir, 2007). Few 
management studies use netnography or secondary data from the web as a source of data. 
Liu and Arnett (2002) is one of the few examples; this study assesses the web content of 
the fortune five hundred companies by using the firms‟ websites as a means of data 
collection. Feinberg and Kadam (2002) also used web sources in their assessment of 
customer service. Jones (1999) suggests it is especially useful to triangulate primary data 
with web data. However, he also emphasises the ethical concerns involved with using the 
web to glean data. Using only web data for the present study would have been hard to 
justify. However, using it for comparative and triangulation purposes is well justified.  
 
A second way this study is triangulated is through the multiple theoretical perspectives that 
were taken to look at the research. Often researchers fixate on one theoretical lens and 
thereby miss insights from other theories (Denzin and Lincoln, 2005). The present study 
looked at the research questions from three main theoretical perspectives:  RBV, dynamic 
capabilities/CAs, and VC value added; which provided additional, multiple angles for 
examining the questions. The third means of triangulation that this study draws on is 
validation. As discussed above, the findings were validated by a questionnaire that the case 
firms completed, which provided another powerful means of triangulation (Kvale, 1987; 
2004). 
 
5.6 methods conclusions 
The purpose of this chapter is to detail the methods implored to investigate the research 
questions of this study. These, as well as the case methodology used, are relatively 
complex. To simplify this, the complex process was broken down into manageable steps 
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that are outlined in Figure 5-1 (at the beginning of the chapter). Investigating the questions 
in this research was very similar to a detective investigating a crime (Yin, 1981). It took 
many sources of data and many hours of collecting and analysing clues, and piecing all of 
the clues together in a coherent way to produce a compelling argument for the themes that 
emerged from the study. The case method taken in this research is inductive in nature but 
also drew on some deductive techniques. It relied on interviews as the primary source of 
data, but several other sources of data also helped to supplement the interview data. The 
methods implored allowed the researcher to uncover important insights on the R&D and 
financial resources and capabilities important to the early growth of life science ventures.  
 
The methods used in this study are not perfect. There are no perfect research methods in 
business (Bell & Bryman, 2003). Quantitative purist might argue that this study lacks 
validity and generasability. Whilst some qualitative experts may argue the case method 
lends itself to narrow and idiosyncratic theory. However, the methods are well justified 
given the current state of development for the theories of interest to this study. Moreover, 
the methods produced trustworthy findings that contributed to the literature on the research 
topics. The next chapter discusses these findings.  
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Chapter 6 – Results and Analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Objectives 
 Present the structure of the analysis. 
 Present the findings from the within-group-analysis. 
 Present the findings from cross-case analysis. 
 Present the triangulation questionnaire responses. 
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6.1 Introduction 
This chapter and chapter seven present the findings of the study. Following Senker and 
Sharp (1997) the firms are divided into three groups for analysis purposes. The analytical 
framework is constructed based on the firms‟ industry subsector: medical device (MDs), 
drug development (DDs) and biological analysers (BAs). A within-case and within-group 
analysis is presented in the first part of this chapter. Followed this is the responses from the 
questionnaire that was administered to the case firms is presented. This serves as a 
framework for the cross-case analysis and to present the findings from a different 
perspective.   
 
A within-case analysis presents data in meaningful and logical manner and allows for 
capturing depth (Miles and Huberman, 1994). However, it does not give a contextual base 
for comparison. Information from a within-case analysis is often used as basis for a cross-
case analysis where such comparisons are made. Although this is common practice, depth 
is often lost in the transfer from the within-case analysis to the cross-case analysis (Yin, 
1981). To minimise this, the present study first presents a short within-case analysis and 
then presents an in depth analysis of the main themes from the study in a cross-group 
analysis. The within-case analysis provides a contextual basis for each firm and the small 
number of firms in the cross-group analysis allows for a basis for comparison, but still 
allows depth in the analysis (Miles & Huberman, 1994). The findings for each group are 
presented in terms of the major themes that were identified in the study. The structure of 
the analysis is outlined below. 
 
A. Within case analysis 
A within case analysis for each firm from the group is presented in this section. A narrative 
of the major events and motivations behind the development of R&D and financial 
resources and capabilities is presented. This section serves to provide a contextual basis for 
each firm, which underpins the cross-group analysis.  
 
B. Cross-group analysis of R&D resources and capabilities development 
This section identifies and discusses the key paths, positions and processes that led to the 
development of the firms‟ R&D resources and capabilities. The matrix of the key paths, 
positions and processes that led to the development of the firms R&D is first presented. 
These matrices are not intended to quantify the data from the study; rather the intent is to 
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present the data in a structured manner (Miles and Huberman, 1994; Yin, 2008). The 
development of these matrices was detailed in the research methods chapter, but to 
summarise, each matrix was developed from each case using an abductive approach 
drawing on the data techniques offered by Ryan and Bernard (2003) and Miles and 
Huberman (1994). The ideas in the table were initially formulated based on the qualitative 
data; i.e. the interviews. Themes were coded and the software RDQP was used to compare 
codes along multiple lines.  
 
Followed by this the paths, positions and processes are each individually analysed. This 
part of the analysis follows Maitlis and Lawerence (2007) and Lawerence (1998) in 
presenting evidence trails to support the analysis. These evidence trails consist of textual 
representations, close-ended questions and secondary data that supports the finding 
(Lawerence, 1998; Maitlis & Lawrence, 2007).    
 
C. Cross-group analysis of financial resources and capabilities development 
This section identifies and discusses the key paths, positions and processes that led to the 
development of the firms‟ financial resources and capabilities. It follows the exact format 
as Section B and is based on the same analytical techniques. 
 
Code blocks corresponding to the themes from the study are presented throughout the 
chapter to help connect the major themes of the study with the analysis. Table 6-1 presents 
the code blocks for the themes that were yielded from the data reduction techniques 
discussed in section 5.4.2. For example: 
 
The pursuit of this technology cost the firm over $15 million in the first five years 
[Fin-pa – costly innovation].   
 
In this example the code block identifies that this text relates to the theme of innovation 
having an influence on the financial paths of the firm.  
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Table 6-1: Themes and text coding 
 Text Code 
R&D PATHS 
Core technology R&D demands R&D-pa core tech  
Path – university partnerships R&D-pa uni partners 
Government partnerships R&D-pa govt partners  
Industry partnerships R&D pa industry partners 
New technologies influenced firm‟s direction R&D-path new tech 
Government approvals: e.g. patent or FDA R&D-pa govt approval 
Scientific developments R&D-pa scientific dev 
R&D POSITIONS 
Core Technology R&D-pos core tech 
Patents R&D-pos patents  
Founders R&D-pos founders 
Skilled scientists R&D-pos scientists 
Star scientists R&D-pos star scientists 
Industry partnerships R&D position industry 
inputs 
University partnerships R&D-pos uni input 
Government partnerships R&D-pos govt input 
R&D facility and research equipment R&D-pos facilities  
R&D PROCESSES 
Sensing and seizing scientific opportunities R&D proc S&S 
Finding and developing research partnerships R&D proc partnering 
Navigating government approval R&D-proc  patenting 
Filing patents R&D-proc patenting 
Learning from earlier research R&D-proc learning 
Transforming R&D  R&D-proc transforming 
FINANCIAL PATHS 
Costly innovation  Fin-path costly innovation 
Raising capital Fin-pa – raising capital 
Public stock offering Fin-pa IPO  
VC Fin-pa VC  
Revenues Fin-pa revenues 
FINANCIAL POSITIONS 
Scientific capabilities Fin-pos scientific cap 
Founders  Fin pos founder  
Executive staff Fin-pos TMT  
Core innovation Fin-pos  core tech 
Firm‟s staff Fin-pos– staff  
FINANCIAL PROCESSES 
Raising capital Fin-proc  RC 
Integrating financial resources  Fin-proc int 
Dealing with Investors Fin-proc inv rel 
IPO Fin-proc IPO 
Transforming financial resources and operations Fin-proc trans 
COMLEMENTARY ASSETS 
R&D complementary asset R&D CA 
R&D specialised complementary asset R&D SCA 
R&D co-specialised complementary asset R&D CCA 
Financial complementary asset Fin CA 
Financial specialised complementary asset Fin SCA 
Financial co-specialised asset Fin CCA 
Source: Author 
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The chapter is structured as follows: 
 
6.2 Drug development firms 
6.3 Medical device firms  
6.4 Biological analyser firms 
6.5 Triangulation and cross-case analysis 
6.6 R&D and finance interdependence 
6.7 Analysis conclusions 
 
This chapter presents the findings of the study. For the sake of parsimony, the findings are 
not at this point compared to the literature; this is done in chapter seven.  
 
6.2 Drug development firms 
This section overviews the evolution of the drug development firms. This group is 
constituted by two small drug development firms that are pursuing novel drug 
technologies. In this section a narrative of each case is presented followed by an in-depth 
cross group analysis. 
 
6.2.1 Drug development firm one (DD1) 
DD1 is a small drug development and diagnostic firm. The firm‟s core technology revolves 
around cardiovascular disease treatment and prevention. The firm was founded in 2000 by 
two scientists and a medical practitioner. Currently the firm employs eighteen staff 
members and is generating less than $1 million in revenues. However, the firm has mainly 
focused on R&D in the first ten years and has just started selling its first product.  
 
The core technology that the founders conceptualised set the central direction of the firm; 
as the CEO puts it, 
  
Our technology has driven all of our major decisions and is still driving everything 
that we do today. (DD1‟s CEO) [R&D-pa and fin-pa core tech] 
 
The founders came up with the idea of combining multiple cardiac techniques together into 
a drug platform [R&D-po founder]. In 2000 they formed DD1 to pursue its development 
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[R&D-pa core tech]. The initial capital for the development came from personal funds 
[Fin-pos founder]. After the founders developed the model for their technology, they then 
started to seek outside capital. To help with this process and to structure the firm, the 
founders hired a highly experienced CEO in the second year of the firm‟s operations. The 
CEO‟s first priority was raising capital. In order to do this he created processes to raise 
money from physicians. The firm created routines of finding, contacting and presenting the 
companies technology to physicians and then asking the physicians to invest in the firm 
[Fin-proc RC]. At the time the main positions that the firm leveraged to „sell‟ the potential 
investors was the market potential of the core technology and the experience the CEO had 
in developing young firms [Fin-pos TMT]. These processes quickly yielded $3 million.  
 
In the first four years the capital went primarily to developing their drug technologies. The 
initial R&D assets and capabilities emanated from the founders, a small staff and research 
partners. Early on the firm did not have any major research partners, but instead developed 
routines for identifying researchers doing complementary work [R&D-proc partnering]. 
They looked for these researchers through their work in scholarly, scientific journals and 
conferences. Once DD1 identified potential researchers, they then presented the prospect 
of using DD1‟s technology and research to attract them, which turned out to be a mutually 
beneficial arrangement, as the researchers got access to useful information and technology 
from DD1, and DD1 received inputs from the independent researchers [R&D CCA]. These 
routines proved highly beneficial to DD1 as they were able to forge important relationships 
with independent researchers. 
 
The independent researchers were very important to helping us advance 
technology for a low cost. Several of their studies advanced our technology and 
provided important independent research backing. (CEO, DD1) 
 
A partnership in year three with the U.S. FDA also had a major impact on the firm‟s R&D 
path [R&D-pa govt partnerships]. This partnership was on a joint study for the firm‟s main 
drug application. The study looked into the estimated development time and cost of the 
drug. Results from the study suggested it would take four years and $10 million to develop. 
At about the same time the firm ran into issues on its patent applications; most notably, it 
was taking longer to obtain the patents than the firm had anticipated [R&D-pa scientific 
dev]. Due to the patent problems and the long time to develop the drug, the firm decided to 
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put their project on hold and focus on an application for a diagnostic device. According to 
the CEO,  
 
The patents were taking too long and we did not have the time or money to get the 
drug to market [R&D-pa govt app]. For this reason we focused on developing a 
diagnostic device from our technology. We focused on this because it could be 
brought to market more rapidly. (DD1‟s CEO) [R&D-pa core tech] 
 
Due to the high development costs of the core technology, the firm has had to constantly 
raise capital. In the first four years this came primarily through private investors, but in 
year four the firm needed substantial capital to finance the change in the firm‟s R&D focus 
[Fin-pa costly innovation]. The firm turned to a public stock offering for this. Although a 
complex ordeal [Fin-pa IPO], the firm was able to navigate it based on the CEO‟s vast 
experience in taking companies public: 
 
I have taken four companies public, so I knew how to do this. I knew that a reverse 
public offering from a shell company would be the fastest and best way to raise a 
large amount of capital. (DD1‟s CEO) [Fin-pos TMT] 
 
Due to the CEO‟s experience the firm successfully raised over $10 million from its first 
stock offering. This capital went to focusing on the development of their diagnostic device. 
The capabilities in raising capital proved vital as the capital that they yielded allowed the 
firm to continue its R&D. These advanced capabilities proved to be important auxiliary 
assets throughout the development of the firm [Fin SCA].   
 
Developing the diagnostic device also proved difficult. The firm expanded its research 
staff and continued to forge relationships with independent researchers [R&D-proc 
partnering]. The firm also established a relationship with the government on a joint 
research project. From the agreement with the government, DD1 received $1 million 
dollars for the research and access to some government labs and research inputs [R&D-pos 
govt inputs]. This helped advance the firm‟s technology, but did not help as much as they 
hoped it would, largely because the government bureaucracy slowed the research and the 
government wanted too much ownership of the IP that was yielded from the study. 
Because of these problems the firm has not looked to enter into other research agreements 
with the government: 
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The government is too difficult to deal with and wants too much of the IP 
(intellectual property) from the research. So we are not going to be pursuing 
partnerships with the government. (DD1‟s CEO) [R&D-pa govt partners]  
 
DD1 formed another important partnership with the University of Mississippi Medical 
Centre in the fifth year [R&D-pa univ partners]. It emanated from a relationship with one 
of the firm‟s private investors, a physician there. The physician lobbied the chancellor to 
enter into a joint research agreement with DD1. The agreement established a relationship 
whereby the university got access to DD1‟s technology in exchange for research services 
[R&D CCA]. This proved vital to DD1‟s development as the research inputs from the 
university greatly helped the firm advance their diagnostic device [R&D-pos Uni inputs]. 
The fact that the firm received the inputs from the university at almost no cost was 
particularly beneficial as the firm was in a very tight cash flow situation. This relationship, 
along with inputs from the firm‟s scientists, greatly helped progress the firm‟s device in 
years seven and eight.  
 
These advancements helped the firm in year eight to raise an additional $10 million 
through a combination of an additional stock offering and private investment. This 
investment proved vital, as the firm needed it to navigate their device through FDA 
approval [Fin-pa costly innovation]. Moreover, all of this transpired in the midst of the 
economic downturn of 2008 when capital became in short supply. 
 
The capital markets dried up. The VCs pulled out and nobody wanted to invest in 
early stage biotech firms. So we were lucky to get the capital to keep us afloat. 
(DD1‟s CEO) [Fin-pa VC]       
 
The firm successfully navigated FDA approval and received clearance for their device in 
2010 [R&D-pa govt approval]. This was a long and strenuous process, but the firm 
successfully leveraged its scientific capabilities and strategic partnerships to get over this 
hurdle. In 2010 the firm also received full clearance on five patents. The firm just started 
marketing its device in 2010 and is hoping that revenues will pick up so that it can start to 
refocus on the drug development path that it set out to pursue. These scientific capabilities 
to progress the core technology and navigate the patenting processes proved instrumental 
in the firm‟s early development [R&D SCA].  
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Although the firm is generating less than $1 million in revenues, it has still enjoyed growth 
since its inception in 2010. The growth is seen in its five domestic and thirty international 
patents; a fully developed device with FDA approval; staff of eighteen employees and a 
relationship with a major university and its network of independent researchers. From a 
financial perspective its growth is most evident from the $28 million that the firm raised 
from 2000 to 2010.  
 
6.2.2 Drug development firm two (DD2) 
DD2 is a small drug development firm that is pursuing a platform technology for the 
prevention and treatment of disease. Their technology is based on toxins from snake 
venom. The firm was founded in 2001 by a scientist to pursue the development of a 
technology that was being developed by a firm that went bankrupt. As of 2010, DD2 
employed eleven people and was generating less than $1 million in revenues. In 2009 the 
firm just started marketing its first product, and it anticipates revenues to jump 
substantially. Moreover, it has several applications that will be ready in 2010 and 2011.  
 
The core technology that the firm is pursuing has provided the central path for the firm‟s 
R&D and its overall strategic direction. To date almost all of DD2‟s resources have been 
dedicated to this technology.  
 
This technology has been in development since the late 1980‟s. Two other firms developed 
and worked on it, but both of these ceased operations, largely due to mismanagement. Both 
had scientists leading them who were not doing a good job from a business perspective. As 
the CEO put it, 
 
DD2 came about primarily as a motivation from a failure of a predecessor 
company to that one. Our interpretation, or my interpretation, the motivator behind 
the whole thing really was that a lot of what was previously done, failed more due 
to bad management than to a poor product. And frankly I thought that they’d do a 
better job. (DD2‟s founder and CEO) [R&D –pa core tech] 
 
The founder of DD2 worked for the second firm that advanced the technology. He was the 
lead researcher on the project, and from a scientific standpoint, he saw that the technology 
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had considerable potential [R&D-pa core tech]. For this reason he decided to create a firm 
to pick up where the last firm left off. In order to capitalise the firm, the CEO used a 
relationship he had with a VC that had invested in the predecessor firm [Fin-po founder]. 
He had worked closely with the VC, and the VC felt that he could revive the technology. 
Without this relationship with the VC, DD2 might not have ever gotten started: 
 
I had a contact with a New York group who were willing to look at financing the 
initial phase of the company. That clearly is one of the biggest breaks that we 
needed. If I did not have this contact, then we would not have got going. Just trying 
to figure out how you’re going to launch this thing and start the revenue generation 
part of it, or at least attracting the investment because very rarely do you get 
revenue depending on the type of product. Thus, this prior relationship proved as 
an important position to obtaining the capital needed to get the firm started. 
(DD2‟s founder and CEO) [Fin-po founder; Fin-pa VC] 
 
Once DD2 was started, the main challenge was reviving the technology and the research. 
The research sat dormant for a few years, and DD2 needed to revive what had been done 
and construct a strategy for their R&D. The founder provided the main scientific position 
to accomplishing this: 
 
So it came from experience. I didn’t jump into it blind. I was very well aware of the 
history, I was very aware of the potential asset of the potential product to be 
developed. (DD2‟s founder and CEO) [R&D-po founder]  
 
This scientist is widely considered one of the main snake venom experts in the world, and 
he was able to use his knowledge to jump start the firm‟s research [R&D-po star scientist].  
To help him the firm hired three other highly trained scientists who helped with this task 
[R&D-po scientist]. Their routines revolved around their vast scientific experience. Put 
differently, the scientists possessed tacit routines on strategizing and executing research. 
This allowed the firm to make several steps toward proving the efficacy of their drug 
technology. However, they burned through a greater amount of capital than expected and 
within two years had to attract another $1 million investment [Fin-pa core tech].  
 
For this round of investment the firm leveraged the background of the founder and the 
firm‟s technological progressions to obtain the needed capital [Fin-po core tech; Fin-po 
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founder]. This capital allowed the firm to continue its technological development, which 
drove the need to establish a partner for specialised testing. More specifically, the firm 
required specialised research equipment and capabilities [R&D SCA]. The firm‟s 
founder‟s relationships provided access to the university facilities; from his previous 
dealings with the universities he was able to swiftly forge agreements for testing DD2‟s 
drugs [R&D-po uni inputs]. Moreover, the firm also established research relationships 
through activity in the scholarly community. Through scientific journals they were able to 
locate several other researchers looking at snake venom. The researchers agreed to work 
with DD1 because of the firm‟s unique technology and the fact that this technology had 
been backed by independent tests. In the third year of operations a high profile scientist 
became a director for the firm. He is associated with several top universities and is highly 
experienced in the field. His inputs have opened access to the wider scientific community 
and have helped the firm establish important research links; including links with research 
partners in Europe and China. These inputs have already helped in the firm‟s growth by 
providing science that has helped progress DD2‟s technology, but more importantly, they 
have opened up future research paths and market opportunities.  
 
Its progress and the new director‟s networks allowed the firm to forge a relationship with a 
partner firm in the field [R&D-pa industry partner]. The partner firm was developing 
similar technologies that complemented DD2‟s research.  DD2 formed a relationship with 
the firm to share resources and technologies. Capital is a particularly important resource 
that DD2 received from the partnership. In the fourth year of operations the partner firm 
infused around $2 million, which kept DD2 viable. At the time, capital was hard to obtain 
in South Florida where the firm is based because of the tight venture capital markets: 
 
Florida has a huge potential for biotech, the financial support isn’t there.  And so 
all these universities have great science, but because there’s no mechanism to 
allow for funding to allow companies to take out the technologies and see if they 
can commercialise these innovations, it’s made raising capital difficult for us. 
(DD2‟s founder and CEO) [Fin-pa VC] 
 
The cash infusion also provided the capital to sanction the firm‟s first clinical trial in the 
UK. DD2 made a conscious effort not to first apply for FDA approval because of the costs, 
time and bureaucracy involved [R&D-pa govt approvals]. The CEO drove this decision as 
he has extensive experience in navigating government drug approval: 
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He has worked and negotiated with drug regulatory agencies in the US, Canada, 
EU, South America, South Africa, and China, enabling companies to move ahead, 
save millions on research and testing in clinical trials, and gain IND approvals. 
(Chairman of DD2) [R&D-po founder] 
 
Based on his experience he felt the UK would be the best place to start clinical trials 
because of their favourable testing procedures for drug applications such as theirs. 
Furthermore, the founder held important relationships in the UK that helped facilitate 
testing procedures; he is Irish and received his PhD from the Imperial College in the UK. 
His background and relationships helped navigate the clinical trials in the UK [R&D-po 
founder].  
 
The clinical trials helped the firm raise an additional $500,000 from private investors [Fin-
po scientific cap]. The firm used this capital to further develop and test their drug for HIV 
and multiple sclerosis applications. These tests revealed that the firm‟s applications for 
these diseases are effective and inexpensive treatments for these diseases. This provided 
validation to the firm‟s research, which the firm built on in the sixth year when they 
clinically proved their drug‟s effectiveness for analgesic applications. These applications 
spurred more interest in the firm and allowed it to continually develop important research 
relationships. Amongst these relationships were several with elite universities and labs. 
The breakthroughs created interest from other firms as well. Most notably, this interest led 
to a merger in the eighth year of DD2‟s existence [R&D-pa industry partner].  
 
Although the firms merged they still operated autonomously. However, the two firms share 
some important resources like scientific assets; the firms have access to one another‟s 
scientists, facilities and networks [R&D CCA]. Shared financial resources are even more 
important, and the partner firm is the one that handles most of the financial matters for 
DD2. This merger has provided the important resources that DD2 needed in order to 
continue its research [Fin CCA]. However, raising capital still remains important to DD2. 
 
The increased R&D and financial resources allowed DD2 to expand its clinical 
development. In late 2009 the firm introduced an over the counter pain medication. Even 
though the firm had a more potent version of the drug that could realise higher profit, the 
firm chose to pursue this version because approval is much more streamlined and 
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inexpensive for over-the-counter drugs [R&D-pa govt approval]. Its approval is significant 
because it marked the beginning of commercialisation for the firm. Another milestone in 
year nine came in the form of one its major patent approvals [R&D-pa govt approval]. This 
patent protects one of the main applications that the firm had worked on for over eight 
years. In year ten the firm received another important patent approval. These are major 
milestones because they give the firm more leeway in how they can license and distribute 
their drugs.   
 
These milestones are building blocks to the firm‟s future. It is anticipating rapid growth 
over the next five years. They have proven their technology and have market-ready 
applications and a network of partnerships and financial resources to back the firm‟s future 
growth. In the first ten years the firm‟s growth is evidenced in its two key patents; full 
FDA approval for two drugs and UK approval for one drug; network of partnerships and 
the $5 million in outside investment capital that the firm has received.  
 
6.2.3 DDs cross-group analysis 
The narratives above provide a contextual basis for the evolution of the DD1 and DD2‟s 
R&D and financial resources and capabilities. This section delves deeper into the key 
paths, positions and processes that led to the development of the firms‟ R&D and financial 
resources and capabilities. It analyses and compares the paths, positions and processes that 
led to each firm‟s R&D resources and capabilities. A similar approach has been taken to 
explore the financial assets and capabilities developed in the early stages of growth.  
 
 6.2.4 R&D resources and capabilities development 
In the early stages of growth both firms focused on the development of their technology, 
the impetus of developing R&D resources and capabilities for both firms. This section 
highlights the paths, positions and processes central to the development of the firms‟ R&D 
resources and capabilities; the paths are the past decisions and actions, and the future 
opportunities that influenced the firms‟ strategic pursuits; the positions are the resources 
that the firms leveraged in their development; and the processes are the routines that the 
firms used to leverage their positions in order to take advantage of their paths (Teece, 
2007; Winter, 2003). Table 6-2 presents the matrices of the paths, positions and processes 
that were yielded from the data reduction techniques discussed in the research methods 
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chapter, and this collates with the text code table presented at the beginning of the present 
chapter. Based on the analysis of the interviews and the close-ended questions, each path, 
position and process for each firm is placed in one of four categories based on its influence 
on the firm‟s development: high (H), medium (M), low (L) or no (N) influence. The major 
paths, positions and processes are discussed in detail below. 
 
Table 6-2: DDs' R&D paths, positions and processes 
 D1 D2 
INFLUENTIAL ON FIRMS’ PATHS 
Core technology conceptualised at a university N N 
Core technology conceptualised at another firm H N 
Core technology conceived by the firm L H 
Government partnerships L L 
Industry partnerships M L 
New technologies influenced firm‟s direction H M 
Government approvals: e.g. patent or FDA H H 
Scientific developments H H 
IMPORTANT POSITIONS 
Patents L H 
Skilled scientists H H 
Star scientists H H 
Industry partnerships L H 
University partnerships L L 
Government partnerships L L 
R&D facility and research equipment L L 
Core technology H M 
KEY PROCESSES 
Sensing and seizing scientific opportunities H H 
Finding and developing research partnerships M L 
Navigating government approval H M 
Filing patents M H 
Learning from earlier research H H 
Transforming R&D  H M 
Source: Author 
 
Paths 
Several paths influenced the strategic R&D pursuits of the firms. Table 6-3 presents 
evidence depicting the importance past decisions and future opportunities that dictated the 
development of DD1 and DD2‟s R&D resources and capabilities has had.  
  
 The most prominent path for the firms emanated from their core technologies. Table 6-3 
(1-6) below provides sample evidence depicting this and also depicting that both firm‟s 
strategic direction was firmly established by the technology that the firms set out to 
develop and commercialise [R&D-pa core tech]. DD2‟s technology was initially 
discovered and developed at other organisations, and the efforts of those organisations set 
the research path for the firm (Table 6-32; 1, 2 and 5). The early stage technologies that 
DD1 conceived and incubated set the central path for the firm‟s R&D, but unlike DD2, the 
firm‟s technology was totally new. The technologies impacted the R&D resources and 
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capabilities needed [R&D-pa core tech]. However, R&D proved vital for both firms, but 
the exact combination of resources and capabilities required differed. DD2‟s technology 
moved the firm to primarily focus on developing specialised testing resources. In 
comparison, DD1‟s path dictated that the firm develop R&D resources for creating a 
technology. Simply put, the technologies that the firms pursued set their strategic 
directions and dictated the R&D resources needed for growth.  
 
Future research opportunities also greatly influenced the R&D paths of the firms. Table 6-
3 (7-9) presents a representative sample of the evidence supporting this. Opportunities to 
develop new applications motivated the firms to develop the research capabilities that were 
needed to develop these applications [R&D-pa new tech]. An opportunity to develop a 
diagnostic device changed the strategic path of DD1 (Table 6-3; 7) [R&D-pa scientific 
dev]. The firm needed to find a product that could quickly be brought to market, and an 
application using their technology for a diagnostic device presented an opportunity for this. 
Thus, in the fifth year of the firm‟s operations it changed R&D paths to focus on this 
device. DD1 almost completely stopped working on drug applications and devoted all of 
its resources to this product. In year eight several progressions related to the firm‟s 
diagnostic device brought them to FDA clearance [R&D-pa govt approval]. This clearance 
allowed the firm to start marketing their device and allowed them to refocus their resources 
on their original path of developing drug applications.  
 
Similarly, DD2 pursued the development of four new applications for their drug 
technology [R&D-pa scientific dev]. These new drugs greatly affected the firm‟s R&D 
paths: the firm developed research resources and capabilities to test and commercialise 
these drugs. Moreover, motivated by the need to quickly generate revenues, DD2 pursued 
the development of an over the counter drug in year eight of their existence (Table 6-3; 8 
and 9). The firm pursued development of this drug because of how quickly an over the 
counter drug could be brought to market [R&D-pa govt approvals]. This new path 
stemmed largely from the need to show investors the firm could produce a drug that could 
generate revenues. This made DD2 devote a significant amount of revenues to this project. 
Several of their other research projects on their other drugs were slowed or halted so that 
they could focus on the over the counter drug.    
 
Gaining government approval (FDA or other government clearance) has also greatly 
influenced the paths of the firms‟ research (Table 6-3; 10-15) [R&D-pa govt approvals]. 
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Initially both firms pursued drug applications that required high level government 
approval. This forced the firms to devote significant resources to pursuing it. DD1 invested 
over $250,000 in a joint research project with the FDA to try to streamline the approval 
process of their main drug application. The results were less than desirable and indicated 
that the drug would take more time and capital to bring to market than originally 
anticipated. The fact that a diagnostic device could more readily be brought through FDA 
approval triggered the firm to refocus their R&D on applying their technology to 
developing a device (Table 6-3; 7) [R&D-pa govt approval]. Although the device required 
a less rigorous FDA process, the firm still devoted several million dollars towards getting 
the device through FDA approval. 
 
Government approvals have also had a major impact on DD2‟s R&D paths, as the firm has 
put several drugs through government testing (Table 6-3; 13-15) [R&D-pa govt approvals]. 
Interestingly, government approvals have motivated the firms down an internationalisation 
path. In order to save on costs and streamline the approval process, DD2 went for their first 
major approval in the UK because of their more efficient approval processes for drugs like 
DD2‟s. The firm has also put three drugs up for FDA approval in the US, which has 
greatly influenced the strategic direction of the firm. This forced the firm to devote a 
significant portion of its R&D resources to FDA-related functions. It has also made the 
firm develop routines for meeting FDA processes. There are dozens of processes that the 
firm has to follow in order to stay in compliance with FDA approval.  
 
Path rigidities have also resulted from the substantial resources invested in government 
approvals (Table 6-3; 10-13). Both firms committed a substantial amount of their resources 
to FDA approval, which limited the investment that they could make in other areas related 
to their technology. The commitment to government approvals made success in these 
endeavours paramount. DD2 enjoyed success in their approvals, but the resources the 
processes consumed also restrained the firm from making investments in other areas of 
R&D that they would have liked to have pursued. DD1, on the other hand, had some major 
FDA setbacks that forced the firm to reconfigure its R&D to focus on the development of a 
device instead of the drug it originally set out to pursue.  
 
Government approval also presented opportunities for both firms. Major milestones in the 
approval process helped the firms attract additional capital and resources needed for their 
technology. It also helped the firms develop several key relationships. For example, DD1 
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entered into an important research collaboration with a university medical centre that was 
largely facilitated because of FDA milestones [R&D-pa uni partners]. Similarly, DD2 
entered into a strong partnership with another firm within the industry [R&D-pa industry 
paths]. These relationships proved influential on the firms‟ R&D paths.  
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Table 6-3: DDs' R&D paths 
FIRM                The core technology drove R&D demands of the firms. 
 
DD1 1. The technology set the stage for the firm. It drove all of our basic functions. Our R&D and 
entire company revolves around it. (DD1‟s CEO) 
 
2. The technology has been everything to us. All of our functions revolve around it and we 
wouldn’t be here without it. (DD1‟s CEO) 
 
3. One hundred per cent of the $28 million invested in the firm went directly or indirectly to 
developing the firm‟s core technology. (Close- ended question; analysis of firm‟s financial 
statements) 
 
DD2 4. DD2 came about primarily as a motivation from a failure of a predecessor company to that 
one.  Our interpretation, or my interpretation, the motivator behind the whole thing really 
was that a lot of what was previously done failed more due to bad management than to a 
poor product.  And frankly I thought that they’d do a better job. (DD2‟s founder and CEO) 
 
5. So we tried to revive the innovative property, that’s perceived to be the asset to the 
company.  (DD2‟s founder and CEO) 
 
6. Ninety per cent plus all of DD2‟s capital expenditures in the first nine years went to 
developing their core technologies.  (Close-ended question; analysis of firm‟s financial 
statements) 
 
                            New scientific opportunities impacted the strategic direction of R&D. 
DD1 7. The cumbersome approval procedure is one of the main reasons that we decided to re-
strategize on developing a device. We hated to shelf the drugs, but we needed to get a product 
to market, and we found that our technology could get approved much quicker and cheaper 
through a diagnostic device.  (DD1‟s CEO) 
 
DD2 8. We re-focused on an over the counter drug because these could more readily be brought to 
market. (Close-ended question; analysis of firm‟s financial statements) 
 
9. Marketing not only generates revenue, but it also helps to give us credibility. For this reason 
we decided to refocus for a short tem attention on developing an OTC drug. (DD2‟s founder 
and CEO) 
 
              FDA and government approvals have impacted the strategic direction of R&D 
DD1 10. We have put a lot into FDA and have had to make our products work because of this 
tremendous investment. (DD1‟s CEO) 
 
11. When you’re a small firm, and you commit $10 million to FDA, you have to make sure that it 
works. (DD1‟s CEO) 
 
12. In the first nine years the firm has invested over $4 million in FDA related matters. (Analysis 
of financial statements) 
 
DD2 13. FDA approval is costly, lengthy and consumes the firm. (DD2’s Chairman) 
 
14. We were familiar with the UK and knew that this process would be more streamlined and 
more efficient. (DD2‟s founder and CEO) 
 
15. That (UK approval) was a major success from that perspective to kind of get on the board 
with regard to demonstrating that our products are worthy of administration.  A certain level 
of credibility is garnered from this. It is helpful in developing relationships and looking good 
to investors. (DD2‟s founder and CEO) 
Source: Author
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Positions 
The firms leveraged several positions in their strategic R&D pursuits. Table 6-4 presents 
sample evidence supporting the most important resources that the firms leveraged in the 
development of their R&D.  
 
The most ubiquitous resource for both firms was their core technology [R&D-po core 
tech]. Table 6-4 (1-5) depicts a representative sample of evidence that underscores the 
importance of the firms‟ technologies to the firms R&D. Both firms leveraged their 
technology to help them attract important inputs. Capital proved to be one of the most 
important assets that the core technology helped the firms attract [R&D and fin co-
specialisation]. The firms‟ core technologies have also allowed them to attract research 
partners that have been vital to progress their technologies [R&D-po core tech].  
 
DD1‟s technology complements research related to many areas of cardiac disease, and this 
has been a resource that has allowed the firm to enter into many different mutually 
beneficial partnerships with independent researchers who gained access to inputs that help 
in their studies. DD1 benefited from important independent testing that helped progress 
their technology (Table 6-4; 1) [R&D CCA]. DD1‟s technology also allowed them to enter 
into a partnership with a large university that was interested in gaining access to DD1‟s 
science (Table 6-4; 2) [R&D CCA].  
 
Quite similarly, DD2‟s technology is a resource that has helped the firm attract inputs from 
a number of universities and independent researchers (Table 5-2; quotes 3, 4 and 5) [R&D-
pos core tech]. Many of these relationships were facilitated through scholarly journals and 
conferences. The researchers were motivated to work with DD2 largely because their 
technology had been verified in the scientific journals. Moreover, it also provided the 
impetus to the firm‟s most important partnership; a firm that they later merged with in year 
7. DD2‟s R&D resources and capabilities complemented the partner firm‟s research [R&D 
CCAs] and thus was the motivating factor to the partnership, which has provided 
invaluable inputs that have helped the firm to grow and develop.  
 
A second position that has been vital to the firm‟s development is their scientific staff. 
DD1‟s staff is made up of five scientists of whom three are PhDs. These scientists have 
made consistent contributions that have helped advance the firm‟s technologies (Table 6-4; 
6) [R&D pos scientists]. The founders‟ provided particularly important early resources to 
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the firm‟s R&D. They are the ones who conceptualised the technology and developed the 
drug prototype [R&D-pos founder]. All three of the founders have had substantial success 
as scientists. One of the founder‟s publication records put him in the top five per cent of all 
research scientists, and the other two hold multiple patents for innovations that have gone 
on to great commercial success. 
 
The founders‟ designed the firm‟s research and hired the scientific staff from whom for the 
first two years most of the firm‟s inputs came (Table 6-4; 7). The firm‟s scientific board, 
which is also made up of several noted scientists, has also helped the firm progress its core 
technology.  
 
In a slightly different vein, DD2‟s R&D revolved around the founder who is a star scientist 
(Table 6-4: 8 and 9) [R&D-pos star scientist; R&D-pos founder]. The founder is the one 
who came up with the main progressions for the firm‟s technologies. He is well-published, 
holds six patents and is recognised as one of the leading experts on snake venom. His 
knowledge and talents provided vital resources that contributed significantly to the firm‟s 
innovations. DD2 also had a small team of scientists who helped the CEO on the 
technology, and their contributions were important [R&D-pos scientists] but were not 
specialised in the sense that they could not have been performed by other trained scientists.  
 
Another important resource for DD2‟s is their specialised research facility. DD2‟s lead 
scientists designed and fitted a facility specific to their operations [R&D-pos facilities]. It 
is highly advanced and customised for their research purposes. Although research facilities 
are important to DD1, they are not highly specialised since the building and equipment 
were readily available on the free market. Some of the testing equipment for DD1 required 
some customisation, but this only constituted one small part of the research facility. Put 
differently, a specialised R&D facility has been an essential resource to DD2, but such a 
facility has not been essential to DD1.  
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Table 6-4: DDs' R&D positions 
                
FIRM The firm’s core technology helped attract and develop other resources. 
DD1 1. We were able to develop a following of independent researchers because they were 
interested in our technology. This was crucial as they made contributions to our product 
that did not cost us anything. Having these free researchers was important to the firm’s 
development. (DD1‟s CEO) 
 
2. The medical college was interested in being a part of what we are trying to do. They saw 
that our technology could help some of their research projects. (DD1‟s CEO) 
 
 
DD2 3. This discovery is significant to our continued research and development, as it identifies the 
mechanism of action for RPI-78M. We believe that our drug is the first to induce the 
expression of IL-27, which represents a novel way to approach the treatment of several 
autoimmune diseases. This makes it of interest to a wide variety of firms and organisations. 
(DD2‟s founder and CEO) 
 
4. The biotechnology research and development field is extremely competitive and is 
characterized by rapid change. Our competitors have substantially greater financial, 
scientific, and human resources, and as a result, greater research and product 
development capabilities. Our competitors have competitive advantages with greater 
potential to develop revenue streams. Our competitors are located in the United States as 
well as around the world. We attempt to compete by establishing strategic partners or 
alliances with pharmaceutical companies, academic institutions, biotechnology companies 
and clinical diagnostic laboratories which will enter into joint ventures, emphasizing our 
drugs’ superior properties. (DD2 Chairman)  
 
 
5. A 2007 article discussing the importance of DD1‟s technology to entering into an 
important partnership with a Chinese biotech firm: DD2’s technology shows great promise 
to helping the 1.3 million people living with tuberculosis. (November 23, 2005 Business 
Wire)  
 
                              The scientists provided important inputs to the firms’ R&D. 
DD1 6.  Our scientists have continually made progressions that have moved the technology along. 
The staff had not made any ground-breaking findings, but they have consistently moved 
things along.  (DD1‟s CEO) 
 
7. The founders were the ones that came up with the breakthroughs. Their novel ideas is what 
got the research going and what we have based all of our products on. One founder in 
particular had worked in a number of fields and used his knowledge and capabilities to 
bring together all of the science needed to develop our platform. (DD1‟s CEO) 
 
DD2 8. We have a small firm here and I guess without me it would never have happened. I’ve been 
more of the driving force on directing the R&D projects. (DD2‟s founder and CEO) 
 
9. By leveraging his comprehensive understanding of regulatory requirements, he has guided 
us on new projects through the correct protocols at a minimum budget, advancing products, 
positioning for licensing, and setting up manufacturing. The application of his knowledge of 
laboratory practices to select new technologies that enhance production, quality control, 
and product formats. (DD2‟s Chairman) 
 
 
Source: Author 
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Processes 
The firms relied heavily on processes related to identifying and integrating scientific 
innovations and techniques. Table 6-5 (1-5) presents a representative sample of evidence 
that underscores the importance of sensing, filtering and integrating processes.  
 
Both firms‟ founders had vast experience in identifying and evaluating scientific 
technologies for DD1 and DD2 [R&D-proc S&S]. These processes were held uniquely 
within the founder‟s own scientific and conceptual knowledge and could not be replicated 
(Table 6-5; 3 and 4) [R&D-pos founder]. They could not explain how they are able to 
evaluate technologies other than that it is intuitive based on their years of experience in 
evaluating them.  
 
As the firms developed, sensing complementary technologies also became important. The 
firms created processes for finding scientific inputs for their R&D. For example, DD1 
developed routines for identifying potential researchers working on complementary 
research [R&D-proc S&S]. These routines revolved around scouring journals to look for 
researchers working in similar areas. Once a researcher was located, the firm then 
contacted the researcher(s) about the prospect of joint research projects. This yielded over 
fifty relationships that led to important contributions to DD1‟s technology. Moreover, this 
routine helped the firm conserve capital as the firm had received important inputs, but it 
also had minimal related expenses.  
 
Learning processes from their daily operations also helped advance the firm‟s R&D (Table 
6-5; 6-8) [R&D-proc learning]. Every day they moved their technology forward based on 
what they had previously accomplished. Both firms have systems for tracking their 
progress, but these are relatively common [R&D-proc leaning]. More than anything the 
firms‟ learning was held within their scientific staff whose knowledge and insight came 
from their previous experience (Table 6-5; 6 and 7) [R&D-pos scientists].  
 
Another area where learning routines proved important to the two firms was with 
government approval [R&D-proc govt approval]. Both firms learned how to better prepare 
themselves for dealing with FDA. DD1 learned from its major FDA setback that drugs are 
expensive and time consuming to clear through FDA approval. Similarly, DD2 learned 
from their early FDA dealings that this process takes a long time and the FDA approval 
decision can be erratic. For this reason for some of their future drugs the firm pursued 
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approval with other countries first. The other countries, such as the UK, have a more 
streamlined and predictable approval processes. 
 
Both firms also learned from their experience with the patent process that it takes longer to 
pursue than they had originally intended. DD1‟s core patents took over nine years to 
execute, whilst two of DD2‟s most important patents took over eight years to execute 
[R&D-proc govt approval]. Moreover, the firms learned that upholding patents is also 
difficult. For this reason both firms made future strategic choices to pursue applications 
that did not completely depend on patents.  
 
Transformation related processes have also been important to both firms (Table 6-5; 9-12) 
[R&D-proc transform]. In the fourth year of existence DD1 realised that because of 
changing conditions in the pharmaceutical industry, they would not be able to progress 
their drug applications to market (Table 5-3; 9). The FDA had changed its approval 
procedures and the firm‟s drugs were taking longer than originally expected to develop. 
This triggered DD1 to reconfigure its R&D resources to focus on the development of a 
diagnostic device that could more readily be passed through FDA approval [R&D-proc 
govt approval]. At that point they also they also had to focus more on new R&D routines 
and partnerships.  
 
In a similar vein, DD2 came to a point where it needed a new drug that could be brought to 
market quickly, and used its transformational routines to reconfigure its R&D to focus on 
the development of an over the counter drug (Table 6-5; 10 and 11) [R&D-proc transform]. 
Several of its projects were stopped and those resources were then devoted to the new 
drug. Transformational routines proved highly beneficial to both firms, as these 
reconfigurations led to marketable products that kept both firms viable. These products 
allowed the firms to generate revenue and, more importantly, showed their ability to 
develop a marketable product, which helped attract more investment capital and other 
resources.  
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Table 6-5: DDs' R&D processes 
 
FIRM  Identifying and sensing technologies 
DD1 1. At the beginning we had to pull together a number of science to try to make our idea work. 
Finding the technologies was vital to making this happen. One of our founders had 
experience in several areas and was important to bringing everything together. (DD1‟s 
CEO) 
 
2. Finding the technology comes from years of experience. There is no formula or set way of 
looking at a technology. You look at some objective things, but in an infant science the 
judgement comes from experience. (DD1‟s CEO) 
 
3. Finding science is important. We have routines in place to find research that can help us. 
One of the most important sources of this is the independent researchers that we reach out 
to. (DD1‟s CEO) 
 
 
DD2 4. It was up to me to collect all these assets together and form a plan to develop products using 
the resources we had and finding what we needed – all in an expeditious way of getting to 
market revenues. (DD2‟s founder and CEO) 
 
5. The firm has entered into dozens of partnerships with organisations with offerings that could 
help us. We have systems of searching within the community and finding these people.  
(DD2‟s founder and CEO) 
 
                              Learning routines have helped advance the firms R&D 
DD1 6. Our scientists have routines for sharing information. It is hard to pinpoint them. I mean we 
have standard reporting and all, but it is the scientists who just know how to take and look at 
their work and figure out what to do with it. This is where the learning happens.  (DD1‟s 
CEO) 
 
DD2 7. The systems we have in place for learning come from the fact that we’re all experienced 
researchers, you know PhD’s, advanced degrees, so it’s just experienced research. (DD2‟s 
founder and CEO)   
 
8. Our learning relies heavily on the existing data for the direction and determined the 
pathway for what type of R&D we still needed to do in order to move forward. (DD2‟s 
founder and CEO) 
 
                              Transforming R&D has proved vital to the firms’ growth and survival 
DD1 9. In year four we saw that FDA approval was getting more difficult and that our drug was not 
progressing as well as we had hoped. This prompted us to focus on the development of a 
diagnostic device. (DD1‟s CEO) 
 
10. We had to change direction. To stay above water we changed to a diagnostic firm. We had 
the resources in place, but they had to change things around. (DD1‟s CEO) 
 
DD2 11. So effectively operations were fairly low key, low numbers of staff until 2009 when 
effectively we existed for the best part of eight years just researching before we really 
started to get any traction.  And the only way we started to get traction was to develop a 
product that was on the market. (DD2‟s founder and CEO) 
 
12. The 2009 quarter fourth report for the SEC has an entire section dedicated to the importance 
of the over the counter drug market and the fact that the firm dedicated a substantial amount 
of its resources to this effort. (Q4 2009 SEC 10k Report) 
 
 
Source: Author 
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6.2.5 Financial assets and capabilities 
The firms‟ R&D demanded significant capital to get their products to a point of 
commercialisation. For the most part, generic financing was not available. For this reason, 
the firms turned to specialised investment sources for the needed capital, which required 
the firms to leverage a unique set of paths, positions and processes to obtain the needed 
capital. This section highlights the paths, positions and processes central to the 
development of the firms‟ financial assets and capabilities. Based on the coding and close-
ended questions, each path, position and processes for each firm is placed in one of four 
categories based on its influence on the firm‟s development: high influence (H), medium 
influence (M), low influence (L) or no influence (N). The analysis for the major paths, 
positions and processes is detailed below. 
 
Table 6-6: DDs' financial paths 
 D1 D2 
INFLUENTIAL ON FINANCIAL PATHS 
Costly innovation  H H 
Raising capital H H 
Public stock offering H M 
VC L L 
POSITIONS 
Scientific capabilities H H 
Founders with strong industry background H H 
Executive staff H L 
Core innovation H H 
Firm’s staff L L 
PROCCESSES RELATED TO 
Raising capital H H 
Integrating financial resources  H H 
Dealing with Investors H M 
IPO H M 
Transforming financial resources and operations H M 
Source: Author 
 
Paths 
Table 6-7 highlights the paths important to the development of the firms‟ financial assets 
and capabilities. There were several past decisions and future opportunities that impacted 
the strategic pursuits of the firms.  
 
In general, the largest influence on the firms‟ financial paths was their technology. The 
impetus for developing financial assets for the firms stemmed from the high cost of 
developing a novel drug technology, which is supported by the representative evidence in 
Table 6-7 (1-7) [Fin-pa costly innovation]. DD1 and DD2 required substantial investment 
during the conceptualisation phase. Most of this investment focused on R&D. Over time 
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developing a platform technology proved quite costly as DD2 spent over $25 million on 
the development of their drugs in the first nine years of existence, whilst D3 spent over $5 
over that same span. The discrepancy in investment is largely attributed to the fact that 
DD2‟s technology was based on an existing drug platform, whilst DD1‟s was freshly 
created by the firm.  
 
The only viable early financing path for DD2 was VC. Capital from a VC financed most of 
the firm‟s early development. In contrast DD1‟s seed capital came from a small group of 
angel investors. This angel investment exhausted quickly as the drug technology proved 
expensive to develop. The firm looked at VC but could not raise capital there because of 
the changing VC funding model (Table 6-7: 3).This triggered the firm to go down an 
alternative path to securing capital. At this point the firm implemented elaborate 
mechanisms for raising funds from physicians familiar with their cardiac technology.  
 
For DD1 and DD2 raising capital through public stock offerings was also an important 
path in the firms‟ development. However, the two firms‟ paths to an IPO were markedly 
different. DD1‟s CEO took the company public on a small public stock exchange through a 
reverse merger where the firm took over another public firm that had gone bankrupt, 
essentially just taking over their stock ticker. By taking over another firm, DD1 expedited 
the public offering process; most notably, it allowed the firm to avoid many of the filings 
that are required for public offerings. This proved successful as it allowed the firm to 
quickly list on a public exchange and raise over $20 million in capital over a five year 
period. In contrast, DD2 merged with another firm that already held a public stock ticker. 
This merger was largely motivated by the access to public funding that would result from 
the merger. The merger provided access to over $3 million in funds in the two years from 
the date of the merger.  
 
For DD1 the public offering path did have a downside in that it consumed and continues to 
consume a tremendous amount of the key executives‟ time (Table 6-7; 9). The TMT 
spends hours filing reports, dealing with investors and dealing with regulatory procedures. 
This is time that could be devoted to more productive means. In contrast, DD2 does not 
have to deal with these processes. This is primarily because the firm DD2 merged with 
handles most of these dealings. Moreover, the merger has freed up DD2‟s executives by 
taking care of most of the financial issues. This has allowed DD2 to focus on the scientific 
end of the business.   
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Table 6-7: DDs' financial paths 
 
IRM The core technology drove the strategic direction of the firm. 
DD1 1. The technology has cost millions to develop. We knew it was going to be expensive, but in 
this business you never know exactly what it is going to cost you. In the last nine years we 
have spent well over $25 million on it. (DD1‟s CEO) 
 
2. Even with the low cost inputs we have received from partners, this has been an expensive 
ordeal. Here we are almost ten years later and raising capital to develop the technology 
remains the main issue that we have to deal with. (DD1‟s CEO) 
 
3. Venture capitalised would not look at us. The model has changed and they no longer look at 
early stage companies. They want all of the return without any of the risk. Venture capital is 
not what it used to be. (DD1‟s CEO) 
 
4. On hundred per cent of the $28 million invested in the firm went directly or indirectly to 
developing its core technology. (Close-ended question; analysis of firm‟s financial 
statements) 
 
DD2 5. Just trying to figure out how you’re going to launch this thing and start the revenue 
generation part of it, or at least attracting the investment because very rarely do you get 
revenue depending on the type of product. (DD2‟s founder and CEO)  
 
6. It’s not cheap to apply for patents to protect your technology, and it is an important and 
costly step to undertake, especially when you go international. (DD2‟s founder and CEO) 
 
7. Ninety per cent plus all of DD2’s capital expenditures in the first nine years went to 
developing their core technologies.  (Close-ended question; analysis of firm‟s financial 
statements) 
 
               IPOs have influenced the direction of the firms. 
DD1 8. Because of the dry VC markets we had to go public. The VCs wanted to come along too late 
in the company’s development and still wanted too much equity. This made the public 
markets an important option for us.  (DD1‟s CEO) 
 
9. I have to spend a lot of timing dealing with the stockholders and issues related to that, but 
we needed to go public to get the capital. If I had my choice, I would rather get the capital 
from other places so that I could avoid all of those headaches. (DD1‟s CEO) 
 
DD2 10. We have had to commit resources to going public and it has affected our operations, but it 
has been a needed source of capital for us. (DD2‟s founder and CEO) 
 
11. The hope of (IPO) financing was to meet our near-term budgets and the financial leverage 
to allow us to become revenue generating and fund the clinical trials of our biotech 
investment. (DD2‟s Chairman) 
 
 
Source: Author 
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Positions 
The firms leveraged several unique positions to develop their financial endowments. The 
most ubiquitous position was their superior technology [Fin-core tech]. Table 6-8 (1-4) 
provides representative evidence illustrating that one of the biggest factors that their 
investors looked at in their investment decisions was the potential profitability of the firms, 
and this potential profitability was driven by the firms‟ technologies.   
 
The founders‟ and executives‟ backgrounds supplied another important resource that the 
firms leveraged in raising capital. Both firms had founders who had successfully started 
drug development firms in the past, and they used this to entice investors (Table 6-8; 6, 7 
and 8). DD1‟s three founders leveraged their networks to raise the seed capital needed to 
get the firm started. To do so the firm then relied heavily on the networks and the 
competencies of the CEO. In comparison, DD2‟s founder had a previous relationship with 
a VC that provided the central position that led to the VC funding of DD2. Put differently, 
had DD2‟s founder not had this relationship, then there would have been little chance the 
firm would have been created to pursue the technology (Table 6-8; 9).  
 
Partners also provided important financial resources. As discussed above, DD2 developed 
a close partnership with a publicly traded firm that resulted in a merger. This merger gave 
DD2 access to capital and financial capabilities (Table 6-8; 13 and 14). The partner firm 
has a highly experienced CFO who has taken away much of the financial responsibilities 
from DD2. This has allowed DD2 to focus on developing their technology. Prior to the 
merger DD2‟s CEO, who is the firm‟s main scientist, devoted a significant amount of his 
time to financially related matters, which diverted him from time in the lab where he is 
most valuable. In contrast, DD2 has only directly received cash from the FDA, but 
partners‟ organisations have provided research inputs that have saved the firm substantial 
financial resources (Table 6-8; 11).  
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Table 6-8: DDs' financial positions 
 
FIRM                Core technology proved critical in the development of financial resources. 
DD1 1. We went out and sold what the potential of our product was. This application has the 
potential to make a big dent in a multi-billion market.  (DD1‟s CEO) 
 
2. They have to see that the technology is going to make money. To invest in a risky business, 
they have to see there is something with big potential. (DD1‟s CEO) 
 
 
DD2 3. The potential of our science is what the investors are looking at. This is why we have been 
able to get the money that we have. (DD2‟s founder and CEO) 
 
4. The assumption is you’re many years away from revenue, you’re delayed from revenue.  So 
you’re going to be relying on earning cash for the product every five years or longer. So the 
investors have to believe that his technology is going to take off and that you have the 
capabilities to get it to market.  (DD2‟s founder and CEO) 
 
                             The founders proved critical to developing the firms’ financial assets and capabilities. 
DD1 5. The founders were the main source of capital early on, and on an on-going basis their 
backgrounds and networks have helped us get more investment.  (DD1‟s CEO) 
 
6. We (the founders) have been the main reason why the firm has been able to raise $28 
million. (DD1‟s CEO) 
 
7. I had experience raising capital and knew how to do it. Sure my access to financiers helps, 
but more importantly I have done it many times in the past. (DD1‟s CEO) 
 
DD2 8. Management is the key element to get money in. It’s best to have a track record, in order to 
give investors comfort factor. Myself and Rik are highly experienced and have helped with 
this. (DD2‟s founder and CEO)   
 
9. Had I not had the existing relationships with the investors the company may not have been 
viable; the product may have never gotten off the ground. (DD2‟s founder and CEO) 
 
10. The Chairman of the firm has personally invested over $2 million in the firm and has also 
lent the firm in excess of $2 million. (10k SEC filing 2010).  
                             Partner firms contributed important financing. 
DD1 11. We got a million from the FDA that was helpful. It financed one of our key research projects 
on our drug platform. (DD1‟s CEO) 
 
12. Partners have not really contributed much cash, although the partnership with the medical 
school has provided us with valuable research inputs. It is hard to quantify how much those 
inputs are worth, but it could be worth millions. For that matter the independent researchers 
have also provided some valuable inputs that would have cost us a lot to develop. (DD1‟s 
CEO) 
 
DD2 13. The merger gave us access to large sums of capital. That has been quite helpful to us. 
(DD2‟s founder and CEO) 
 
14. The firm has entered into five different partnerships that have contributed in access of $3 
million towards the firm’s research. (Closed ended question with CEO) 
 
 
Source: Author 
  
164 
 
Processes 
The firms developed several processes that led to the development of their financial 
endowments. The first set revolved around prospecting and securing capital. Both firms‟ 
paths of developing a platform technology were quite costly [Fin-pa costly innovation]. 
Table 6-9 (1-4) depicts representative evidence of how the firms developed skills and 
competencies in prospecting and negotiating for capital. Developing these routines proved 
critical as the economic downturn of 2008 adversely affected the firms‟ ability to raise 
capital.  
 
The shortage of capital also made the firms develop routines for reconfiguring their 
financial resources to focus on fewer and more immediate projects [Fin-proc trans]. This 
shortage of capital was one of the main motivators behind DD1 reconfiguring its resources 
to focus on the development of a diagnostic device. Similarly, DD2 abruptly refocused its 
research efforts in year seven to focus on the development of an over the counter drug. The 
firm cut funding to other projects and focused its investment on this [Fin-pa core tech].  
 
A closely related set of processes that the firms developed revolved around integrating and 
conserving capital (Table 6-9; 6-9) [Fin-proc int]. The firms ran into serious problems 
early on because of miss-forecasting their budget needs. They received what they 
anticipated as a sufficient amount of capital, but burned through it quicker than they 
projected. This made them develop systems for monitoring their cash flows and projected 
spending. Closely related, the firms religiously practiced routines in cost savings. They 
operated with as few employees as possible, purchased as little equipment as possible and 
outsourced many non-essential functions.   
 
Similarly, both firms developed routines for strategically investing their capital in the most 
appropriate areas. This was particularly difficult early on as the firms were not certain 
which technological paths they would pursue. Both firms pursued platform technologies 
that had many potential paths. The experience of founders provided an important position 
for these firms in this process. These founders possessed knowledge in this area from their 
experience in start-up life science firms, and they used this to help strategically guide their 
new firm in investing and budgeting their capital.  
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Table 6-9: DDs' financial processes 
 
FIRM Prospecting for capital has been vital to the firms. 
DD1 1. From day one raising capital has been the most important routine. We are 
constantly seeking more investment from our current investors and seeking 
new investors. (DD1‟s CEO) 
 
2. I am the main fundraiser, but I have a few staff members to help with this. 
The board also helps with this on occasion. My title is CEO, but it might be 
more appropriate to call me Chief Fundraising Officer. (DD1‟s CEO) 
 
 
DD2 3. On an on-going basis has raising capital been important. Raising capital 
becomes an all-consuming event in a start-up operation. (DD2‟s founder 
and CEO)  
 
4. Our ability to continue into our tenth year of operations relies on our ability 
to raise capital. Raising capital is vital. (DD2‟s Chairman) 
 
                            Conserving capital is a vital routine. 
DD1 5. In this business there is only enough cash on hand for a few months. It is 
important to pick and choose the best place to invest this money. This 
decision is made off of what has the biggest impact. There is no way to 
describe how we do this other than it comes from our experience in start-
ups.  (DD1‟s CEO) 
 
6. We had to pick where to invest our money. In a perfect world we could have 
kept the drug and diagnostic research both going, but because of the limited 
funds, we have to choose one. (DD1‟s CEO) 
 
DD2 7. The public markets helped us raise capital to invest in our research. We 
have had to commit resources to going public, and it has affected our 
operations, but it has been a needed source of capital for us. (DD2‟s 
founder and CEO) 
 
8. This (IPO) financing provides us with the capital to meet our near-term 
budgets and the financial leverage to allow us to become revenue 
generating and fund the clinical trials of our biotech investment. (DD2‟s 
Chairman) 
 
 
Source: Author 
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6.2.6 Drug development firms’ conclusion 
DD1 and DD2 were started to develop and commercialise drug technologies. This path 
made R&D and financial resources and capabilities paramount during the early phases of 
growth. The strategic R&D pursuits drove the need for specialised financing: the firms‟ 
technologies were costly and time consuming to develop, which caused the firms to sustain 
years from inception without any revenues. Thus the firms required specialised financial 
resources and capabilities to acquire investment capital.  
 
In order to pursue the path of developing a novel technology, the firms leveraged their 
scientific talents and founders‟ experience. From these the firms created processes to 
develop the needed financial and R&D resources and capabilities. Generally speaking, the 
firms relied on sensing, seizing, learning and organising processes to leverage their 
positions to take advantage of the strategic paths available to them. Although there were 
distinguished similarities in the development of the firms‟ R&D and financial resources, 
there were also numerous differences. The most noticeable difference was the amount of 
capital obtained and the different IPO paths that the firms went down. D1 raised 
substantially more capital than D2 did, and D2 went public through a merger, whereas D1 
filed for an IPO.  
 
Despite the differences, both firms successfully leveraged a unique set of paths, positions 
and processes to develop the R&D and financial resources and capabilities needed to 
navigate the early growth process. Moreover, key individuals were the driving force 
behind the firm‟s growth. The founders of DD1 and the CEO are the ones that discovered 
the technology, raised the needed capital and provided access to networks. Similarly, the 
founder of DD2 discovered their technology, attracted the early investment, established 
key relationships and made scientific breakthroughs that advanced the firm‟s technology.  
 
6.3 Medical device firms (MDs) 
This section overviews the development of the medical device firms. This group consists 
of two firms that are pursuing the development of novel medical devices. In this section a 
narrative of each case is presented followed by an in-depth cross- group analysis. 
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6.3.1 Medical device firm one (MD1) 
MD1 is a small firm that was founded in 2000. Since then it has developed a device for 
back and spinal treatment. Their device elongates the spine, which alleviates muscle 
tension and back pressure, and in many instances, this relieves pressure that otherwise 
would require invasive surgery. Currently the firm employs a staff of seven and is 
generating less than $2 million in revenue. In the first six years it focused on the 
development of the device. In year six the firm started generating revenues.  
 
An idea for a device that allows for greater flexibility in spinal treatment motivated the 
inception of the firm. The founder had been a practicing physician for many years and had 
conceived the device whilst working with patients on another device. He noticed that there 
might be a way to give the patient greater flexibility. From this he sketched out some ideas 
and started working on a prototype in his basement. After a couple of years he developed a 
working prototype, which led him to formalise MD1. The initial idea for the device has 
driven the path of the firm: 
  
The idea for the machine is the whole business. This is why we are here (MD1‟s 
founder and chairman) [R&D-pa core tech].  
 
Initially the founder was the only one working on the product‟s R&D. After he formalised 
the firm, he then contracted a couple of engineers to help him develop a prototype. The 
founder provided all of the inputs to the engineers, and they worked with him on designing 
the device and guiding him on what would be practical [R&D-po founder]. Over a three 
year period this iterative process yielded two different prototypes. The prototypes 
functioned and proved more effective than other devices on the market, but the founder 
still felt the device could be improved. Up until that point the founder worked on the 
project part time and financed the development out of personal funds [Fin-po founder].  
 
In the third year the founder decided to make a more substantial commitment to the device. 
Specifically, he decided he needed to dedicate himself full time to this project, hire a full 
time engineer and lease a production facility. To finance this commitment he liquidated his 
assets: 
 
168 
 
And here, we liquidated and moved from Florida, I mean, from New York to 
Florida, partnered with a colleague, hired new engineer, and began new prototype. 
(MD1‟s founder and chairman) [R&D and fin transformation] 
 
He also decided to move the firm‟s operations to Florida where substantial cost savings 
could be realised [Fin-pa costly innovation]. Florida had much less expensive facilities 
available, and contractors in the area were also much less expensive.  When he moved to 
Florida, he re-connected with a former colleague who had also moved there. Eventually he 
decided to bring the colleague on as a partner. This was a big boost to the company as the 
new partner is highly experienced in developing devices and has two doctorates: a 
physician doctorate and a PhD in electrical medical science. The partner brought 
knowledge in developing the device and also committed financial resources to the firm.    
 
Upon moving to Florida, the priorities for the firm were establishing the R&D facility, 
hiring an engineer and developing a new prototype. They quickly accomplished these 
goals, and in the fourth year they developed a new prototype that they pursued FDA 
approval for.  
 
The firm was not experienced in the FDA approval process, so the founder took it upon 
himself to navigate it himself [R&D-pos founder]. He quickly became proficient in FDA 
procedures and successfully filed all of the paperwork and had the testing done for the 
device. In less than two years the firm traversed the FDA process and gained full approval 
for the product. What also aided the firm in this is the fact that this is not an invasive 
device, so the FDA approval is not as long or as entailed as it is for invasive devices.  
 
The FDA approval triggered the firm to start its first production run in year six. They 
contracted with a manufacturer to build the devices for them. Based on the successful test 
results of the device, the firm was able to pre-sell ten units. This provided capital to the 
firm that allowed it to avoid outside financing. Sales quickly expanded in the seventh year, 
but then when the economic recession hit in year eight, the firm‟s sales quickly dropped 
off: 
 
In fact, the series tipped after that one, and then in 2008 the economy went boom.  
Everything fell.  (MD1‟s founder and chairman) 
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The sudden decrease in sales adversely affected the firm and forced the owners to open up 
a medical practice to help subsidise it. As the recession carried on, practitioners were not 
making large capital investments in devices such as MD1‟s, which continued to weigh on 
MD1 as they had substantial overhead to pay for: 
 
Doctors suddenly didn’t want to spend anything for equipment, unless it was cheap, 
cheap, cheap, and this was an expensive machine.  This stuff is expensive to make 
and our R&D is expensive to maintain. If you don’t sell a certain volume, you can’t 
support this.  So we have managed to hold on. (MD1‟s founder and chairman) 
[R&D-pa costly innovation] 
 
In year eight a financial break came from foreign sales [Fin-pa revenues]. The firm had 
done no overseas marketing, but physicians from outside of the US had learned of the 
technology and solicited MD1 to purchase devices. In year nine the firm quickly received 
and filled orders from Asia, the Middle East, Europe and Canada. This forced the firm 
down an internationalisation path. The firm does not have substantial overseas operations, 
but they do have to provide training to the overseas customers. The firm either had to fly to 
the overseas location or they have had to bring in the overseas customers to train them at 
their Florida headquarters. These sales are helping to finance the firm‟s continued growth.  
 
MD1 is constantly improving their product and production techniques. Every week they 
spend time brainstorming on how to make it better by experimenting with new ideas 
[R&D-proc learning]. Due to these routines, in year nine the firm received ISO 13485 
certification, which is extremely difficult to obtain and which is significant because it 
indicates a high degree of quality for medical devices. Having the certificate itself has been 
a boost to the firm‟s marketing efforts. 
 
In year ten the firm leveraged its international sales to help with its domestic operations: 
 
But, we feel confident that the international market is going to keep this company 
going until the domestic market regains its momentum. (MD1‟s founder and 
chairman) [Fin-pa revs] 
 
It is also for the first time actively seeking outside investment. The founder had looked into 
VC early on in the venture, but could not generate a lot of interest because of the niche 
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nature of the device. However, now that the device is fully developed and market-proven, 
they are confident that they will be able to obtain an equity investment of some type. 
Moreover, the increased activity in international markets is helping to finance the firm, and 
at the time of the study, the economy had started to pick up and domestic demand had 
increased.  
 
Although the firm is not generating significant revenues, it has still enjoyed considerable 
growth. The growth is most evident in an FDA approved and market-tested device. It is 
also evident in the six patents the firm holds, the eleven employees working at the firm and 
the many independent tests that have validated their device‟s efficacy.   
 
6.3.2 Medical device firm two (MD2) 
MD2 is a small firm developing a diagnostic technology that tests for infectious diseases. 
Their technology detects active markers of diseases in infections, and their technologies‟ 
main advantage is the ability to identify active infections, unlike the competitions tests, 
which cannot discern between active and inactive. This is a platform technology, but to 
this point MD2 has been forced to cut back their scope and focus on the development of 
one application. The firm was founded in 2003 to further develop and commercialise an 
innovation that was created at the University of Florida. Currently the firm employs ten 
staff members and as of 2010 was not generating revenues. However, the firm has just 
received approval for its first application and will be generating revenues in 2011.  
 
The technologies that the firm licensed have set the strategic direction of the firm. 
 
Without these innovations we would we would have no business.  (MD2‟s CEO) 
[R&D-pa core tech] 
 
In 2003 the firm‟s founder came across the patents because of his connection with the 
University of Florida. In previous dealings he had worked with the university on acquiring 
technology. He reached a favourable deal for the access to the patents whereby a small 
upfront fee was paid, and a portion of the future profits would be paid. Although the 
patents already had shown clinical promise, they were still far from a market-ready state. 
This created a path that demanded substantial R&D and financial resources and 
capabilities [R&D-pa core tech].  
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Raising capital became the firm‟s first priority. The University of Florida helped them 
engage with an angel investment network. This resulted in an individual investing $2 
million dollars, and the initial capital funded the development of the firm‟s R&D.  Initially 
the owner and a couple of scientists worked on the chemistry needed to further the 
technology. They made several progressions that helped the firm raise an additional $4 
million in 2008. Even so this capital proved extremely difficult to raise because the capital 
markets had tightened up due to the recession.  
 
I think we began seeing it in late 2006.  Certainly through 2007 the capital markets 
were drying up because you could see bad things were coming, and they would see 
that based on that part of the business… I think that part of the financial 
community sees it first.  And so from that period of time until literally 2009, it was 
extremely difficult to get capital. (MD2‟s CEO) [Fin-pa VC] 
 
Despite the tight capital markets, the firm successfully raised the amount needed and 
continued to develop the core technology. The research progress also helped the firm 
attract additional research partners. In 2008 the firm forged an important international 
research partnership with the University of Toronto [R&D-po uni]. This partnership was 
facilitated largely through the scholarly community. MD1 knew of the work the university 
was conducting because of the great number of papers that they were producing. Similarly, 
the university had seen some publications related to MD1‟s technology and was interested 
in sharing resources [R&D CCA]. This partnership provided important inputs that helped 
the firm develop the chemistry that they needed for their technological development.  
 
At the same time the firm received important inputs from a star scientist who was 
consulting for the company [R&D-po star scientist]. He holds over ten patents and is 
widely regarded as one of the top researchers in the field, and he contributed important 
findings that helped the firm develop a saliva application for their technology. This 
breakthrough opened up several opportunities for the firm such as creating an interest in 
their technology that helped attract research inputs from a number of research institutions. 
However, the firm needed to develop a complementary device to deliver the new 
technology. At the time there was not an exact device on the market to satisfy this need. In 
order to find such a device the CEO, who had previously lived in Scotland, turned to a 
specialised company he had worked with in Inverness that possessed the capabilities to 
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develop one. This proved to be a vital partnership as the firm was able to quickly develop 
the needed device for MD2 [R&D CCA].  
 
The quick advancement of the device triggered the firm to start the government clearance 
procedures for it. Due to the CEO‟s previous experiences with the US FDA, the firm 
decided first to seek approval for their saliva-based device in Europe. The CEO had much 
better experiences with the EU than he did with the FDA: 
 
The FDA is becoming more difficult, less predictable, and actually I think selling is 
slowing technology down, which is why we’re going to be launching in Europe first 
because of that. (MD2‟s CEO) [R&D-pa govt approval] 
 
The advancement of the technology towards a state of commercialisation greatly helped 
the firm attract an additional $8 million in private equity financing in 2010. Like the earlier 
rounds of financing, this one proved difficult to obtain. The firm‟s CEO leveraged the 
progress in the technology and the networks of the previous investors in order to obtain the 
capital needed to progress their device. However, the firm would have preferred to raise a 
much greater amount of capital to progress several applications. Their core technology has 
many different potential applications in many different areas.  
 
However, the changing capital markets prohibited the firm from raising the capital needed 
to develop more than one application at a time. Furthermore, the CEO represents the main 
fundraising capability and is constrained by the amount of time he must devote to dealing 
with the current investors and other operations of the firm. 
 
Now that the firm is at a point of commercialisation, they are projecting that the revenues 
from their device will help subsidise the development of other applications. However, 
raising capital is still a top priority for the firm as they still project to consume substantial 
sums of capital. The CEO emphasises the importance of raising capital: 
 
Raising capital is always important in this business. You are always burning 
through capital, so it is important to have a continual supply coming in. (MD2‟s 
CEO) [Fin-pa costly innovation] 
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Although the firm has not started to generate revenues, it has still enjoyed considerable 
growth. One of its proudest accomplishments is advancing its technology through the 
economic downturn of 2008. Small firms in this industry were particularly hit hard by the 
downturn, as they are reliant on VC and other forms of risk capital to develop their 
technologies. Growth to this point is also evident from the growth of their staff to ten 
employees, over twenty publications on their research and the development of a strong 
network of partners.  
 
6.3.3 MDs cross-group analysis 
The narratives above provide a contextual basis for the evolution of the firms‟ R&D and 
financial resources and capabilities. This section delves deeper into the key paths, positions 
and processes that led to the development of the firms‟ R&D and financial resources and 
capabilities. Following this the financial resources and capabilities development will be 
presented in the same fashion.  
 
 6.3.4 R&D assets and capabilities development 
In the early stages of growth both firms focused on the development of their technology. 
This was the impetus to developing R&D assets. In the same fashion as the last section, 
Table 6-10 presents the matrices of the paths, positions and processes that were yielded 
from the data reduction techniques discussed in the research methods chapter. Based on the 
analysis of the interviews and the close-ended questions concerning each path, position and 
processes for each firm is placed in one of four categories based on its influence on the 
firm‟s development: high (H), medium (M), low (L) or no (N) influence. The major paths, 
positions and processes are discussed in detail below. 
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Table 6-10: MDs' R&D paths positions and processes 
 MD1 MD2 
INFLUENTIAL ON FIRMS’ PATHS 
Core technology conceptualised at a university N H 
Core technology conceptualised at another firm N N 
Core technology conceived by the firm N N 
Government partnerships L L 
Industry partnerships L M 
New technologies influenced firm‟s direction H H 
Government approvals: e.g. patent or FDA H H 
Scientific developments H H 
IMPORTANT POSITIONS 
Patents H M 
Skilled scientists H H 
Star scientists H H 
Industry partnerships L H 
University partnerships L H 
Government partnerships L L 
R&D facility and research equipment M M 
KEY PROCESSES 
Sensing and seizing scientific opportunities H H 
Finding and developing research partnerships L M 
Navigating government approval H H 
Filing patents M M 
Learning from earlier research H H 
Source: Author 
 
 
Paths 
Three main paths influenced the development of the firms‟ R&D. Table 6-11 presents 
evidence depicting the importance of the firms‟ core technology, government approvals 
and research setbacks to the development of MD1 and MD2‟s R&D resources and 
capabilities.  
 
The firms‟ technologies dictated their R&D paths (Table 6-11; 1-5) [R&D-pa tech 
demands]. Although both firms‟ technologies dictated their strategic paths, the two firms‟ 
technologies evolved in different fashions.  
 
MD1‟s technology was conceptualised and developed by a practicing physician who had 
no R&D or business experience. The idea for the device emanated whilst treating patients 
where he had an idea for a more effective back treatment device. Thus MD1 had to come 
up with the idea from scratch. In contrast, MD2‟s core innovation was created at a 
university. This idea had been worked on for several years at there and had reached a point 
where it became commercially attractive. At this point MD2‟s founder licensed the rights 
to it and formed a company to further pursue its development. The relative state of 
development of the firms‟ innovations had a bearing on the research paths of the firms. 
175 
 
MD2‟s more developed technology required testing and refining; whereas, MD1‟s device 
required conceptualisation and development.  
 
Although MD1‟s device needed more development, it still came to market quicker than 
MD1‟s device did. MD1 was able to bring their device to market within six years, whilst 
MD2‟s took over eight. This is largely attributed to the difference in technology that the 
two firms pursued. MD1‟s technology is not an invasive device or chemically based, 
whereas MD2‟s device is. Invasive and chemically-based devices take longer to develop 
and have more government regulation to contend with.  
 
It is evident from these two cases that the technology that a life science venture is created 
to pursue can come from different sources, but regardless of source, the technology drives 
the R&D paths of the firm. Furthermore, these cases show that novel technology can have 
varying development time horizons, even from firms in the same field. 
 
Government approvals had a large bearing on the firm‟s strategic paths (Table 6-11; 6-11) 
[R&D-pa govt approvals]. Both firms had to dedicate substantial resources to gaining 
government approval. MD1‟s founder was inexperienced, but still led the firm‟s product 
through government approval (Table 6-11; 7). In comparison MD2‟s founder was highly 
experienced in gaining government approval for medical devices, so he chose to first 
pursue government approval in Europe (Table 6-11; 9 and 10). The net effect of the of 
government approvals is that both firms strategized around this and devoted significant 
resources to it, and it drove MD1 down an internationalisation path.  
 
In a similar fashion, the patent process influenced the R&D paths of the firms [R&D-pa 
govt approvals]. Both firms applied for and received several patents. For both firms the 
commitment to patents tied up substantial resources, which created path rigidities. 
Unfortunately this limited other R&D related activities that they could invest in.  
 
The third major path that influenced the firms‟ R&D is research setbacks (Table 6-11; 11-
13). MD1‟s first prototype did not perform as well as they would have liked, which forced 
the firm to significantly increase their R&D efforts (Table 6-11; 11). This triggered the 
founder of MD1 to sell his physician practice and liquidate his personal finances to invest 
in MD1‟s R&D resources so that the firm could build a better prototype. Similarly, MD2 
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ran into some troubles getting through the patent application process and also had some 
setbacks in their testing.  
 
These setbacks forced both firms to reorganise their R&D. MD1 cut back on the number of 
projects they pursued, whilst MD2‟s setbacks led them to recreating their entire prototype. 
 
The two firms‟ reorganisation paths were markedly different. MD1 cut back its R&D to 
conserve resources. In contrast, MD2 expanded its R&D; the firm hired additional staff 
and leased a larger research facility. Despite the fact that MD1 cut back its R&D spending 
whilst MD2 increased its R&D spending during their reorganisations, resources provided 
the central motivation behind the new paths the firms pursued. MD1 cut R&D spending 
and focused on developing one application, instead of the three applications it had initially 
pursued. This move was aimed to save resources to keep the firm viable. In contrast, MD2 
increased spending because they felt the only way to keep the firm viable was to come up 
with a new prototype for their device. Consequently, the new prototype required the firm 
to expand its R&D.  
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Table 6-11: MDs' R&D paths 
 
FIRM  The core technology drove R&D demands of the firms. 
MD1 1. The idea for the machine is the whole business. This is why we are here. (MD1‟s chairman) 
 
2. We are the only articulating 10-way adjustable positioning spinal elongation system in the 
world. We are the first major evolutionary improvement to spinal traction and elongation 
in the last 50 years. (MD1 co-chairman) 
 
3. One hundred per cent of the $2 million invested in the firm went directly or indirectly to 
developing the firm’s core technology. (Close- ended question) 
 
MD2 4. Without these innovations we would we would have no business.  (MD2‟s  CEO) 
 
5. Almost all of MD2’s $10 million capital expenditures in the first seven years went to 
developing their core technologies.  (Closed ended question; analysis of firm‟s financial 
statements) 
 
                                FDA and government approvals have impacted the strategic direction of R&D. 
MD1 6. We had to learn how to navigate FDA approval. This was important to the development of 
our device. Without it, it cannot be used.  (MD1‟s Chairman) 
 
7. I did not have experience in FDA, but it is essential, so I took the time to familiarise myself 
with the process and navigated it for the company. (MD1‟s Chairman) 
 
8. There is a lot that went into the patents. It is important to devote the resources to this 
because the patents protect the device. (MD1‟s Chairman) 
 
MD2 9. The FDA is becoming more difficult, less predictable, and actually I think selling 
technology is slowing down, which is why we’re going to be launching in Europe first 
because of that. (MD2‟s CEO) 
 
10. The regulatory process is tedious. It’s unpredictable now.  The agency is inconsistent and 
erratically changes directions.   It’s now kind of coming back to a more centred position, 
but what used to take in our industry for relatively safe products you could predict that if 
you made your submission, then within 90 days you got an answer.  It’s much less 
determinant (sic) now.  (MD2‟s CEO) 
                              Scientific setbacks impacted the strategic direction of R&D. 
MD1 11. I said to him, You know, I see what’s going on here.  I think this whole prototype needs to be 
redone.  I said, Okay.  Let’s re-do the whole thing. That’s what we did. (MD1‟s Chairman) 
 
12. The firm developed three prototypes and went through over twenty designs. (Close- ended 
questions with CEO)  
 
MD2 13. We’ve had to restrict our expenditure R&D to focus on the first product that we hope to 
launch later this year. (MD1‟s CEO) 
Source: Author
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Positions 
Table 6-12 presents evidence supporting the most important positions to the development 
of the firms‟ R&D resources and capabilities.  
 
Both firms‟ founders proved to be both direct and indirect critical resources to their firms‟ 
R&D (Table 6-12; 1-4) [R&D-pa founder]. MD1‟s founder came up with the idea for the 
technology He was also the driving force behind the early prototype. The partner he 
brought in, skilled in many technical areas, provided inputs that allowed the firm to refine 
the prototype with regard to the computer interface.   
 
In a slightly different vein, MD2‟s founders drove the development of their R&D. He did 
not conceptualise the technology, but instead he used his technical and business skills to 
sense it out (Table 6-12; 3) [R&D-po founder]. He then used his experience to put together 
a staff and a plan to further develop and pursue the commercialisation of the technology. 
Although the founders‟ inputs were substantially different, the founders of the two firms 
were the key resources behind the R&D.  
 
Scientists are another position that significantly contributed to the development of the 
firms‟ R&D (Table 6-12; 5-9). MD2‟s scientific staff is made up of seven researchers as 
compared to MD1‟s staff of three, and both firms‟ scientific staff proved to be important 
resources. Moreover, both firms received large contributions from star scientists (Table 6-
12; 6 and 8) [R&D-po star scientist]. The co-owner of MD1 is an accomplished scientist in 
the field and has substantial experience in developing devices. His contributions, along 
with the contributions of the founder‟s inputs, are what enabled the firm to create and 
progress their core technology. Two star scientists renowned in the field proved 
particularly important to MD2‟s  technology.  
 
The firms‟ core technology also provided an important resource to the firms‟ R&D (Table 
6-12; 10-13) [R&D-pos core tech]. MD1‟s technology quickly progressed to a state of 
commercialisation in year six. At this point they used the revenues from the sale of the 
devices to supplement the R&D of the firm (Table 6-12; 11). In contrast, MD2‟s 
technology took over nine years to get to market, but the technology proved more 
beneficial to attracting other R&D inputs than MD1‟s. More specifically, MD2‟s 
technology complemented many areas of research related to the treatment of infection 
(Table 6-12; 12) [R&D CCA]. This triggered several key research partnerships that led to 
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important R&D resources. For example, the firm developed a close relationship with the 
University of Toronto, which wanted access to MD1‟s technology. This relationship 
proved mutually beneficial as MD1 received important testing and access to specialised 
technology, and the university received access to MD2‟s technology, which helped in 
several of their research projects [R&D CCA]. In addition the firm developed a 
relationship with a Scottish firm that proved mutually beneficial.  
 
The different effects the firms‟ core technologies had on the development of their R&D is 
largely attributed to the nature of their innovations and the protection status of the 
innovations. By its nature MD2‟s technology complements several areas, whereas MD1‟s 
technology does not. Also MD2‟s technology is harder to copy, and it is easier to defend 
their intellectual property than MD1‟s technology is. For this reason MD2 was more 
relaxed about working with partners. They were not afraid that their technology would be 
stolen. Despite these differences, both firms‟ technologies proved to be important 
resources that aided in the development of their R&D resources and capabilities. 
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Table 6-12: MDs' R&D positions 
 
FIRM     The founders provided important R&D inputs. 
MD1 1. So, I started to fabricate, in my basement, a prototype to test certain positions’ postures 
and movements.  And when I felt that this was something that could work, I then hired an 
engineer and I had some drawings done, and I went back and forth with the engineer on 
the drawings, to fine tune what I wanted,  and I had a, actually two prototypes in New 
York, made.  (MD1‟s Chairman) 
 
2. Oh yes, I was the one driving the design of the device. (MD1‟s Chairman) 
 
MD2 3. He evaluated the patents and saw that they had large profit potential. He is a PhD and 
has many years of experience in the industry that helped with this. (MD2‟s CEO) 
 
4. The founder and Chief Scientific Officer holds over twenty patents and has helped three 
other companies successfully develop and commercialise medical devices in the past. 
(Information taken from firm prospectus.) 
               The scientists provided important inputs to the firms R&D. 
MD1 5. The new engineer actually built the new working prototype. He took those prototype 
drawings and made it out of extruded aluminium, and from this we got patents  and made 
it into production material drawing that could brought to a and made.  (MD1‟s 
Chairman) 
 
6. He (co-owner) has extensive experience and was able to make some critical 
contributions right away. He has an extensive electronics background that was a big 
help to creating the controls. (MD1‟s Chairman) 
 
MD2 7. The company’s technical progressions could not have been made without our scientists.  
(MD2‟s CEO) 
 
8. There is a researcher we have in California who has made some significant 
contributions to our technology. He is well known and has a substantial scientific 
background.  (MD2‟s CEO) 
 
9. The company has a scientific advisory board made up of top scientists and researchers 
who are leaders in their fields. The scientific advisory board provides input and 
advice. (MD2‟s CEO)  
 
                   The core innovation proved important to R&D. 
MD1 10. We have interest from hospitals from all over the world that are interested in working 
with us because of it is a revolutionary device. (MD1‟s founder) 
 
11. We were able to get to start selling it in 2006, and these revenues really helped with the 
continued development of the device.  (MD1‟s founder) 
MD2 12. There are a number of organisations that are interested in our technology because of its 
ability to identify active infections. (MD2‟s CEO)  
 
13. We have been able to reach out to a number of universities because of their interest in 
using our science. They want to stay at the cutting edge, and our product is at the cutting 
edge.  (MD2‟s CEO) 
Source: Author 
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Processes 
Table 6-13 presents a representative sample of evidence depicting the important processes 
that led to the development of MD1 and MD2‟s R&D resources and capabilities. They 
relied on several of the same routines with some small differences.  
 
One set of routines that both firms developed is transformational capabilities (Table 6-13; 
1-4). Early on in the venture MD1 had to rapidly redefine its R&D to produce a new 
prototype that could effectively treat spines and get through FDA testing [R&D-proc 
trans]. The firm quickly reorganised its R&D resources to focus on this development. It 
hired new staff members, brought a new partner into the ownership structure and came up 
with a drastically different design (Table 6-13; 1 and 2). The founder orchestrated the 
transformation as he saw the need for a new prototype. 
 
 Similarly, MD2 ran into some early research issues that, coupled with financial 
constraints, forced the firm to refocus its R&D on its main application (Table 6-13; 3 and 
4). Similar to MD1, the founders and the CEO drove this transformation. They saw this 
need and redesigned the firm‟s research to focus on just one application. 
 
Clearly the ability to reconfigure R&D resources and capabilities is critical. Had these 
firms not adjusted, then they would not have survived. MD1 would not have been able to 
get their device through FDA approval and MD2 would have exhausted their resources 
trying to develop four applications and would not have gotten them to market.   
 
In addition the firms‟ R&D revolved around learning daily from their earlier research 
(Table 6-13; 5-8) [R&D-proc learning]. Neither firm had an advanced system for this but 
instead relied on the tacit abilities of their staff. MD1‟s learning mainly emanated from the 
two owners and the engineer they employed. They did not have a formal system but 
instead shared ideas and independently worked on tasks aimed at progressing their 
technology. Likewise, MD2‟s scientific staff did not have many formalised procedures. 
Rather they worked independently and shared ideas and updates relevant to the firm‟s 
research.  
 
One set of processes important to MD2, but not MD1 is sensing complementary 
technology (Table 6-13; 9-11) [R&D-proc S&S]. MD2 was established through the 
founder‟s abilities to sense out technology. The routines they developed relied heavily on 
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the networks of the founders and CEO. The firm also developed systems for scouring 
scientific journals to find complementary technologies. In contrast, MD1 did not have such 
routines in place. The founder is where the core technology emanated, and the firm‟s 
scientific progressions came almost exclusively from internal sources.    
 
These differences are largely attributed to the difference in the two firms‟ technologies. 
MD2‟s technology complemented many other areas related to infectious disease [R&D 
CCA]; whereas, MD1‟s technology is unique and does not have widespread application. 
Some of the difference in the importance of technology sensing is also attributed to the 
background of the founders. MD2„s founders and TMT are highly connected and these 
connections resulted in access to complementary technologies. In contrast, MD1„s 
founders are not highly experience and connected (Table 6-13; 9). This is one of the 
reasons that they did not have access to complementary technologies, and did not take in 
knowledge from outside sources. 
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Table 6-13: MDs' R&D processes 
                             Transforming R&D has proved vital to the firms’ growth and survival. 
MD1 1. You know, I see what’s going on here.  I think this whole prototype needs to be redone.  I 
said, Okay.  Let’s re-do the whole thing. That’s what we did and within a year we had an 
FDA cleared device. (MD1‟s Chairman) 
 
2. This needed to be formalised, so I brought in an engineer and brought an old colleague on 
board to really refine the machine.  (MD1‟s Chairman) 
 
MD2 3. We have reorganised our research to focus on our main application. Ideally we would like 
to focus on three applications, but because of resource constraints, we have had to focus on 
one application. (MD2‟s CEO) 
 
4. I think we were fortunate to just make it through there and stay alive, which is why it has 
taken us as long as it has for what should have been out in three years instead of six years; 
primarily because of the inability to raise capital. This has forced us to reorganise and focus 
on one application. (MD2‟s CEO)  
 
               Learning routines have helped advance the firms’ R&D. 
MD1 5. It was an iterative process of seeing what worked and what didn’t. It was a continual 
learning process.  (MD1‟s Chairman) 
 
6. It was a long process to develop the first prototype. They say, Well, how about?  No, I want 
the machine to do this.  Well, then they show me something.  Well, how about we do it like 
that? and I was, Well, well, that will work. Or That won’t work. You need to make it go like 
this.  And we’d go back and forth, until what I wanted was achieved. That started probably 
2000, up until 2003. (MD1‟s Chairman) 
 
MD2 7. We have a chief scientific officer who coordinates all of the scientific activity. There are 
many different things going on, so it is important to coordinate these things. We learn from 
our earlier tests and apply these to refining our device. (MD2‟s CEO)   
 
8. Our learning routines have led to several significant progressions of our technologies. 
(MD2‟s founder and CEO) 
 
               Sensing and taking in outside knowledge proved vital to R&D. 
MD1 9. I am a doctor (medical physician) and I have never developed anything before, so I did not 
have any contacts with alliances that could help me out. All of this came from my practical 
experience and experimentation with the machine. (MD1‟s Chairman) 
 
 
MD2 10. The rest of the technologies were either developed here at Gene Ex in Miami or through 
partners and consultants that we have used under contract. We have taken in knowledge for 
our product from a number of source. (MD2‟s CEO) 
 
11. We’re really bringing a bunch of science together.  Some of it is fairly new here, but much of 
what we like so much—I think innovation—is bringing a kernel of new stuff together with 
other stuff, but I’ve found over the years the most successful accomplishments are the things 
that have been developed in other spaces and you bring them together; and we’ve done a bit 
of that. (MD2‟s CEO)  
Source: Author 
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6.3.5 Financial assets and capabilities 
Table 6-14 highlights the paths, positions and processes central to the development of the 
firms‟ financial resources and capabilities. Based on the coding and close-ended questions, 
each path, position and the processes for each firm is placed in one of four categories based 
on its influence in development: high influence (H), medium influence (M), low influence 
(L) or no influence (N). The analysis of the major paths, position and processes is detailed 
below. 
 
Table 6-14: MDs' financial paths, positions and processes 
 MD1 MD2 
INFLUENTIAL ON FINANCIAL PATHS 
Costly innovation  H H 
Raising capital L H 
Public stock offering N N 
VC L L 
POSITIONS 
Scientific capabilities M H 
Founders  H H 
Executive staff H H 
Core innovation H H 
Firm’s staff L M 
PROCCESSES RELATED TO 
Raising capital L H 
Integrating and conserving financial 
resources  
H H 
Dealing with Investors N M 
IPO N N 
Transforming financial resources H h 
Source: Author 
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Paths 
Table 6-15 highlights the paths important to the development of the firms‟ financial 
resources and capabilities. There were several past decisions and future opportunities that 
impacted the financial demands of the firms. 
 
The core technology had the largest bearing on their financial paths [Fin-pa costly 
innovation]. Both firms‟ financial strategies revolved around their core technology. MD2‟s 
core technology required $3 million in the first three years. This investment went to 
developing important chemical technology and testing for the device. Moreover, the firm 
has also invested substantially in items related to government approval for their device; 
most notably, patents and EU product approval. The substantial costs forced the firm down 
a path of attracting outside investors. Early on an angel investor emerged to provide most 
of the early capital. Followed by this a VC investment came in. Throughout the first nine 
years of existence MD2 has invested over $10 million in their technology. In consequence 
of choosing to develop costly technology, raising funds has been at the forefront of MD2‟s 
strategic direction (Table 6-15; 5). The firm‟s research is dependent on it, and the firm‟s 
ability to raise capital is dependent on progressions in its research (Table 6-15; 6) [R&D 
and finance co-specialisation].   
 
In contrast, MD1‟s technology was less expensive to develop, largely because of the path 
of developing a non-intravenous device and the fact that the founder provided most of the 
early scientific inputs. This allowed the founder to self-finance the early development of 
the firm. The nature of the core innovation also made raising capital difficult, as they could 
not get a lot of interest in the device because of its niche nature (Table 6-15; 2) [Fin-pa 
VC]. It has profit potential, but it does not have the large scale profit potential that VCs 
look for in a potential investment, yet another reason the firm went down a self-financing 
path. 
 
The device‟s continued development consumed hundreds of thousands of dollars, which 
triggered the founder to bring on a partner in year four. In year six the firm started selling 
its device and these revenues opened up new financial paths for the firm [Fin-pa revs]. 
These revenues helped finance the development of the firm‟s technology. This also helped 
to deter the need for outside investment. The firm also got a big boost in year eight when 
the technology helped them attract international customers. In that year several foreign 
customers solicited MD1 to purchase their device. Their interest stemmed from MD1‟s 
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superior technology. At that point the firm had done no overseas marketing, but the foreign 
customers had heard of MD1‟s technology and located the company on the internet. 
Consequently, the firm received revenues that have essentially kept the firm viable.  
 
Apparent in these cases is that the owners‟ experience levels influenced the financial paths 
of the firms. MD2‟s experienced founders sought out and found early stage investors, 
which helped to minimise the personal investment they had to contribute to the venture. In 
comparison, MD1‟s founder was not experienced in starting a device firm and was not 
familiar with raising capital. However, both firms‟ strategies proved effective, as they both 
successfully financed the development of a marketable device.   
 
These cases also show how external events can greatly influence the financial paths and 
outlooks of small life science ventures. The recession of 2008 greatly hindered the firms‟ 
abilities to finance their R&D, and because of this both firms had to drastically change 
their financial strategies (Table 6-15; 8-11). For MD1 the sales of their device greatly 
dropped off. This adversely affected their ability to finance their R&D (Table 6-15; 9). 
Moreover, it left them with great overhead costs that proved difficult to meet. This 
triggered the owners‟ of MD1 to open new financial paths including opening a clinic to 
generate revenues. 
  
In comparison, MD2 found it more difficult to raise the capital in the midst of the recession 
(Table 6-15; 10 and 11) [Fin-pa VC]. The markets had largely dried up because of the 
recession forcing MD2 to downsize its operations and focus on the development of only 
one of its applications, instead of the four that it had originally set out to develop.   
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Table 6-15: MDs' financial paths 
 
FIRM               The core technology drove the financial strategies of the firm. 
MD1 1. The machine took a significant dollar amount to develop. The costs for the design and 
development have cost a substantial amount. (MD1‟s Chairman) 
 
2. The main word that the venture capital people use is scalability. See, scalability.  A 
machine like mine, you may have a few thousand treating doctors in the world, and only a 
percentage of those might buy the machine. So, it’s not a big scalability. So, it’s a real 
boutique-y market.  (MD1‟s Chairman) 
 
3. But we feel confident that the international market is going to keep this company going 
until the domestic market regains its momentum.  (MD1‟s Chairman) 
 
4. One hundred per cent of the capital invested in the firm went directly or indirectly to 
developing the firm‟s core technology. (Close-ended question) 
 
MD2 5. The core technology has driven our need to raise capital.  (MD2‟s CEO)  
 
6. So, the sell to the investors has been this is great technology.  It’s a great market.  If we 
can finance it we should have a very successful commercial enterprise.  (MD2‟s CEO) 
 
7. Because of the cost of developing the innovation - that makes raising capital paramount.  
(MD2‟s CEO) 
 
                             Environmental factors have influenced the firms’ financial strategies. 
MD1 8. In fact, the series tipped after that one, and then in 2008, the economy went boom.  
Everything fell.  (MD1‟s Chairman). 
 
9. Doctors suddenly didn’t want to spend anything for equipment, unless it was cheap, cheap, 
cheap, and this was an expensive machine.  This stuff is expensive to make and our R&D is 
expensive to maintain. If you don’t sell a certain volume, you can’t support this.  So, we have 
managed to hold on. (MD1‟s founder and chairman). 
 
MD2 10. And so from that period of time until literally 2009, it was extremely difficult to get capital.  
I think we were fortunate to just make it through there and stay alive. (MD2‟s founder and 
CEO) 
 
11. We saw it first. The capital markets dried up and many of the investors were on the side line. 
Then when things got better, investors went to the stock market because it was so easy to get 
great returns as the market rebounded. This made it difficult for firm like to get the high risk 
– high reward capital.  (MD2‟s CEO) 
 
 
 
Source: Author 
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Positions 
The firms relied on two main positions to develop their financial resources and 
capabilities; their top management team (TMT) and their technology. However, the way 
the firms leveraged these varied substantially.  
 
The TMTs of the firms provided the most important positions in the development of the 
firms‟ financial resources and capabilities [Fin-po TMT]. Table 6-16 (1-7) depicts a 
representative sample of evidence that underscores the importance of the firms‟ TMT to 
developing its financial resources and capabilities. MD1‟s founder provided all of the seed 
capital to fund the firm in the first three years. He then brought on a partner who also 
contributed financial resources. MD1‟s founders‟ capabilities in conserving capital also 
provided an important position because it saved money that otherwise would have had to 
come from outside investors; the founders used their scientific capabilities to reduce the 
amount that had to be spent in the development of the firm‟s product. For example, the 
founder navigated the FDA approval process for the firm, which saved the firm upwards of 
a million dollars. The founder and his partner also opened a clinic in the ninth year to 
generate more revenues for the firm. This proved vital as these revenues provided 
resources that allowed the firm to stay viable during the economic recession.    
 
Similarly, MD2‟s TMT provided the important inputs to the financial resources and 
capabilities of the firm, but in a different way than MD1‟s did (Table 6-16; 5-7). MD2‟s 
founder‟s background proved vital to the early investment that the firm received. He is 
well known and well connected, and he used this to help the firm attract the early 
investment the firm needed to get started. In year two the firm hired a highly experienced 
CEO who has been its main fundraiser. He used his experience and networks to attract $10 
million in capital. Moreover, MD2‟s TMT‟s capabilities in reorganising and cutting costs 
have kept the firm viable (Table 6-16; 7) [Fin-po TMT].  
 
Interestingly, the two firms‟ TMTs had drastically different backgrounds and approached 
the financing of their respective firms drastically differently (Table 6-16; 8-11), but both 
firms‟ TMTs supplied vital resources that significantly contributed to the capabilities of 
their firms [Fin-po TMT].    
 
Technology is the second position that the firms drew on to develop their financial 
resources and capabilities, but like the TMTs, the firms leveraged their technology in 
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different ways. MD1 quickly moved its product to commercialisation and used the 
revenues the technology generated to help finance the continued development of the 
technology. In contrast, MD1 used its technology to help attract investors. The technology 
showed promise to lead in a highly profitable market, which MD1 used to help attract 
investors. Although the two firms‟ technology differed greatly and had different impacts 
on the firms‟ finances, both technologies proved to be vital resources.    
 
 
Table 6-16: MDs' financial positions 
 
FIRM  The founders and top managers provided key financial positions. 
MD1 1. I paid for all of the early development of the firm. (MD1‟s Chairman) 
 
2. Since he came on board, we have shared the expenses in developing the machine. (MD1‟s 
Chairman) 
 
3. I was able to keep costs down by doing a lot of the functions of the firm myself and 
strategically finding the lowest cost inputs. (MD1‟s Chairman) 
 
4. One hundred per cent of the capital has been provided by the founder and his partner. 
(Close-ended question) 
 
MD2 5. The founders were important to bringing in the capital. They knew some key people and had 
a background in business that the investors liked. (MD2‟s CEO)  
 
6. It is important to know how to find investors and work with them. Myself and our CFO are 
experienced in this, and this has helped us bring in the capital that we need to continue the 
technology’s development. (MD2‟s CEO) 
 
7. The board had to sit back and make some cost cutting decisions to stay viable. (MD2‟s 
CEO) 
                              The firms’ technology helped develop financial resources. 
MD1 8. The sales of the machine took off initially, and this helped us develop the company.  (MD1‟s 
Chairman) 
 
9. In 2008 the international revenues picked up and these have given us a big boost. These 
have really helped us through the recession. (MD1‟s CEO) 
 
MD2 10. The investors look at how profitable a device can be, and ours is in a profitable market, so 
that’s one of the tools that we used to attract investors. (MD2‟s CEO) 
 
 
Source: Author 
 
 
Financial processes 
Both firms relied on a number of routines to develop the financial resources necessary for 
their firm‟s growth. Table 6-17 presents a representative sample of evidence of the key 
processes that the firms used to develop their financial resources and capabilities. For the 
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most part the firms‟ routines were quite similar, but there were also some noticeable 
differences.  
 
One of the main differences is the importance of routines in prospecting and raising 
capital. This proved highly important to MD2, whereas these processes did not play a 
major part in MD1‟s operations. The routines that MD2 developed for raising capital came 
from the tacit knowledge and abilities of the founders and the TMT. They had raised 
capital for new life science ventures in the past and knew how to prospect and negotiate 
with early stage investors (Table 6-17; 3 and 4). The outside investors that MD2 brought in 
also made the firm develop investor relation routines, the most important of which 
revolved around communications with investors [Fin-proc inv rel]. This was handled 
primarily through the efforts of the CEO and CFO.  
 
It is evident from these two cases that new innovations are costly to develop and that 
capital is paramount to the development of innovation, but this capital can emanate from 
different sources. The source of capital has a major bearing on the processes that a firm 
must develop. MD1 self- financed the venture and did not have to develop routines related 
to raising capital. In contrast, MD2 financial strategy revolved around attracting outside 
capital, which made routines related to prospecting capital paramount. There are merits 
and demerits of each source of capital. Outside investment capital lessens the risk to the 
founders, but it takes a substantial resource commitment to processes related to raising it 
and dealing with the investors, especially the time the TMT has to devote to these 
functions. Regardless of the source of capital, it is evident that key individuals – i.e. the 
founders and TMTs – are the ones who drive the processes related to raising it.   
 
One set of routines that both firms relied heavily on revolved around conserving funds 
(Table 6-17; 6-8) [Fin-proc int]. Because of the costly nature of their products and their 
shortage of capital, both firms had to save money in every way possible. This proved 
difficult, as the firms‟ innovation was expensive. To conserve funds MD1 internally 
performed as many design functions as possible. This was led by the firm‟s two owners 
who contributed most of the R&D functions. The owners even attempted several functions 
that they were not versed in. For example, they produced the technical drawings for some 
of the designs, and the founder navigated the FDA approval process for the firm‟s device, 
even though he had no experience in these areas. MD1 also constantly looked for ways to 
save capital in their production. They constantly negotiated with suppliers and found new 
191 
 
ones (Table 6-17; 5 and 6). In a similar vein, MD2 developed processes for keeping their 
operations as lean as possible. Whenever possible they outsourced functions to university 
partners who would perform the functions for little to no costs. MD2 also learned how to 
use cost effective contract researchers for many functions (Table 6-17; 7 and 8).  
 
Clearly cost cutting routines are vital to the development of a life science venture‟s 
financial resources and capabilities. Cutting costs in every way possible without adversely 
affecting R&D greatly helped both of these firms, as both firms successfully developed a 
medical device whilst still controlling for costs.  
 
Closely related to conserving funds, the firms also developed routines for transforming 
their financial resources (Table 6-17; 10-13) [Fin-proc trans]. In year three MD1 
transformed from a relatively informal operation of just one founder to a formal 
organisation. The firm hired a staff and leased an R&D facility. The firm‟s owner had to 
come up with capital to finance this transformation, which he did by liquidating his 
personal assets and moving the firm to Florida because of lower operational costs that the 
state offered (Table 6-17; 11). MD1 also had to transform its finances again in year eights 
because of the recession of 2008, which caused MD1‟s sales to quickly drop off, greatly 
affecting their ability to finance their R&D and operations. In response the firm‟s owners 
opened a medical clinic to help finance the firm. After seeing the recession would have a 
prolonged effect on the firms, the owners quickly leased a facility for a medical clinic and 
started generating revenues from this to supplement the firm‟s financial resources. At 
about the same time MD1 started receiving international orders, which helped to augment 
the financial resources of the firm [Fin-pa revs]. Then the firm quickly reorganised its 
operations to focus on international markets by ramping up their international sales and 
marketing efforts, which helped to increase revenues.  
 
Similarly, the recession of 2008 forced MD2 to use it transformational routines to alter its 
financial strategy. The firm‟s CEO knew that they did not have the capital to sustain four 
major research projects, and that additional investment would be difficult to raise. In 
response the CEO and the board of directors made the decision to cut three of the R&D 
projects and scale back the firm‟s operations. Although this hurt the firm, as the three 
projects that were cut showed great commercial potential, the quick move proved 
beneficial because it allowed it to stay viable during the recession that loomed from 2008 
until the time of this study (winter 2010-2011). The firm also transformed itself when a 
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major investment of $6 million in year seven was received, allowing it to expand its 
operations, causing it to revamp its financial strategy. Moreover, this capital allowed the 
firm to bring their device to a point of commercialisation, which has made the firm invest 
in related areas.  
 
These two cases demonstrate how life science ventures have to create processes to adjust 
their financial resources and reorganise their financial strategies in response to internal and 
external events. It is also evident that these processes are driven at the individual level; i.e. 
the TMTs are the ones leading the processes related to financial transformation. They are 
the ones that recognise the need for change, and they are the ones that determine the 
strategic changes to be made.    
  
193 
 
Table 6-17: MDs financial processes 
 
FIRM              Prospecting for and dealing with investors has been vital to MD2. 
MD1 1. We just sent a few VC prospectuses out, but it had been all self- financed to this 
point. (MD1‟s CEO) 
 
2. Close-ended question: has the firm spent significant effort pursing outside 
investment: No. (Close-ended question) 
 
MD2 3. Raising capital is critical in this business. We are consistently meeting with our 
investors and new investors to raise capital. (MD2‟s CEO) 
 
4. We have experience and know how to raise capital. It is something that we know 
how to do from our experience.  (MD2‟s CEO) 
 
5. We have routines in place for dealing with investors. They want updates and there 
is a good amount of time that goes into working with them. (MD2‟s CEO) 
  
                             Conserving capital is a vital routine. 
MD1 6. We constantly looked for ways to keep our costs down. From performing functions 
ourselves to finding lower cost suppliers. We are always looking to do things more 
efficiently. (MD1‟s CEO) 
 
7. Lean and mean is how we operate. Self-financing a business forces you to keep 
costs down in every possible way. (MD1‟s CEO) 
 
MD2 8. It is easy for costs to run up in this business. For this reason you have to watch 
costs closely and constantly look for the most cost-efficient but still effective way of 
doing things. (MD2‟s CEO)   
 
9. There are a number of things that we do on a regular basis to keep costs down, such 
as having partners and research contractors provide certain functions. (MD2‟s 
CEO)  
                    Transformation capabilities have been important to the firm’s financial resources. 
MD1 10. We constantly looked for ways to keep costs down. (MD1‟s CEO) 
 
11. I decided to cash in my chips, liquidate all my assets, and cut my living expenses 
down by coming to Florida. I cut my engineering and fabricating cost down by 
coming to Florida. (MD1‟s Chairman) 
 
MD2 12. We had to focus on only one project. We needed to control costs where we could. 
(MD2‟s founder and CEO) 
 
 
Source: Author 
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6.3.6 MDs conclusion 
Both firms had a similar end goal: to develop and commercialise a novel medical device. 
This decision made R&D and financial resources and capabilities paramount during the 
early phases of growth. Although there are noticeable similarities in the development of 
the firms‟ resources and capabilities, there are also numerous differences. The most 
noticeable difference is the type of financing that the two firms obtained. MD1 was 
financed by the owners and proceeds from the revenues from their device, whilst MD2 
acquired its capital from private investors and VCs. Consequently, MD1 did not have to 
devote substantial time to investor-related matters. In contrast, MD2 developed advanced 
capabilities in raising capital and working with investors. The most striking similarity of 
MD1 and MD2‟s resources and capabilities was the importance of key individuals in 
driving the development of the firms‟ R&D and financial resources and capabilities.  
 
6.4 Biological analyser firms (BAs) 
This section overviews the development of the biological analyser firms, which consist of 
two firms that are pursuing the development of instruments that analyse biological and 
molecular matter. In this section a narrative of each case is presented followed by an in-
depth cross group analysis. 
 
6.4.1 Biological analytics firm one (BA1) 
BA1 is an engineering micro-firm that has developed an instrument for detecting and 
analysing biological materials and particles. They have a platform technology with 
widespread applications. One of the applications with the most potential is for identifying 
viruses and bacteria: from a cheek swab on a human their technology can break the sample 
into simple particles that can be analysed within minutes. The main advantages of this are 
twofold: one is that the sample takes minutes to analyse, which is unlike the current testing 
procedures which can take weeks. The second main advantage is that, unlike the current 
testing procedures, every virus a person has can be identified; whereas with the current 
testing procedures only the viruses being tested for will be detected. Another application 
for the machine is for testing for explosive and biological materials, which is especially of 
interest to security agencies.    
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The company is a spin-off from Yale University. However, the technology was not 
actively marketed by Yale. Rather the professor who founded the technology at Yale was 
contacted by the founder of BA1 who was a former student who had stayed in close 
contact. BA1‟s founder knew of the innovation because of his relationship with the 
professor, and because of recent events in global terrorism, he saw that the technology had 
the potential to help in the defence of bioterrorism. Specifically he envisioned that the 
technology could be coupled with electronic systems to quickly identify harmful biological 
agents. Based on this vision he convinced the professor to commercialise the innovation, 
which in turn has driven the entire strategic direction of the firm: 
 
The idea for the device has set the entire stage for the company. This is what we 
have been doing for the last seven years. (BA1‟s CEO) [R&D-pa core tech] 
 
After licensing the technology from Yale in 2004, he then opened an R&D facility in south 
Florida. There he and a small team of two other engineers have further developed the 
device. They formed an early research partnership with the US Army that has proven 
critical as the Army has supplied important inputs from a biotechnology standpoint. The 
firm‟s product pulls together three areas: biology, physics and electronics. BA1‟s founders 
held advanced knowledge in electrical engineering and physics, but not biotechnology. In 
this area the Army researchers have provided most of the main inputs needed to construct 
BA1‟s instrument:  
 
We complement one and another. They need our instruments’ ability to break down 
and analyse particles and we need their biotechnology to understand what to look 
for in the particles. (BA1‟s CEO) [R&D CCA] 
 
Initially BA2 financed the development of the device mostly from personal funds and a 
small amount of investment from friends and family. Due to the small amount of capital 
that the firm started with, keeping costs down became an important routine:  
 
It has been a struggle. We have boot-strapped and cut costs in every way possible. 
(BA1‟s founder and CEO) [Fin-proc int] 
 
At the end of the first year the firm received a boost in funding from a SBIR grant for 
$183,000 to aid in the R&D of their instrument. The firm had been able to quickly navigate 
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the small business innovation research (SBIR) grant process because of the founder‟s skill 
and experience. Previously he had applied and been awarded dozens of SBIR grants. He 
used the capabilities and skills to help BA1 quickly get a grant: 
 
I have filed over 150 grants, so I could complete one of these applications 
blindfolded. This was not a problem because of my experience.  (BA1‟s CEO) 
[R&D-po founder] 
 
Even though the firm spent less than $500,000 on R&D in the first two years, they were 
still able to develop an instrument that successfully particalised and analysed several 
viruses. The efficacy of the tests helped the firm develop several partnerships. Because of 
this they received interest from some of the largest and most prominent research 
organisations in the world, such as Scripps and the National Institute of Health. The firm 
received some important inputs from these organisations, but kept their distance from 
larger organisations in order to protect their ideas and technology; several of the 
breakthroughs for the firm‟s device are not patented because the firm wanted to preserve 
its capital for functions other than patenting. The firm does have several patents they will 
file for, but at the time they were able to protect their innovations without patents by not 
sharing too much information with partners. The only partner the firm shared information 
was with the US Army, but only because of a very strong non-disclosure agreement 
between them.  
 
The firm quickly refined and improved their main instrument, and in year two came out 
with a miniaturised version that is less than four inches by four inches [R&D-pa new tech]. 
Its portability increased the interest in the product. Several more defence agencies became 
interested in it because such a device could be used where there could be harmful biologic 
agents. In addition, this device also captured the interest of the US agriculture department 
because at that time several harmful diseases had started to enter the US from agriculture 
imports. The agency had had to kill many animals and destroy large stocks of fruits and 
vegetables that were suspected of having certain diseases. BA1‟s instrument had the 
potential to quickly test and identify whether or not the disease is present, and if it is not, 
then the agriculture product would not have to be destroyed.  
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Because of these potential government uses, BA1 received several small government 
research contracts from years three to five that totalled over $500,000 [Fin-po govt]. In 
addition, in years four and five the firm received over $200,000 in orders from universities 
for components related to their devices technology [Fin-po revs]. They received these 
orders because components of BA1‟s device are useful with certain lab machines. 
Interestingly, BA1 did not actively market these components, but the universities found out 
of the firm‟s components through networks. Also interesting is that over half of these sales 
were to foreign universities.  
 
This additional funding went to further refining the technology. In collaboration with the 
Army, the firm successfully developed an electro spray aerolisation source, which 
increased the range of bacteria and viruses that the firm‟s instrument could analyse [R&D-
pa new tech]. Prompted by this the firm and the Army decided to apply for a major grant to 
further develop and apply the technology to defence applications. This grant would be for 
over $7.6 million of which BA1 will receive $5.3 million. At the time of this study the firm 
was a month away from hearing from the grant committee. If the firm receives the grant, it 
will drastically change the direction of the firm: 
 
This grant will transform the company. It will bring in resources that will allow us 
to fully execute the technologies potential. Five million dollars is an incredible 
boost to a small company. (BA1‟s CEO) 
 
Simply put, the firm will have the financial resources to patent the technology, which will 
allow it to quickly and drastically increase its revenues. Moreover, it will afford the firm 
the capital needed to develop other applications for the instrument that have even greater 
market values. For example, the medical applications have market potential well into the 
billions. To this point the firm has not pursued that path because the defence path they 
have taken has provided them access to grants and contracts that have financed the 
development of the technology. In addition, the medical path will require FDA approval, 
which is costly and lengthy to obtain [R&D-pa govt approval]. However, if the firm 
receives this grant, it will open up several potential paths, and medical applications is one 
of the first the firm will look to pursue because of its market potential. 
 
By traditional measures the firm has not seen much growth since its inception seven years 
ago. Its revenues are less than $250,000; it has a small R&D facility and only three 
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employees. However, the firm has developed and proven a revolutionary device that has 
the potential to have a major impact in several large and profitable areas. Moreover, it has 
developed several key relationships and built a strong image in the industry. So although 
the traditional measures of growth are not significant, the firm has still seen significant 
development.  
 
6.4.2 Biological analytics firm two (BA2) 
BA2 is small firm that makes instrumentation for analysing molecular agents. The firm‟s 
core technology revolves around the ability to measure chiral drugs and 
biopharmaceuticals. Initially the firm was founded in 2000 by a PhD graduate student in 
chemistry along with a professor to pursue the commercialisation of the graduate student„s 
chiral research; she had come up with a unique technique for analysing chiral drugs, and 
saw that this could have major market potential. This innovation has been the driving force 
behind the firm„s strategic direction: 
 
We were working on my research and I suggested that we commercialise the 
technology. So I did the marketing study and wrote the business plan and the 
business formed around it. (BA2‟s CEO) [R&D-pa new tech] 
 
Early resources for the firm came from the university [R&D-po uni]. She had access to 
labs and one of the professors provided important inputs. From these resources the firm 
was able to develop a successful prototype for an instrument that could finely measure 
chiral drugs. This triggered her to start BA2. Because of the policy of her university on her 
particular type of research, she was able to maintain full rights of the innovation.  Initially 
the firm was funded out of personal savings; the founder drew on her credit cards and took 
a loan of $150,000 from her mother [Fin-po founder]. She used these resources along with 
inputs from universities to develop her product. The professor who had worked with her 
during her research had moved to one of the top universities in chiral science, which 
opened up inputs for BA2. At this point the professor became a partner in the firm, and he 
and his new university offered valuable inputs. From a scientific standpoint BA2 got 
access to a wide variety of equipment and personnel, which provided important inputs to 
progressing BA2‟s technology. Moreover, the university also had an incubation program 
for helping small technology firms grow. This helped the young firm in strategic planning 
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and making connections. These early resources enabled BA2 to develop a functional 
prototype in year two that they were able to patent. 
 
The patent proved vital as it afforded the firm the intellectual property protection to form a 
partnership to commercialise the instrument. The founder was able to strike an agreement 
with a large biopharmaceutical for producing the instrument, whereby BA2 provided the 
intellectual capital for the instrument and the partner firm produced and marketed it. 
According to the terms of the agreement each firm was given fifty per cent of the revenues. 
This event proved critical to BA2‟s development, as it provided important revenues that 
helped finance the continued development of the firm‟s technology [Fin-po revs].  
 
The increase in revenues afforded the firm capital to continue to develop applications from 
their technology. It allowed them to hire additional scientists and develop a network of 
relationships that helped the firm make several developments in their applications. One 
particular relationship that the firm formed was with the University of Glasgow‟s life 
science department where one of the leading researchers in chiral drug technologies was 
based [R&D-po uni]. He provided important inputs that in conjunction with the firm‟s 
internal developments allowed them to develop a revolutionary new instrument. This 
instrument was named in R&D Magazine’s „Top 100 for 2004‟. This prestigious award 
given on the basis of a rigorous review process is particularly impressive because it is 
amongst every type of innovation – not just life science innovations.  
 
This award gave BA2 a big boost of credibility within the scientific community. It helped 
in marketing their products and it also helped them attract research partners: 
 
It gave us a lot of credibility because it’s a very prestigious award. It gave us a lot 
of credibility. So that gave us credibility. So sales with big companies came shortly 
after. (BA2‟s CEO) [Fin-po core tech] 
 
The award also helped the firm relocate to south Florida. A city in south Florida was 
actively recruiting firms to move there with tax incentives, and this award made BA2 
attractive to the town. Moreover, the award aided the firm in landing its first government 
grant. In year six the firm applied for a small business innovation research grant (SBIR) 
and was awarded $500,000 [Fin-po govt]. The SBIR grants are for small firms that have 
innovative products that have great potential to help society and the US economy. This 
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$500,000 research grant provided a big boost to the firm and has provided capital to 
expand BA2‟s research staff and spending on needed equipment and testing.  
 
In year six the firm also received an important patent that allowed it to market its second 
instrument. The boost in revenues provided financing to continue the development of two 
more applications of BA2‟s technology [Fin-po revs]. To develop these applications the 
firm relied on their founder‟s inputs along with their scientific staff. By that point their 
staff had grown to twelve researchers who were almost all PhDs. These scientists provided 
important support, but the two founders provided the main scientific inputs to the new 
applications: 
 
We (the founders) have provided essential science to our products. (BA2‟s CEO) 
[R&D-po founder] 
 
Not only were the founders‟ scientific inputs vital, but so was their access to networks. 
Both were well-connected within the greater scientific community. The second founder is 
one of the leading experts in chiral drug science. He is one of the most cited professors in 
the field, is the head of the department at the top university in the field and is the editor of 
one of the top scientific journals in field. From this he has gained name recognition that 
has benefited BA2.  
 
The first founder is also well-connected, but she became so in a different fashion. She 
attends over twenty tradeshows a year where she participates in networking events [R&D-
proc net]. In addition, she chairs many industry-related organisations. From these she has 
become well known in the life science community: 
 
I served as the president of the society for our field of spectroscopy and I got to 
know a lot of people. I serve on many different committees, I chair a conference 
and the people recognize my name. (BA2‟s CEO) [R&D-po founder] 
 
These connections have provided access to partners that have provided important inputs. 
One important input that came from her networks in year eight is angel investment. Her 
networks also helped the firm expand sales and service capabilities in Europe in year nine. 
This has proved vital to the firm‟s growth as European sales have quickly picked up and 
are helping to finance the firm‟s continued growth [Fin-po revs].  
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At the time of this study (year ten) the firm had just come out with an updated version of 
their chiral measurement instrument that is even more effective than their current 
instrument. The firm is confident that it will see sustained growth in the next few years as 
they have four fully developed products and several new applications under development.  
 
Until this point growth is evidenced in the over $3 million in annual sales, the four patents 
the firm holds, the staff of fifteen and the extensive relationships they have with other 
firms and research institutions.  
 
6.4.3 BAs cross-group analysis 
The narratives above provide a contextual basis for the evolution of the firms‟ R&D and 
financial resources and capabilities. This section delves deeper into the key paths, positions 
and processes that led to their development. It analyses and compares the paths, positions 
and processes that led to each firm‟s R&D resources and capabilities. Following this the 
financial resources and capabilities development is presented in the same fashion.  
 
6.4.4 R&D assets and capabilities development 
In the early stages of growth both firms focused on the development of their technology. 
This was the impetus of developing R&D assets and capabilities for both firms. In the 
same fashion as the last section, Table 6-18 presents the matrices of the paths, positions 
and processes that were yielded from the data reduction techniques discussed in the 
research methods chapter. Based on the analysis of the interviews and the close-ended 
questions, each path, position and processes for each firm is placed in one of four 
categories based on its influence on the firm‟s development: high (H), medium (M), low 
(L) or no (N) influence. The major paths, positions and processes are discussed in detail 
below. 
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Table 6-18: BAs' R&D paths, positions and processes 
 BA1 BA2 
INFLUENTIAL ON FIRMS’ PATHS 
Core technology conceptualised at a university H H 
Core technology conceptualised at another firm N N 
Core technology conceived by the firm N N 
Government partnerships H L 
Industry partnerships L M 
University partnerships L H 
New technologies influenced firm‟s direction M M 
Government approvals: e.g. patent or FDA M M 
Scientific developments H H 
IMPORTANT POSITIONS 
Patents M M 
Skilled scientists M M 
Star scientists H H 
Industry partnerships L M 
University partnerships L H 
Government partnerships H L 
R&D facility and research equipment L L 
KEY PROCESSES 
Sensing and seizing scientific opportunities H M 
Finding and developing research partnerships H H 
Navigating government approval L L 
Filing patents L M 
Learning from earlier research M M 
Transforming R&D M M 
Source: Author 
 
Paths 
Several paths influenced the strategic R&D pursuits of the firms. The most ubiquitous path 
emanated from the firms core technology. Table 6-19 (1-4) presents a representative 
sample of evidence illustrating the importance of the core technology to the firms R&D.  
 
Both firms' technologies came from universities [R&D-pa uni partners]. For both of these 
firms the technology that emanated from a university set the central R&D path of the firm 
(Table 6-19; 1-4). BA2‟s founder created the technology whilst she was at graduate school; 
whereas, BA1‟s founder convinced his former professor to release a technology developed 
some years past. BA1‟s technology required the firm to develop competencies to bring 
together techniques from the areas of electronics, physics and biotechnology. In 
comparison, BA2 developed competencies revolving around measuring and analysing 
chiral drugs. Both firms‟ technologies required substantial resource investment and forced 
them to acquire specialised financing to pay for their R&D [R&D and Fin co-
specialisation].  
 
Internal and external events also impacted the firms R&D paths (Table 6-19; 5-9). For 
BA1 the fear of global terrorist attacks triggered a demand for an instrument that could 
quickly detect and analyse harmful biological agents (Table 6-19; 5). This outbreak also 
provided government resources that influenced the direction of BA1‟s R&D. Similarly, a 
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change in drug technology increased the demand for chiral drugs and created the main path 
for BA2‟s technology.  
 
Internal breakthroughs by the firms also influenced the strategic paths of their R&D (Table 
6-19; 5 and 9); i.e. the firm made substantial discoveries that greatly affected their R&D. 
For example, BA1 successfully miniaturised its instrument, which opened up new potential 
applications for their product [R&D-pa new tech]. Likewise, BA2 found new applications 
for its technology that opened up R&D opportunities. Thus it is apparent from these cases 
that environmental factors can have a major impact the strategic path of a life science 
venture.  
 
The pursuit of partnerships had a major bearing on the firms R&D paths (Table 6-19; 14-
17). An opportunity with the US Army allowed BA1 to synthesise their electronic and 
physics capabilities with the Army‟s biotechnology [R&D CCA], which enabled BA1 to 
develop a device that could detect and analyse viruses and bacteria. Without this 
partnership the firm‟s R&D would have taken a much different direction.  
 
Slightly less drastic, BA2 received R&D inputs from one of the leading universities in 
chiral chemistry allowing them to progress their chiral instrument technology [R&D-pa uni 
partner]. This partnership had a particularly large bearing in the firm‟s early R&D paths as 
it supplied the resources needed to develop the firm‟s core technology. Another partnership 
with the University of Glasgow allowed the firm to develop their second application 
enabling them to pursue this path.   
 
BA1 clearly was more reliant on partners then BA2; however; both firms‟ strategic R&D 
paths were significantly affected by partners. Had these firms not had these partnership 
opportunities, then their R&D would have evolved in a much different fashion, and there is 
a good chance that the firms might not have been able to have successfully developed their 
products. From these two cases it is apparent that partners affect the R&D paths of the 
firms. Nevertheless, path rigidities can prevail from partnerships. For example, BA1 had 
strong agreements in place with the US Army that have limited the latitude of the 
applications that it can pursue. These constraints are partly contractual and partly a result 
of the substantial resource commitment that BA1 has made to the Army. Such narrow path 
rigidities have not resulted from BA2‟s partnerships.  
 
204 
 
Government approval processes, particularly patenting, also affected the firms R&D paths 
(Table 6-19; 10-13) [R&D-pa govt approval]. BA2 pursued and received four patents. To 
get the patents the firm had to devote substantial resources, particularly scientific ones, to 
the application process. An advantage that the patents provided was affording the firm the 
protection to introduce new products and develop new research partnerships. In 
comparison, BA1 licensed four patents that their core technology is based on, and they 
have several ideas that they plan to patent. However, in order to conserve resources they 
decided to wait to start the patent application for these newer ideas in order to conserve 
resources for other functions. It has also challenged the firm to choose strategically whom 
they work with in order to protect their ideas. In other words, they do not want too many 
close partners, especially industry partners, because they fear that their ideas could be 
stolen.   
 
Another path that has impacted the firms‟ R&D paths is the FDA (Table 6-19; 14 and 17) 
[R&D-pa govt approval]. Both firms‟ technology has human applications, but the 
cumbersome FDA approval process has driven the firms away from these. Rather than 
committing substantial resources, they chose instead to focus on applications that do not 
require approval. Although the FDA has not directly influenced the strategic pursuits of the 
firms, it has had an impact on their strategies.     
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Table 6-19: BAs' R&D paths 
FIRM            The core technology drove the R&D demands of the firms. 
BA1 1. The idea for the device has set the entire stage for the company. This is what we have been doing for the 
last seven years. (BA1‟s CEO) 
 
2. The patents from Yale are what it all started with. The product has revolved around those patents. 
(BA1‟s CEO) 
BA2 3. We were working on my research and I suggested that we commercialise the technology. So I did the 
marketing study and wrote the business plan and the business formed around it. (BA2‟s CEO) 
 
4. Almost all of BA2‟s $3 million capital expenditures in the first seven years went to developing their core 
technologies.  (Close-ended question) 
 
              Internal and external events impacted the firms R&D endowments. 
BA1 5. Bioterrorism has become a big problem and has created a need for a device like ours that can quickly 
analyse biological agents.  (BA1‟s Chairman) 
 
6. Now, the hallmarks of it (BA1’s instrument after it was redone) are; it’s very fast. Like, in five minutes, 
you have results, and there’s (sic) no chemicals involved. So, for a variety of reasons, it’s very attractive 
to virologists, biologists and we confirmed that presentation of impressive test results. (BA1‟s CEO) 
 
7. There is a lot that went into the patents. It is important to devote the resources to this because the patents 
protect the device’. (BA1‟s Chairman) 
 
BA2 8. Chiral drugs are becoming the standard in the pharmaceutical industry. I saw this and knew that a 
technology that complemented chiral drugs would be a good market to get into. It has as almost 80% of 
drugs are chiral based. (BA2‟s CEO) 
 
9. We have been able to adapt our technology to create ideas. This has opened up new research paths that 
have led to new products.  (BA2‟s CEO) 
           The pursuit of partnerships had a major bearing on the firms’ R&D. 
BA1 10. The Army has been a very important partner. We have a key patent from them that has really affected our 
instrument. (BA1‟s CEO) 
 
11. The Army has really helped shape the firm. Their biotech inputs are important and having them as a 
partner has helped to get grants.  (BA1‟s CEO)  
 
BA2 12. The partnership with Syracuse has been very important. It provides a lot of science that has helped the 
firm develop. (BA1‟s CEO) 
 
13. Networking is important to getting inputs that we need. We have established a wide variety of partners, 
which has helped us in developing our technology. (BA2‟s CEO) 
           Government approval processes affected the firms R&D.   
BA1 14. We have several applications that will need FDA approval. We have strategically stayed away from these 
to avoid the cost and time associated with this. (BA1‟s CEO)  
 
15. There are several ideas that could be patented, but the patenting process triggers a series of events and 
forces us to invest in this. Instead the ideas are protected because we control all of the information and do 
not share it with anyone who might try to take it. (BA1‟s CEO) 
 
BA2 16. The pursuit of the patents has been an important influence on our R&D. We have had to put a lot into 
these, and gaining these patents has opened up opportunities for us. (BA2’s CEO) 
 
17. Our products do not require FDA approval, so that has allowed us to avoid having to devote R&D 
resources to this. (BA2‟s CEO) 
Source: Author 
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Positions 
Several positions proved important to the development of the firms‟ R&D. Table 6-20 
presents evidence supporting the most important ones.   
 
The firm‟s core technology is one of the most important resources that the firms used to 
develop their R&D resources and [R&D-po core tech]. Table 6-20 (1-4) depicts a 
representative sample of evidence that underscores the importance of the firms‟ 
technologies to the firms R&D. One important input that the firms‟ core technologies 
helped with is attracting research partners. Both firms‟ technologies are ground-breaking 
and have the potential to fundamentally influence the industry, motivated other 
organisations to reach out to BA1 and BA2.   
 
BA1„s technology has potential to change homeland security procedures. Specifically their 
technology can quickly identify and analyse diseases from a sample of small particles, 
which could allow homeland security to become more effective in looking for biological 
weapons. This ability is a position that the firm has leveraged to enter into several key 
relationships – most notably with the US Army and the US department of Agriculture. 
 
In a similar fashion, BA2‟s technological positions facilitated several key relationships. 
Their relationship with a top university stems largely from the universities desire to be 
attached to a leading edge technology. Moreover, the firm has attracted relationships with 
several of the top biopharmaceutical firms in the world who want to use BA2‟s technology 
to aid in the development of their drugs.  
 
The firms‟ scientists have also proven important resources to the firms‟ R&D [R&D-po 
scientists]. BA1‟s is constituted primarily by the two founders who have developed many 
innovations in the industry and have a combined fifty years in new product development 
experience. They have drawn on this experience to help progress BA1‟s instrument. 
Moreover, they have deep connections that allow them to draw on the knowledge of others 
when they have questions about their research (Table 6-20; 10 and 11). 
 
In a similar vein, BA2‟s founders have been critical resources to BA2‟s R&D (Table 6-20; 
12 and 13) [R&D-po founders]. The founders came up with the idea, and one of the 
founders is renowned in the field. He is the chair of the department at a university that is 
widely regarded as one of the top in this field [R&D-po star scientists]. Moreover, the 
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founders of BA2 are well-connected, and their networks and networking abilities have 
been an important resource that has contributed to the development of their technology. 
For example, their relationship with a University of Glasgow professor provided access to 
science that allowed them to develop one of their main applications. Unlike BA1 though, 
BA2 also has a scientific staff of fifteen members that is an important asset to the firm‟s 
R&D [R&D-po scientists].The staff has not made any breakthrough discoveries, but they 
are versed in many areas and make incremental contributions that have collectively made a 
large impact on the development of BA2‟s technology.   
 
It is evident from these cases that founders are an important resource to the development of 
life science ventures. The founders of BA1 and BA2 contributed much of the key research 
inputs, and drove the development of the other R&D resources that their firms needed.   
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Table 6-20: BAs' R&D positions 
FIRM                The core innovation proved important to R&D. 
BA1 1. Our technology is why the Army wanted to work with us. It has the potential to greatly help 
with what they are doing with terrorism. (BA1‟s CEO) 
 
2. An Army report showing BA1‟s instruments superior technology and recommending to the 
government enter into a research partnership with BA1 because of this technology. 
(Government report) 
BA2 3. All these big organisations wanted to work with us because of our superior technology. 
(BA2‟s CEO)  
 
4. Over the last several years the vibrational circular dichoism (BA2’s core technology) 
technique has dramatically revitalised the utility and spectroscopy within pharmaceutical 
drug discovery. (Dr. Don Pivonka, research director of a large multinational 
biopharmaceutical firm) 
 
                                Partners provided vital R&D inputs. 
BA1 5. We got important inputs from a number of partners. The patents come from Yale and the 
Army has provided all of the biotech inputs.  (BA1‟s Chairman) 
 
6. Without partner inputs we would not have been able to put it (their instrument) together. 
(BA1‟s Chairman) 
 
BA2 7. We have gotten important help from a number of different places. Syracuse has certainly 
been important, but Glasgow and a number of other places have been important as well.  
(BA2‟s CEO) 
 
8. We have a network of strong partners that provide information and testing that have been 
critical to the firm. (BA2‟s CEO) 
 
9. The firm has relationships with ten of the top biopharmaceutical organisations in the world.  
(Information from company prospectus)  
 
                Founders have provided critical R&D inputs. 
BA1 10. I was the one who found the core patents and had the idea to bring everything together. 
(BA1‟s founder) 
 
11. My partner and I have been the ones developing the device. We have help from a number of 
partners, and we have some part- time staff, but it is us driving this.  (BA1‟s founder) 
BA2 12. My partner and I were the ones that came up with the science for the technology. This is 
the basis of the products.  (BA2‟s CEO)  
 
13. We (the two founders) are still important to the research. He performs a lot of research 
and is involved and comes up with a lot of our scientific ideas, and I am overseeing 
everything and bringing a lot of different science together.  (BA2‟s CEO) 
Source: Author 
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Processes 
Four main processes proved to be important to the development of BA1 and BA2‟s R&D 
endowments: sensing technology, networking, transforming and learning. Table 6-21 
depicts a representative sample of the evidence supporting the importance of these 
processes.  
 
One of the most important set of processes revolved around sensing and seizing 
technological opportunities [R&D S&D]. Table 6-21 (1-4) demonstrates this. BA1 and 
BA2‟s founders sensed out opportunities that had great market potential.  
However, the two firms sensed their opportunities out in much different ways. BA1‟s 
founder was highly experienced in industry and used one of his connections to find the 
technology for his firm; whereas BA2‟s founder was very inexperienced and used her 
academic knowledge and skills to sense out an opportunity arising due to changing 
science.  
 
On a continual basis technological sensing capabilities have been important to both firms, 
as they have both continually sought out and found complementary technologies that have 
contributed to their core technologies. BA1 found complementary biotechnologies that 
have proven vital to the development of their instrument. Similarly, BA2 has found 
complementary drug and electronics technologies that have aided in the progression of 
their instruments. 
 
Most of these complementary technologies have surfaced from the firms‟ founders‟ 
networking routines (Table 6-21; 1-4) [R&D-proc network]. Both founders have developed 
advanced networking capabilities that have resulted in complementary technologies and 
important research inputs. However, the two firms‟ networking routines are markedly 
different. BA2‟s founder participates in over twenty trade shows a year where she often 
speaks and attends networking events. She is also active on the board of several industry-
related organisations. In addition she has made a routine of staying in contact with her 
important industry contacts. The second founder of BA2 is also highly networked, but his 
networks emanate from his prestigious position as the head professor of chemistry at a top 
university. Because of this position many people interested in his research contact him.  
 
BA1‟s founders are also well-networked but these have developed from a much different 
set of processes than BA2‟s did. The main founder of BA1 has made connections from his 
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experience in the industry (Table 6-21; 5). He is also able to make key contacts from his 
informal networking routines. These routines are based on finding and contacting people 
whom he believes can help with his firm‟s research. Moreover, BA1 also has an advisory 
board member who is extremely well-connected.   
 
These cases show that networking routines can be important to the development of a firm‟s 
R&D. It also shows that a firm‟s networks and networking capabilities can vary greatly, 
but still have a similar end result.  
 
A third important set of processes revolves around learning and communicating (Table 6-
21; 9-12) [R&D-proc learning]. These processes proved vital to both firm‟s R&D. 
However, BA2 has more formalised systems in place for this than BA1 does. On a regular 
basis BA2‟s staff meets to discuss their research objectives. They also have routines for 
sharing information, and their sub-departments have formalised research routines. In 
contrast, BA1 does not have such formalised systems. Instead their small staff meets 
sporadically and communicates with their research partners on an ad hoc basis. Although 
the two firms‟ routines differ in their formality, they are still important to both firms. These 
cases illustrate that different learning and communication routines can be effective.  
 
Transformational-related processes are the fourth set of processes that have been important 
to both firms‟ R&D (Table 6-21; 13-15) [R&D-proc learning]. Early on BA2 realised that 
the changing conditions in the pharmaceutical industry would pose a large opportunity for 
instruments that specialise in chiral drugs. This motivated the firm to focus its R&D on 
developing instruments for these types of drug applications, and they devoted almost all of 
their resources to this.  
 
In a similar vein, BA1 focused its R&D on the development of a technology that could 
answer the call for help from homeland security to find a device that could quickly detect 
harmful biological agents. Thus the firm focused its R&D processes on developing such a 
device and because of this, successfully developed a prototype within two years. In a 
similar scenario, BA1 responded rapidly when an agricultural disease outbreak created a 
great demand for an instrument that could quickly detect the disease. The firm reorganised 
its R&D resources to focus on this application, and in consequence, this helped the firm 
land a research grant, and has sparked interest in a large order for the firm‟s instruments 
from the US Department of Agriculture.   
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It is evident from these two cases that the ability to respond to changing industrial and 
environmental factors is important to staying viable and creating a product that is in 
demand. Both firms recognised and responded to outside factors and their growth to date is 
largely attributed to the capabilities to reorganise themselves in response to these factors.  
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Table 6-21: BAs' R&D processes 
FIRM          Sensing and seizing technological opportunities proved important. 
BA1 1. I have had to find technology that complements ours. I have ways of staying informed in the scientific 
community that provides this information. (BA1‟s CEO) 
 
2. I knew of the patents and saw that this could be a big opportunity. I have been in industry for years and 
knew when I heard of this that it was going to have a lot of potential. Being able to sense the technology 
comes from an innate feeling based on experience. (BA1‟s CEO) 
BA2 3. We were working on the technology in my school’s lab, and I saw that the competing professor’s work 
and knew that what we had could commercialise. I knew from my research that the industry was moving 
towards a chiral model. (BA2‟s CEO) 
 
4. We have processes for staying in touch with the scientific community. Our staff stays on top of research. 
We have connections with several top universities and we attend over twenty trade shows a year. These 
allow us to find emerging technologies and stay abreast on everything. (BA2‟s CEO) 
            Networking has proved vital to the firms’ R&D endowments. 
BA1 5. I have networks in place from my years of experience. These are helpful when I have a question or need 
something done.   (BA1‟s Chairman) 
 
6. Networking capabilities are still important. I have learned how to find key people and reach out to them. 
Sometimes this is just making some calls and sometimes I network through conferences. (BA1‟s CEO) 
 
BA2 7. Networking is very important to us. We attend over twenty shows a year and make contacts with 
everyone that we can. These have led to important partnership. (BA2‟s CEO) 
 
8. My partner and I are well- networked. He is a distinguished professor and knows many people through 
this. He is the editor of a journal, and people know him because of his stature in the field. I, on the other 
hand, have gotten involved in many organisations and attend many networking events. From the last ten 
years of doing this people know me. (BA2‟s CEO) 
           Learning and communication have been important to R&D. 
BA1 9. We consistently see what we can do to improve it (BA1’s instrument). We learn from the earlier prototypes 
and then bring in new parts and pieces and ideas. (BA1‟s CEO) 
 
10. It is important to get input from the users. From this we can learn what we need to change. So it is 
important to reach out to them.  (BA1‟s CEO)  
 
BA2 11. We have formal meetings where we get the staff together to share ideas and update everyone on what is 
going on. Each unit also meets on a regular basis to strategize on what they have learned. (BA1‟s CEO) 
 
12. Learning also happens at the individual level. We have PhDs who are all trained and know how to go 
about their research and learn from what they did earlier. (BA2‟s CEO) 
           Transforming capabilities has proven important to R&D. 
BA1 13. We knew that the device had to become smaller. So we set out to develop a miniaturised version. This 
made us devote a significant amount of resources, but we were able to accomplish this.  (BA1‟s CEO)  
 
BA2 14. We saw the changes going on in the drug industry and focused our product on a technology that could 
help with this. (BA2’s CEO) 
 
15. We saw a need to develop a new product and quickly devoted resources to this, and from this we were able 
to come out with a new unit. (BA2‟s CEO) 
Source: Author 
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6.4.5 Financial assets and capabilities 
The firms‟ R&D demanded significant capital to bring their products to a point of 
commercialisation. For this reason, the firms leveraged their paths, positions and processes 
to obtain the capital needed to finance their growth. Table 6-22 highlights the paths, 
positions and processes central to the development of the firms‟ financial resources and 
capabilities. Based on the coding and close-ended questions, each path, position and 
processes for each firm is placed in one of four categories based on its influence on the 
firm‟s development: high influence (H), medium influence (M), low influence (L) or no 
influence (N). The analysis for the major paths, positions and process is detailed below. 
 
Table 6-22: BAs' financial paths, positions and processes 
 BA1 BA2 
INFLUENTIAL ON FINANCIAL PATHS 
Costly innovation  H H 
Raising capital L L 
Public stock offering N N 
VC L L 
POSITIONS 
Scientific capabilities M H 
Founders  H H 
Networks with investors L L 
Investors were connected within financial 
community 
L L 
Executive staff H H 
Core innovation H H 
PROCCESSES RELATED TO 
Raising capital L L 
Conserving capital H H 
Dealing with Investors L L 
IPO N N 
Transforming financial assets and capabilities H H 
Grant writing H M 
Source: Author 
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Paths 
Several past decisions and future opportunities guided the financial needs of the firms. 
Table 6-23 highlights the paths important to the development of the firms‟ financial assets 
and capabilities.  
 
The core technology had the largest bearing on the financial demands of the firms. Both 
firms‟ financial strategies revolved around their core technology. The firm‟s respective 
novel technology required substantial capital to develop. BA1 spent over $2 million in 
developing their core innovation, whilst BA2 spent over $3 million [Fin-pa core tech].  
 
Early on the firms made the strategic choice to follow a path of financing their incubation 
through personal investment (Table 6-23; 6 and 7). However, the firm‟s strategies 
stemmed from a much different set of factors. BA1 decided to pursue this strategy because 
they wanted to avoid VC because of past experiences [Fin-pa VC]. They knew that VC is 
hard to deal with, and they could access capital from other places that did not require 
equity or control in the firm. In comparison, BA2‟s main founder was very inexperienced 
and did not know how to finance a venture. The only thing she thought she could do was to 
self-finance. This led her to obtain a $150,000 loan from her mother to start the business. 
In hindsight she wished she would have considered other financial strategies, but at the 
time she did not know any better and she was too busy concentrating on the other functions 
of the business. 
 
Both firms‟ strategies proved successful, as they acquired the capital needed to start their 
firms. These two cases suggest that previous experience influences the financial strategies 
of a life science venture; with the more experienced founder knowing how to source 
capital for a new venture, and the inexperienced scientist having to learn how to finance a 
venture throughout the process of starting the firm. 
 
Closely related, SBIR grants also influenced the strategic financial paths of the firms 
(Table 6-23; 5 and 9) [Fin-pa govt], but in different ways. From the onset BA1‟s strategy 
revolved around obtaining an SBIR grant to finance the early development of the firm. The 
firm successfully obtained $180,000 in the first year, which effectively launched the 
venture; this provided them the capital boost to focus full time on the venture. In contrast, 
BA2 did not receive an SBIR grant until year six. This is largely because the firm did not 
know how to obtain such a grant. After learning of the grant the firm looked into the 
215 
 
process and decided to apply for one. This proved beneficial as the firm received a 
$500,000 grant that greatly helped the firm. For both firms‟ grants provided critical capital 
inputs that had a substantial impact on their financial paths (Table 6-23; 5 and 9).  
 
The initial commercialisation of the firms‟ products is another area that impacted their 
financial paths (Table 6-23; 10 and 13) [Fin-pa revs]. In year three BA2 started generating 
revenues that provided capital to further invest in the firm‟s technology. Likewise, BA1 
started generating revenues in year four that contributed capital to the firm‟s research.  
 
Large capital infusions or the potential for large capital infusions have had a bearing on the 
financial paths of the firms (Table 6-23; 11 and 14) [Fin-pa raising cap]. In year eight BA2 
received an angel investment of over $1million. This has allowed the firm to expand its 
R&D resources and invest in several new applications that have large market potential. 
Similarly, BA1 at the time of this study was in the final steps of a major grant application. 
This grant would award BA1 $5.3 million for the continued development of their 
instrument, and it would offer many new financial paths to the firm. More specifically, it 
would afford the firm capital to invest new applications and it would allow the firm to 
apply for several patents.  
 
It is evident from these cases that major R&D breakthroughs opened up new financial 
paths that have had or will have a major bearing on the firms‟ R&D.  
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Table 6-23: BAs' financial paths 
 
 FIRM            The core technology drove the financial demands of the firms. 
BA1 1. This has cost a lot of money, so we have had to put a lot of thought and effort into financing 
the development of the technology. (BA1‟s CEO) 
 
2. We have had to boot strap and cut costs whenever possible to develop this technology. It has 
been a struggle, but we have been able to develop the device. (BA1‟s CEO) 
BA2 3. So we had to come up with money to develop it. Initially I took a loan from my mother and 
paid for things on my credit cards. (BA2‟s CEO) 
 
4. Almost all of BA2‟s $8 million capital expenditures in the first seven years went to developing 
their core technologies.  (Close-ended question) 
 
                           Strategic financial choices have influenced the firms’ development. 
BA1 5. The grants have provided the bulk of the funding. This has allowed us to develop our product. 
It has also made us devote time to the grant process.   (BA1‟s CEO) 
 
6. We choose to self-finance and get grants. We knew that this was going force us to boot strap 
and cut costs. (BA1‟s CEO) 
 
BA2 7. I made the choice to self- finance the venture because I didn’t know any other way to finance 
the business. (BA2‟s CEO) 
 
8. A friend of mine put me in touch with a venture capitalist, and he started asking me a bunch of 
questions about business models that I had no idea what he was talking about. So I hung up 
because I had no idea what he was talking about and decided that I did not need venture 
capital. So I continued to pay for the venture through self- finance.  (BA2‟s CEO)  
 
9. I wish I would have used SBIR grants earlier. I just did not know what they were. Once we 
found out about them we applied and got them. They have been a big help to the firm’s 
finances. (BA2‟s CEO) 
                         New financial resources have influenced the firms’ financial paths. 
BA1 10.  We started getting some revenues in that have been helpful to financing some of our other 
operations. (BA1’s CEO) 
 
11. If we get this grant, it will transform our financial picture. It will allow us to invest in many 
different areas and will financially transform the firm. (BA1‟s CEO) 
 
12. The $5.3 million will go to us and will allow us to move forward with several different 
applications. (BA1‟s CEO) 
 
BA2 13. The revenues really helped generate money that we used to invest back in the company. (BA2‟s 
CEO) 
 
14. In 2008 we got the angel investment, which has helped us get a few more projects going and 
was especially beneficial to our European expansion. (BA2‟s CEO) 
Source: Author 
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Positions 
The firms leveraged several positions to develop their financial resources and capabilities. 
Table 6-24 presents evidence supporting the main ones.  
 
The founders of the firms proved to be important resources to the development of financial 
assets and capabilities [Fin-po founders]. Table 6-24 (1-5) depicts a representative sample 
of evidence that underscores the importance of the firms‟ founders. BA1‟s founder 
provided much of the early seed capital and is the main reason the firm secured early grant 
money (Table 6-24; 1 and 2). In a similar fashion BA2‟s main founder also provided most 
of the early capital. Furthermore, both firms‟ founders proved important to conserving 
funds to keep their young ventures viable (Table 6-24; 3 and 5). They both operated on a 
„shoestring budget‟ where they cut costs and obtained as many free or low cost inputs as 
possible. It is evident that the founders were the ones who were driving the early financial 
positions of the firm.  
 
The second main position that the firms drew on to develop their financial resources and 
capabilities is their core technology (Table 6-24; 6-10) [Fin-po core tech]. BA1‟s 
technology helped it attract funding grants that allowed the firm to finance a large portion 
of its operations. Likewise BA2‟s technology helped them attract grants and an angel 
investor. The firms‟ technology showed large potential to help society, which is what the 
firms leveraged to attract the grants. For BA2 the large profit potential of the technology is 
what attracted the angel investor.  
 
Both firms technology started generating revenues early on that helped to finance the 
firms‟ development. This revenue provided important financial resources that the firms 
used to supplement their development. It is evident from these two cases that the 
technology‟s cost of development is a central path that drives the demand for capital, but 
potential profitability of the technology provided a resource to leverage in attracting grants 
and investment. Moreover, these cases illustrate that technology that comes to market 
quickly can greatly help the firm by providing financial resources that supplement the 
firms‟ development.  
 
Closely related, the firms‟ technology helped attract partners who provided capital and 
money saving inputs (Table 6-24; 1-14). For example, interest in a technology to help in 
bioterrorism defence led to a partnership between the BA1 and the US Army. The Army 
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provided some funds, but even more importantly they provided R&D inputs worth millions 
of dollars. Had BA1 had to internally develop these competencies, then the firm would 
have had to have acquired additional capital. 
 
Similarly, BA2‟s technology helped them attract several important relationships (Table 6-
24; 13 and 14). These relationships helped the firm save capital by providing low cost 
R&D inputs. For example, the technical inputs from one of their university relationships 
would have cost millions of dollars to develop.  
 
It is evident from these cases that partnerships influence financial resources. These cases 
show that partners have a major direct and indirect effect on the firm‟s financial resources. 
In some instances partners directly infuse capital into the firms, and in some cases the 
partners indirectly supplement a firm‟s financial resources from the inputs that they 
provide. In some instances, such as BA1, these indirect financial contributions can be one 
of the most important financial positions of a firm.  
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Table 6-24: BAs' financial positions 
 
FIRM The founders and top managers provided key financial positions. 
BA1 1. A good portion of the funds have come from personal savings, and I have been the one that 
has sought out the grants. (BA1‟s CEO) 
 
2. I am the one that has gone after the grants and completed the applications. (BA1‟s CEO) 
 
3. I have been reaching out to partners and keeping costs down in every possible way. Because 
of my inputs we have been able to save a substantial sum of capital. (BA1‟s CEO) 
 
BA2 4. I went out and got a 150K loan from my mother and put a bunch of expenses on my credit 
cards. (BA2‟s CEO)  
 
5. I have kept the costs down and this is how we were able to get the business going without a 
big upfront investment. I was doing everything at first and was operating out of my school’s 
lab. (BA2‟s CEO) 
 
                              The firms’ technology helped develop financial resources. 
BA1 6. One of the main reasons that we got the grants is because the technology filled the need the 
grant was looking for. They put requests out for certain areas and our technology fit.  (BA1‟s 
CEO) 
 
7. We are in the running for this major grant because our technology is superior. Our product 
analysed the particles many times faster than the other applicant’s product did. This has 
given us a big leg up. (BA1‟s CEO) 
 
8. The firm won three SBIR grants, which totalled $925,000. These grants are based on the 
potential of a technology to help the US government solve a problem, and these grants are 
ultra-competitive as less than 15% of applicants are awarded a grant (NIH, 2011). 
 
BA2 9. Our technology is why we were able to get the two SBIR grants. The committees look at the 
potential of an innovation and award money largely on the potential of a technology. (BA2‟s 
CEO) 
                              Partners indirectly provided financial resources. 
BA1 10. The Army provided a lot of valuable inputs. It could have cost us in the millions to develop 
the biotechnology inputs that we got from them. (BA1‟s CEO) 
 
11. The partners provided inputs that we could not have afforded to develop. (BA1‟s CEO) 
BA2 12. Our partners have been a big help to saving us money. The university has been a big help. 
The science and labs we had access to was (sic) worth a lot of money. (BA2‟s CEO) 
 
13. It is hard to exactly quantify the value of the resources that the partners have contributed, but 
it would be quite large. From the inputs to the testing to the access to researchers. It is a lot. 
(BA2‟s CEO) 
Source: Author 
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Processes 
A number of routines proved important in the development of the financial resources and 
capabilities necessary for the firms‟ development. For the most part the firms‟ routines 
were quite similar, but there were also some noticeable differences. Table 6-25 presents a 
representative sample of evidence illustrating the most important financially-related 
processes. 
 
Processes revolving around conserving capital have proven vital to the firms‟ financial 
resources (Table 6-25; 1-4) [Fin-proc conserve]. These were especially important early on. 
BA1 has „boot-strapped‟ most of its operations. It has a small staff of three who perform 
all of the main scientific and functional duties of the firm. They have been paid at under 
market wages with the intent that they will receive large dividends once the firm grows. 
Furthermore, BA1 has operated out of low cost operational facilities to cut down on 
overhead expenses. The main motivation for cost savings stems from the lack of large 
capital reserves, which is a result of the firm‟s strategic decision to avoid equity investors 
such as VCs. Driving the cost-saving routines is the CEO who has drawn on his many 
years of experience to implement cost-cutting routines without losing essential functions 
(Table 6-25; 1-4).  
 
Comparatively, BA2 has also developed an advanced set of routines in cutting costs. 
Initially the firm was run out of the university lab where the founder was finishing her 
PhD. Even after completing her doctorate, she kept the business housed there to cut down 
on costs. For the first couple of years she was the only employee. There was ample need 
for other employees, but she performed all of the tasks in order to conserve capital. As the 
firm has grown, it has kept to its cost-cutting ways. The firm currently operates in an area 
that has incentivised them to be there, and it operates as lean as possible in all areas of its 
operations. 
 
These two cases demonstrate clearly that cost cutting routines are especially important to 
life science ventures – especially in the early operations and particularly to firms that are 
incubated out of personal savings. 
 
The second set of processes that the firms have become proficient in is grant writing (Table 
6-25; 6-7). Their proficiencies stem from different sources however. BA1‟s grant writing 
abilities come primarily from the main founder who has written dozens of grants in his 
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career (Table 6-25; 5). He has used his knowledge and capabilities in this area to land over 
five grants for BA1. These grants have provided the bulk of the capital that has financed 
the firm‟s development.  
 
In contrast, BA2 had to learn processes related to finding, applying and executing a grant. 
The firm‟s main founder did not know what an SBIR grant was until four years into the 
firm‟s operations (Table 6-25; 6). After learning about the grant, she created systems to 
apply for SBIR grants, which proved successful, as the firm has landed over $900,000 in 
grant funds. These grants provided a big boost to the firm‟s R&D and allowed them to 
expand from two product offerings to four.  
 
The evidence from these two cases illustrates how influential the SBIR grants can be on 
small firms. Although the grants required the firms to invest substantial time and develop 
routines for navigating the application and maintenance processes, the capital from the 
grants proved vital to their early growth.  
 
Processes related to transforming financial strategies also played an important role in the 
firms‟ growth (Table 6-25; 8-11) [Fin-proc transform]. BA1 went through several periods 
where they had to adapt their operations because of cash flow problems. This required the 
firm to cut back operations and strategically choose the areas to invest their limited capital. 
Most recently the firm has had to prepare for its largest possible transformation from the 
$5.3 million grant that they are anticipating receiving. This capital will fundamentally 
change the firm‟s financial operations and strategies. The person leading the 
transformation processes for the firm has been the CEO. He has drawn on his experience 
and successfully found a way to manipulate the firm around to accommodate the 
drastically changing financial situations of the firm. If BA1 receives this grant, they will 
have to create more formalised systems for accounting and operating the firm. Because of 
the size of the grant, the firm will have to put more sophisticated routines in place for 
reporting on how the funds have been used.    
 
Similarly, BA2 has undergone several organisational transformations that have influenced 
the firm‟s financial resources. The firm‟s main founder was the only employee in the first 
couple of years, and she performed almost every one of the firm‟s functions. In the third 
year the firm started generating revenues, and the firm‟s operations expanded rapidly. 
Within a few months the firm realised a growth path and quickly went from a firm of one 
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employee to a firm of over ten employees. This growth forced them to develop routines for 
managing cash flows and strategizing for larger investments. The main founder and a 
couple of the staff members designed a reporting system that has allowed the firm to 
navigate its increased financial complexity.  
 
These two cases illustrate how quickly financial situations can change in life science 
ventures. Cash flows quickly come and go in this industry, and it is important that firms 
rapidly respond and adapt their financial resources and strategies to accommodate this 
rapid change. When new capital is introduced, firms must introduce processes for 
managing their expanded financial resources, and when cash flows become tight, it is 
imperative that firms implement routines for strategically conserving capital.   
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Table 6-25: BAs' financial processes 
FIRM               Conserving capital is a vital routine. 
BA1 1. It has been a struggle. We have constantly kept costs down in every way that we 
can. Paying ourselves very little, only purchasing the necessities and getting things 
done as cheaply as possible.  (BA1‟s CEO) 
 
2. Boot-strapping is imperative when trying to keep costs down like we have. Since 
the beginning we have been operating bare bones. We have grown accustomed to 
saving money. It has become ingrained in us. (BA1‟s CEO) 
 
MD2 3. When you are paying for things on credit cards you have to watch every expense 
and get things done as cheaply as possible. (MD2‟s CEO)   
 
4. We have processes for keeping costs down and strategically outsourcing to save 
capital. We are small and keep our operations highly efficient. (MD2‟s CEO)  
                           Grant writing processes have proved vital. 
BA1 5. I have applied for over 150 grants, so I know how the process works. For the 
company these processes have importance. First you have to present your product 
so that it meets the need. Then you have to convince the committees that it does this. 
Once you receive the grant you then have to have processes in place for making the 
government happy with you.  (BA1‟s CEO) 
 
MD2 6. I did not even know what the grants were. Once we found out about them we then 
created systems for finding the appropriate grants, applying for them and then 
maintaining them. (MD2‟s CEO)   
 
7. Grant processes have served us well. Finding and writing grants has been 
important to learn. (MD2‟s CEO)  
Transformation capabilities have been important to the firm’s financial  
resources. 
BA1 8. When we got the larger grant in this it changed the way we did things and how we 
approached our products development. (BA1‟s CEO) 
 
9. If we get this $5 million we will revamp our operations. We will be able to move 
forward with initiatives such as our patents and it will make us formalise our 
operations. (BA1‟s Chairman) 
 
MD2 10. The increased capital changed the company. We had to put in systems for 
accounting and HR and had to more formally strategize about how and where to 
invest. (MD2‟s CEO) 
 
11. As your financial situation changes, so does the company. Our systems have 
expanded and the strategic outlooks change as well. (MD2‟s CEO) 
 
 
Source: Author 
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6.4.6 BA firms’ conclusion 
Financial and research resources and capabilities drove the firms‟ early growth. The R&D 
resources and capabilities demanded substantial investment: the firms‟ technologies were 
costly to develop and took a long time to develop, which made the firms sustain several 
years from the inception without any revenues. This coupled with the strategic choice of 
both firms to self-finance the venture, made saving capital and obtaining government 
grants paramount. In order to pursue the path of developing a novel technology, the firms 
leveraged their scientific talents and founders‟ experience. From these the firms created 
processes to develop the needed financial and R&D resources and capabilities. In general 
the firms relied on sensing, seizing, learning and organising processes to leverage their 
positions to take advantage of the strategic paths available to them. Although there were 
distinguished similarities in the development of the firms‟ R&D and financial 
endowments, there were also numerous differences. The most apparent difference was the 
relative experience level of the two firms‟ founders; BA1 had a highly experienced founder 
whilst BA2 had a very inexperienced founder. These experience levels had a major bearing 
on the firms‟ R&D and financial resources and capabilities development. 
 
In the final analysis though, both founders successfully navigated a unique set of paths, 
positions and processes to develop and commercialise a novel instrument for analysing 
particles and biological agents.  
 
6.5 Triangulation and cross-case analysis 
This section presents the responses to the validation questionnaire that each firm 
completed in the final step of this research. It serves to triangulate the earlier analysis, and 
it also serves as a framework for the cross-case analysis. Each major path, position and 
process that surfaced is discussed along with any discrepancy that arose between the earlier 
analysis of the interview data and the response to the questionnaire. 
 
The questionnaire that the firms completed is based on pragmatic validation, which is a 
powerful means to triangulate findings. This is a form of validation in which the 
perspective of the findings is judged by the sample of interest (Kvale, 1987). In in the 
present study it is the key informant from the case firms. Each of the major influences 
found to be important to the development of R&D and financial resources and capabilities 
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was presented in a survey to each of the case firms in this study, and the respondents rated 
the importance of each influence. This data does not serve for statistical testing, but instead 
each response is compared to the analysis from the qualitative data for each of the firms. 
This serves to validate and triangulate the findings. In general, most of the findings were 
validated, but there were a few small discrepancies. In those instances the researcher 
gathered more information to clarify the discrepancy, and an explanation for the 
discrepancy is offered.   
 
The questions are divided into two sections; one for R&D and one for finance. Each 
section is further broken into three groups of questions. The first group of questions asks 
about the important paths that led to the development of the firm‟s resources and 
capabilities. The second group of questions asks about the important positions used in the 
development of the firm‟s resources and capabilities. The third group of questions asks 
about the important processes leading to the development of the firm‟s resources and 
capabilities. The results from all of the firms‟ responses are presented below along with a 
discussion of how the results of the survey compared to the findings from the qualitative 
analysis.     
6.5.1 Triangulation of R&D paths 
The first set of questions looked at „to what extent did opportunities and past decisions 
have on the development of the firm‟s R&D?‟ It is evident from the earlier analysis and 
Table 6-26 that innovation is the most ubiquitous influence on the R&D path of the firms. 
University partnerships also proved influential on the firms R&D paths. Several other past 
decisions and future opportunities also influenced the development of the firms‟ R&D 
resources and capabilities, but these influences varied amongst the firms. The 
discrepancies that surfaced from the responses and the earlier analysis are noted in the 
discussion below. 
 
All of the firms rated the core technology as very important (Table 6-26; 1). This is in line 
with the earlier analysis and is one of the most important themes of this study. The firms‟ 
strategies revolved around a novel technology. The pursuit of this technology drove the 
firms to develop a unique set of R&D resources and capabilities in its pursuit. Thus the 
core technology has clearly been an important path in the development of the firms‟ R&D.   
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In general, VC did not have a major influence on the firms R&D paths (Table 6-26; 2). 
Three of the firms (BA1, DD1, and MD1) did not receive VC, so it is to be expected that 
VC did not have an influence on these firms R&D. However, only DD1‟s VC, of those that 
drew on VC, had a major influence on R&D paths. Their VC provided capital and 
management inputs that greatly affected the firm‟s strategic R&D pursuits; i.e. it afforded 
them the capital to develop their R&D resources and capabilities.  
 
The firms ranking of the importance of industry partners on their R&D paths varied greatly 
(Table 6-26; 3). However, for the most part this is in line with the data gathered in the first 
part of this study. BA1 and BA2 relied heavily on partners for inputs, and these industry 
partners had a major impact on the firms‟ R&D paths, whereas the other firms did not have 
strong relationships with firms in the field and in some of the cases purposely avoided 
partnerships. The response from DD1 did vary somewhat from the analysis of the earlier 
data. For DD1, it seemed apparent that industry relationships were important to their R&D 
paths, but there was only one partner firm that influenced the strategic path of DD1, and 
they merged with this firm. Thus the respondent to this survey did not see them as a 
partner firm, but instead a part of DD1. The relative importance of partners seemed to 
revolve around the firm‟s strategy and availability of partners. Moreover, whilst the 
importance of partners varied, the study did show that partners can have a profound effect 
on a firm‟s R&D evolution. For example, industry partner inputs to BA2‟s R&D had a 
significant impact on their R&D.     
 
An important theme from this study is the importance of university partnerships to the 
R&D paths of the firms (Table 6-26; 4). Three of the firms‟ (BA1, BA2 and MD2) 
innovations emanated from universities, and for almost all of the firms, university 
partnerships opened up research opportunities that influenced the strategic pursuits of the 
firms. MD1 is the one exception to this, as they had no university relationships. Overall 
university science opened up R&D opportunities for the firms and university partnerships 
influenced the direction of the firms R&D. This is one of the major themes to surface from 
this study.   
 
For the most part government partnerships did not influence the strategic direction of the 
firms‟ R&D (Table 6-26; 5). The two exceptions to this are BA1 and BA2. Both of these 
firms entered agreements that greatly influenced their firms R&D paths. BA1 had a couple 
of relatively large research projects that impacted the firm, whereas BA1‟s entire existence 
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had been driven by research partnerships with the government. Thus the opportunity for 
government partnerships has had a major bearing on these firms‟ R&D paths.   
 
Scientific discoveries by the firm had a large bearing on the strategic paths of the firms‟ 
R&D (Table 6-26; 6). All of the firms made progressions that changed the outlook of their 
R&D and motivated the firms to reorganise their resources to accommodate the scientific 
discoveries. The one discrepancy from the earlier data is with BA1 ranking this a 4. 
Further information revealed that this is because the founder clearly thought this was a 
major progression for the firm, but he did not view this as a scientific breakthrough on a 
large scale. However, further information clarified that internal scientific discoveries did 
have a major bearing on the firm‟s R&D paths by opening up new R&D paths for the firm. 
Overall scientific progressions by the firms had a major impact on the R&D paths of the 
firms. More specifically, these opened up new research avenues that affected the strategic 
pursuits of the firms.  
 
Scientific developments in the wider industry are seen as having a low influence on the 
R&D paths of the firms, except for BA1 and MD2, which marked these as high (Table 6-
26; 7). For the five firms there were no major events in the industry that presented great 
opportunities or adversely affected the firms R&D paths. MD1‟s rating of scientific 
breakthroughs as extremely high came as a slight surprise, as the earlier data suggested that 
these events had an impact, but not a vital impact. The follow up revealed that there were a 
couple of developments in the industry that allowed MD1 to develop its device, and this is 
why scientific discoveries in the industry was rated so highly. In general, discoveries in the 
industry did not have a major impact on the firms, but BA1 and MD1 show that these 
discoveries can have a bearing on the on a firm‟s R&D paths.  
  
Five of the firms rated „FDA, EU or other government approvals‟ as high to extremely 
high; whereas, DD1 rated this as influential and BA1 rated this as not influential at all 
(Table 6-26; 8). DD1‟s response differed a little from the results found earlier in the study, 
which is largely explained by the respondents‟ experience in the industry where FDA and 
government approval are simply part of the drug development process. Further information 
revealed that these approvals in fact have been highly influential on the strategic R&D 
pursuits of the firm. BA1‟s view of this category as having a low influence was driven by 
the fact that the firm has invested almost no resources in FDA approval. However, further 
clarification indicates that the firm has strategically planned around FDA approval, so this 
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did have an indirect effect on BA1‟s R&D paths. Overall, FDA and other government 
approvals have been highly influential on the strategic paths of the firms. The firms have 
strategized around FDA and in most cases devoted significant resources to these 
procedures. Moreover, in many cases the substantial resources devoted to FDA limited the 
other areas the firms could focus their R&D. 
 
The respondents rated patents as influential to highly influential on the development of 
their R&D (Table 6-26; 9), which reaffirms the earlier findings that patents and the pursuit 
of patents have an impact on R&D paths. In general the firms developed their R&D based 
on patents or the pursuit of R&D affected what decisions were made in regards to R&D; 
e.g. three of the firms (BA2, DD1 and MD1) strategized largely around obtaining patents.  
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Table 6-26: R&D paths triangulation 
   1= to no extent  7 = to a very great extent 
   1 2 3 4 5 6 7 
1. Your firm‟s core innovation(s) BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
2. VCs BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
3. Industry partnerships BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
4. University partnerships BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
5. Government partnerships BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
6. Scientific breakthroughs by your firm BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
7. Scientific breakthroughs in the industry BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
          
8. FDA, EU or other approvals BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
9. Patenting BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
Source: Author 
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6.5.2 Triangulation of R&D positions 
Table 6-27 summarises the important positions that the firms leveraged in the development 
of their R&D resources and capabilities. From this it is evident that four resources proved 
important to the firms‟ entire R&D: (1) core technology, (2) scientific staff, (3) star 
scientists and the (4) founders. Several other resources also proved important, but the 
relative importance of these resources varied amongst the firms. The results that surfaced 
in the first part of the study are consistent with the responses below.  
 
A central theme to emerge from this study is that the core technology is an important 
resource that the firms leverage in the development of their R&D resources and 
capabilities. This theme recurred throughout the interview analysis and is validated by 
Table 6-27 (1) below. It is apparent that the firms leverage their core technology to attract 
other R&D inputs; specifically partner opportunities arise because other firms want access 
to the unique technology. Moreover, discoveries in the technology allow the firms to build 
other R&D assets such as patents from discoveries in their core technologies.   
 
Another important resource that all of the firms leveraged in the development of their 
R&D are their scientists. The respondents rated their scientific staff as „important to 
extremely important‟ (Table 6-27; 2). This is in line with the earlier analysis findings that 
scientists contribute important inputs to a firm‟s R&D. Specifically, they contributed 
knowledge resources that allowed the firms to progress their R&D. Not surprisingly, these 
cases show how vital of a resource scientists are to the development of a firm‟s R&D.  
 
If their scientific staff is a core resource, this is even more so for their leading scientists.  
With their record of scientific discovery, as evidenced by patenting and academic citations, 
they are core resources to the development of life science innovations. This theme emerged 
from the earlier analysis and is confirmed by the rankings of this category below in Table 
6-25 (3). For most of the firms the star scientists made contributions that greatly helped in 
the progression of the firms‟ technologies. For example, a star scientist for BA2 
contributed several chemical techniques that allowed their instrument to analyse chiral 
chemicals. All of the responses to this question aligned with the analysis from the earlier 
part of the study that star scientists can be important resources to the development of novel 
life science innovations.  
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One of the central themes to come from the earlier analysis is the importance of the 
founders to the development of the firms‟ R&D (Table 6-27; 4). This is validated by the 
very high responses the respondents put for the importance of the founders to the 
development of R&D. All of the firms had founders who were critical resources to their 
firm‟s R&D. Specifically, they made large contributions to the development of their firms‟ 
technology. The firms‟ founders created or sensed out the core innovation and then 
continued to use their scientific knowledge and skills to help progress their firm‟s R&D.  
 
The respondents‟ ratings on the inputs of their executive staff and board varied, which 
collates with the earlier analysis (Table 6-27; 5). MD1, MD2 and BA3 executive staff and 
board members are important resources to the firms R&D. They provided scientific 
knowledge and access to other scientific inputs that have been vital resources to these 
firms‟ R&D. In contrast the other three firms‟ (BA1, DD1 and DD2) executives and board 
members have been important but have not provided critical R&D resources. They have 
mainly contributed ideas and occasionally helped the firms make contacts that help in the 
firm‟s research.   
 
The firms rating of the importance of university resources varied, which reflects the earlier 
findings from the study (Table 6-27; 6); three of the firms (BA1, BA2 and DD1) rated the 
importance of university resources as high to extremely high, two of the firms (DD2 and 
MD1) rated this as moderately important and one firm rated this as of no importance. The 
firms that relied on university resources received important scientific inputs from 
universities. These resources proved vital to the firms. For example, BA2 had research 
performed in a university lab that had capabilities that few labs in the world have. Firms in 
which university partnerships were of moderate importance mostly used the universities 
for testing inputs. Interestingly, the universities provided resources to all of the firms, but 
the relative importance of these inputs varied. There was no theme as to what drove the 
importance other than that prior strong connections with a university influenced the 
relative importance of university resources. BA1, BA2 and DD1‟s strong connections with 
the universities resulted from either the firm‟s founder being an alumnus of the university 
or the firm‟s founder having worked with the university in the past. 
 
The responses to the importance of industry partner resource inputs varied amongst the 
firms (Table 6-27; 7), but this is in line with the earlier findings. There was not a general 
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theme to emerge on the discrepancy of the relative importance of partners. Each firm had a 
unique motivation for either working or not working closely with industry partners.  
 
The importance of government resources to the firms varied amongst the respondents 
(Table 6-27; 8), but collated with the earlier analysis. Only one of the firms received vital 
resource inputs from the government – BA1. This firm‟s development revolved around 
these resource inputs. In comparison BA2 and DD1 received some inputs on a couple of 
R&D projects that helped the firms, but overall the government resources did not prove 
vital; whilst DD2, MD1 and MD2 received no resources from the government. Overall 
government resource inputs did not have a major bearing on the firms‟ R&D, but in certain 
circumstances government inputs did provide a boost, as was the case of BA1 where 
government resources contributed substantially to the firm‟s R&D.  
 
The respondents rating of the importance of patents as a resource to the firms‟ R&D varied 
greatly (Table 6-27; 9). Three of the firms (BA1, BA2 and MD1) rated patents as an 
important resource. For these firms patents provided protection, which allowed them to 
move their product to a point of commercialisation without fear of losing intellectual 
property. For DD1 and MD2 the patents were not of critical importance, but they did prove 
to be resources that the firms leveraged to develop research opportunities. Patents proved 
to be of no importance to DD2‟s early growth. This firm applied for patents, but it took 
eight years to get them, so the firm‟s patents did not provide important R&D resources. 
However, the follow-up with the firm indicates that now that the firm has the patents, they 
will become important resources to their R&D. Interestingly, the importance of patents 
varied amongst the firms and the reason for the variation differed. The one theme to 
emerge on this is that the relative ability of the firm to protect the intellectual property 
without patents influenced the relative importance of patents. However, the cases only 
provided some indications of this, and there is not substantial evidence to put this forth. 
Also interesting is that patents and the patenting process was highly influential on the 
firms‟ R&D paths; i.e. the pursuit of obtaining patents affected their R&D strategies. 
However, the relative importance of the patents as a resource varied in importance. 
 
Specialised research facilities are a resource varied in terms of its importance, which for 
the most part is in line with the earlier findings. The firms that rated this as extremely 
influential needed facilities that are very rare and have highly sophisticated equipment. The 
high rating for this from BA1 was stronger than had emerged in the earlier interviews, but 
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further information revealed that the Army facility where they conducted a lot of research 
proved vital as there are almost no other research facilities in the world that have the 
capabilities to bring together the three sciences that the firm‟s technology is based on; thus 
this has been a vital resource to BA1. Specialised research facilities provided some 
important inputs for MD1 and MD2, but these were for select R&D functions. In other 
words, a specialised R&D facility has only been important resource for certain functions. 
For BA2 and DD2 most of their research could be conducted at just about any laboratory, 
so specialised R&D facilities did not prove important to them.   
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Table 6-27: R&D positions triangulation 
   1= to no extent  7 = to a very great extent 
   1 2 3 4 5 6 7 
1. Your firm‟s core technology BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
2. Your firm‟s  scientific staff BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
3. Star scientists BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
4. Founders BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
5. Executive staff and board of directors BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
6. University inputs  BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
7. Industry partners inputs BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
8. Government inputs BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
9. Patents BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
10. Specialized R&D facility***  BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
Source: Author 
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6.5.3 Triangulation of R&D processes 
Table 6-28 presents the important processes used to help develop the firms‟ R&D 
resources and capabilities. It can be summarised that by trend each firm relied on a unique 
set of processes to develop its R&D. However, sensing technology and learning are 
important processes that all of the firms used to develop their R&D. Only a few minor 
discrepancies surfaced from the responses and the earlier interviews. These are discussed 
below. 
 
One of the main themes from the earlier analysis is that sensing out technology has clearly 
been an important set of routines for the firms. This is validated here as all of the 
respondents marked this question as extremely high (Table 6-28; 1). All of the firms had 
routines in place that allowed them to identify a technology to develop and commercialise. 
Some of the firms sensed out technologies that were already in development, whilst the 
others used sensing routines to find an idea for a novel life science innovation. These 
routines revolved around scanning the scientific community for emerging science, staying 
in contact with people in the industry and being abreast of industry trends and 
developments. These routines happened at the network and firm levels, but on the 
individual level is where these routines transpired the most; i.e. each of the firms in this 
study had an individual or a small group of individuals driving their technological sensing 
routines. 
 
The responses on the importance of networking routines varied amongst the firms (Table 
6-28; 2), which collates with the earlier findings. These routines proved very important to 
BA1 and BA2. Both of these firms received important R&D inputs from their networks, 
and their networks resulted from their networking capabilities. For three of the firms (DD1, 
MD1 and MD2) networking routines proved moderately important. These firms are fairly 
well networked and have used their networking capabilities to capture some key R&D 
inputs. Lastly, networking routines did not prove important to DD2‟s R&D.  
 
Key individuals (i.e. the founders and TMTs) drove the networking for the firms. Their 
networking processes ranged from as simple as picking up and calling a contact that might 
be able to help the firm to as complicated as BA2‟s CEO‟s system for embedding herself 
into a network through trade show attendance, volunteering in industry events and 
participating in formal networking events.  
236 
 
 
Learning processes have proven to be important to the firms‟ R&D (Table 6-28; 3). The 
earlier findings indicated that these processes helped the firms progress their core 
technology, which aided in attracting new resources. This is substantiated by the high 
ratings that the respondents marked for this question. These processes transpired at the 
network, firm and individual levels. BA1 and BA2 practised learning routines at the 
network level. They worked with their partners on joint research where they learned from 
earlier research paths. For example, with their partners they dissected why certain projects 
did not work.  
 
Similarly, learning in R&D took place in all of the cases at the firm level. The firms 
worked with everyone within the organisation as to what progressions had been made and 
as to what could or could not be done based on their earlier research. The results for all of 
the cases also indicated that learning routines are most evident at the individual level. All 
of the firms have researchers who work autonomously on their individual projects and 
have their own systems in place for how they dissect problems and take in new information 
from their earlier findings.      
 
The responses on the importance of routines related to tracking and sharing information 
varied amongst the firms (Table 6-28; 4), which is in line with the earlier findings. For four 
of these firms (BA, BA2, DD1 and MD2) these routines allowed the firms to share 
information amongst the various researchers working on the firm‟s technology. In general, 
the routines relied on written and oral communication, and in BA2‟s case they have a 
formalised system for tracking and sharing scientific information amongst their research 
team. All the firms‟ information-sharing routines helped their researchers collaborate and 
strategize on the most effective way to progress their R&D. For DD2 and MD1 these 
routines did not prove important. This is largely because these firms‟ technologies were 
developed by a very small group of individuals that did not need to share information to a 
wide audience.    
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 Table 6-28: R&D processes triangulation 
  1= to no extent  7 = to a very great extent 
  1 2 3 4 5 6 7 
1. Finding (sensing) the core technology BA1       
  BA2       
  DD1       
  DD2       
  MD1       
  MD2       
         
3. Networking BA1       
  BA2       
  DD1       
  DD2       
  MD1       
  MD2       
         
4. Learning from previous research paths BA1       
  BA2       
  DD1       
  DD2       
  MD1       
  MD2       
         
5. Tracking and sharing information BA1       
  BA2       
  DD1       
  DD2       
  MD1       
  MD2       
Source: Author 
 
6.5.4 Triangulation of financial paths 
The responses to the important paths are presented in Table 6-29. It is evident from this 
table that the core technology and government-related processes had a major impact on the 
development of the firms‟ financial resources and capabilities. Several other opportunities 
and past decisions also influenced the firms‟ financial demands, but the relative importance 
of these varied amongst the firms. In general the responses to the questionnaire aligned 
with the earlier analysis. This confirms the detailed discussions in sections, 6.2, 6.3 and 6.4 
above.  
 
An important theme from this study related to the development of financial resources and 
capabilities is that the costly nature of developing a novel technology dictated the firms‟ 
financial strategies and outlooks (Table 6-29; 1). DD1 is the one respondent who did not 
mark this as a highly influential path. Instead he marked this as low. This came as a 
surprise as the earlier analysis indicated that the great cost involved with developing a drug 
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technology drove DD1 to develop advanced financial resources and capabilities. However, 
further information revealed that the drug technology itself was not overly expensive to 
develop, but the activities involved with developing the drug were expensive. Items such 
as FDA testing and developing production capacities did create a demand for specialised 
financial resources and capabilities. Thus the core technology indirectly drove the financial 
paths of the firm.  
 
In short, all of these firms were new life science ventures that were financially constrained 
yet pursued the development of costly technology. This dictated the financial paths that the 
firms went down. 
 
Table 6-29 (2) depicts that raising capital proved as an important path to three of the firms 
(DD1, DD2 and MD2), but not to the other three firms (BA1, BA2 and MD1). Further 
information gathered from the firms which raising capital was not highly important 
revealed that this is because of these firms‟ decision to self-finance a large portion of their 
early growth; this meant they did not have to spend a lot time and effort on raising capital.  
 
Only two of the respondents (MD2 and DD1) rated investor relations as influential on the 
financial paths of the firms (Table 6-29; 3). This is not a surprise as these responses are in 
line with the findings from the interviews. For the most part the firms did not have to 
expend considerable time dealing with investors. Interestingly, MD2 is the only one of the 
three VC-backed firms that had investors that impacted the financial paths of the firm. 
They along with DD1 had to spend considerable time meeting with investors. This has 
been time that has drawn from the TMTs time and has had an effect on the firms‟ financial 
paths.  
 
For the most part an initial public stock offering (IPO) has not had a large impact on the 
firms‟ financial paths (Table 6-29; 4). Four of the firms are not publicly traded and have 
not looked into the process of going public. DD1 and DD2 are publicly traded, and this has 
greatly affected their financial paths. The need for public financing for these firms 
stemmed from the great cost in developing novel drugs. Surprisingly DD1 rated IPO as 
having no influence. However, further information revealed that this is because the firm 
did not go public on their own accord, but instead merged with a publicly traded firm. 
Further information also revealed that the public stock markets have had an effect on the 
firm‟s strategic path; mainly through the capital that it offers.  
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Another important theme relating to this study comes from the impact that government 
approvals have on the financial paths of life science firms. The earlier findings put forth 
that these approvals have had a major bearing on the firms‟ financial paths, and Table 6-29 
below confirms this. These approvals are expensive and time-consuming and have had a 
major impact on the financial paths of the firms; i.e. they have had to strategically acquire 
the capital needed for this. Had the firms not have had to contend with these government-
related processes, then they could have avoided considerable financial demands; which 
would have had a significant impact on their financial paths. BA1 is the one firm that these 
processes did not affect. This is because BA1 made the strategic choice not to pursue 
applications that required government approval. However, these processes still indirectly 
influenced BA1‟s financial paths as the firm strategized largely around avoiding 
applications that required FDA or other government approvals.  
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Table 6-29: Triangulation of financial paths 
    1= to no extent  7 = to a very great extent 
   1 2 3 4 5 6 7 
1. Costly to develop innovation(s) BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
2. Raising capital BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
3. Dealing with investors BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
4. Initial public stock offering (IPO) BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
5. Costly government approvals such as patents or FDA  BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
Source: Author 
 
6.5.5 Triangulation of financial positions 
Table 6-30 summarises the responses to the questions about the important positions 
(resources) that the firms leveraged in the development of their financial resources and 
capabilities. It is evident from this table that the firms relied on a unique set of resources to 
develop their financial resources and capabilities. Only a few discrepancies surfaced from 
the responses and the earlier analysis. These are noted in the discussion below.  
 
One of the main themes to come from the earlier analysis is the importance of the founders 
to the development of the firms‟ financial resources and capabilities. For the most part this 
is validated by the very high responses the respondents put for the importance of the 
founders to R&D (Table 6-30; 1). All of the firms had founders who were critical 
resources to their financial resources and capabilities. The one exception to this is DD1 
who rated this as very low. Further information from the firm reveals the initial founders 
were not influential in raising capital, but instead the CEO is the one who did most of the 
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fund raising. However, the CEO has been a part of the company almost since inception and 
holds significant stock. After further consideration the firm sees him as a founder, and thus 
with him included as a founder, the firms‟ founders did provide critical resources to the 
firm‟s financial resources and capabilities.   
 
The founders‟ resource contributions came in the forms of the capital they invested, access 
to their network of investors and their capabilities in raising capital. In all of the cases the 
firm‟s founders made substantial resource contributions in these forms that greatly aided in 
developing their firm‟s financial resources and capabilities.  
 
The responses to the question about the impact of the executives and board member‟s 
resource contributions to the development of the firm‟s financial resources and capabilities 
varied (Table 6-30; 2). This reflects the earlier findings that demonstrated how some of the 
firms had significant financial resource inputs from their executives and board members. 
Four of the firms‟ (BA1, DD1, MD1 and MD2) executives and boards made substantial 
resource contributions. More specifically, they contributed capital, access to financial 
networks, and capabilities in raising capital. BA2 is the only one to mark this category as 
low, as their executives and board members did not contribute financial resources.   
 
For the most part VCs did not contribute many resources that helped the case firms 
develop their financial resources and capabilities (Table 6-30; 3). Even the firms that 
received VC (DD1, DD2 and MD2) only rated VC resources as having a low to moderate 
impact on the development of financial resources and capabilities. These firms received 
some capital from the VCs, and the VCs also opened up networks, but these resource 
inputs did not prove critical to these firms. The other three firms did not receive VC, which 
explains their low rating of VC influence. Interestingly, all of the firms, even the ones that 
received VC, expressed their displeasure with the VC model. This is largely why the firms 
have tried to stay away from VC resource inputs. Specifically the firms felt that VCs no 
longer want to invest in risky ventures and that it has become overly difficult to attract VC 
investment.    
 
In general the firm‟s core technology helped them attract investment capital (Table 6-30; 
4). All of the firms, except MD1, received some form of outside capital, and the 
technology is one of the reasons why the outside capital was invested. Put differently, 
outside investors saw the large profit potential of the technology and invested largely based 
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on this. For BA1 and BA2 the grant committees saw that their technologies had the 
potential to help fill a government need. 
 
It came as a bit of surprise that both DD1 and DD2 only rated the technology as a 
moderately important resource to attracting capital, as the earlier analysis indicated that the 
technology provided important positions to developing the firms‟ financial resources and 
capabilities. However, further information reveals that in fact the technology did help raise 
capital, but there were a few times when the firms‟ technology hindered attempts to raise 
capital because it had not progressed as far as it should have. For example, DD1 ran into 
some delays with patent approval, and this hindered their ability to raise capital. Because 
of this, the investors feared the technology might not make it to market. Thus DD1 and 
DD2‟s technology did help attract capital, but there were also instances in which it 
hindered the firms‟ abilities to raise funds. 
 
Overall all the firms‟ technologies provided an important resource that helped them 
throughout their early growth. Progressions in the firms‟ technologies towards a state of 
commercialisation provided an additional resource that the firms used to attract additional 
capital. For example, developing the saliva-based instrument made MD2‟s product 
marketable, which greatly aided the firm in attracting a major investment in 2009.  
 
There is a polarised difference in how important a resource the firms‟ respective staff has 
been to the development of their financial resources and capabilities (Table 6-30; 5); with 
some of the firms‟ staff proving to be an important resource and some of the firms‟ staffs 
proving not to be. Four of the firms‟ (BA1, DD1, DD2 and MD2) staff was critical to the 
company because they lent their expertise that the firms used to help attract investment 
capital. BA1 and DD2 also had staff members who directly made financial contributions to 
the firms. On the other end, BA2 and MD1‟s staffs did not prove important to the firms‟ 
financial resources and capabilities. They did not help the firm attract financing and did not 
directly contribute financial resources.    
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Table 6-30: Triangulation of financial positions 
   1= to no extent  7 = to a very great extent 
   1 2 3 4 5 6 7 
1. Founder(s) BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
2. Executive staff‟s and board members 
experience 
BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
3. Venture capital investor(s) BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
4. Core technology BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
5. Company‟s staff BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
Source: Author 
 
 
6.5.6 Triangulation of financial processes 
Table 6-31 presents the important processes used to help develop the firms‟ financial 
resources and capabilities. This table shows that processes related to conserving capital and 
learning from earlier financial decisions had a major bearing on the development. Only a 
few minor discrepancies surfaced from the responses and the earlier interviews. These are 
noted in the discussion below. 
 
The importance of routines related to prospecting for capital varied (Table 6-31; 1). These 
processes proved highly important to DD1, DD2 and MD2, and can largely be attributed to 
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the vast amount of money that these firms‟ innovations demanded. In order to obtain the 
needed capital, DD1, DD2 and MD2 had to develop advanced routines related to finding 
and selling the idea of investing in the firm and negotiating terms. For example, DD1 has a 
system where they contact physicians about the possibility of investing. If a physician is 
interested, then the CEO meets with the potential investor. Similarly, these firms have 
systems in place for negotiating with the potential investors. These routines have also been 
important to BA1 and BA2, but these are not systems that they use on a regular basis. 
Instead there have been select times when they have relied on these. For MD1 these 
routines have been of no importance because the firm has made little attempt to draw in 
outside investors, which is a result of the founder‟s decision to self-finance the venture. All 
of the firms‟ innovations have been capitally intensive to develop, but BA1, BA2 and 
MD1‟s have been less expensive, and these firms were able to source the capital for their 
innovations with less effort than the other three firms have been able to.  
 
Processes revolving around dealing with investors (Table 6-31; 2) have had a varying 
effect on the firms‟ financial assets and capabilities. DD1 and DD2 have developed 
advanced routines for dealing with their investors. This has involved meeting with the 
investors, creating reports and completing compliance paperwork. For the most part these 
are lower-level routines that have become ingrained in the firms. These processes have had 
some influence on BA2, but the firm‟s TMT only devotes a small amount of time to these 
routines. For three (BA1, MD1 and MD2) of the firms these routines were reported to have 
had almost no influence on their financial resources and capabilities. In the cases of BA1 
and MD2 this is largely because the firms have taken in a limited amount of capital from 
outside investors. The low response from MD2 contrasts to the earlier analysis. However, 
further information clarified that the respondent did not view this question correctly and 
that this has been influential on the firm‟s development.    
 
An important finance-related theme from this study is the importance of budgeting and 
conserving capital. Table 6-31 (3) shows that the firms saw these as important processes to 
their financial pictures, which reflects the earlier findings. The firms have developed 
routines for saving capital that revolve around sensing out low cost inputs and strategically 
investing in the most cost effective projects. The firms have also developed routines for 
budgeting their capital. For the most part, capital flows have been erratic, leading to 
inconsistent cash flows. All the firms created routines for projecting spending and have put 
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emergency plans in place, such as short-term credit lines to pay for expenses when cash 
flows become problematic.  
 
One inconsistency from the earlier analysis and the response to this question arose from 
MD2. The respondent only marked this as moderately important, when the earlier analysis 
indicated that this as being quite important to the firm. Further information revealed that 
the respondent felt this is very important.   
 
Most of the respondents listed routines relating to learning from earlier financial paths as 
very high (Table 6-31; 5). This is consistent with the earlier findings that one of the most 
important factors to the development of the firms‟ financial resources and capabilities 
stemmed from the processes that they created to learn from earlier financing decisions. 
These processes were driven by the firms‟ TMTs who learnt how to identify potential 
investors, conserve capital and create strategies to conserve capital. However, these are not 
formal routines that the TMTs think about and put a lot of effort in developing. Rather 
these learning routines occur every day based on the cumulative experience of the past. 
 
For the most part routines related to filing for an initial public offering did not affect the 
firms (Table 6-31; 6). The one exception is DD1, which had to expend considerable effort 
in developing routines for compliance and marketing their stock, which related to their 
IPO. The CEO is the one who has driven this process for DD1. DD2 is also publicly 
traded, but it merged with an already publicly-traded firm, so it avoided having to develop 
many of these routines. Moreover, the firm it merged with has a finance team that deals 
with the on-going maintenance routines of the firm‟s publicly-traded stock. The other firms 
did not file for an IPO because they were not ready to do so, did not have the financial 
capabilities to do this or they simply did not want to commit to creating the processes 
needed for taking the firm public. DD1 would have preferred to have not had to deal with 
these processes, but the high cost of developing their drug forced them down this path. 
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Table 6-31: Financial processes triangulation 
   1= to no extent  7 = to a very great extent 
   1 2 3 4 5 6 7 
1. Prospecting for capital BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
          
2. Dealing with financiers  BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
3. Budgeting and conserving capital  BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
5. Learning from earlier financial paths BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
6. Filing for an initial public offering (IPO) BA1        
  BA2        
  DD1        
  DD2        
  MD1        
  MD2        
          
          
Source: Author 
 
 
6.6 R&D and finance interdependence 
The analysis presents a clear connection of the interdependence of financial and R&D 
resources and capabilities of innovative life science ventures. Based on this analysis, 
Figure 6-1 presents a model as to how R&D and financial resources and capabilities 
developed in the six innovative life science ventures that this study examined. 
 
Firms are started to develop and commercialise an innovative technology, which is 
represented in the figure by the core technology oval. The technology is either purchased 
from another organisation (firm, university or government) or conceptualised prior to the 
start of the new firm. This core technology feeds into the R&D and the financial paths and 
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positions. The technology‟s past paths dictate the development that needs to go into the 
innovation; i.e. how much development does the technology need? Which dictates how 
much financing is called for? For example, an innovation at an earlier stage requires more 
development than an innovation purchased at a later stage. The potential of the technology 
and the complementary technologies available are the key drivers to the technologies‟ 
future paths, and firms develop their innovation to pursue these paths. Often the 
technology comes with scientific capital, such as patents or key scientific personnel, which 
feed into the R&D positions of the firm.  
 
The firm develops R&D processes based on their R&D paths and positions, and then these 
processes create the R&D resources and capabilities of the firm. The feedback loops (i.e. 
the dotted lines in Figure 6-1 from R&D resources and capabilities to the paths and 
positions represent the R&D resources and capabilities feeding back into the firm‟s R&D 
paths and positions; i.e. the R&D resources and capabilities create new research 
opportunities and strengthen the R&D positions of the firm.   
 
The core technology is also important to the financial paths of the firm. It dictates the 
capital needed and what source(s) of finance are called for. In all of the cases studied, the 
firms required a large investment to develop the core technology. Moreover, the core 
technology took an extended time to develop, which made the firms sustain long periods 
without revenues. Thus the core technology made specialised financing necessary for the 
firms. None of the firms in the study could source capital from generic places such as 
banks. Thus from the results is clear that financial resources and capabilities for innovative 
start-up life science firms are often specialised resources , not generic resources ; i.e. the 
financial resources  and capabilities cannot be easily obtained and take specialised abilities 
to create (Teece, 1986; Trispas, 1997).  
 
The core technology also feeds into the financial positions because the market potential of 
the core technology is what influences how much capital the firm can raise. All of the 
firms in this study raised the needed capital largely based on the potential profits of the 
innovation. Put differently, the investors and grant committees saw great potential in the 
firms‟ innovations. Initially the firm develops financial processes based on its paths and 
positions. These processes then create the financial resources and capabilities. The 
feedback loops from financial resources and capabilities to the paths and positions 
represent the financial resources feeding back into the firms‟ financial paths and positions; 
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i.e. the firms further developed their capabilities in raising capital, and the additional 
capital increases their financial positions.  
 
The R&D and financial resources and capabilities in turn feed into each other. As the firm 
increases its financial resources and capabilities, it feeds these into the paths and positions 
of the R&D resources and capabilities. The capital gives the firm positions to further 
develop R&D, and it also gives the firm the capital needed to open up new R&D paths, 
such as developing a new product. Similarly, R&D feeds into the financial resources and 
capabilities of the firm. An increase in R&D gives the firm additional positions from which 
to raise capital; i.e. the innovation is more developed and shows even more market 
promise. This opens up new financing paths for the firm; i.e. the firm has more options for 
raising future capital because of the R&D resources and capabilities of the firm.  
 
The feedback loops from the R&D and financial resources and capabilities represent the 
R&D and resources and capabilities‟ contributions to progressing the technology. Because 
of the developments in the firms‟ finances and R&D, it is able to get the core technology 
closer and closer to a point of commercialisation, which ultimately perpetuates the firm‟s 
growth. 
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Figure 6-1: Model of technology, R&D and financial interdependence 
 
 
Source: Author
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6.7 Analysis conclusions 
It is clear from this analysis that R&D and financial resources and capabilities are 
paramount to the growth of innovative life science ventures. R&D and finance build on 
one another and then feed into the development of the firm‟s innovation throughout the 
growth process. The R&D and financial resources and capabilities develop from a unique 
set of paths, positions and processes. Especially important to R&D is the core technology 
that the firm sets out to develop. This establishes the R&D needs and ultimately the 
strategic direction of the firm. Unique resources, especially scientific human capital, allow 
the firm to develop processes to seize R&D paths. Financial resources and capabilities also 
develop along the path of the core technology. Developing novel life science innovations is 
costly and requires specialised financing. The firms use their technological positions, 
scientific human capital and founders‟ backgrounds as the positions to create the 
capabilities to secure the capital.  
 
Variation existed amongst the firms in terms of the development of their R&D and 
financial resources and capabilities and the impact these resources and capabilities had on 
growth. For example, the relative importance of industry partners, the firm‟s board of 
directors, networking and raising capital differed substantially. For some of these firms, 
these paths, positions and processes proved important, whilst for others they did not. 
Moreover, the exact set of paths, positions and processes varied amongst the firms. 
However, what was consistent was that the core technology, scientific human capital, 
experienced founders and alliances were drivers to the development of R&D and financial 
resources and capabilities. The next chapter discusses the importance of these findings in 
relationship to the literature. 
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Chapter 7 – Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter objectives 
 
 To discuss the findings in relation to the research objectives presented in chapter 4. 
 
 To discuss the theoretical contributions this study made. 
 
 To identify implications for practitioners and policy makers. 
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7.1 Introduction 
This thesis examined the resource and capability development of life science ventures. It 
focused on R&D and financial resources and capabilities, what they are and how they are 
determined and deployed by firms‟ towards growth. Previous work has examined the R&D 
and financial resources and capabilities of life science firms, but only a few studies 
examine these for new life science ventures. The few related R&D studies mostly focus on 
the role of academic and institutional partners‟ research inputs (Calabrese & Silverman, 
2000; Coombs & Deeds, 2000). As such, they fail to take a holistic view of how early 
R&D resources and capabilities are formulated. In a similar vein, only a few studies look at 
the development of financial resources and capabilities of life science ventures. The few 
previous studies on the topic mainly focus on finance from a ROI standpoint (Lerner, 
1995; Powell et al., 2002). There is a surprising shortage of studies that investigate how 
life science ventures develop capabilities to build or acquire financial resources. Similarly, 
there are only a handful of studies that probe the role of financial resources and capabilities 
on the development of a firm from a management standpoint; i.e. how financial resources 
and capabilities influence the early growth of a firm.  
 
This chapter presents the findings from this study that are related to the knowledge gaps 
discussed above. Implications for the literature are first presented followed by the 
implications for practitioners and policy makers. The chapter is structured as follows: 
 
7.2 Development of R&D and financial resources and capabilities 
7.3 Effect of R&D and financial assets and capabilities 
7.4 R&D and financial interdependence 
7.5 Dynamic capabilities  
7.6 VC and grants 
7.7 Implications for practitioners and policy makers 
7.8 Shortcomings 
7.9 Recommendations for future research 
7.10 Summary and final conclusions 
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7.2 Development of R&D and financial resources and capabilities 
The first research objective of this study was to explore and examine how life science 
ventures develop R&D and financial resources and capabilities. This study used an RBV 
influenced dynamic capabilities perspective to examine this objective. The dynamic 
capabilities literature emphasises that paths, positions and processes are important to the 
development of key resources and capabilities (Teece et. al., 1997; Teece, 2007). Work has 
looked at important resources and capabilities (Arora & Ceccagnoli, 2006; Arthurs & 
Busenitz, 2006; Freear & Wetzel, 1990), but little work examines the paths, positions and 
processes that lead to the development of key resources and capabilities. Trispas (1997) is 
one of the few studies of note to look at the paths, positions and processes that lead to the 
development of key resources. However, this study focuses mainly on how changing 
technology influences the paths of developing key resources. It does not provide great 
depth on the positions and processes and how paths, positions and processes interact to 
create the capacities to develop resources.  The present study examined this. Specifically 
the study looked at the paths, positions and processes that lead to the development of R&D 
and financial resources and capabilities. The development of R&D and financial resources 
and capabilities are divided into sections: 7.2.1 and 7.2.2.  
 
7.2.1 R&D Paths, positions and processes 
The results from this study indicate that life science firms develop R&D resources and 
capabilities along a unique set of paths, positions and processes. This section details the 
main findings of the study related to this.  
 
R&D paths 
The first question related to R&D paths that this study explored is „How does an 
innovation affect the development of a firm?’ This question also aimed to explore how the 
source and type of innovation affects the development of a firm‟s R&D.  
 
One of the most prevalent themes presented throughout the analysis is that the innovation 
that a firm pursues dictates the firm‟s R&D trajectories. The firms developed their R&D 
resources and capabilities based on the demands of their core innovation. These demands 
emanated from the type of innovation. Although the case firms are all in the life science 
industry, the number, type and focus of the firms‟ innovation(s) dictated the R&D 
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resources and capabilities needed by each. For example, the drug development firms‟ 
technologies called for R&D knowledge and capabilities revolving around biochemistry 
research capabilities; whereas BA1 and MD1‟s core innovations called for advanced 
engineering capabilities. This is consistent with the new technology-based firm (NBTF) 
literature, which suggests that firms‟ inception and growth is often based on a core 
technology (Lynskey, 2009; Onetti, Zucchella, Jones, & McDougall-Covin, 2010).  It was 
also evident from the findings that firms that have a more focused innovation are more 
successful in developing their innovation. BA1, BA2 and MD2 focused on mainly one 
innovation in the first five years, and they were able to successfully develop their 
innovations; whereas MD1, DD1 and DD2 pursued a platform technology that took a lot 
longer to develop, which was largely attributable to the resource shortages that the pursuit 
of several innovations caused. It is evident from the study that a more concentrated R&D 
focus is better for life science ventures, and it is the first proposition the study puts forth: 
 
P1) Firms that have a narrower scope of R&D focus are more successful in 
commercialising their innovations because they are better able to attain the core 
resources and capabilities needed to develop their innovations.  
 
This is an important proposition as it could help life science ventures to understand that it 
is better to focus their R&D. The results of this study indicate that a narrower scope of 
focus allows firms to fully develop an innovation, whereas the pursuit of multiple 
innovations stretches resources and puts firms in great a danger of exhausting resources 
before they have advanced their innovations.   
 
The second R&D path-related question that this study looked at is „Do partnerships have a 
major bearing on the development of R&D and financial resources and capabilities?’ This 
question also looked to see how firms know what they have to offer and how firms know 
what potential partners have to offer. 
 
The analysis clearly indicated that partnerships have a major bearing in the development of 
a firm‟s R&D. This confirms the bulk of the existing literature; however, little work 
examines this through a dynamic capabilities or CAs lens. Rothaermel (2001a, 2001b, 
2005) are major exceptions, as these studies specifically examine alliances and CAs. These 
studies provide much insight on the importance of alliances to developing CAs, but these 
studies did not factor in how partnerships influence the overall R&D paths. The present 
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study extends Rothaermel‟s work by providing depth on how partnerships cause life 
science firms to rearrange their scientific base to accommodate their partners‟ R&D inputs. 
For example, BA1 entered into a research partnership with the US government, which then 
dictated the early strategic direction of the firm‟s R&D resources. The firm refocused 
almost all of its R&D resources to focus on the co-development project with the Army. 
Not all of the firms were this significantly influenced by partners, but all of the firms had 
partners that impacted the strategic makeup of their R&D. 
 
The study‟s results also indicate that firms identify potential partners from their founders‟ 
networks and the scholarly scientific community. All of the firms had at least one major 
partner who emanated because of the founder‟s background. The founders knew what 
partners had to offer because of their unique scientific and management experiences. 
Similarly, potential partners know what the firms had to offer because of the backgrounds 
of their founders. For example, BA1‟s founder had previously worked with one of the US 
Army‟s chief scientists, and because of this, the chief scientist knew what BA1‟s founder 
was working on and what its potential was. Similarly, DD1‟s founder had worked with 
their VCF in the past, and because of this the VCF knew what the potential of DD1‟s 
technology was; and DD1 knew what the VCF had to offer. This is supportive of the 
literature, which has also indicated that the founders are important in the development of 
partnerships (Witt, 2004).  
 
In a similar fashion, this study found that scholarly journals and conferences are facilitators 
of partnership. Five of the firms used the scholarly community to help them facilitate R&D 
partnerships. For example, DD1 identified independent researchers doing work on areas 
related to their technology through scientific journals. Likewise, MD2 found two 
universities doing research related to their technology from scientific journals. The 
journals allowed the firms to identify what these organisations were doing and what they 
could possibly offer in a partnership. Staying active in the scientific journals and 
conference also helped five of the firms in this study gain credibility. Their publications 
and conference presentations let other firms know what they had to offer, and the scholarly 
process they underwent certified their credibility. This is supportive of Zucker and Darby 
(1996) who suggest that biotech firms publish to help them market their products. 
However, the present study extends this finding by showing how scholarship helps firms 
develop credibility. The discussion in this paragraph leads to the second proposition: 
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P2)  Life Science ventures that publish in scholarly journals and attend conferences 
are better able to identify complementary technologies and assess the capabilities of 
potential partners.  
 
This is an important proposition, as the literature has not paid much attention to the role of 
scholarly activity in the development of life science firms. Prior research has noted that it 
is corrleated with higher rates of commercialisation (Zucker and Darby, 1996), but it has 
not shown how this can be an important facilitator of partnerships. Thus this proposition 
has the potential to help life science ventures identify and vet potential partners.  
 
In examining the R&D paths of the firm, an important influence that emerged from this 
study is the importance of government approvals. Directly or indirectly, government 
approval procedures and regulations influenced the R&D paths of the firms in this study. 
FDA approval proved as one of the largest influences. Most of the firms in this study 
developed products that required FDA approval, and in order to obtain it, the firms had to 
meet compliance and testing standards. This forced the firms to design their R&D around 
gaining these approvals, and it forced the firms to devote substantial resources to it. 
Studies have noted that the FDA is a major hurdle to life science firms (Grabowski, 2002; 
Olson, 1997), but they have not specifically looked at how these approvals affect a firm‟s 
R&D‟s strategic paths. The present study adds to these by providing insight on how 
government approvals affect the R&D paths of life science ventures.  
 
Interestingly, FDA approval procedures forced three of the firms from this study down an 
internationalisation path.  The firms sought approval for their products first in European 
markets because they felt they could get their products approved for market more 
efficiently there than they could in the US, an interesting finding because the literature on 
life science ventures does not provide great insight on how government approval 
procedures can force life science ventures down an internationalisation path. The 
internationalisation literature puts forth that government approval can influence 
internationalisation (Brewer, 1993), but there is little work that explicitly applies this to life 
science ventures. Thus the third proposition of this study puts forth: 
 
P3) Life Science ventures that internationalise are motivated to do so to avoid FDA 
regulatory bureaucracy, and this is forcing firms to develop resources and 
capabilities for operating in international markets. 
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This proposition is notable because applying for foreign government approvals instead of 
US FDA has a major bearing on a firm‟s development. The literature and industry reports 
have noted that the propensity to outsource functions such as testing has increased 
dramatically in recent years (Giovannetti, 2010); however, it has not shown that firms are 
starting to look first at foreign market government approval instead of US FDA approval. 
Evidence from the present study indicates that firms are now in some cases looking to gain 
foreign market approvals first because these are more streamlined, allowing them to get 
their product to market quicker. It is also forcing the firms to develop resources 
andcompetencies in operating in international markets. 
 
R&D Positions 
This study found that a number of positions are important to the development of a firm‟s 
R&D. One particular position that this study is interested in is key individuals. More 
specifically, the fourth research question of the study looked at „Are highly trained, skilled 
and experienced individuals driving the development of R&D and financial resources and 
capabilities?’ This question also aimed to examine whether star scientists are vital to the 
development of life science ventures‟ R&D. 
 
All of the firms in this study‟s R&D revolved around the knowledge and capabilities of an 
individual or small group of individuals. Five of the firms noted the particular importance 
of standout scientists. This is supportive of the life science literature, which suggests that 
star scientists are often the impetus of new life science innovations (Rothaermel & Hess, 
2007; Zucker & Darby, 1996, 2001). However, none of the individuals involved with a 
case firm in this study were in the Science and Technology Agents of Revolution (STAR) 
database. Indexing of individuals in this database is based on a complex set of criteria that 
traces the publishing, patenting and commercial activity of a researcher. This database 
originated from Zucker and Darby (1992) where they identified the top 327 biotechnology 
researchers and found that firms who collaborate with these individuals have a much 
higher rate of commercialising innovation. Whilst their findings were profound and have 
been well supported (Zucker & Darby, 2001; Zucker et al., 2002; Zucker et al., 1998), and 
star scientists do account for a statistically significant amount of innovation, overall they 
only account for a small percentage of life science innovation (Higgins, Stephan, & 
Thursby, 2011).  
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The findings from the present study extend the work done by Zucker and Darby (1992) by 
suggesting that standout scientists, not necessarily star scientists, play a key role in the 
development of life science firms. The present study identifies standout scientists as 
individuals who have scientific achievements in the top five percent of all scientists, but 
are not in the elite .005% of the scientists in the world as defined by the Zucker and Darby 
(2011) STAR database. Four of the firms in this study had founders or employed scientists 
who were highly noted in the field but were not in the STAR database. For example, 
BA2‟s co-founder was named by The American Chemistry Society in 2010 as one of the 
top fifty researchers in chemistry. Similarly, DD2‟s founder holds seven patents and is 
noted in several publications as one of the leading experts in snake venom. These 
individuals drove the R&D capabilities of these firms. The last two paragraphs discussion 
leads to proposition four: 
 
P4) Firms that employ one or more standout scientist are better able to develop 
R&D resources because of the standout scientist(s) R&D capabilities and scientific 
contributions. 
 
This proposition is significant, as it has already been noted that star scientists are driving 
innovation. However, star scientists still only account for a small percentage of life science 
innovation. Evidence from the present study suggests that standout scientists are having a 
profound impact on the R&D of life science ventures, and could possibly account for a 
large portion of innovation in the industry. For this reason, a more inclusive ranking 
system needs to be constructed to capture the impact of standout researchers – not just the 
elite star scientists that represent less than .005% of the scientists in the field (Higgins et 
al., 2011). Such a scale could help firms understand what is driving the development of 
new innovation; it could help firms in identifying standout researchers; and it could also 
help investors in the evaluation of life science firms.  
 
Another interesting finding of this study is the importance of foreign-born and trained 
scientists. Four of the firms employed foreign-born and foreign-trained scientists who 
played key roles in the development of their technology, and it is evident that these 
scientists also made key contributions to the R&D positions of the firm. These scientists 
provided insights based on their overseas training and research that were invaluable to the 
development of their firms‟ technologies. This finding is consistent with the 
internationalisation and NBTF literatures, which suggest that foreign-born employees are 
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often a central asset to a firm‟s growth and internationalisation (Portes, Guarnizo, & 
Haller, 2002; Saxenian, 2002). Whilst this finding is more supportive than novel, it is 
novel in its extension to a dynamic capabilities framework; i.e. foreign-born employees 
can be an important position to the development of a firm‟s R&D resources and 
capabilities.  
 
R&D Processes 
The fifth research question of this study looked at „What processes are vital to creating 
R&D resources and capabilities?’ 
 
The dynamic capabilities literature underscores several processes that lead to the 
development of capabilities. Sensing opportunities is a higher-level process identified in 
the literature (Teece, 2007). In an in-depth study on the IBM Corporation, Harreld and 
Tushman (2007) found that sensing opportunities is a dynamic capability that IBM has 
developed, and it has been one of the firm‟s main sources of competitive advantage. 
Similarly, Trispas and Gavetti (2000) in an in-depth study of the Polaroid corporation 
found that sensing new technological opportunities was an important dynamic capability 
that the firm developed, and this has been one of the firm‟s main competitive advantages. 
In a similar vein, Kaplan, Murray and Henderson (2003) take an in-depth statistical look at 
fifteen pharmaceutical firms‟ TMTs‟ ability to recognise scientific opportunities. Their 
findings suggest that sensing is clearly an important routine. The present study‟s results 
support these studies and extend these findings to life science ventures. Specifically, the 
results indicate that the ability to sense and seize scientific opportunities is important to the 
development of R&D resources and capabilities of a life science venture. All of the firms 
identified a core innovation to develop, and the ability to identify a technology that 
presented both scientific and market potential provided an impetus to the firms‟ growth. 
The firms identified a technology and then assessed the development it needed and 
whether or not the technology could realistically be developed; i.e. did the firm have the 
capabilities and resources to accomplish this. The firms in this study excelled in this area, 
and this was an important driver to their growth.  
 
Learning is perhaps the most cited dynamic capability in the literature. Numerous authors 
emphasise the importance of learning processes (Eisenhardt & Martin, 2000; Romme et al., 
2010; Winter, 2000; Zollo & Winter, 2002). Accordingly, firms learn from their past paths 
and use this information to adapt their positions to pursue future paths that are available to 
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them. The present study’s findings suggest that learning from earlier research paths is 
vital to the development of R&D resources and capabilities. All of the firms learned from 
their earlier paths and used this knowledge to further the development of their 
technologies. In particular, the firms learned how to use their research setbacks to advance 
their technology. For example, MD1 suffered several failed developments, but the firm 
established processes for dissecting the reason for the setbacks and then used this 
information to find ways to overcome them.  
 
This study also finds that in small life science ventures learning processes transpire at the 
network, firm and individual levels. Most of the firms in this study had partners that they 
learned from on joint research projects. Moreover, all of the firms in this study practiced 
inter-organisational learning; i.e. employees from within the firm worked together to 
acquire new knowledge. Learning prevailed most evidently at the individual level for the 
firms in this study. All of the firms employed researchers who worked independently and 
acquired new scientific knowledge based on their individual work. Previous studies have 
indicated that key individuals are often the source of learning (Cohen, 1991; Rothaermel & 
Hess, 2007). The present study extends the importance of individuals to the learning 
process of life science ventures.  
 
The third process this study found vital to the development of R&D resources and 
capabilities is partnering. This is supportive of earlier research that suggests that firms 
secure important inputs through alliances and partnerships (Das & Teng, 2000; Eisenhardt 
& Schoonhoven, 1996; Haeussler et al., 2010). Furthermore, networking is a dynamic 
capability that firms can derive competitive advantages from (Blyler & Coff, 2003; Mort & 
Weerawardena, 2006). The present study’s results confirm this and extend it to innovative 
life science ventures. This study‟s findings also support the idea that partnerships can stem 
from many different places such as past business dealings, personal friendships and 
scholarly journals (Harris andWheeler, 2005; Hite and Hesterly, 2001; Hsu, 2007). 
 
A fourth important set of processes that surfaced as important to the development of R&D 
resources and capabilities revolved around integrating new knowledge. All of the firms 
took in new knowledge into their operations that they synthesised into their research. Their 
capabilities to use this knowledge underpinned their ability to progress their technology. 
This finding supports absorptive capacity as a dynamic capability that firms derive 
competitive advantages from (Deeds et al., 2000; Zahra & George, 2002). This is an 
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important finding as it provides needed empirical support to absorptive capacity as a 
dynamic capability. Previous studies have established this a source of competitive 
advantage (Cockburn & Henderson, 1998; Lane & Lubatkin, 1998) and have alluded that 
absorptive capacity can be viewed as a dynamic capability, but few studies have directly 
offered support to absorptive capacity in a dynamic capabilities framework; the present 
study does so. 
 
As the discussion above indicates, the results suggest that firms rely on a combination of 
processes to create their R&D resources and capabilities. Processes relating to sensing, 
learning, partnering and integrating proved important to all of the firms.  
 
7.2.2 Financial paths, positions and processes  
For the most part, generic financing has not been available to the firms in this study, which 
is no surprise as start-up life science firms are limited in their funding sources because of 
their risky nature (P. Gompers & Lerner, 2001). In order to develop the needed financial 
resources, the firms leveraged a unique set of paths, positions and processes. 
 
Financial paths 
The first research question looked at „How does an innovation affect the development of 
firms’ resources and capabilities?’ This question also looked at how the source and type of 
innovation affects the financial demands of firms. 
 
Financing is an important path to the growth of life science ventures. Often these firms 
develop an innovative technology that is costly to develop (Colombo & Grilli, 2009). 
Furthermore, technology takes extensive time to develop, and firms go years without 
revenues whilst the technology is being developed (Zucker et al., 2002). This makes 
specialised high-risk capital germane to the development of life science ventures (Baum & 
Silverman, 2004). All but one of the firms in this study used a form of specialised 
financing, and the decision to use specialised financing stemmed from the large amount of 
capital that was needed to pursue the development and commercialisation of a novel life 
science innovation. Thus this study supports other research which shows that the novel 
innovation that life science firms pursue is costly to develop (Chakma & Sammut, 2011). 
Evidence from the study also suggests that the type of innovation has a profound effect on 
a firm‟s financial demands.  Furthermore, the study suggests that firms looking to pursue 
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larger scale innovation have more financial difficulties. The three firms (DD1, DD2 and 
MD2) that pursued several innovations had to devote substantial time and resources to 
developing the financial resources needed to fund several different projects. This distracted 
from the scientific activities of the firms. Moreover, it also stretched the financial resources 
of the firms and made all three of the three firms terminate at least one of the innovations 
they were developing. In contrast, MD1, BA1 and BA3 narrowly focused on one type of 
innovation and were able to successfully develop their product largely because their 
financial resources were not stretched across several major projects. From this discussion 
proposition five is put forth: 
 
P5) Life science ventures that attempt to develop several innovations 
simultaneously develop slowly and risk failure as they create large financial 
requirements. 
 
The third research question looked at „How does the pursuit of financing impact the 
development of life science ventures?’ It was specifically interested in how the financial 
strategies of firms affect their financial trajectories. 
 
The results indicate the financial strategies of the firms have a major bearing on the 
financial trajectories of a firm. All of the firms followed a unique financial strategy. Two 
of the firms (BA2 and MD1) made the choice to self-finance their early growth, which 
influenced the investments that could be made; i.e. it limited the funds that the firms had 
available to invest in the development of their technology. On the other hand, this choice 
freed them from having to devote resources to prospecting for capital and dealing with 
investors. In comparison, three of the firms relied heavily on outside investors for capital. 
These investors supplied large sums of capital, but raising this capital and dealing with the 
investors significantly affected the firm‟s operations. Studies have examined the financial 
strategies of new ventures (Freear & Wetzel, 1990; Van Auken, 2001; Willoughby, 2008). 
However, these studies have not provided deep insights on the long term effects of a firm‟s 
early financial strategies. Based on the findings from the present study the following 
proposition is put forth: 
 
P6) Firms that self-finance their growth will have significantly different financial 
trajectories than firms that pursue equity investors, as they will have less capital 
available, but will maintain greater organisational flexibility.   
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This is a notable proposition because rigidities are created from the early financial 
strategies, and these limit the financial choices available to firms in the future. For 
example, DD1 and DD2‟s public stock offering committed them to substantial government 
regulations, which consumed significant time from the firms‟ TMTs. In hindsight, both 
firms would have liked to have reversed their decisions to go public, but it was a decision 
that they could not change. Conversely, BA1 pursued government grants that did not 
commit the firm to a stratified financial path. This allowed the firm more flexibility in its 
future financial options. 
 
Financial positions 
The second research question explored „Are highly trained, skilled and experienced 
individuals driving the development of resources and capabilities?’   
 
The results clearly indicate that founders provide important resources that feed into the 
development of the firm‟s financial resources and capabilities. All of the firms relied 
heavily on their founders‟ background to develop their financial resources and capabilities. 
For example, DD2‟s founders‟ network provided access to important financing 
opportunities. The firm‟s founder had previously worked with VCs, and these past 
experiences aided them in securing financing. DD1, MD2 and BA1‟s founders also 
provided an important position that the firms used to „sell‟ the financiers on investing in 
the firm. The most extreme examples of this from this study are DD2 and MD2. Both of 
these firms‟ founders were famous in their respective fields, and because of this name 
recognition, the firms attracted significant investor interest. Put differently, investors 
wanted to invest in these firms because of the founders‟ successful track records. This 
finding is supportive rather than unique as several studies note the importance of the 
founder‟s background to raising capital (Colombo et al., 2004; Sengupta, 2011; Storey & 
Tether, 1998). The findings also show that founders do not have to have experience in 
running a life science firm to successfully raise capital. BA2 and MD2 founders had no 
business experience but were still able to develop the financial resources needed to 
progress their innovation towards a state of commercialisation.  
 
It is evident from this study that the background and experience level of the founder(s) 
impacts the financial strategies of a firm. The two firms with inexperienced founders, BA2 
and MD2, initiated the venture on a self-financing path mainly because they did not have 
264 
 
knowledge or contacts to pursue other financing routes. In comparison, BA1‟s founder was 
highly experienced in using government grants to finance new life science ventures, and 
thus he pursued this route for financing BA1‟s growth; whereas, DD1, DD2 and MD2‟s 
founders were experienced in attracting and working with equity investors and for this 
reason used VCs and private investors to incubate their new ventures. The discussion in 
this section leads to proposition seven: 
 
P7) Inexperienced founders are more likely to self-finance their venture‟s early 
growth, as opposed to experienced founders who use their background to secure 
financial resources from outside sources.  
 
Another resource that this study found important to financial resources is the firms‟ 
technology. The firms leveraged their technical assets and capabilities to develop their 
financial resources and capabilities. Almost all of the firms displayed advanced 
technological knowledge and skills that helped attract specialised finance. Previous 
research on early stage financing indicates technological capabilities are important to 
raising capital (Gompers & Lerner, 2001; Kollmann & Kuckertz, 2009), so this is more 
supportive than novel. However, the findings from the present study add fresh insights to 
this by showing that technological knowledge in some cases helps firms attract alternative 
forms of investment. BA1 and BA2 used their technology to win government grants.  The 
reason the government awarded the firms the grants is because the firms‟ technologies 
showed promise to help solve a problem that the government wanted to address. 
 
Financial processes 
The fifth research question this study explored is „What processes are vital to creating 
R&D and financial resources and capabilities?’ 
 
The R&D of life science firms is costly. This makes raising capital a vital process for new 
technology-based firms (Colombo & Grilli, 2009). The results from the present study 
indicate that sensing and seizing funding opportunities are important processes. Several of 
the firms in this study relied on routines related to identifying, meeting and negotiating 
with investors. These routines allowed these firms to raise the capital they needed to 
pursue the development of their innovation. For DD1, DD2 and MD2 these routines 
consistently proved important, but all of the firms in this study, except MD1, developed 
routines related to sensing and seizing capital investment. The firms identified capital from 
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a number of sources; VCs, private investors, public stock markets and government grants.  
This study also supports that these processes are driven by one or two individuals from a 
firm. In all but one of the cases in this study the founder or founders drove this process and 
provided the primary inputs into sensing and seizing funding opportunities.  
 
A second suggestion from this study is that processes related to integrating and conserving 
financial resources are vital processes to life science ventures. Almost all of the firms ran 
into troubles forecasting the development costs of their R&D. DD1, for example, started to 
develop a new application for its technology, and it ended up costing much more than the 
firm originally budgeted for. Consequently, the firm went through its initial capital quicker 
than expected. Similarly, MD2 spent three times the anticipated amount on the 
development of their technology. At one point or another all of the firms ran into 
budgeting issues. For this reason it proved important for all of the firms to create routines 
for closely monitoring their spending. Whilst this is not a fresh finding, it is supportive of 
previous work that indicates budgeting is an important process for new ventures (Braden, 
1993; Freear & Wetzel, 1990). 
 
Closely related, this study finds that routines for conserving capital are vital to the 
financial endowments of the firms. The firms in this study were financially restrained, and 
for this reason all but one of the firms developed advanced systems for cutting costs. Some 
examples of these routines included finding the lowest cost inputs, developing partnerships 
to obtain low cost or free inputs and cutting out operations that were not essential.  It is 
evident from this study that strategic cost cutting is a capability that is vital to the financial 
picture of young life science firms. This finding is in line with previous work that has 
shown how cost cutting is essential to the financial strategies of young ventures (Auken, 
2005; Winborg & Landstrom, 2001). 
 
A third set of processes the present study found important relate to IPOs. DD1 and DD2 
went public on a US stock exchange. This was primarily motivated by a need for a 
substantial sum of capital that was the result of the development of costly innovations.  In 
order to go public, the firms engaged in a number of processes. First, the firms completed 
substantial amounts of legal paperwork with the SEC. The TMTs of these firms spent 
hundreds of hours working with their teams of lawyers to ensure everything was properly 
documented as well as meeting with publicists to promote the stock offering. This included 
meeting with reporters and attending SEC events. The firms also developed systems for 
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reporting their financial and operational issues to the SEC, which was a significant burden 
on the firms as it consumed a substantial amount of the TMTs‟ time. It also forced the 
firms to develop a compliance team to gather the information needed for the SEC.  
 
The findings related to the processes involved with the public stock offering are not new. 
Studies indicate that processes related to public offerings consume vast amounts of 
resources (Dona & David, 1997; Ibbotson, Sindelar, & Ritter, 1988; Poulsen & 
Stegemoller, 2008). In particular, firms invest massive amounts of time and resources in 
the filing and marketing of their stock offering. Research also suggests that the capital 
raised is often not worth the resources exerted (Aggarwal & Rivoli, 1991; Poulsen & 
Stegemoller, 2008). However, this research has not gone into great depth on this. The 
present study‟s findings extend this work by showing that the public offering is a resource 
drain that detracts from a firm‟s operations because of the tremendous amount of the 
TMTs‟ time that is consumed. From this the eighth proposition of the study is put forth: 
 
P8) IPOs consume valuable time from top management teams, and managers that 
spend less time on IPOs are better able to help their firms develop operational 
resources.  
 
As the discussion in this section indicates, the results widely support that firms rely on a 
combination of processes to create their financial resources and capabilities.  Processes 
relating to sensing, seizing, integrating and conserving capital proved important to all of 
the firms.  
 
7.3 The effect of R&D and financial assets and capabilities  
The second objective of this research is to examine the effect of R&D and financial 
resources and capabilities on the early growth of life science ventures. This study carefully 
investigated how these resources and capabilities formulate, and how these help firms in 
early growth. This section overviews the importance of R&D and financial resources and 
capabilities to early growth.  
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7.3.1 Effect of R&D resources and capabilities 
The sixth research question of this study from an R&D perspective looked at „How are 
R&D resources integral to life science ventures?’ 
 
Results from this study strongly indicate that R&D resources and capabilities are vital to 
the early growth of innovative life science ventures. These resources and capabilities 
provided a leverage point from which to attract and develop other resources. The R&D 
resources consisted of the firms‟ research facilities, patents, employees and networks. 
Whilst the firms‟ R&D capabilities consisted of their abilities to sense and seize 
opportunities, learn from previous research paths, network, integrate new resources into 
their research, and the capabilities of transforming their R&D resources. In sum, these 
resources and capabilities provided important competitive positions that allowed the young 
resource constrained firms examined in this study to compete in a high velocity industry; 
these can be viewed through the VRIN framework.  
 
First, R&D resources and capabilities are valuable. The results of this study definitively 
indicate that R&D resources and capabilities are of high worth. The R&D resources and 
capabilities of the firms in this study allowed the firms to develop products with high 
market values. This finding is supportive of the R&D literature, which indicates that most 
valuable new products and services are the result of R&D (Cassiman & Veugelers, 2006; 
Cohen & Levinthal, 1989; Sampson, 2007). Second, R&D resources and capabilities are 
rare. The R&D resources and capabilities of the firms in the present study are not readily 
available as they are closely linked to the particular skills and knowledge of individuals. 
Each of the firms possessed resources and competencies which few firms in the world 
possess. This is supportive of the R&D literature, which shows that advanced research 
abilities are rare (Liao, Wang, Chuang, Shih, & Liu, 2010; Pisano, 1990).  
 
Third, the R&D resources and capabilities of the firms in this study were imperfectly 
imitable. This is most apparent in the fact that all of the firms held multiple patents, and 
legally patents cannot be perfectly imitated (Markman, Espina, & Phan, 2004). Moreover, 
all of the firms held tacit research knowledge and processes that could not be imitated. 
Fourth, R&D resources and capabilities are non-substitutable. The firms in this study could 
not substitute their R&D resources and capabilities. The progression of the firms‟ 
technologies depended on their R&D resources and capabilities; there was nothing else 
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that the firms could use in place of these to develop the state of the art technologies that 
they were pursuing.  
 
It is apparent from the discussion in this section that R&D resources and capabilities are 
vital to the early development of life science ventures.  
 
Complementary assets 
The seventh and eighth questions of this study pertained to CAs: 7) Can R&D resources 
and capabilities serve as a CA? And 8) Can R&D resources and capabilities serve as 
SCAs? 
 
This study offers support of R&D resources as a category of CAs for life science ventures. 
Teece (1986) suggests that complementary technology is a category of CAs; i.e. 
technologies that go along with the core technology that a firm is attempting to 
commercialise. Similarly, Gans et al. (2002) suggest that the research resources needed to 
get through government approval is a category of CA. Moorman and Slotegraaf (1999) 
discuss product development capabilities and allude to R&D as a potential category of CA. 
Similarly, Lowe and Taylor (1998) allude to R&D as a CA, but do not explicitly call R&D 
a CA. The results from the present study support R&D as a unique category of CA. R&D is 
an auxiliary set of resources and capabilities that allows a firm to progress an innovation 
towards a state of commercialisation.   
 
The present study also found that R&D resources and capabilities can be viewed through a 
SCAs lens. SCAs are specialised auxiliary resources and capabilities that are needed to 
commercialise an innovation (Teece, 1986). An example of an SCA is service capabilities 
of a medical device firm. In many cases medical devices require specialised service 
capabilities to maintain the product, and if a firm is unable to service the device, then the 
device cannot be commercialised. These capabilities are such that they require 
sophisticated and often tacit knowledge that cannot easily be replicated. Several studies 
have noted R&D as a CA, but few of studies have explored whether R&D is an SCA. The 
present study extends this by examining whether R&D resources and capabilities can serve 
as SCAs. In general, the firms in the present study required auxiliary R&D resources and 
capabilities that were highly specialised. These were capabilities that few firms in the 
world possessed, and they were needed to get the firms‟ innovations to a point of 
commercialisation. 
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The discussion in this section indicates that R&D resources and capabilities can serve as a 
CA and SCA, and that these are important resources to the development of life science 
ventures. Thus proposition nine puts forth: 
 
P9) Life science ventures with advanced R&D complementary assets are more 
successful in brining their innvotations to market, as the R&D complementary assets 
allow them to progress their innovations to a point of commercialisation.  
 
This proposition is significant as R&D has been alluded to as a CA, but it has not been 
directly offered. Furthermore, R&D has not been viewed through an SCA‟s lens. The CA‟s 
model emerged to explain the auxiliary assets and capabilities needed in the 
commercialisation of an innovation (Taylor & Helfat, 2009; Teece, 1986). Thus this 
finding is significant, as it supports this model and extends it by fortifying R&D as a CA 
and it extending R&D as an SCA.  
 
7.3.2 Effect of financial resources and capabilities 
The sixth research question of this study from a financial prospective looked at „How are 
financial resources integral to life science ventures?’ 
 
Results from this study indicate that financial resources and capabilities are vital to life 
science ventures. The firms‟ financial resources consisted mainly of their capital reserves 
and access to financial networks, whilst the firms‟ financial capabilities consisted of their 
abilities to sense and seize funding opportunities, network with financiers, conserve capital 
and work with financiers. These capabilities led to specialised financing in the forms of 
VC investment, IPO, unique investment funds and government grants. This specialised 
financing provides important competitive positions that can be viewed through the VRIN 
framework (Barney, 1991). 
 
First, specialised finance is valuable. This study clearly indicated that specialised financing 
is a precious commodity that is paramount to a life science venture‟s early growth. Second, 
specialised financing is rare. Financing for life science ventures is hyper-competitive. 
There are three thousand young life-science firms in the U.S, and yet there are only a 
handful of VCs that specialise in life science investments (BIO, 2010). Furthermore, the 
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firms in this study are so specialised that there were only a handful of financiers that would 
consider investing in their technologies.  
 
Third, specialised finance is imperfectly imitable. Whilst, most of the firms in this study 
could have received the needed capital from other sources, the paths, positions and 
processes that the firms leveraged to develop the capabilities to get the financing are in-
imitable. Fourth, specialised financing is non-substitutable. Specialised financing proved 
absolutely critical to the growth of all of the firms. A couple of the firms reduced the 
amount of specialised financing they needed. For example, BA1 limited the capital needed 
because their abilities to outsource important functions to partners for a minimal capital 
outlay. However, BA1, as well as the other firms in this study, could not completely find a 
substitute for the specialised financing their technology demanded.  
 
It is apparent from the discussion in this section that financial resources and capabilities 
are vital to the early development of life science ventures. Financial capabilities create 
competencies that allowed the firms to secure the needed capital for the firms‟ 
development. In general, these competencies were a source of competitive advantage, as 
the case firms out competed scores of other firms for capital. Moreover, in some cases the 
financiers contributed more than just capital, which also fed into the competency base of 
the firms. These contributions are discussed in further detail in section 7.6.  
 
Complementary assets 
The seventh and eighth questions of this study pertained to CAs, (7) ‘Can financial 
resources and capabilities serve as a CA and (8) can financial resources and capabilities 
serve as a SCA?’ 
 
Early stage financing of high technology firms is well-researched (Colombo & Grilli, 
2009; Davila, Foster, & Gupta, 2003). However, no research of note looks at financial 
resources and capabilities through a CA‟s lens. Most of the research focuses on the 
processes of raising VC (Dimov & Milanov, 2010; Kollmann & Kuckertz, 2009) and the 
management contributions of the VCs (Gompers & Lerner, 2001; Gorman & Sahlman, 
1989). Although the extant research does not explicitly look at finance through a CA‟s 
lens, financing lends itself to being a CA. From a definitional standpoint, it is an auxiliary 
asset needed for the commercialisation of an innovation (Rothaermel, 2007; Teece, 1986; 
Trispas, 1997). Results from the present study support this idea by showing that financial 
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resources and capabilities are auxiliary resources and capabilities that complement other 
important assets. Some scholars may argue that finance is a core function, and therefore it 
is not a CA. But under this logic any category of CA offered in the literature could be 
considered as such. Furthermore, results from the present study suggest that financing for 
life science ventures is much more entailed than just being a source of capital. Certainly 
the capital is needed, but financing is much more encompassing than just being a proxy or 
a transactional tool. The capital is a generic asset, but capabilities in raising capital, 
working with specialised financiers and conserving capital was displayed by all of the 
firms in this study. 
 
In certain cases these financial capabilities are an SCA; they are specialised auxiliary 
resources and capabilities needed in the commercialisation of an innovation that cannot be 
easily developed or contracted for (Teece, 1986). For example, DD2 and MD2 developed 
an innovation and successfully brought it to market largely because of their specialised 
financial capabilities. Another example of specialised financial capabilities are BA1‟s 
capabilities to conserve capital and to operate on a lean budget. All of the firms displayed 
specialised financial capabilities that proved instrumental to advancing their innovations 
towards a state of commercialisation.  
 
The discussion in this section indicates that financial capabilities can serve as CAs and 
SCAs, which leads to the tenth proposition: 
 
P10) Firms that recognise the complementary and potentially specialised nature of 
finance and proactively manage these assets in relation to their R&D are more 
successful in brining their innovations to a point of commercialisation. 
 
This proposition is significant, as financial capabilities have not been viewed through a 
CA‟s lens. Thus this finding extends the CAs model by offering a new category. The 
purpose of the CAs model is to offer an analytical tool for examining the auxiliary assets 
and capabilities needed in the commercialisation of an innovation (Teece, 1986). Findings 
from this study indicate that by ignoring financial capabilities, the CA model is missing an 
important set of auxiliary capabilities that are important to the commercialisation of 
innovation.  
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7.4 R&D and financial interdependence 
This study was particularly interested the bilateral dependence of R&D and financial 
resources and capabilities. Questions 6a and 6b addressed this: 6a) How closely linked are 
R&D and financial resources and capabilities and 6b) Do R&D and financial resources 
co-evolve? 
 
The literature notes the interdependence of R&D and finance to the growth of NTBFs 
(Chakma & Sammut, 2011; Colombo & Grilli, 2009). However, it does not emphasize the 
interdependence of these in the development of life science ventures. From this study it 
emerged that there is a bilateral dependence between R&D and finance. This is supportive 
of the growth literature, which suggests that at or near inception developing a product and 
securing financing are the two main focuses of start-up technology firms (Delmar et al., 
2003; Kazanjian & Drazin, 1990).  
 
Results from the present study suggest that the core technology and R&D potential of the 
firm are instrumental in attracting specialised investment which comes primarily from 
specialised sources such as VC or grants; which concurs with other studies (Baum & 
Silverman, 2004; Colombo & Grilli, 2009; Timmons & Bygrave, 1986). The present 
study‟s findings underscore the fact that specialised investment is not easily raised and that 
unique capabilities lead to the acquisition of specialised investment. The specialised 
funding is paramount to developing a research infrastructure. Firms use the capital to hire a 
research staff, build research facilities, pay for testing and buy complementary 
technologies. In turn, these R&D resources and capabilities help develop a product which 
helps attract additional investment.  
 
The results from this study indicate that R&D and financial resources and capabilities are 
interconnected; i.e. financial paths and positions influence R&D paths and positions and 
vice versa. This is not a surprise as previous work has shown that finance is critical to the 
start-up of life science firms (Davila et al., 2003; Hellman & Puri, 2000), and work has 
also shown that R&D is the impetus to new technology-based firm growth (Autio, 1997; 
Gubeli & Doloreux, 2005). However, these studies have merely noted that financial 
resources and capabilities pay for R&D. The present study’s results indicate that R&D and 
financial resources and capabilities have paths, positions and processes that influence one 
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another and are inextricably linked. More specifically, the present study shows that 
financial resources are largely dependent R&D resources and vice versa.  
 
A detailed overview of this was discussed in chapter six, and Figure 7-2 below presents a 
simplified model of this. The model depicts that the core innovation that a firm pursues 
feeds into the R&D (1a) and financial (1b) resources and capabilities of the firm. The core 
innovation dictates how much development the innovation needs and how much capital is 
needed. In turn, the R&D and financial resources and capabilities feed into each other (2). 
The financial resources and capabilities fund the development of R&D, and developments 
in R&D attract additional funding. In turn, progressions in finance and R&D perpetuate the 
innovation towards a state of commercialisation (3a and 3b), and ultimately the 
progressions in the technology perpetuates the firm‟s growth (4).  
 
 
Figure 7-1: Model of R&D and financial interdependence 
 
Source: Author 
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As the discussion above indicates, this study found clear evidence that there is a strong bi-
lateral dependence between R&D and finance in life science ventures, and the co-
development of R&D and financial resources are critical to the early growth of life science 
ventures. From this proposition eleven is put forth: 
 
P11) There is a co-specialised relationship between R&D and financial resources 
and these co-evolve throughout the growth process of life science ventures, and 
firms that are adept at co-developing these resources are more successful in 
commercialising their innovations. 
 
7.5 Dynamic capabilities and RBV 
This study took a RBV influenced dynamic capabilities framework to look at the research 
questions, and in doing so the study made some important contributions to dynamic 
capabilities and the RBV. Most notably, it contributes to Helfat‟s (2009a) call for deep 
empirical work on dynamic capabilities. Accordingly, the theory is still in its nascent phase 
of development and needs deep work to extend it. One of the major contributions of the 
present study is showing an output of dynamic capabilities – R&D and financial resources 
and capabilities. Results from the study indicate that a life science firm‟s ability to 
reconfigure its resources and capabilities leads to the development of R&D and financial 
resources and capabilities. All of the firms in this study faced large resource constraints 
and competed against large established competitors, yet all these firms successfully 
developed and brought their innovations to a point of commercialisation. The analysis in 
chapter five underscored several dynamic capabilities that allowed the firms to develop the 
key resources needed to compete in such a competitive environment.  
 
All of the firms leveraged a unique set of paths, positions and processes to develop 
capabilities that resulted in the development of key resources. To represent this, Figure 7-2 
presents a dynamic capabilities framework of how the case firm BA1 developed its key 
R&D and financial resources.  
 
The firm was presented an opportunity to develop a novel device for analysing biological 
materials, which established the main course of the firm. A second path that profoundly 
affected the firm was the establishment of a key partnership with the U.S Army. This 
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relationship provided critical R&D and financial inputs that that influenced the 
development of the firm‟s key resources. The third major path that influenced the firm‟s 
strategic course was the decision not to take in equity invesement. This limited the scope 
and speed of the development of the firm‟s key resources, but it also allowed the firm to 
maintain flexibility, which allowed the firm to stay dynamic.  
 
The second box in Figure 7-2 depicts the three most important positions (resources) that 
BA1 leveraged in order to pursue its paths. The most prominent position was the founder. 
He directly contributed to the R&D and financial resources of the firm. From a financial 
standpoint, he invested his own capital in the firm, and from an R&D standpoint, his 
scientific knowledge and capabilities allowed the firm to progress their technology. He 
also indirectly contributed resources, in that his background helped attract inputs from 
other organisations. For example, the U.S Army contributed substantial scientific 
knowledge to BA1, and the reason the Army worked with BA1 is because of the 
longstanding relationship BA1‟s founder had with the Army‟s chief scientist. The second 
position that the firm leveraged was their network position. The firm was well networked 
and used this to obtain key inputs. The third position that the firm relied heavily on was 
their technology. Their unique device was of interest to several prominent organisations, 
and the firm leveraged this to obtain key inputs.  
 
The third box in Figure 7-2 shows that the firm developed and practiced several processes 
(routines) in order to maximise its paths and positions. One of the most important routines 
to BA1 was sensing and seizing opportunities. The central reason the firm successfully 
developed their device stemmed from their abilities to discover scientific opportunities. 
The founder established the firm based on three different sciences that he sensed out. Then 
on an ongoing basis the firm constantly sensed and seized science that helped in the 
development of their device. A second process that the firm relied on related to conserving 
resources. The financial and scientific capital available to BA1 was limited. For this 
reason, strategically using and conserving these resources was critical to the firm‟s 
development. Learning is a third process that proved important to BA1‟s ability to develop 
key resources. For example, the firm constantly learned from its earlier research. It also 
learned from its earlier financial decisions and interactions with partners. In turn, this 
learning greatly aided in the development of the firm‟s key resources. 
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The last box in Figure 7-2 shows the output of the firm‟s dynamic capabilities. From 
leveraging its paths and positions the firm created processes that led to important 
capabilities. In turn, these capabilities led to the development of advanced R&D and 
financial resources, which proved critical to the firm‟s ability to compete in an ultra 
competitive industry. More specifically, the firm developed patents, tacit and unique 
scientific knowledge, financial endowments, partnerships and a unique technology that 
allowed the firm to carve out a position in the market.   
 
Although the firms differed in their development, the case of BA1 described above is 
representative of how all of the firms in this study leveraged their dynamic capabilities to 
create the resources on which they competed. One of the biggest criticisms of dynamic 
capabilities is that it does not show what the outputs of dynamic capabilities are (Helfat, 
2009a). Thus one of the largest contributions of this study is showing that dynamic 
capabilities lead to the development of key resources. Furthermore, this study contributes 
to the dynamic capabilities literature by showing how firms develop and use their dynamic 
capabilities. This is also a significant contribution as few studies have holistically 
examined how firms do this (Arend and Bromiley, 2009).   
 
Figure 7-2: BA1's dynamic capabilities outputs 
Source: Author  
 
The findings from this study also weigh in on the on-going debate as to whether resources 
are still relevant to dynamic capabilities. Some scholars believe that there is little use for 
the RBV in dynamic capabilities (Arend & Bromiley, 2009), whilst others see resources as 
what firms use their dynamic capabilities to reconfigure (Helfat & Peteraf, 2003; 
Makadok, 2001; Teece, 2007). Makadok (2001) goes one step further by suggesting that 
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firms build competitive advantages from both their resource picking abilities and their 
capabilities to reconfigure their resources. Findings from the present study are supportive 
of this notion. All of the case firms displayed competencies in choosing innovations to 
commercialise and picking important complementary resources to further develop their 
innovations. Moreover, resources are clearly an important part of how the firms developed 
and used their dynamic capabilities. Chapter five presents strong evidence on numerous 
resources that proved vital to the development of the firms‟ R&D, but these resources only 
provided value because the firms used their capabilities to maximise the value of these 
resources. For example, specialised R&D facilities provided important resources to BA1 
and DD2, but these facilities only proved valuable to them because they were able to use 
their capabilities to integrate these resources into their R&D.  
 
Emprical support for dynamic capabilities 
In addition to the unique contributions related to dynamic capabilities, the results from this 
study reaffirm several dynamic capabilities that are offered in the literature. For example 
the study supports that learning is an important dynamic capability (Eisenhardt & Martin, 
2000; Winter, 2000; Zollo & Winter, 2002). The within-group analysis in chapter five 
presented ample evidence of the importance of learning to both R&D and finance and is 
substantiated as well by Tables 6-25 and 6-28 in chapter six. This study shows that 
learning allows firms to use their earlier R&D results to further the progress of their 
research. From a financial standpoint, findings from this study suggest that firms learn 
from their previous financing paths. These findings are consistent with earlier studies 
which suggest that learning is a higher level dynamic capability that allows firms adapt to 
rapidly changing environments (Easterby Smith & Prieto, 2008; Verona & Ravasi, 2003; 
Zollo & Winter, 2002).   
 
This study also offers support to sensing and seizing as a dynamic capability. Accordingly, 
all of the firms in this study were heavily reliant on their ability to find and take advantage 
of research and financing opportunities. The firms‟ processes for sensing and taking 
advantage of these opportunities were paramount to the firms‟ growth. These findings 
reaffirm work done by Herreld et al. (1997), which shows sensing and seizing are key 
capabilities in rapidly changing environments. The third dynamic capability that the 
present study’s findings embrace is R&D. Based on case studies of petroleum firms, Helfat 
(1997) suggests that R&D is a dynamic capability that firms use to change their product or 
operations to make to enhance their competitive positions. Findings from the present study 
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unequivocally support this, as all of the case firms used advanced R&D capabilities to 
create new products and/or to advance existing products –ultimately improving the firms‟ 
competitive positions. Table 6-26 and 5-27 from chapter five highlight the unique R&D 
resources and capabilities that allowed the firms to develop a novel life science innovation.  
 
A fourth dynamic capability that this study supports is transformational capabilities. All of 
the firms in this study displayed transformational capabilities. Almost all of the firms had 
situations influenced by outside events or internal breakthroughs that forced the firms to 
transform their operations. For example, DD1‟s drug did not progress quickly, which 
forced the firm to transform its R&D to focus on the development of a diagnostic device. 
Several of the firms also encountered events that forced them to reconfigure their financial 
resources. For example, BA2 won a large grant that changed their financial trajectory. This 
grant forced the firm to reorganise its financial resources and priorities. The support of 
transformational capabilities is a notable contribution as the theory of dynamic capabilities 
is based on the central tenet that firms that rearrange their resources and capabilities in 
response to changing conditions perform better (Rindova & Kotha, 2001; Teece et al., 
1997; Winter, 2003). However, little empirical work directly supports this; the results from 
the present study give insights into how and why young life science ventures reconfigure 
their R&D and financial resources. These results also support the idea that strategic 
decisions are triggered by events, and that firms must be able to alter their strategies to 
respond to these events (Canales and Villa, 2005).  
 
7.6 VC and government grants 
This study also produced findings related to VC and government grants. VC is highly 
influential on life science firms (Baum & Silverman, 2004). For this reason, and also 
because of the researcher‟s interest in VC, this study incorporated the influence of VC on 
the development of capabilities and resources in life science ventures. In a similar fashion, 
findings relating to grant-backed firms also emerged as three of the case firms received 
sizable government grants. Although VC and grants are not the central focus of this study, 
some important findings from the study related to these areas surfaced. This section details 
these findings. 
 
For all of the firms in this study that received VC, it provided essential capital, and in most 
of the cases important management inputs. However, all of the VC backed firms, 
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unsolicited, offered an in-depth description of their desire to avoid VC in the future. This is 
mainly because of the founders‟ dilution of equity that happens when VCs invest in a 
company. It is not just the dilution in equity that causes concern, but also the loss of 
control. Once the firms dilute beyond a certain point, they lose control of their overall 
operations. MD2 ran into this problem, and because of it, one of the research projects that 
the founders thought had great potential was discontinued because the VCs wanted to stop 
it, and the VCs had gained enough control to do so. These findings are consistent with 
previous studies, which show that VCs often take large amounts of equity (Hsu, 2004; 
Sahlman, 1990) and that conflicts often arise because of the founders‟ dilution (Berglof, 
1994; Hellmann & Puri, 2002).  
 
Interestingly, BA1, DD1 and MD2‟s CEOs –-without prompting– referred to VC as „a 
necessary evil‟. Similarly, four executives from four different firms (BA1, DD1, MD1 and 
MD2) discussed in detail how the VC model is „broken‟. They specifically pointed to the 
dilution of equity and the amount of resources consumed in attracting VC and dealing with 
the VCs.  
 
Another interesting finding relating to VC that this study gleaned is the impact the 
recession that started in 2008 had on the funding for life science ventures. The recession 
caused clear funding obstacles for the firms in this study. Four of the firms without 
prompting went into detail on how VC for life science ventures „dried up‟. Furthermore, 
the same firms discussed how the recession has fundamentally changed the funding model 
of VCs. They suggested that VCs are no longer interested in financing early stage ventures, 
and VCs would only invest in later stage firms. The impact of this did have a bearing on 
this research as it affected the financial paths of the firms in this study. The research did 
not go into great depth on how the VC model has changed, but the findings are worth 
noting and may be used for future studies examining the impact of the recession on the 
funding of life science ventures.  
 
In order to avoid the drawbacks of the traditional VC funding model, two of the firms 
followed alternative financing paths. BA1 and BA2 financed their early growth through 
personal funds and then received a considerable amount of financing from small business 
innovation research (SBIR) grants. They both received close to a million dollars through 
these grants, which provided the bulk of the financing needed to get the firms to a point of 
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commercialisation. These grants required no equity from the firms and allowed the 
founders to keep the decision-making powers in the firm.  
 
Overall the strategy of avoiding VC worked well for BA1 and BA2. This is consistent with 
the previous research, which suggests that grant-funded firms display superior performance 
in comparison to VC backed firms (Gans & Stern, 2003; Lerner, 1996). What the literature 
does not show is why SBIR firms demonstrate superior performance. Lerner (1996) 
conjectures this may because of the intense competition for the grants, which results in 
only the very best firms getting them. The results from the present study suggest that grant-
backed firms acquire the capital they need, but do not have to contend with the 
inefficiencies created by outside investors.  
 
This section underscores the study‟s finding relating to the recent changes and challenges 
that life science ventures face in financing their development. From this discussion the 
following propositions is set forth: 
 
P12) Grant-backed firms‟ superior performance compared to VC backed firms is a 
result of the grant backed firms not having outside investors creating inefficiencies 
that stifle development.  
 
7.7 Implications for practitioners and policy makers 
The discussions above underscore the findings in relation to the context of life science 
ventures and the key theories that this study draws on. This section goes into more depth 
on the findings from a practical standpoint; more specifically, it provides insights that 
managers of life science ventures can use in their quest to develop R&D and financial 
resources and capabilities. Following Starkey and Madan‟s (2001) argument that academic 
research in management needs to have a connection with the practice of it, the present 
study was designed to have implications for scholars, practitioners and policy makers. This 
study makes several unique contributions to the practical base of knowledge.  
 
First, the findings underscore the importance of examining the paths, positions and 
processes available to develop key resources and capabilities. From this strategies can be 
set forth to position a firm. Closely related, this study also supports the valuable, rare, 
imperfectly-imitable and non-substitutable (VRIN) framework as an analytical tool for life 
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science managers to use when evaluating resources. Managers must analyse the resources 
required for their firms and gauge whether or not the resources can serve as a source of 
competitive advantage. Analysing whether or not each resource is valuable, rare, and 
imperfectly imitable and non-substitutable will determine it. Once key resources and 
capabilities are identified, it is then important for firms to examine the options for 
developing the resources they need: what paths are available to the firm? What positions 
does the firm have to leverage in these paths? What processes is the firm skilled in and 
what processes could they create? For example, MD1 identified several unique options for 
developing their spinal technology and carefully evaluated the possible outcomes of the 
paths available to the firm. From this analysis the firm made the strategic choice to self-
finance and self-develop their device, and these choices has allowed the firm to maintain 
organisational flexibility whilst still developing a state of the art device.  
 
Second, findings from the present study emphasise the importance of partnerships in life 
science ventures. The R&D literature underscores the importance of partnerships in the 
development of novel innovations (Blumenthal et al., 1986; Calabrese & Silverman, 2000; 
Coombs & Deeds, 2000). However, it has largely been neglected from a start-up firm point 
of view and has failed to offer prescriptive insights for practitioners. The present study 
isolates the importance of partners from a life science venture‟s perspective. The results 
indicate that managers must become proficient in sensing partners and developing routines 
to work with their partners. A major catalyst to the development of the firms in this study 
was their ability to find partners that were a good strategic fit; i.e. partners that offered 
needed inputs and were amicable to work with. For example, BA1‟s partnership with the 
US government is the central reason that the firm successfully developed a leading edge 
instrument for identifying diseases. Another prime example of the importance of partners 
is the importance of BA2‟s partnership with a top university. This university provided 
scientific inputs that proved vital to the development of their chiral drug technology. The 
findings from this study also suggest that that scholarly journals and conferences provide a 
means to find and vet potential partners. In addition, this study also indicates that partners 
are often inhibitive to growth. In short, this study reinforces the alliance literature, which 
shows there are both positives and negatives with partnerships (Cassiman & Veugelers, 
2006; Sampson, 2007). Consequently, it is important for managers to carefully sense and 
evaluate potential partners.  
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Third, firms should analyse at what point in development specific resources and 
capabilities will become critical. Several of the firms from this study did not properly 
estimate the timing and the amount of financing they would need. This delayed their 
entrance into the commercialisation phase and caused a bottleneck in the firms‟ growth. 
For example, MD2 did not properly time its funding rounds, which forced the firm to 
abruptly stop three important projects that they had started because they had not brought in 
enough capital. In general, the study shows that the proper timing of the development or 
acquisition of resources allows firms to avoid many troubles.  
 
Fourth, this thesis underscores the importance of international paths. DD1 and MD2 
greatly expedited the commercialisation of their products because they first put them 
through European approvals. This proved much more efficient and cost effective then FDA 
approval. BA1, BA2 and MD1 also greatly aided their early growth by actively marketing 
their products overseas. The overseas revenues greatly helped the firms finance their 
growth.  
 
Fifth, this study‟s findings suggest new ventures should explore all financing options 
before committing to a VC path. Although the results of this study are supportive of the 
literature that indicates VC is often needed for life science ventures because of the high 
degree of risk (Baum & Silverman, 2004; Colombo & Grilli, 2009), the results also suggest 
that alternative routes of financing are available. As discussed in the literature 
implications, two of the case firms acquired financing from alternative sources; whereas, 
the other four firms did not even consider alternative paths. There might not have been any 
other paths available for the firms that did not pursue alternative financial paths, but the 
results of the study imply that it is not difficult or time consuming to look for them. For 
example, one particular source that many firms often do not consider is government grants. 
 
Policy implications 
On top of the management implications, this study also provides insights for policy 
makers. For starters, it adds to Lerner‟s (1996) findings that SBIR grants are effective in 
developing innovative firms. The present study adds to this by showing not only do these 
grants offer the needed capital for firms to develop, but these grants also offer an 
alternative to equity financing. This helps firms by affording them the capital they need, 
but without the drawbacks of equity financing. BA1 and BA2 were greatly aided by 
government grants, and for these firms the grants proved highly effective. The grants are 
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the central reason that BA1 commercialised its technology, resulting in the creation of jobs 
and the delivery of a technology that benefited society.  
 
Another policy implication from this study is that governments from around the world 
need to better coordinate and standardise testing and development procedures for life 
science innovations. The literature notes this (Giovannetti, 2010; Martínez-Torres & Toral, 
2010), but it does not provide prescriptive advice on how governments can work together 
to alleviate this problem. Moreover, Bio and several other large life science trade 
associations are lobbying for increased standardisation amongst governments across the 
world, but little movement has been made towards this (Bio, 2009). The present study 
suggests that the lack of standardisation is slowing the dissemination of innovation. This is 
hurting the firms that create innovations because these firms are required to expend extra 
resources in duplicating processes and procedures in order to obtain foreign market 
approvals. Moreover, this is greatly hurting the proclivity of internationalisation because 
often small life science firms do not have the resources to duplicate the entry procedures 
required in different foreign markets. Most of the case firms in this study focused mainly 
on one market because of the extra resources and time required to obtain approval for 
multiple markets. What is worse is people from all around the world are being barred from 
technologies that could help cure disease. 
 
In short, the negative effect of this on life science firms was evident in most of the case 
firms in this study, as most of them desired to more rapidly enter foreign markets, but 
refrained largely because of the extra regulatory steps needed to enter them. Biotech policy 
makers need to find ways to increase the globalisation of biotech innovations, whilst still 
protecting their citizens from harmful technologies. This is being worked on (BIO, 2009), 
and is a tall order, but one that should receive even further attention.  
 
7.8 Shortcomings 
Management is a complex topic made up of many actors and outside factors. It is nearly 
impossible to properly examine all of these in a single study (Easterby-Smith et al., 2002), 
and for this reason almost all studies in management are flawed to some extent – the 
present study is no exception. The most glaring shortcoming of this study is that it relied 
on a small subset of life science firms. The life science industry is fundamentally different 
than most other industries – even other technology based industries (Owen-Smith et al., 
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2002b; Powell et al., 2002). Life science innovations take years to develop, and there is 
much more regulation in life science than there is for most other industries, which further 
slows the commercialisation of innovation (Murray and Wolfson, 2010). The fact that this 
study used life science firms raises questions on the generalisability of the findings. 
However, this was factored into the study design as the questions and analysis were 
carefully crafted to provide both practical and theoretical implications. Furthermore, even 
if future research finds that the present study‟s results are only applicable to life science 
firms, then the findings will still make an impact, as the industry is a major and important 
part of the global economy. Moreover, the author has a practical background working with 
life science firms and the main motivation of this study was to help managers of life 
science firms better understand the key resources and capabilities needed in early growth. 
 
Properly planned and executed qualitative research is valid, needed and important (Yin, 
2008). However, qualitative research is always scrutinized for validity, and many 
quantitative purists will fault qualitative work without cause (Johnson & Onwuegbuzie, 
2004). Consequently, it is important to reiterate that the approach taken in the present 
study was appropriate and properly executed. First, the theoretical constructs of the 
relevant theories were clearly not well developed; therefore, these theories needed 
qualitative work to extend them (Edmondson & McManus, 2007). Second, the study was 
properly designed and executed to minimise the impact of researcher bias and to establish 
trustworthiness in the findings. The six firms used in this study is an ideal number for case 
research (Eisenhardt, 1989a). Furthermore, a substantial amount of data was collected and 
the study was triangulated through multiple techniques (Yin, 2008). One shortcoming that 
arose from the high volume of data that the study generated is that some of its richness was 
lost in the presentation. Another shortcoming that arose from the data is that there was only 
one researcher who analysed it. Subject experts reviewed several important sections of the 
data, but given the researcher‟s constraints, it was not possible to have another researcher 
analyse all of the data.  
 
Another potential shortcoming of this study stems from the theoretical framework used. 
Even for qualitative work, dynamic capabilities presents many challenges because of its 
lack of theoretical development (Helfat & Peteraf, 2009). Potential problems arose with the 
present study because the study‟s framework is based on a relatively undeveloped theory. 
However, the multiple theoretical inputs used to design and analyse this research 
minimised this problem; i.e. the RBV provided a means of theoretical triangulation.  
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A third potential problem emanated from the study‟s holistic approach to examining the 
development of R&D and financial resources and capabilities. Developing resources and 
capabilities is a complex phenomenon that evolves over time, and it is difficult to capture 
in a single study. Notwithstanding, scholars contend that it is possible to isolate process-
based phenomenon over time in a single study – if the study is properly executed and 
factors in the element of time (Pettigrew, 1992). The present study followed this advice 
and longitudinally examined the development of R&D and financial resources and 
capabilities.   
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7.9 Recommendations for future research 
This study put forth a number of findings relating to the development of R&D and 
financial resources and capabilities. There are opportunities for future research to both 
qualitatively and quantitatively extend the present study‟s findings in several ways. For 
example, a study is already underway to develop measurable constructs on how to gauge 
the background of a standout scientist.  
 
This research found that inward and outward international activity contributes to the 
development of R&D and financial resources and capabilities. Work is underway using the 
present study‟s findings to create measurable constructs to quantify the importance of 
international activity. The findings here provide a good basis for this, but there still 
opportunity to unearth deeper insights on these triggers.  
 
Another major finding from this study is that the traditional VC financing model used by 
many life science firms is inherently flawed. VC is critical because it provides the capital 
needed for high risk ventures to grow (Chakma & Sammut, 2011; Gans & Stern, 2003; 
Timmons & Bygrave, 1986), and VCs in most instances offer non-financial value from 
their management inputs (Hsu, 2004; Unger et al., 2010), but VC financing also has its 
drawbacks (Kortum & Lerner, 2000). The present study unearthed the idea that the VC 
model is broken, which presents an opportunity to go into more depth as to if and why this 
is through qualitative interviews. Similarly, the findings suggest that there are funding 
models for high technology ventures that are superior to the traditional VC model. There is 
a developed literature on angel investors, but little research has looked at grants as a source 
for funding life science ventures. Lerner (1996) is one of the few noted studies on this 
topic, but this study simply compares performance of grant- backed firms against VC-
backed firms. Findings from the present study suggest there are other reasons as to why 
grant-backed firms perform better, namely that grant-backed firms avoid the drawbacks of 
equity investors. There is ample room for future work to go into more depth on this, and 
also to look for other reasons for this difference.  
  
287 
 
7.10 Summary and final conclusions 
The author is a partner in a life science-related venture, and this research was spurred by a 
desire to unearth deeper insights on the development of key resources and capabilities 
needed in their early growth. Initially the study looked at the effect of internationalisation 
and VC on the development of key assets in life science ventures. The exploratory 
interviews and initial literature revealed a more relevant question: What influence do R&D 
and financial resources and capabilities have on the early growth of life science ventures? 
A further look into the life science literature revealed several gaps related to this question; 
most notably, little investigates how R&D and financial resources and capabilities are 
formulated and how these resources and capabilities affect the early growth of life science 
ventures. This motivated the author to holistically examine the R&D and financial 
resources and capabilities needed in the early growth of life science firms. 
 
This study unearthed several unique insights on the development of R&D and financial 
resources and capabilities. This study was especially interested in life science firms, which 
are firms that are in turbulent environments and are driven by innovation (Azzone & Dalla 
Pozza, 2003; Bergeron & Chan, 2004). Despite the fact these firms are in such dynamic 
environments, few studies have examined them through a dynamic capabilities lens. Life 
science firms are technology-based, highly dynamic and important to the global economy. 
For these reasons and because the researcher was interested in the industry, life science 
firms served as the focus. 
 
The research influences and the fact that this study drew on a relatively undeveloped 
theory made a qualitative research approach appropriate (Edmondson & McManus, 2007). 
Case studies have gained credibility in the field of management (Eisenhardt, 1989a; Yin, 
1981, 2008). For this reason and the flexibility that case studies offer, this study implored a 
case method. Six case firms were carefully selected, and the data for the firms came from 
multiple rounds of interviews with multiple key informants and a considerable amount of 
secondary data. The research started with a broad interest on resources and capabilities and 
honed down the resources and capabilities that emerged as important. The multiple rounds 
of interviews allowed more specific questions to be designed from the earlier round of 
interviews, which allowed the study to further hone down on the key themes. The analysis 
began with a multiple step process of abstracting themes. From this the categories of 
themes emerged that provided the structure for the analysis. The firms were categorised 
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into three groups and a within-case, cross-group and cross-case analysis was performed. 
Following Maitlis and Lawerence (2007), a systematic trail of evidence supported the 
findings. Although the methods are not highly unique, what is unique is the massive 
amounts of data that this study collected and analysed. The study yielded over 500 pages 
of transcripts and over 3000 pages of secondary data. What is also unique is the depth of 
analysis for the relatively large number of case firms and massive amount of data that the 
study drew on. Another interesting aspect of the research is the unique questionnaire that 
the study used to triangulate and validate the findings.  
 
This thesis examined the resource and capability development of life science ventures. It 
was particularly interested in R&D and financial resources and capabilities; what they are, 
how they are determined and deployed by firms towards competitive advantage. Table 7-1 
presents the unique contributions of this study. These are contributions that offer 
something materially different from what is already offered in the literature, and advance 
the body of knowledge on the research topics. Clearly the study produced significant 
insights on the research topics.  
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Table 7-1: Study's propositions 
P1) Firms that have a narrower scope of R&D focus are more successful in 
commercialising their innovations because they are better able to attain the core resources 
and capabilities needed to develop their innovations.  
 
P2)  Life Science ventures that publish in scholarly journals and attend conferences are 
better able to identify complementary technologies and assess the capabilities of potential 
partners.  
 
P3) Life Science ventures that internationalise are motivated to do so to avoid FDA 
regulatory bureaucracy, and this is forcing firms to develop resources and capabilities for 
operating in international markets. 
 
P4) Firms that employ one or more standout scientist are better able to develop R&D 
resources because of the standout scientist(s) R&D capabilities and scientific contributions. 
 
P5) Life science ventures that attempt to develop several innovations simultaneously 
develop slowly and risk failure as they create large financial requirements. 
 
P6) Firms that self-finance their growth will have significantly different financial 
trajectories than firms that pursue equity investors, as they will have less capital available, 
but will maintain greater organisational flexibility.   
 
P7) Inexperienced founders are more likely to self-finance their venture‟s early growth, as 
opposed to experienced founders who use their background to secure financial resources 
from outside sources.  
 
P8) IPOs consume valuable time from top management teams, and managers that spend less 
time on IPOs are better able to help their firms develop operational resources.  
 
P9) Life science ventures with advanced R&D complementary assets are more successful in 
bringing their innovations to market, as the R&D complementary assets allow them to 
progress their innovations to a point of commercialisation. 
 
P10) Firms that recognise the complementary and potentially specialised nature of finance 
and proactively manage these assets in relation to their R&D are more successful in 
bringing their innovations to a point of commercialisation. 
 
P11) There is a co-specialised relationship between R&D and financial resources and these 
co-evolve throughout the growth process of life science ventures, and firms that are adept at 
co-developing these resources are more successful in commercialising their innovations. 
 
P12) Grant-backed firms‟ superior performance compared to VC backed firms is a result of 
the grant backed firms not having outside investors creating inefficiencies that stifle 
development.  
 
Source: Author 
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In conclusion, this study makes a number of incremental but important contributions to the 
practice and scholarship of management. First, it unearths key paths, positions and 
processes that lead to the development of R&D and financial resources and capabilities. 
Second, it offers insights on the influence of R&D and financial resources and capabilities 
in the early growth of life science ventures. Third, it offers empirical support to the 
dynamic capabilities framework (i.e. the paths, positions and processes framework). This 
framework can serve as it did in this study to further the examination of the development 
of key resources, but it can also be adapted for more general uses for strategic 
management. Put differently, results from this study contribute to the resurgence of the 
dynamic capabilities framework and offer a base for other studies to use in the examination 
of dynamic capabilities. Fourth, this study at least partially answers Helfat‟s (2009) call for 
deep empirical research to examine what the outputs of dynamic capabilities are. The 
present study examined what Teece (2007) sees as one of the most important outputs of 
dynamic capabilities, the development of key assets. Specifically this study looked at the 
paths, positions and processes leading to the development of R&D and financial resources 
and capabilities. Fifth, this study gives rise to the idea that the VC funding model is 
flawed.  
 
This thesis provides a platform for a research career. Two papers have already been 
published from this thesis: the first presents the results from exploratory interviews on the 
influences on the development of resources and capabilities, and the second is on the 
important resources that serve as the antecedents to dynamic capabilities. Another paper 
that stems from the present study reviews and reconceptualises dynamic capabilities based 
on the extant literature and the findings from the present study. Several top scholars have 
reviewed the paper, and it is under revision for one of the top journals in management. In 
addition, several other papers will soon be written based on this thesis. For example, one 
paper will present the empirical findings on the paths, positions and processes that lead to 
the development of R&D and financial resources and capabilities. These are the papers 
slated in the near-term. There are opportunities for many more papers to emanate from this 
thesis in the long-term.  
 
The life science industry is an important part of the global economy. Innovations from the 
industry have been the main force that has increased the average life expectancy of a 
person living in the U.S from sixty-six in 1950 to seventy-eight in 2008 (Bio, 2009). 
Moreover, innovations in the industry produce over $80 billion in revenue per year. Small 
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firms are germane to this innovation, as it is estimated that forty per cent of innovation 
emanates from firms that employ fewer than 250 (Van Beuzekom and Arundel, 2009). 
Despite the importance of small firms, little is known on how small resource constrained 
firms develop the R&D and financial resources and capabilities to develop financially and 
scientifically capitally intensive innovations. This study makes considerable contributions 
to filling this gap. 
 
In short, this is a rigorous, well planned and executed study that provides great depth on 
the R&D and financial resources and capabilities germane to the early growth of life 
sciences ventures. It makes several unique contributions to the scholarship and practice of 
management. 
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Appendix A: Data Reduction Tables 
Table A1: Level 1 data summary 
PRIORI THEMES  
Founder‟s experience  (Toole & Czarnitzki, 2009) 
Founder‟s education  (Toole & Czarnitzki, 2009) 
Industry alliances (Audretsch, 2001; Rothaermel, 2001) 
University alliances (Anselin, Varga, & Acs, 1997; Gubeli & Doloreux, 2005) 
Government alliances (Giesecke, 2000) 
VC monitoring activities (P. A. Gompers, 1995) 
VC inputs (P. Gompers & Lerner, 2001) 
International inputs (Athreye & Godley, 2009; Welch & Luostarinen, 1993) 
International markets (Andersson & Wictor, 2003) 
R&D capabilities (Tripsas & Gavetti, 2000) 
Complementary technologies (A. Arora & Gambardella, 1990; Teece, 2007) 
Sensing and seizing technological opportunities (Teece, 2007) 
Distribution assets and capabilities (Trispas, 1997) 
Service assets and capabilities (Teece, 1986)  
Intellectual property (A. M. Arora & Ceccagnoli, 2006; Trajtenberg, 1990) 
R&D facilities (Pisano, 1990)  
Production assets (Schmenner, 2009) 
INDUCTIVE THEMES  
Unique technology  
Industry developments  
FDA  approval  
Pursuit of patents influences development 
Failed R&D projects 
Raising capital is necessary 
Raising capital consumes time and resources 
Core technology is vital to raising capital 
Integrating resources is vital 
Raising VC wastes time and energy 
TMTs waste time with VC 
The VC model is broken 
Source: Author 
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Table A2: Level 2 data repackaging 
R&D   Founder‟s experience 
 Founder‟s education 
 Industry alliances 
 University alliances 
 Government alliances 
 International inputs 
 International markets 
 R&D capabilities 
 Complementary technologies 
 Sensing and seizing technological 
opportunities 
 Intellectual property resources 
 R&D facilities 
 
Financial  Founder‟s experience 
 Founder‟s education 
 Industry alliances 
 Government alliances 
 VC inputs 
 FDA  approval 
 Raising capital is necessary 
 Raising capital consumes time and 
resources 
 Core technology is vital to raising 
capital 
 Integrating resources is vital 
VC model is flawed  VCs do not want to invest in early stage 
firms 
 TMTs waste time with VC 
 Raising VC wastes time and energy 
Source: Author 
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Table A3: Level 3 data structure and framework 
Metathemes Emergent Themes 
R&D paths   Unique technology  
 Partnership opportunities 
 Gaining FDA approval 
 Complementary technologies 
 Scientific developments 
 
 
R&D positions  Core technology 
 Patents 
 Scientists 
 Star scientists 
 Founders 
 Networks 
 Research facilities 
 
R&D processes  Seizing scientific opportunities 
 Learning from earlier research 
 Navigating government approval 
 Developing scientific partnerships 
 Transforming R&D 
Financial paths  Core technology made specialised 
financing necessary 
 Obtaining capital is resource 
consuming 
 VC 
 IPO 
 Revenue generation 
Financial positions  The core technology 
 Scientific staff  
 Founders 
 TMTs 
 Government resources 
Financial processes  Sensing financing opportunities 
 Integrating financial resources 
 Budgeting financial resources 
 IPO related processes 
 Dealing with investors 
Source: Author 
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Appendix B: Interview Schedule I 
 
 
 
Preliminary Research on 
Resources, Dynamic Capabilities 
and the Role of Venture Capital in 
Life Science Firms 
 
Professor Marian V Jones 
Jon Carrick 
 
 
 
 
 
 
 
 
 
  
Instructions to Interviewers 
Fill in one booklet per firm (or per interviewee). 
The interview should follow the format of open questions, answered 
in the respondent‟s own words; followed by closed, checklist 
questions. 
1. Write the answers to the open questions as told by the 
respondent, use as much space as necessary. 
2. Follow each section of open questions immediately with the 
corresponding closed questions in order to verify the 
respondent‟s story. 
3. Ask the closed questions precisely and enter the answers in 
the spaces provided 
4. Once the form is completed, ask the respondent to elaborate 
on any issues that have emerged during the interview that 
they think are of particular importance to the future 
development of their firm 
Time: 
Date: 
Interviewer 1: 
Interviewer 2: 
Company Name: 
Address: 
 
 
Telephone:   e-mail 
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Section A. Open Questions: The Firm’s current position 
Q. Please tell us about this firm. In your own words please describe your firm, the 
business it does, the nature of its products, its role within the industry and its 
competitiveness in domestic and any foreign markets. 
Prompts (for guidance) Please allow the respondent to answer in their own way, and 
record their responses in their own words 
 Business, products 
and manufacturing 
or production 
processes 
 
 Firms‟ role in its 
industry (identify the 
industry). 
 
 Suppliers, buyers, 
new entrants, 
substitute products, 
concentration. Your 
position on the 
industry value chain 
 
 Customers / 
domestic market, 
who, where? 
 
 Competitive 
position, market 
share, unique niche, 
etc. source of 
competitive 
advantage in 
domestic market 
 
 Describe your firms 
overseas markets, 
where are they, how 
many are they, what 
do you sell there, 
what is your source 
of competitive 
advantage there? 
 
 
Continue on reverse if necessary 
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 Section A. Closed Questions: The Firm’s current position  
(Please ask questions and record answers precisely in this section.) 
 
A1. Business and Products 
 
1.1 Would you classify your firm primarily as: 1. a manufacturing firm ______ 2. a firm 
producing services ______ 3. an R&D laboratory_________ or 4. other, please 
describe_______________________? (tick one) 
 
1.2 What percentage of your firm‟s annual income comes from: 1. Sale of hardware 
products________ %, 2. Sale of software products__________ %, 3. Sale of 
services_________ %, 4. Research grants_________ %, 5. Other _____________% 
(check total = 100%) 
 
1.3 What proportion of your firm‟s annual income comes from: 1. Business activities/ 
sources in the UK ________%, 2. Business activities / sources overseas 
___________ % ? (check total = 100%) 
 
1.4 What is your major product? 
____________________________________________________________________
______ ? 
 
1.5  Is your major product sold to: 1. consumer markets _________ , 2. organisational 
markets ________ 3. both _________ ? 
 
1.6 Would you describe your product as: (tick all that apply) 
 
 Having a narrow range of applications within one or a few industries / 
markets______________  
 Having a wide range of industry applications across a number of industries / 
markets_________________ 
 Specific to a target group of customers with particular needs_______________ 
 A niche product with local applicability (UK 
only)_________________________ 
 A niche product with global applicability (foreign markets) 
__________________ 
 General to a wide range of industries / markets in UK and abroad 
______________ 
 
1.7 Would you describe your major product as: (tick one only) 
 Innovative, leading edge technology ___________________________ 
 An incremental innovation of relatively new technology_______________ 
 Other, please describe 
________________________________________________________________
________________________________________________________________
________________________________________________________________
____________________________________ 
 
1.7 Do you have a portfolio of products? 1. Yes __________, 2. No __________? (tick 
one) 
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1.8 Could any of your products be described as a Cash Cow? 1. Yes ____ 2. No ____ 3. 
Might be in the future _______ ? 
 
A2. Industry Structure 
 
2.1 Approximately how many direct competitors do you have in the US _________ ? 
 
2.2 Are your main competitors large firms ____________, or small firms 
_____________? 
 
2.3 If you have few competitors, can you identify them by name? 
______________________________________________? 
 
2.4 If you have few competitors, are these firms US owned _________________, foreign 
owned ___________, both ______ ? 
 
2.5 How unique is your product or service ______________________________ ? 
 
2.6 How important is your product e.g. could customers use something else in its place 
_____________? What _____________________________ ? 
 
A3. Competitive Advantage 
3.1 Please describe the source of your firm‟s competitive advantage in the US? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
___ 
 
 
3.2 Please describe the source of your firm‟s competitive advantage in its overseas 
markets if any? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________ 
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Section B. Open Questions: The Firm’s Foundation Process 
 
Q. In your own words, please describe how your firm was founded, who was involved, 
how it was supported, why it was founded and the aspirations, aims and objectives of the 
founding members. 
Prompts (for guidance) Please allow the respondent to answer in their own 
way, and record their responses in their own words 
 Was there a particular reason for 
its foundation eg to exploit a new 
technology or innovation, or 
other? 
 
 Is there any pre-foundation 
history that influenced the 
establishment of this firm eg spin-
out or spin-off, MBO etc.? 
Reasons? Opportunities or 
threats? 
 
 Who were the founders, describe, 
them, what role did they play in 
founding, what role do they play 
now? 
 
 What international connections 
did the firm, or its founders have 
at foundation? What 
role/contribution have these made 
to the growth of the firm (in 
general internationally). 
 
 How was the firm resourced at 
foundation (financial, physical 
resources, human resources)? 
Where did the resources come 
from, how did the firm go about 
getting them? 
 
 Where there any important 
university connections? 
 
 Were there any important industry 
partnerships?  
 
 Did the firm use Venture Capital 
in the foundation process? What 
were the main motivations for 
using VC?  
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 Section B. Closed Questions: The Firm’s Foundation Process 
(Please ask questions and record answers precisely in this section.) 
 
1. In what year was the firm founded? ________________ 
2. a) Was the firm founded specifically to develop a scientific/technological 
innovation? 
 Yes______________(go to 2.1) 
 b) Since founding, has your firm developed a scientific / technological innovation? 
 Yes______________(go to 2.1) 
 (If no to both 2a and 2b, go to 3) 
2.1 Please describe that innovation 
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________ 
2.2 What was the source of the firm‟s first scientific/ technological innovation?  
Yes/No  Source Country 
 In-house development  ____________________ 
 University ____________________ 
 Other firm ____________________ 
 Previous employer ____________________ 
 Acquisition of patent rights from third party ____________________ 
 Other_________________________________________________________ 
2.3 Does the firm have intellectual property rights for that innovation here and/or 
abroad? (Note all countries and sequence in which IPRs were sought.) 
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
________________________________  
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2.4 Does the firm have FDA approval for the US Market?  
2.5 Yes _________  Date __________ 
2.6 No _______      Pending__________ 
 
3. Why was the firm founded? 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
4. How was the firm financed? (tick all that apply) 
 Research Grant ____________________________________________ 
 Enterprise / start-up funding from Government ______________________ 
 Bank loan ___________________________________________ 
 Founder‟s personal sources _____________________________________ 
 Other __________________________________________________ 
5. Was the firm founded as an independent new firm with no corporate history? 
Yes________(go to 7), No _____ (go to 6) 
6. Was the firm founded as: (tick one only) 
a. A spin-off from another firm ___________________________________ 
b. A spin-off from a university __________________________________ 
c. Merger/takeover ____________________________________________ 
d. Management worker buy-out___________________________________ 
e. Other _________________________________________________ 
7. How many founders were there? _________________________. 
8. What personal, social or business contacts and networks with individuals or 
organisations overseas, did the founding team have at start-up? 
________________________________________________________________
________________________________________________________________
________________________________________________________________ 
9. To what extent have those links and networks contributed to the development 
and growth of the firm? 
________________________________________________________________
________________________________________________________________
________________________________________________________________
__________________________________ 
  
302 
 
 
10. The table below relates to the human and social capital of the firm at founding. 
Please record relevant details on each of the founders. 
 
 Founder 
1 
Founder 
2 
Founder 
3 
Founder 
4 
Founder 
5 
Age      
Gender      
Nationality      
Current role/position?      
Previous entrepreneur? 
Yes/No 
     
Family history of 
entrepreneurship Yes/No 
     
Highest Level of 
education, e.g 
School Cert, College 
degree/diploma (CD), 
University 1st Degree 
(UD), 
Advanced degree(AD), 
Doctoral degree (Dr), 
Professional bodies, 
     
Overseas education? 
Where ? Country (ies) 
 
     
Overseas working 
experience 
Where? Country (ies) 
 
SME/MNE?  
Role Position? 
 
     
Working experience in a 
Domestic 
internationalising firm? 
     
Foreign language ability? 
Languages? 
Spoken/written/fluent? 
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Section C. Open Questions: Critical Events and Milestones 
(Timeline) 
Q. Please tell us about events in the history of the firm that you see as major milestones, 
or critical incidents in the development of the firm, or things that happened, internally or 
externally, that triggered change in the firm’s development process? 
Enter the foundation date of the firm at the left of the time-line. 
1. Record the nature of each event 
2. Write the date on the approximate place on the time-line 
3. Write the story surrounding the event (continue over for space) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foundation Date________ 
Study Date: _______2005 
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Section C. Open Questions: Prompts Relating to Events on the Firm’s 
Timeline 
Q. Please allow the respondent to discuss each event as fully as possible. The prompts 
relate to each relevant event 
 
Prompts (for guidance) Please allow the respondent to answer in their own way, 
and record their responses in their own words 
 When did the firm get venture 
capital investment? 
 What triggered this event? 
 
 Were business networks and 
alliances important in any of these 
milestones? What role did VC 
play in aligning these networks?  
 
 What were the implications for 
the future growth and 
development of the firm? 
 
 What were the implications for 
the functional areas of the firm: 
R&D, manufacture, marketing, 
distribution, new product 
development, commercialisation, 
funding, etc. 
 
 What implications did the event 
have for internationalisation or 
international aspects of the firm‟s 
business? 
 
 What new processes or strategies 
were triggered? 
 
 What aspects of the firm‟s 
business were dropped? 
 
 What were the immediate effects 
on profitability, financing, sales, 
revenues, etc. 
 
 In retrospect, what were the long-
term effects? 
 
 
Continue on reverse if necessary 
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Section D. Open Questions: The Internationalisation Process 
(Timeline) 
Q. Please tell us about the firm’s internationalisation process from its first international 
links and contacts, to its first international contracts and investments, to its current 
situation as regards involvement in international business. 
Enter the foundation date of the firm at the left of the time-line. 
1.Record the nature of each internationalisation event recounted, as far as 
possible as the respondent describes it, with countries. 
2. Write the date on the approximate place on the time-line 
3. Write the story surrounding the internationalisation event (continue over 
for space) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foundation Date________ 
Study Date: _______2005 
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Section D.1. Open Questions: Prompts Relating to Events on the Firm’s 
Internationalisation Timeline  
Q. Please allow the respondent to discuss each event as fully as possible. The prompts 
relate to each relevant event
 
Prompts (for guidance) Please allow the respondent to answer in their own 
way, and record their responses in their own words 
 What role did the VC play in the 
internationalization of the firm? 
 
 How did your firm‟s involvement in 
international business evolve? 
 
 What was the nature of the cross-border 
arrangements you had? Export, import 
licensing in or out of technology, source 
of technological knowledge, raw 
materials etc. 
 
 What was the purpose of them? Increase 
knowledge, expand sales, exploit 
opportunities, avoid unfavourable 
conditions in home country? 
 
 Were there any investments involved 
(FDI), investment in technology etc.? 
 
 What were the implications of your 
international involvement for the 
functional areas of the firm: R&D, 
manufacture, marketing, distribution, new 
product development, commercialisation, 
funding etc. 
 
 How important is your international 
activity to firm growth and development 
in general? 
 
 What did the firm learn from its overseas 
involvement in relation to overseas 
markets, new product development, 
marketing techniques and processes, 
technological techniques and processes, 
R&D, technology transfer and the 
protection of intellectual property 
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Section E. Open Questions: Boldness, Creativity and innovativeness of 
International Ventures 
Q. Please tell us about anything in your firm’s international activities that you would 
consider to be bold / innovative / venturesome / creative? (If the respondent feels that 
nothing they do is particularly bold / innovative / venturesome or creative, ask them to 
explain why and what makes them say so). 
 
Prompts (for guidance) Please allow the respondent to answer in their own 
way, and record their responses in their own words 
 What particular international activities in 
which your firm is involved could be 
described in those terms? 
 Why would you describe them in that 
way? 
 
 Did the VCs have an influence an 
influence on these events? Did they 
encourage innovation? 
 
 Have the VC(s) helped increase your 
capabilities? 
 
 Have the VC(s) helped you become more 
dynamic and able to expand change your 
capabilities quickly to respond to the 
market? 
 
 How did these activities evolve, develop 
or come about? 
 
 What was it within the firm that led to 
these developments? 
 
 What stimuli/ events in the external 
environment? 
 
 Were there specific opportunities or 
threats that were responded to? (new 
markets, new production methods etc.). 
 To what extent did you actually search to 
find this stimulus? 
 
 Did anyone provide you information or a 
hint, or advice on that stimulus, and if yes, 
how did you use it? 
 How would your competitors see you in 
terms of: 
1. Your optimism to achieve difficult 
/specific goals? 
2. Your creativity in discovering 
attractive stimuli that others don‟t 
see?  
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Section F. Open Questions: R&D and Product Portfolio Management 
Q. Please describe the role of R&D in your firm, how it is organised, its relation to your 
portfolio of products, and to the development of new products for local and overseas 
markets.  
Prompts (for guidance) Please allow the respondent to answer in their own 
way, and record their responses in their own words 
 How have the VC(s) affected 
the R&D of the firm? 
 Has the VC involvement 
adversely affected the R&D 
process? 
 
 Do you have an in-house 
R&D department and if so, 
how much importance is given 
to it in terms of numbers of 
employees, annual investment 
as a percentage of turnovers 
etc. 
 
 When was the R&D 
department established? 
 
 What role does it play? 
Research for internal 
purposes, research for other 
firms under contract? 
Research for strategic 
partners? 
 
 What international 
connections, contracts, and 
involvement does your firm 
have in relation to R&D? 
 
 What are the purposes of the 
international connections, and 
how does the firm benefit? 
 
 What R&D-based 
international connections has 
the firm had that have resulted 
in commercial business 
ventures? 
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Section F. Closed Questions (Please ask questions and record answers 
precisely in this section.) 
 
F.1 Strategy and Planning 
1.1 Would you describe your firm‟s development as: (tick one only) 
1. Organic (evolutionary process in response to events and triggers) ______________  
2. Strategic (develops according to our pre-determined plans)___________ 
3. A combination of 1. and 2. __________  
 
1.2 Does your firm have a formal, written strategic plan? Yes / No. 
 
1.3  If yes, does that plan make explicit reference aims and objectives relating to your 
firm‟s involvement or future involvement in international business activity? Yes / No. 
 
1.4 If yes, does that plan contain explicit targets for Research and Development? Yes / No 
. For 1 year, 2 years, 3 years, 4 years, 5years, over 5 years?  
 
1.5 If yes, does that plan make explicit reference to(Yes/No) 
 
1. Product portfolio planning ____________; 
2. New product development____________;  
3. Adaptation of products for foreign markets _________;  
4. Entry into new foreign markets_________ 
5. Withdrawal from any current international business activities 
_________; 
6. Cessation of R&D _________. 
 
F.2 Firm Performance and Projections 
 
2.1 How would you rate the performance of this firm in its first five years, on a scale of 1-
10, with 1 being unsuccessful, 10 being successful? 
 
Unsuccessful  1 2 3 4 5 6 7 8 9 10  Successful 
 
2.2  Was the firm profitable in the each of the first five years? 
 
Year 1 Y/N Year 2 Y/N Year 3 Y/N Year 4 Y/N Year 5 Y/N 
 
2.3  What percentage of the firm‟s revenue was derived from overseas in each of the first 
five years? 
 
Year 1 _____% Year 2 _____% Year 3 _____% Year 4 _____% Year 5 _____% 
 
2.4  What is your firm‟s current percentage of profits is derived from foreign operations? 
________% of total profits? 
 
2.5  What is your firm‟s current percentage of sales is derived from foreign operations? 
________% of total sales? 
 
2.6  Would you mind telling us the approximate total sales of your firm in the last financial 
year £_________________? 
 
2.7 Would you mind telling us the profitability of your firm in the last financial year as a 
percentage of total sales______ % 
 
2.8 How many staff (FTEs), including working directors, does your firm currently 
employ_________? 
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Appendix C: Interview Schedule II 
 
 
 
Research on R&D and financial 
assets and capabilities. 
 
Jon Carrick 
 
 
 
 
 
 
 
 
 
  
Instructions to Interviewers 
Fill in one booklet per firm (or per interviewee). 
The interview should follow the format of open questions, answered in the 
respondent‟s own words; followed by closed, checklist questions. 
5. Write the answers to the open questions as told by the respondent, use 
as much space as necessary. Follow each section of open questions 
immediately with the corresponding closed questions in order to verify 
the respondent‟s story. 
6. Ask the closed questions precisely and enter the answers in the spaces 
provided 
7. Once the form is completed, ask the respondent to elaborate on any 
issues that have emerged during the interview that they think are of 
particular importance to the future development of their firm 
Time: 
Date: 
Interviewer 1: 
Interviewer 2: 
Company Name: 
Address: 
 
 
Telephone:   e-mail 
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Section A. Open Questions: R&D and financial assets and 
capabilities 
Q. In your own words please describe your firm’s important R&D and financial assets and 
capabilities and how these were developed. 
  
Prompts (for guidance) Please allow the respondent to answer in their own way, and 
record their responses in their own words 
 Key paths 
-Core technology 
-Scientific 
opportunities 
-Partnerships 
 
 Key positions 
-Core technology 
-Scientific staff 
-Founder 
 
 Key processes 
-Learning 
-Sensing 
-Integrating 
 
 R&D  
-VC Influence 
-Founders 
connections 
 
 
 Financing 
-VC Influence 
-Founders 
connections 
 
 
 
 
 
Continue on reverse if necessary 
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Section B. Open Questions: Critical Events and Milestones 
(Timeline) 
Q. Please tell us about events in the history of the firm that you see as major alliance 
milestones important to the firm’s development process?  
Enter the foundation date of the firm at the left of the time-line. 
4. Record the nature of each event 
5. Write the date on the approximate place on the time-line 
6. Write the story surrounding the event (continue over for space) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Foundation Date________ 
Study Date: _______2010 
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 Section B. Open Questions: Effect of R&D and financial assets and 
capabilities on early growth (Timeline) 
Q. In your own words please describe the effect of R&D assets on the early growth of the 
firm. Define early growth: from the time the firm started until the time that it started to 
generate a significant amount of revenue. 
  
Prompts (for guidance) Please allow the respondent to answer in their own way, and 
record their responses in their own words 
 Key paths 
-Core technology 
-Scientific 
opportunities 
-Partnerships 
 
 Key positions 
-Core technology 
-Scientific staff 
-Founder 
 
 Key processes 
-Learning 
-Sensing 
-Integrating 
 
 R&D Alliances 
-VC Influence 
-Founders 
connections 
 
 
 Financing alliances 
-VC Influence 
-Founders 
connections 
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Section C. Open Questions: The Value of Alliances 
Q. In your own words, please describe how your firm’s important alliances have affected 
your firm’s early growth.(Define early growth for respondent)  
 
Prompts (for guidance) Please allow the respondent to answer in their own way, 
and record their responses in their own words 
 
 Did any of the alliances 
help the firm obtain 
financing? 
 
 Did any of the alliances 
lead to development in 
R&D? 
 
 Did the alliances formed 
through the facilitation of 
the VCs result in more 
valuable alliances?  
 
 Did the alliances formed 
from within the VCs 
portfolio have more value 
than the other alliances?  
 
 How did the alliances help 
in the early growth of the 
firm? What involvement 
did the VC have in these? 
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Section C. Closed Questions: Major Partners 
 
 Alliance 
Partner 1 
Alliance 
Partner 2 
Alliance 
Partner 3 
Alliance 
Partner 4 
Alliance 
Partner 5 
Firm Type/same 
industry 
     
Alliance Facilitated 
by 
     
Relationship duration      
Purpose of alliance      
Specialised Assets 
created from 
alliance 
 
     
Alliance was critical 
to firms early 
growth 
     
Alliance was critical 
to firms 
internationalisation 
     
Is partner 
international 
     
Did alliance help in 
the firms 
internationalisation 
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Section C. Closed Questions: The Firm’s Alliances 
(Please ask questions and record answers precisely in this section) 
 
C.1 Alliances and Types of Alliances 
 
1.8 How many strong alliances does your firm have_________? 
 
1.9 What was the primary way that these alliances were formed? 1. CEO contacts______ 
2. VC facilitating alliances with other firms within their portfolios_____ 3. VCs 
facilitating alliances with firms outside of their portfolios____ 4. Industry networking 
events____  
5. Other, please describe____________________. 
 
1.10How many products did R&D alliances help your firm develop or jointly 
develop_____________? 
 
1.11How many of the R&D alliances were facilitated by your VC_____________? How 
many of these were from firms within the VCs portfolio_______? 
 
1.12 How important were the VCs in facilitating alliances ? 
Unimportant 1 2 3 4 5 6 7 8 9 10 Very Important 
 
 
C.2 Alliance Formation 
2.1 Please describe how your major alliances were formed? 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_______________________________________________________________________ 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
______________________________________________ 
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Section D. Open Questions: The VC Business Model 
Q. Please tell us your opinion of the VCs business model? (Make sure to explain what is 
meant by the VC business model.) 
 
Prompts (for guidance) Please allow the respondent to answer in their own way, 
and record their responses in their own words 
 What was the most detrimental part of 
the VCs business model?  
 
 
 
 In what ways was the VCs business 
model good for your firm? 
 
 
 
 Have the VC(s) helped you become 
more dynamic and able to expand 
change your capabilities quickly to 
respond to the market? 
 
 
 
 Did the firm‟s executives waste a lot of 
time meeting with the VCs and writing 
reports for them? 
 
 
 Is the VC business model broken? 
  
 
 If you were to do it all over again would 
you pursue VC for the firm? 
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Section D. Closed Questions (Please ask questions and record answers 
precisely in this section) 
 
E.1 Strategy and Planning 
1.6 Was it the intent of the firm from its inception to attract VC investment? Yes / No. 
 
1.7  Did the strategic direction of the firm change once VC came on board? Yes / No. 
 
1.8 Did the VC encourage the internationalisation of the firm? Yes/No. 
 
1.9 Did the VCs encourage you to incorporate alliances into your strategy? Yes/No.  
 
1.10Overall was the VC investment positive on your firm‟s early growth?  
 1.5a Why or Why not? 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_____________________ 
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Appendix D: Triangulation Survey 
 
Questionnaire 
 
R&D and financial resource development of small life science firms 
Jon Carrick / University of Glasgow 
 
 
Dear 
Name: Given Name: 
Position: 
Company: 
Responsible for the firms since: 
 
 
In my research I am analysing the variables that impact the development of small life science 
firms. Your valuable feedback is very important to me, and I would greatly appreciate if you 
would complete this questionnaire and return it to me as soon as possible. 
 
 
 
 
 
The questionnaire will need approximately 45 minutes. 
I assure that all information will be kept strictly confidential and will only be used for 
the purpose of this project. Thank you very much for your support. 
Contact address: 
 
 
Jon Carrick 
5720 Old Ocean BLVD 5W 
Ocean Ridge, FL 33435 
+1-561-214-3657 
Email: carrickjon 
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Closed question on R&D and Financial Assets 
and Capabilities 
 
1. R&D assets and capabilities  
 
Focus: R&D paths (past decisions and future opportunities) that influenced the 
development of your firm‟s R&D assets and capabilities. Put differently, these pursuits 
influenced the strategic direction of the firm‟s R&D. To what extent did the following 
opportunities have on the development of your firms R&D? 
 
                                                                        1= to no extent  7 = to a very great extent 
  1 2 3 4 5 6 7 
1. Your firm‟s core innovation(s)        
2. Venture capital investment        
3. Industry partnerships        
4. University partnerships        
5. Government partnerships        
6. Scientific breakthroughs by your firm        
7. Scientific breakthroughs in the industry        
8. FDA, EU or other approvals        
9. Patenting        
10. Other:        
11. Other:         
 
Focus: Resources influencing the development of your R&D assets and capabilities. 
To what extent did the following resources have on the development of your firms R&D? 
                                                                                1= to no extent  7 = to a very great extent 
  1 2 3 4 5 6 7 
1. Your firm‟s core technology        
2. Your firm‟s knowledge and capabilities        
3. Your firm‟sscientific staff        
4. Star scientists*        
5. Founders        
6. Executive staff and board of directors        
7. University inputs         
8. Industry partners‟ inputs        
9. Government inputs        
10. Patents        
11. Specialized R&D facility***         
12. Other:        
13. Other:        
 
*Star scientists are individuals who are highly accomplished. These individuals hold a 
great number of patents, have scientific papers that are frequently cited, have been central 
to the development of notable products in the field or a combination thereof.  
 
*** Specialized R&D facilities are those that could not readily be leased or built 
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Focus: Processes influencing the development of your firm‟s R&D assets and capabilities. 
To what extent did the following processes have on the development of your firms R&D? 
                                                                              1= to no extent  7 = to a very great extent 
  1 2 3 4 5 6 7 
1. Finding (sensing) the core technology        
2. Finding (sensing) complementary technologies        
3. Networking        
4. Learning from previous research paths        
5. Tracking and sharing information        
6. Other:        
7. Other:        
 
Focus: Effect of R&D on the firm‟s early growth; early growth is defined as the time from 
when the firm was incepted until the time it developed and commercialised its main 
product (s). 
 
How important were your firm‟s R&D assets and capabilities to the following: 
                                                               1= no importance  7= highly important 
  1 2 3 4 5 6 7 
1. Developing the core technology        
2. Refining the core technology        
3. Developing a platform technology        
4. Allowing firm to progress technology        
5. Developing new applications         
6. Aiding in the attraction of key employees        
7. Aiding in the attraction of research partners         
8. Aiding in the attraction of investment capital        
9. Gaining FDA, EU, or other approvals        
10. Helping in the firm‟s growth        
11.  Other:         
12. Other:        
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2. Financial assets and capabilities  
 
Focus: Financial paths (past decisions and future opportunities) that influenced the 
development of your firm‟s financial assets and capabilities. Put differently, these pursuits 
influenced the strategic direction of the firm‟s financial assets and capabilities. To what 
extent did the following have on the development of your firm‟s financial assets and 
capabilities? 
                                                                                1= to no extent  7 = to a very great extent 
  1 2 3 4 5 6 7 
1. Costly to develop innovation(s)        
2. Raising capital        
3. Dealing with investors        
4. Initial public stock offering (IPO)        
5.  FDA, EU or other approvals        
5. Other:        
6. Other:        
 
Focus: Resources influencing the development of your financial assets and capabilities. 
To what extent did the following resources have on the development of your firm‟s 
financial assets and capabilities: 
                                                                                1= to no extent  7 = to a very great extent 
  1 2 3 4 5 6 7 
1. Founder(s)‟ experience        
2. Founder(s)‟ networks within financial community        
3. Executive staff‟s and board members‟ experience        
4. Executive staff‟s and board members‟ networks        
5. Networks within financial community        
6. Venture capital investor(s)‟ networks        
7. Venture capital investor(s)‟ management 
contributions 
       
8. Core technology‟s value in attracting capital        
9. Company‟s staff        
10. Other:        
11. Other:        
 
Focus: Processes influencing the development of your firm‟s financial assets and 
capabilities. 
To what extent did the following processes have on the development of your firm‟s 
financial assets and capabilities? 
                                                                                1= to no extent  7 = to a very great extent 
  1 2 3 4 5 6 7 
1. Prospecting for capital        
2. Negotiating for capital        
3. Dealing with financiers         
4. Budgeting capital for operations        
5. Learning from earlier financial paths        
6. Filing for an initial public offering (IPO)        
7. Other:        
8. Other:        
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Focus: Effect of financial resources on the firm‟s early growth; early growth is defined as 
the time from when the firm was incepted until the time it developed and commercialised 
its main product (s). 
 
How important were financial assets and capabilities to the following? 
                                                                                1= no importance  7= highly important 
  1 2 3 4 5 6 7 
1. Developing the core technology        
2. Developing key R&D assets and capabilities        
3. Allowing firm to progress its technology        
4. Aiding in the attraction of key employees        
5. Gaining FDA, EU or other approvals        
6. Helping in the firm‟s growth        
7. Other:        
8.  Other:        
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